{"cb3864911b0fa97f03600c828a1149d36cc7631b": [["In 2007, with Modernising Medical Careers, 1 much more defined curricula and assessment in the work place were introduced.", [["assessment", "TEST", 77, 87]]], ["The laudable aim was to improve feedback through repeated small assessments of the performance of various tasks described in the syllabus, across clinical skills, professional skills and technical skills.", [["repeated small assessments", "TEST", 49, 75], ["small", "OBSERVATION_MODIFIER", 58, 63]]], ["Some knowledge was examined in the work place, but the main assessment of knowledge remained the formal exam.", [["the formal exam", "TEST", 93, 108]]], ["However, many were initially resistant to the new ways of training, with the introduction perhaps not helped by mandatory minimum numbers of workplace-based assessments (WBAs) in each training year, which very quickly became de facto maximums and submissions of just short of that number were often seen at their Annual Review of Competency Progression (ARCP).", [["training", "TREATMENT", 58, 66]]], ["Many would see the WBA as a summative, rather than formative, assessment and only ask to be assessed on their best cases, fearing criticism.", [["WBA", "PROTEIN", 19, 22], ["assessment", "TEST", 62, 72]]], ["Prepopulated assessments sent via The Intercollegiate Surgical Curriculum Programme (ISCP) to be validated by trainers lost the opportunity for feedback, unless it was, as sometimes, a record of the discussion that had taken place after the training event.", [["Prepopulated assessments", "TEST", 0, 24]]]], "PMC7507586": [["More than 45 000 articles in the PubMed database and around 3200 studies registered in ClinicalTrials.gov, of which greater than half are clinical trials, is the result of ongoing and relentless research into the global pandemic nature of an acute respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which made its initial appearance in December 2019 in China.", [["respiratory", "ANATOMY", 248, 259], ["respiratory disease", "DISEASE", 248, 267], ["acute respiratory syndrome coronavirus", "DISEASE", 289, 327], ["SARS-CoV-2", "ORGANISM", 331, 341], ["severe acute respiratory syndrome coronavirus", "SPECIES", 282, 327], ["SARS-CoV-2", "SPECIES", 331, 341], ["3200 studies", "TEST", 60, 72], ["an acute respiratory disease", "PROBLEM", 239, 267], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 278, 327], ["SARS-CoV", "TEST", 331, 339], ["acute", "OBSERVATION_MODIFIER", 242, 247], ["respiratory disease", "OBSERVATION", 248, 267], ["severe", "OBSERVATION_MODIFIER", 282, 288], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["respiratory syndrome", "OBSERVATION", 295, 315]]], ["As of August 28, the total confirmed cases of coronavirus disease 2019 (COVID-19) surpass 24.5 million people, with over 830 000 global deaths [1].", [["coronavirus disease", "DISEASE", 46, 65], ["deaths", "DISEASE", 136, 142], ["coronavirus", "ORGANISM", 46, 57], ["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109], ["coronavirus disease", "PROBLEM", 46, 65], ["COVID", "TEST", 72, 77], ["coronavirus disease", "OBSERVATION", 46, 65]]], ["An estimated 40% to 45% of persons infected with SARS-CoV-2 will remain asymptomatic, but they can transmit the virus to others for an extended period, perhaps longer than 14 days [2].", [["SARS", "DISEASE", 49, 53], ["persons", "ORGANISM", 27, 34], ["SARS-CoV-2", "ORGANISM", 49, 59], ["persons", "SPECIES", 27, 34], ["CoV-", "SPECIES", 54, 58], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "PROBLEM", 49, 53], ["CoV", "TEST", 54, 57], ["asymptomatic", "PROBLEM", 72, 84]]], ["The primary presentation of symptomatic infection is that of an influenza-like illness or viral pneumonia, with about 20% of these patients developing severe or critical manifestations [3].", [["infection", "DISEASE", 40, 49], ["influenza-like illness", "DISEASE", 64, 86], ["viral pneumonia", "DISEASE", 90, 105], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["symptomatic infection", "PROBLEM", 28, 49], ["an influenza-like illness", "PROBLEM", 61, 86], ["viral pneumonia", "PROBLEM", 90, 105], ["critical manifestations", "PROBLEM", 161, 184], ["symptomatic", "OBSERVATION_MODIFIER", 28, 39], ["infection", "OBSERVATION", 40, 49], ["influenza", "OBSERVATION", 64, 73], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["pneumonia", "OBSERVATION", 96, 105], ["severe", "OBSERVATION_MODIFIER", 151, 157]]]], "b3e8210b179bf188b0bd3d45b4b085162d9c218a": [["IntroductionThe outbreak of coronavirus disease 2019 (COVID-19) caused a great threat to world-wide public health in 2020 with the majority of deaths occurring in older adults.", [["coronavirus disease", "DISEASE", 28, 47], ["COVID-19", "CHEMICAL", 54, 62], ["deaths", "DISEASE", 143, 149], ["coronavirus", "ORGANISM", 28, 39], ["coronavirus disease 2019 (COVID-19", "SPECIES", 28, 62], ["coronavirus disease", "PROBLEM", 28, 47], ["coronavirus disease", "OBSERVATION", 28, 47]]], ["The development of effective treatments and vaccines against COVID-19 is now more than ever becoming a pressing and urgent challenge to overcome 1,2 .IntroductionHowever the successful vaccination of the elderly against pathogens is considered one of the big challenges in our society 3, 4 .", [["COVID-19", "CHEMICAL", 61, 69], ["effective treatments", "TREATMENT", 19, 39], ["vaccines", "TREATMENT", 44, 52], ["COVID", "TEST", 61, 66], ["urgent challenge", "TREATMENT", 116, 132], ["Introduction", "TREATMENT", 150, 162], ["the successful vaccination", "TREATMENT", 170, 196], ["pathogens", "PROBLEM", 220, 229], ["effective", "OBSERVATION_MODIFIER", 19, 28]]], ["Immunosenescence, which is characterized by poor induction and recall of B and T memory responses upon exposure to new antigens, can lead to reduced immune responses following immunization of older adults.", [["Immunosenescence", "DISEASE", 0, 16], ["B", "CELL", 73, 74], ["reduced immune responses", "PROBLEM", 141, 165], ["immunization", "TREATMENT", 176, 188]]], ["While most vaccines are less immunogenic and effective in the older population 3 , little is known about the molecular mechanisms that underpin immune senescence.", [["immune senescence", "OBSERVATION", 144, 161]]], ["Autophagy is thought to be one of the few cellular processes that underlie many facets of cellular ageing including immune senescence 5 .", [["cellular", "ANATOMY", 42, 50], ["cellular", "ANATOMY", 90, 98], ["cellular", "CELL", 42, 50], ["cellular", "CELL", 90, 98], ["immune senescence", "PROBLEM", 116, 133], ["thought to be", "UNCERTAINTY", 13, 26], ["few", "OBSERVATION_MODIFIER", 38, 41], ["cellular processes", "OBSERVATION", 42, 60], ["many", "OBSERVATION_MODIFIER", 75, 79], ["facets", "OBSERVATION_MODIFIER", 80, 86], ["cellular ageing", "OBSERVATION", 90, 105]]], ["By delivering unwanted cytoplasmic material to the lysosomes for degradation, autophagy limits mitochondrial dysfunction and accumulation of reactive oxygen species (ROS) 6 .", [["cytoplasmic", "ANATOMY", 23, 34], ["lysosomes", "ANATOMY", 51, 60], ["mitochondrial", "ANATOMY", 95, 108], ["mitochondrial dysfunction", "DISEASE", 95, 120], ["oxygen", "CHEMICAL", 150, 156], ["cytoplasmic material", "CELLULAR_COMPONENT", 23, 43], ["lysosomes", "CELLULAR_COMPONENT", 51, 60], ["mitochondrial", "CELLULAR_COMPONENT", 95, 108], ["reactive oxygen species", "SIMPLE_CHEMICAL", 141, 164], ["ROS", "SIMPLE_CHEMICAL", 166, 169], ["autophagy", "PROBLEM", 78, 87], ["mitochondrial dysfunction", "PROBLEM", 95, 120], ["reactive oxygen species", "PROBLEM", 141, 164], ["mitochondrial dysfunction", "OBSERVATION", 95, 120], ["reactive", "OBSERVATION_MODIFIER", 141, 149], ["oxygen species", "OBSERVATION", 150, 164]]], ["Autophagy degrades protein aggregates that accumulate with age and its age-related decline could contribute to \"inflammaging\" 7 , the age-related increase in inflammatory cytokines in in blood and tissue.IntroductionLoss of autophagy strongly promotes production of the inflammatory cytokines TNFa, IL-6 and IL1-b 8, 9 .", [["blood", "ANATOMY", 187, 192], ["tissue", "ANATOMY", 197, 203], ["inflammaging", "DISEASE", 112, 124], ["blood", "ORGANISM_SUBSTANCE", 187, 192], ["tissue", "TISSUE", 197, 203], ["TNFa", "GENE_OR_GENE_PRODUCT", 293, 297], ["IL-6", "GENE_OR_GENE_PRODUCT", 299, 303], ["IL1-b 8", "GENE_OR_GENE_PRODUCT", 308, 315], ["inflammatory cytokines", "PROTEIN", 158, 180], ["inflammatory cytokines", "PROTEIN", 270, 292], ["TNFa", "PROTEIN", 293, 297], ["IL", "PROTEIN", 299, 301], ["IL1", "PROTEIN", 308, 311], ["Autophagy degrades protein aggregates", "PROBLEM", 0, 37], ["inflammatory cytokines in in blood and tissue", "PROBLEM", 158, 203], ["the inflammatory cytokines TNFa", "TEST", 266, 297], ["IL", "TEST", 299, 301], ["IL1", "TEST", 308, 311], ["protein aggregates", "OBSERVATION", 19, 37], ["increase", "OBSERVATION_MODIFIER", 146, 154], ["inflammatory cytokines", "OBSERVATION", 158, 180], ["blood", "ANATOMY", 187, 192], ["tissue", "ANATOMY", 197, 203], ["inflammatory", "OBSERVATION_MODIFIER", 270, 282]]], ["We previously found autophagy levels decline with age in human peripheral CD8 + T cells 10 .", [["peripheral CD8 + T cells", "ANATOMY", 63, 87], ["human", "ORGANISM", 57, 62], ["peripheral", "CELL", 63, 73], ["CD8", "GENE_OR_GENE_PRODUCT", 74, 77], ["human peripheral CD8 + T cells", "CELL_TYPE", 57, 87], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["autophagy levels decline", "PROBLEM", 20, 44], ["autophagy levels", "OBSERVATION", 20, 36]]], ["Deletion of key autophagy genes leads to a prematurely aged immune phenotype, with loss of function in mouse memory CD8 + T cells 11 12 , hematopoietic stem cells 13 , and macrophages 9 with a myeloid bias 13 .", [["memory CD8 + T cells", "ANATOMY", 109, 129], ["hematopoietic stem cells", "ANATOMY", 138, 162], ["macrophages", "ANATOMY", 172, 183], ["myeloid", "ANATOMY", 193, 200], ["mouse", "ORGANISM", 103, 108], ["CD8", "GENE_OR_GENE_PRODUCT", 116, 119], ["hematopoietic stem cells 13", "CELL", 138, 165], ["macrophages 9", "CELL", 172, 185], ["myeloid", "CELL", 193, 200], ["autophagy genes", "DNA", 16, 31], ["mouse memory CD8 + T cells", "CELL_TYPE", 103, 129], ["hematopoietic stem cells 13", "CELL_LINE", 138, 165], ["macrophages", "CELL_TYPE", 172, 183], ["mouse", "SPECIES", 103, 108], ["mouse", "SPECIES", 103, 108], ["Deletion of key autophagy genes", "PROBLEM", 0, 31], ["a prematurely aged immune phenotype", "PROBLEM", 41, 76], ["loss of function", "PROBLEM", 83, 99], ["T cells", "TEST", 122, 129], ["hematopoietic stem cells", "TEST", 138, 162], ["macrophages", "TEST", 172, 183], ["a myeloid bias", "TEST", 191, 205], ["autophagy genes", "OBSERVATION", 16, 31], ["hematopoietic stem cells", "OBSERVATION", 138, 162], ["macrophages", "ANATOMY", 172, 183], ["myeloid bias", "OBSERVATION", 193, 205]]], ["In addition, we find in autophagy-deficient immune cells the same cellular phenotype that cells display in older organisms; they accumulate ROS and damaged mitochondria 9, 12 .IntroductionImportantly, we can improve CD8 + T memory responses from aged mice with spermidine 12 , an endogenous metabolite synthesized from arginine.", [["immune cells", "ANATOMY", 44, 56], ["cellular", "ANATOMY", 66, 74], ["cells", "ANATOMY", 90, 95], ["mitochondria", "ANATOMY", 156, 168], ["CD8 + T", "ANATOMY", 216, 223], ["ROS", "CHEMICAL", 140, 143], ["spermidine", "CHEMICAL", 261, 271], ["arginine", "CHEMICAL", 319, 327], ["spermidine", "CHEMICAL", 261, 271], ["arginine", "CHEMICAL", 319, 327], ["immune cells", "CELL", 44, 56], ["cellular", "CELL", 66, 74], ["cells", "CELL", 90, 95], ["ROS", "SIMPLE_CHEMICAL", 140, 143], ["mitochondria", "CELLULAR_COMPONENT", 156, 168], ["CD8", "GENE_OR_GENE_PRODUCT", 216, 219], ["mice", "ORGANISM", 251, 255], ["spermidine 12", "SIMPLE_CHEMICAL", 261, 274], ["arginine", "SIMPLE_CHEMICAL", 319, 327], ["immune cells", "CELL_TYPE", 44, 56], ["CD8", "PROTEIN", 216, 219], ["mice", "SPECIES", 251, 255], ["mice", "SPECIES", 251, 255], ["autophagy", "TEST", 24, 33], ["deficient immune cells", "PROBLEM", 34, 56], ["older organisms", "PROBLEM", 107, 122], ["spermidine", "TREATMENT", 261, 271], ["immune cells", "OBSERVATION", 44, 56]]], ["It was shown in yeast and other model organisms that spermidine extends life-span via increased autophagy 14 .", [["spermidine", "CHEMICAL", 53, 63], ["spermidine", "CHEMICAL", 53, 63], ["spermidine", "SIMPLE_CHEMICAL", 53, 63], ["yeast", "SPECIES", 16, 21], ["yeast", "SPECIES", 16, 21], ["increased autophagy", "PROBLEM", 86, 105], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["autophagy", "OBSERVATION", 96, 105]]], ["Several downstream mechanisms of spermidine-induced autophagy have been described in mice, including the inhibition of histone deacetylases 14 .", [["spermidine", "CHEMICAL", 33, 43], ["spermidine", "CHEMICAL", 33, 43], ["spermidine", "SIMPLE_CHEMICAL", 33, 43], ["mice", "ORGANISM", 85, 89], ["histone deacetylases 14", "GENE_OR_GENE_PRODUCT", 119, 142], ["histone deacetylases 14", "PROTEIN", 119, 142], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["spermidine-induced autophagy", "PROBLEM", 33, 61], ["histone deacetylases", "TREATMENT", 119, 139]]], ["Recently we uncovered a novel pathway in which spermidine lends a residue for the hypusination of the translation factor eIF5a, which is necessary for the translation of a three proline motif present in the master transcription factor of autophagy and lysosomal biogenesis, called TFEB 15 .", [["lysosomal", "ANATOMY", 252, 261], ["spermidine", "CHEMICAL", 47, 57], ["spermidine", "CHEMICAL", 47, 57], ["proline", "CHEMICAL", 178, 185], ["spermidine", "SIMPLE_CHEMICAL", 47, 57], ["eIF5a", "GENE_OR_GENE_PRODUCT", 121, 126], ["lysosomal", "CELLULAR_COMPONENT", 252, 261], ["TFEB 15", "GENE_OR_GENE_PRODUCT", 281, 288], ["translation factor", "PROTEIN", 102, 120], ["eIF5a", "PROTEIN", 121, 126], ["proline motif", "PROTEIN", 178, 191], ["master transcription factor", "PROTEIN", 207, 234], ["TFEB 15", "PROTEIN", 281, 288], ["a novel pathway", "TREATMENT", 22, 37], ["a residue", "PROBLEM", 64, 73], ["a three proline motif", "TREATMENT", 170, 191], ["lysosomal biogenesis", "OBSERVATION", 252, 272]]], ["We demonstrated this pathway operates in activated B cells, which upon activation have an unusually high protein synthesis rate, owing to the high production of immunoglobulins.", [["B cells", "ANATOMY", 51, 58], ["B cells", "CELL", 51, 58], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 161, 176], ["activated B cells", "CELL_TYPE", 41, 58], ["immunoglobulins", "PROTEIN", 161, 176], ["activated B cells", "PROBLEM", 41, 58], ["an unusually high protein synthesis rate", "PROBLEM", 87, 127], ["the high production of immunoglobulins", "TREATMENT", 138, 176], ["activated B cells", "OBSERVATION", 41, 58], ["unusually", "OBSERVATION_MODIFIER", 90, 99], ["high protein", "OBSERVATION", 100, 112], ["synthesis rate", "OBSERVATION", 113, 127]]], ["It is likely that B cells may be particularly reliant on the unfolded protein response, the proteasome, and autophagy, to cope with this high rate of protein synthesis.", [["B cells", "ANATOMY", 18, 25], ["B cells", "CELL", 18, 25], ["B cells", "CELL_TYPE", 18, 25], ["proteasome", "PROTEIN", 92, 102], ["B cells", "PROBLEM", 18, 25], ["the proteasome", "TREATMENT", 88, 102], ["this high rate of protein synthesis", "PROBLEM", 132, 167], ["is likely", "UNCERTAINTY", 3, 12]]], ["B cells may have evolved special coping strategies including the translational signalling for autophagy via eIF5A and TFEB.", [["B cells", "ANATOMY", 0, 7], ["B cells", "CELL", 0, 7], ["eIF5A", "GENE_OR_GENE_PRODUCT", 108, 113], ["TFEB", "GENE_OR_GENE_PRODUCT", 118, 122], ["B cells", "CELL_TYPE", 0, 7], ["eIF5A", "PROTEIN", 108, 113], ["TFEB", "PROTEIN", 118, 122]]], ["We therefore sought to extend our findings to another immune cell type, CD8+ T cells, to investigate whether this pathway may be conserved in a related adaptive immune subset and possibly broadly applicable.IntroductionHere we show for the first time that autophagy is indeed highly active in human CD8+ T cells after the in vivo encounter of antigens in donors from two different experimental vaccination trials.", [["immune cell", "ANATOMY", 54, 65], ["CD8+", "ANATOMY", 72, 76], ["T cells", "ANATOMY", 77, 84], ["CD8+", "ANATOMY", 299, 303], ["T cells", "ANATOMY", 304, 311], ["immune cell type", "CELL", 54, 70], ["CD8", "GENE_OR_GENE_PRODUCT", 72, 75], ["T cells", "CELL", 77, 84], ["human", "ORGANISM", 293, 298], ["CD8", "GENE_OR_GENE_PRODUCT", 299, 302], ["T cells", "CELL", 304, 311], ["donors", "ORGANISM", 355, 361], ["CD8", "PROTEIN", 72, 75], ["T cells", "CELL_TYPE", 77, 84], ["human CD8", "PROTEIN", 293, 302], ["T cells", "CELL_TYPE", 304, 311], ["antigens", "PROTEIN", 343, 351], ["human", "SPECIES", 293, 298], ["human", "SPECIES", 293, 298], ["autophagy", "PROBLEM", 256, 265], ["experimental vaccination trials", "TREATMENT", 381, 412]]], ["Our data show that polyamine levels fall with age in peripheral mononuclear cells.", [["peripheral mononuclear cells", "ANATOMY", 53, 81], ["polyamine", "CHEMICAL", 19, 28], ["polyamine", "CHEMICAL", 19, 28], ["polyamine", "SIMPLE_CHEMICAL", 19, 28], ["peripheral mononuclear cells", "CELL", 53, 81], ["peripheral mononuclear cells", "CELL_TYPE", 53, 81], ["Our data", "TEST", 0, 8], ["polyamine levels fall", "PROBLEM", 19, 40], ["age in peripheral mononuclear cells", "PROBLEM", 46, 81], ["polyamine levels", "OBSERVATION", 19, 35], ["peripheral", "ANATOMY_MODIFIER", 53, 63], ["mononuclear cells", "OBSERVATION", 64, 81]]], ["When supplemented with spermidine, the dysfunctional autophagic flux can be rejuvenated in CD8+ T cells from old donors, and levels of the important effector molecules IFN and perforin are enhanced as a consequence.", [["CD8+", "ANATOMY", 91, 95], ["T cells", "ANATOMY", 96, 103], ["spermidine", "CHEMICAL", 23, 33], ["spermidine", "CHEMICAL", 23, 33], ["spermidine", "SIMPLE_CHEMICAL", 23, 33], ["CD8", "GENE_OR_GENE_PRODUCT", 91, 94], ["T cells", "CELL", 96, 103], ["donors", "ORGANISM", 113, 119], ["IFN", "GENE_OR_GENE_PRODUCT", 168, 171], ["perforin", "GENE_OR_GENE_PRODUCT", 176, 184], ["CD8", "PROTEIN", 91, 94], ["T cells", "CELL_TYPE", 96, 103], ["effector molecules", "PROTEIN", 149, 167], ["IFN", "PROTEIN", 168, 171], ["perforin", "PROTEIN", 176, 184], ["spermidine", "TREATMENT", 23, 33], ["the dysfunctional autophagic flux", "PROBLEM", 35, 68], ["old donors", "TEST", 109, 119], ["autophagic flux", "OBSERVATION", 53, 68], ["effector molecules", "OBSERVATION", 149, 167]]], ["Moreover, autophagy and effector function are maintained by spermidine in T cells from young donors.", [["T cells", "ANATOMY", 74, 81], ["spermidine", "CHEMICAL", 60, 70], ["spermidine", "CHEMICAL", 60, 70], ["spermidine", "SIMPLE_CHEMICAL", 60, 70], ["T cells", "CELL", 74, 81], ["donors", "ORGANISM", 93, 99], ["T cells", "CELL_TYPE", 74, 81], ["effector function", "OBSERVATION", 24, 41]]], ["Lastly, in human CD8+ T cells we show that spermidine signals via eIF5A and TFEB to maintain autophagy levels.", [["CD8+", "ANATOMY", 17, 21], ["T cells", "ANATOMY", 22, 29], ["spermidine", "CHEMICAL", 43, 53], ["spermidine", "CHEMICAL", 43, 53], ["human", "ORGANISM", 11, 16], ["CD8", "GENE_OR_GENE_PRODUCT", 17, 20], ["T cells", "CELL", 22, 29], ["spermidine", "SIMPLE_CHEMICAL", 43, 53], ["eIF5A", "GENE_OR_GENE_PRODUCT", 66, 71], ["TFEB", "GENE_OR_GENE_PRODUCT", 76, 80], ["human CD8", "PROTEIN", 11, 20], ["T cells", "CELL_TYPE", 22, 29], ["eIF5A", "PROTEIN", 66, 71], ["TFEB", "PROTEIN", 76, 80], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["T cells", "TEST", 22, 29], ["spermidine signals", "TEST", 43, 61], ["eIF5A", "TEST", 66, 71], ["TFEB", "TEST", 76, 80], ["autophagy levels", "TEST", 93, 109]]], ["This study demonstrates that the function of human CD8+ T cells can be improved with spermidine.", [["CD8+ T cells", "ANATOMY", 51, 63], ["spermidine", "CHEMICAL", 85, 95], ["spermidine", "CHEMICAL", 85, 95], ["human", "ORGANISM", 45, 50], ["CD8", "GENE_OR_GENE_PRODUCT", 51, 54], ["spermidine", "SIMPLE_CHEMICAL", 85, 95], ["human CD8+ T cells", "CELL_TYPE", 45, 63], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["This study", "TEST", 0, 10], ["human CD8", "TEST", 45, 54], ["spermidine", "TREATMENT", 85, 95]]], ["Taken together with our previous work on B cells, this leads us to the hypothesis that both T and B cell responses to infections and vaccinations are exquisitely reliant on sufficient autophagy levels, which are maintained by intracellular spermidine.", [["B cells", "ANATOMY", 41, 48], ["B cell", "ANATOMY", 98, 104], ["intracellular", "ANATOMY", 226, 239], ["infections", "DISEASE", 118, 128], ["spermidine", "CHEMICAL", 240, 250], ["spermidine", "CHEMICAL", 240, 250], ["B cells", "CELL", 41, 48], ["T", "CELL", 92, 93], ["B cell", "CELL", 98, 104], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 226, 239], ["spermidine", "SIMPLE_CHEMICAL", 240, 250], ["B cells", "CELL_TYPE", 41, 48], ["B cells", "TREATMENT", 41, 48], ["infections", "PROBLEM", 118, 128], ["vaccinations", "TREATMENT", 133, 145]]], ["This work highlights the potential of spermidine as a vaccine adjuvant in the older adults.ResultsFirst we optimised a flow cytometry-based assay to reliably and reproducibly measure autophagy, before applying it to measure autophagy after in vivo antigen stimulated T cells post-vaccination.", [["T cells", "ANATOMY", 267, 274], ["spermidine", "CHEMICAL", 38, 48], ["spermidine", "CHEMICAL", 38, 48], ["spermidine", "SIMPLE_CHEMICAL", 38, 48], ["T cells", "CELL", 267, 274], ["antigen stimulated T cells", "CELL_TYPE", 248, 274], ["spermidine", "TREATMENT", 38, 48], ["a vaccine adjuvant", "TREATMENT", 52, 70], ["a flow cytometry", "TEST", 117, 133]]], ["To inhibit the autophagic flux and thereby degradation of LC3-II, the lysosomal inhibitor bafilomycin A was added to the culture for 2 hrs before washing out non-membrane bound LC3-I and staining.", [["lysosomal", "ANATOMY", 70, 79], ["bafilomycin A", "CHEMICAL", 90, 103], ["bafilomycin A", "CHEMICAL", 90, 103], ["LC3-II", "GENE_OR_GENE_PRODUCT", 58, 64], ["lysosomal", "CELLULAR_COMPONENT", 70, 79], ["bafilomycin A", "SIMPLE_CHEMICAL", 90, 103], ["LC3-I", "GENE_OR_GENE_PRODUCT", 177, 182], ["LC3-II", "PROTEIN", 58, 64], ["LC3", "PROTEIN", 177, 180], ["the autophagic flux", "PROBLEM", 11, 30], ["LC3-II", "TREATMENT", 58, 64], ["the lysosomal inhibitor bafilomycin", "TREATMENT", 66, 101], ["the culture", "TEST", 117, 128], ["autophagic flux", "OBSERVATION", 15, 30]]], ["In show a significant increase in autophagic flux that is not observed in HCV nonspecific CD8+ T cells (Fig 1c) .", [["CD8+ T cells", "ANATOMY", 90, 102], ["CD8", "GENE_OR_GENE_PRODUCT", 90, 93], ["HCV nonspecific CD8+ T cells", "CELL_TYPE", 74, 102], ["HCV", "SPECIES", 74, 77], ["a significant increase in autophagic flux", "PROBLEM", 8, 49], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["autophagic flux", "OBSERVATION", 34, 49], ["not observed", "UNCERTAINTY", 58, 70]]], ["In antigen-specific T cells, autophagic flux is highest shortly after vaccination but had declined to levels equivalent to antigennon-specific T cells cells by the end of the study (week 36 or 52).", [["T cells", "ANATOMY", 20, 27], ["autophagic", "ANATOMY", 29, 39], ["T cells cells", "ANATOMY", 143, 156], ["antigen", "GENE_OR_GENE_PRODUCT", 3, 10], ["T cells", "CELL", 20, 27], ["antigennon", "SIMPLE_CHEMICAL", 123, 133], ["T cells cells", "CELL", 143, 156], ["antigen-specific T cells", "CELL_TYPE", 3, 27], ["antigennon-specific T cells cells", "CELL_TYPE", 123, 156], ["autophagic flux", "TEST", 29, 44], ["vaccination", "TREATMENT", 70, 81], ["antigennon", "TEST", 123, 133], ["the study", "TEST", 171, 180], ["autophagic flux", "OBSERVATION", 29, 44]]], ["Together, these data show that antigen exposure induces autophagic flux in CD8+ T cells in humans in vivo.", [["autophagic", "ANATOMY", 56, 66], ["CD8+", "ANATOMY", 75, 79], ["T cells", "ANATOMY", 80, 87], ["CD8", "GENE_OR_GENE_PRODUCT", 75, 78], ["T cells", "CELL", 80, 87], ["humans", "ORGANISM", 91, 97], ["CD8", "PROTEIN", 75, 78], ["T cells", "CELL_TYPE", 80, 87], ["humans", "SPECIES", 91, 97], ["humans", "SPECIES", 91, 97], ["these data", "TEST", 10, 20], ["antigen exposure", "PROBLEM", 31, 47], ["autophagic flux", "TEST", 56, 71], ["autophagic flux", "OBSERVATION", 56, 71]]], ["In previous work we found autophagic flux was reduced in CD8+ T cells from 24 month old mice 12 .", [["CD8+", "ANATOMY", 57, 61], ["T cells", "ANATOMY", 62, 69], ["CD8", "GENE_OR_GENE_PRODUCT", 57, 60], ["T cells", "CELL", 62, 69], ["mice", "ORGANISM", 88, 92], ["CD8", "PROTEIN", 57, 60], ["T cells", "CELL_TYPE", 62, 69], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["autophagic flux", "PROBLEM", 26, 41], ["autophagic flux", "OBSERVATION", 26, 41]]], ["To test whether this is true in humanCD8+ T cells from human individuals, and whether this correlates with vaccineimmunogenicity, we measured autophagic flux in vaccinees of various ages that were given an experimental RSV vaccine (Fig1a and Supplementary Fig S3b) .", [["CD8+", "ANATOMY", 37, 41], ["T cells", "ANATOMY", 42, 49], ["human", "ORGANISM", 32, 37], ["CD8", "GENE_OR_GENE_PRODUCT", 37, 40], ["T cells", "CELL", 42, 49], ["human", "ORGANISM", 55, 60], ["RSV", "ORGANISM", 219, 222], ["humanCD8", "PROTEIN", 32, 40], ["T cells", "CELL_TYPE", 42, 49], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 55, 60], ["RSV", "SPECIES", 219, 222], ["vaccineimmunogenicity", "PROBLEM", 107, 128], ["autophagic flux", "PROBLEM", 142, 157], ["an experimental RSV vaccine", "TREATMENT", 203, 230], ["autophagic flux", "OBSERVATION", 142, 157]]], ["As older adults are particularly susceptible to severe disease from RSV infection, the vaccine was given to two age groups (18-50 years and 60-75 years of age).Figure 1 Autophagy is induced by vaccination in antigen-specific T cells and correlates with donor age.", [["T cells", "ANATOMY", 225, 232], ["RSV infection", "DISEASE", 68, 81], ["adults", "ORGANISM", 9, 15], ["RSV", "ORGANISM", 68, 71], ["T cells", "CELL", 225, 232], ["antigen-specific T cells", "CELL_TYPE", 208, 232], ["RSV", "SPECIES", 68, 71], ["severe disease", "PROBLEM", 48, 62], ["RSV infection", "PROBLEM", 68, 81], ["the vaccine", "TREATMENT", 83, 94], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["disease", "OBSERVATION", 55, 62], ["RSV", "OBSERVATION_MODIFIER", 68, 71], ["infection", "OBSERVATION", 72, 81]]], ["Peripheral blood mononuclear cells were isolated from blood samples of vaccinated healthy donors.", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["blood samples", "ANATOMY", 54, 67], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["blood samples", "ORGANISM_SUBSTANCE", 54, 67], ["donors", "ORGANISM", 90, 96], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["blood samples", "TEST", 54, 67], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34]]], ["LC3-II was measured in CD8+ cells using flow cytometry afterAs expected, the naturally-derived population of RSV-specific IFN\u03b3 producing CD4+ and CD8+ T cells in peripheral circulation in response to the infection declines with age (Fig. S4 ).Figure S4Correlation of age with total and peptide-pool specific T cell IFNg response to RSV exposure measured by ELISpot in CD8 + cells, donors as in Fig 1E.", [["CD8+ cells", "ANATOMY", 23, 33], ["CD4+ and CD8+", "ANATOMY", 137, 150], ["T cells", "ANATOMY", 151, 158], ["peripheral circulation", "ANATOMY", 162, 184], ["T cell", "ANATOMY", 308, 314], ["CD8 + cells", "ANATOMY", 368, 379], ["infection", "DISEASE", 204, 213], ["LC3-II", "GENE_OR_GENE_PRODUCT", 0, 6], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["RSV", "ORGANISM", 109, 112], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 122, 126], ["CD4", "GENE_OR_GENE_PRODUCT", 137, 140], ["CD8", "GENE_OR_GENE_PRODUCT", 146, 149], ["T cells", "CELL", 151, 158], ["peripheral circulation", "MULTI-TISSUE_STRUCTURE", 162, 184], ["T cell", "CELL", 308, 314], ["RSV", "ORGANISM", 332, 335], ["CD8", "GENE_OR_GENE_PRODUCT", 368, 371], ["donors", "ORGANISM", 381, 387], ["LC3-II", "PROTEIN", 0, 6], ["CD8", "PROTEIN", 23, 26], ["IFN\u03b3", "PROTEIN", 122, 126], ["CD4", "PROTEIN", 137, 140], ["CD8", "PROTEIN", 146, 149], ["T cells", "CELL_TYPE", 151, 158], ["CD8 + cells", "CELL_TYPE", 368, 379], ["RSV", "SPECIES", 109, 112], ["RSV", "SPECIES", 332, 335], ["LC3", "TEST", 0, 3], ["flow cytometry", "TEST", 40, 54], ["RSV", "TEST", 109, 112], ["CD4", "TEST", 137, 140], ["T cells in peripheral circulation", "PROBLEM", 151, 184], ["the infection declines", "PROBLEM", 200, 222], ["total and peptide", "TREATMENT", 276, 293], ["pool specific T cell IFNg response", "TREATMENT", 294, 328], ["RSV exposure", "PROBLEM", 332, 344], ["ELISpot", "TEST", 357, 364], ["flow cytometry", "OBSERVATION", 40, 54], ["peripheral", "ANATOMY_MODIFIER", 162, 172], ["circulation", "ANATOMY", 173, 184], ["infection", "OBSERVATION", 204, 213], ["cell IFNg", "OBSERVATION", 310, 319]]], ["No MHC class I pentamers were available for RSV to identify antigen-specific T cells, however, bulk T cells of the >60year vaccinees showed significantly lower basal autophagic flux (Fig. 1d) .", [["T cells", "ANATOMY", 77, 84], ["T cells", "ANATOMY", 100, 107], ["RSV", "ORGANISM", 44, 47], ["antigen", "GENE_OR_GENE_PRODUCT", 60, 67], ["T cells", "CELL", 77, 84], ["bulk T cells", "CELL", 95, 107], ["MHC class I pentamers", "PROTEIN", 3, 24], ["T cells", "CELL_TYPE", 77, 84], ["bulk T cells", "CELL_TYPE", 95, 107], ["RSV", "SPECIES", 44, 47], ["RSV", "PROBLEM", 44, 47], ["antigen", "TEST", 60, 67], ["bulk T cells", "TEST", 95, 107], ["significantly lower basal autophagic flux", "PROBLEM", 140, 181], ["basal", "ANATOMY_MODIFIER", 160, 165], ["autophagic flux", "OBSERVATION", 166, 181]]], ["We correlated autophagy levels in T cells withFigure S4IFN\u03b3 ELISpot responses in individual vaccinees and found a strong inverse correlation in the aged group (Fig. 1e ) between autophagy and IFN\u03b3 responses, but not in the young group (Fig. 1f) .", [["T cells", "ANATOMY", 34, 41], ["T cells", "CELL", 34, 41], ["S4IFN\u03b3", "GENE_OR_GENE_PRODUCT", 53, 59], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 192, 196], ["T cells", "CELL_TYPE", 34, 41], ["S4IFN", "PROTEIN", 53, 58], ["IFN\u03b3", "PROTEIN", 192, 196], ["autophagy levels", "TEST", 14, 30]]], ["Taken together these data suggest that reduced T cell autophagy in aged T cells may underpin reduced T cell responses to vaccination.Figure S4We have recently shown that treating old but not young mice with the metabolite spermidine improves autophagy levels in B lymphocytes due to an age-related decline of endogenous spermidine 15 .", [["T cell", "ANATOMY", 47, 53], ["T cells", "ANATOMY", 72, 79], ["T cell", "ANATOMY", 101, 107], ["B lymphocytes", "ANATOMY", 262, 275], ["spermidine", "CHEMICAL", 222, 232], ["spermidine", "CHEMICAL", 320, 330], ["spermidine", "CHEMICAL", 222, 232], ["spermidine", "CHEMICAL", 320, 330], ["T cell", "CELL", 47, 53], ["T cells", "CELL", 72, 79], ["T cell", "CELL", 101, 107], ["mice", "ORGANISM", 197, 201], ["spermidine", "SIMPLE_CHEMICAL", 222, 232], ["B lymphocytes", "CELL", 262, 275], ["spermidine", "SIMPLE_CHEMICAL", 320, 330], ["aged T cells", "CELL_TYPE", 67, 79], ["B lymphocytes", "CELL_TYPE", 262, 275], ["mice", "SPECIES", 197, 201], ["mice", "SPECIES", 197, 201], ["these data", "TEST", 15, 25], ["reduced T cell autophagy", "PROBLEM", 39, 63], ["reduced T cell responses", "PROBLEM", 93, 117], ["the metabolite spermidine", "TEST", 207, 232], ["autophagy levels", "TEST", 242, 258], ["endogenous spermidine", "TREATMENT", 309, 330], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["cell autophagy", "OBSERVATION", 49, 63], ["cell", "OBSERVATION", 103, 107], ["lymphocytes", "ANATOMY", 264, 275]]], ["Here we sought to confirm this in human lymphocytes.", [["lymphocytes", "ANATOMY", 40, 51], ["human", "ORGANISM", 34, 39], ["lymphocytes", "CELL", 40, 51], ["human lymphocytes", "CELL_TYPE", 34, 51], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39]]], ["Firstly, we determined spermidine and putrescine levels in PBMC by gas chromatography-mass spectrometry (GC-MS), and found an inverse correlation between age and spermidine but not with putrescine (Fig. 2a) .", [["PBMC", "ANATOMY", 59, 63], ["spermidine", "CHEMICAL", 23, 33], ["putrescine", "CHEMICAL", 38, 48], ["spermidine", "CHEMICAL", 162, 172], ["putrescine", "CHEMICAL", 186, 196], ["spermidine", "CHEMICAL", 23, 33], ["putrescine", "CHEMICAL", 38, 48], ["spermidine", "CHEMICAL", 162, 172], ["putrescine", "CHEMICAL", 186, 196], ["spermidine", "SIMPLE_CHEMICAL", 23, 33], ["putrescine", "SIMPLE_CHEMICAL", 38, 48], ["PBMC", "CELL", 59, 63], ["spermidine", "SIMPLE_CHEMICAL", 162, 172], ["putrescine", "SIMPLE_CHEMICAL", 186, 196], ["PBMC", "CELL_TYPE", 59, 63], ["spermidine and putrescine levels", "TEST", 23, 55], ["PBMC", "TEST", 59, 63], ["gas chromatography", "TEST", 67, 85], ["mass spectrometry", "TEST", 86, 103], ["spermidine", "TREATMENT", 162, 172]]], ["We hypothesized that low levels of spermidine are responsible for low levels of autophagy and poor T cell function in PBMC from old donors.", [["T cell", "ANATOMY", 99, 105], ["PBMC", "ANATOMY", 118, 122], ["spermidine", "CHEMICAL", 35, 45], ["spermidine", "CHEMICAL", 35, 45], ["spermidine", "SIMPLE_CHEMICAL", 35, 45], ["T cell", "CELL", 99, 105], ["PBMC", "CELL", 118, 122], ["donors", "ORGANISM", 132, 138], ["PBMC", "CELL_TYPE", 118, 122], ["low levels of spermidine", "PROBLEM", 21, 45], ["low levels of autophagy", "PROBLEM", 66, 89], ["poor T cell function", "PROBLEM", 94, 114], ["old donors", "PROBLEM", 128, 138], ["low levels", "OBSERVATION_MODIFIER", 21, 31]]], ["We therefore tested whether supplementation with spermidine recovers T cell autophagy and function.Figure S4As activation of PBMC with anti-CD3/CD28 optimally induces autophagy levels on day 4 18 , we activated PBMC from old donors in the presence of spermidine for 4 days and tested their autophagic flux and function by flow cytometry.", [["T cell", "ANATOMY", 69, 75], ["PBMC", "ANATOMY", 125, 129], ["PBMC", "ANATOMY", 211, 215], ["spermidine", "CHEMICAL", 49, 59], ["spermidine", "CHEMICAL", 251, 261], ["spermidine", "CHEMICAL", 49, 59], ["spermidine", "CHEMICAL", 251, 261], ["spermidine", "SIMPLE_CHEMICAL", 49, 59], ["T cell", "CELL", 69, 75], ["S4As", "GENE_OR_GENE_PRODUCT", 106, 110], ["PBMC", "CELL", 125, 129], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 135, 143], ["CD28", "GENE_OR_GENE_PRODUCT", 144, 148], ["PBMC", "CELL", 211, 215], ["donors", "ORGANISM", 225, 231], ["spermidine", "SIMPLE_CHEMICAL", 251, 261], ["S4As", "PROTEIN", 106, 110], ["PBMC", "CELL_TYPE", 125, 129], ["anti-CD3", "PROTEIN", 135, 143], ["CD28", "PROTEIN", 144, 148], ["PBMC", "CELL_TYPE", 211, 215], ["spermidine", "TREATMENT", 49, 59], ["anti-CD3/CD28", "TREATMENT", 135, 148], ["autophagy levels", "PROBLEM", 167, 183], ["spermidine", "TREATMENT", 251, 261], ["flow cytometry", "TEST", 322, 336], ["cell autophagy", "OBSERVATION", 71, 85], ["autophagic flux", "OBSERVATION", 290, 305], ["flow cytometry", "OBSERVATION", 322, 336]]], ["Both autophagic flux and the secretion of IFN\u03b3 measured by ELISA was improved significantly in T cells from older vaccinees ( Fig. 2b and c) , Similarly, increasedFigure S4IFN\u03b3 can be detected after spermidine treatment by intracellular staining for flow cytometry (Fig. 2d) .", [["T cells", "ANATOMY", 95, 102], ["intracellular", "ANATOMY", 223, 236], ["spermidine", "CHEMICAL", 199, 209], ["spermidine", "CHEMICAL", 199, 209], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 42, 46], ["T cells", "CELL", 95, 102], ["S4IFN\u03b3", "GENE_OR_GENE_PRODUCT", 170, 176], ["spermidine", "SIMPLE_CHEMICAL", 199, 209], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 223, 236], ["IFN\u03b3", "PROTEIN", 42, 46], ["T cells", "CELL_TYPE", 95, 102], ["S4IFN\u03b3", "PROTEIN", 170, 176], ["Both autophagic flux", "PROBLEM", 0, 20], ["the secretion of IFN\u03b3", "PROBLEM", 25, 46], ["ELISA", "TEST", 59, 64], ["spermidine treatment", "TREATMENT", 199, 219], ["intracellular staining", "TEST", 223, 245], ["flow cytometry", "TEST", 250, 264], ["autophagic flux", "OBSERVATION", 5, 20]]], ["Interestingly, spermidine supplementation also increases the expression of Perforin (Fig. 2e) but not of Granzyme B (Fig. 2f) .", [["spermidine", "CHEMICAL", 15, 25], ["spermidine", "CHEMICAL", 15, 25], ["spermidine", "SIMPLE_CHEMICAL", 15, 25], ["Perforin", "GENE_OR_GENE_PRODUCT", 75, 83], ["Fig. 2e", "GENE_OR_GENE_PRODUCT", 85, 92], ["Granzyme B", "GENE_OR_GENE_PRODUCT", 105, 115], ["Fig. 2f", "GENE_OR_GENE_PRODUCT", 117, 124], ["Perforin", "PROTEIN", 75, 83], ["Fig. 2e", "PROTEIN", 85, 92], ["Granzyme B", "PROTEIN", 105, 115], ["spermidine supplementation", "TREATMENT", 15, 41], ["Perforin (Fig. 2e", "TREATMENT", 75, 92], ["spermidine supplementation", "OBSERVATION", 15, 41]]], ["DFMO also partially blocks IFN and Perforin expression in anti-CD3/CD28 activated CD8+ T cells, which can also be rescued by spermidine (Fig. 3b and c) .", [["CD8+", "ANATOMY", 82, 86], ["T cells", "ANATOMY", 87, 94], ["DFMO", "CHEMICAL", 0, 4], ["spermidine", "CHEMICAL", 125, 135], ["DFMO", "CHEMICAL", 0, 4], ["spermidine", "CHEMICAL", 125, 135], ["DFMO", "SIMPLE_CHEMICAL", 0, 4], ["IFN", "GENE_OR_GENE_PRODUCT", 27, 30], ["Perforin", "GENE_OR_GENE_PRODUCT", 35, 43], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 58, 66], ["CD28", "GENE_OR_GENE_PRODUCT", 67, 71], ["CD8", "GENE_OR_GENE_PRODUCT", 82, 85], ["T cells", "CELL", 87, 94], ["spermidine", "SIMPLE_CHEMICAL", 125, 135], ["c", "GENE_OR_GENE_PRODUCT", 149, 150], ["IFN", "PROTEIN", 27, 30], ["Perforin", "PROTEIN", 35, 43], ["anti-CD3", "PROTEIN", 58, 66], ["CD28", "PROTEIN", 67, 71], ["CD8", "PROTEIN", 82, 85], ["T cells", "CELL_TYPE", 87, 94], ["DFMO", "TREATMENT", 0, 4], ["partially blocks IFN", "PROBLEM", 10, 30], ["anti-CD3", "TEST", 58, 66], ["T cells", "PROBLEM", 87, 94]]], ["As before, Granzyme B was not affected by DFMO + spermidine (Fig 3d) .", [["DFMO", "CHEMICAL", 42, 46], ["spermidine", "CHEMICAL", 49, 59], ["DFMO", "CHEMICAL", 42, 46], ["spermidine", "CHEMICAL", 49, 59], ["Granzyme B", "GENE_OR_GENE_PRODUCT", 11, 21], ["DFMO", "SIMPLE_CHEMICAL", 42, 46], ["spermidine", "SIMPLE_CHEMICAL", 49, 59], ["Granzyme B", "PROTEIN", 11, 21], ["Granzyme B", "PROBLEM", 11, 21], ["DFMO + spermidine", "TREATMENT", 42, 59]]], ["T cells from young donors, with their high endogenous spermidine levels, do not respond to spermidine supplementation (Fig. 3e, f and g) .", [["T cells", "ANATOMY", 0, 7], ["spermidine", "CHEMICAL", 54, 64], ["spermidine", "CHEMICAL", 91, 101], ["spermidine", "CHEMICAL", 54, 64], ["spermidine", "CHEMICAL", 91, 101], ["T cells", "CELL", 0, 7], ["donors", "ORGANISM", 19, 25], ["spermidine", "SIMPLE_CHEMICAL", 54, 64], ["spermidine", "SIMPLE_CHEMICAL", 91, 101], ["T cells", "CELL_TYPE", 0, 7], ["young donors", "PROBLEM", 13, 25], ["their high endogenous spermidine levels", "PROBLEM", 32, 71], ["spermidine supplementation", "TREATMENT", 91, 117]]], ["We previously found that spermidine maintains autophagic flux via hypusination of eIF5A and TFEB 15 , and we sought to test this pathway in human T cells.", [["T cells", "ANATOMY", 146, 153], ["spermidine", "CHEMICAL", 25, 35], ["spermidine", "CHEMICAL", 25, 35], ["spermidine", "SIMPLE_CHEMICAL", 25, 35], ["eIF5A", "GENE_OR_GENE_PRODUCT", 82, 87], ["TFEB 15", "GENE_OR_GENE_PRODUCT", 92, 99], ["human", "ORGANISM", 140, 145], ["T cells", "CELL", 146, 153], ["eIF5A", "PROTEIN", 82, 87], ["TFEB 15", "PROTEIN", 92, 99], ["human T cells", "CELL_TYPE", 140, 153], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["TFEB", "TEST", 92, 96], ["autophagic flux", "OBSERVATION", 46, 61]]], ["4a ) and also confirmed that it decreases LC3-II expression in a dose-dependent manner (Fig. 4b) .", [["LC3-II", "GENE_OR_GENE_PRODUCT", 42, 48], ["LC3", "PROTEIN", 42, 45], ["decreases", "OBSERVATION_MODIFIER", 32, 41], ["LC3", "OBSERVATION", 42, 45], ["II expression", "OBSERVATION_MODIFIER", 46, 59]]], ["GC7 reduces TFEB and hypusinated eIF5A in CD8+ T cells activated for 4 days (Fig 4c) .", [["CD8+", "ANATOMY", 42, 46], ["T cells", "ANATOMY", 47, 54], ["GC7", "SIMPLE_CHEMICAL", 0, 3], ["TFEB", "GENE_OR_GENE_PRODUCT", 12, 16], ["eIF5A", "GENE_OR_GENE_PRODUCT", 33, 38], ["CD8", "GENE_OR_GENE_PRODUCT", 42, 45], ["T cells", "CELL", 47, 54], ["GC7", "PROTEIN", 0, 3], ["TFEB", "PROTEIN", 12, 16], ["eIF5A", "PROTEIN", 33, 38], ["CD8", "PROTEIN", 42, 45], ["T cells", "CELL_TYPE", 47, 54]]], ["It also diminishes the autophagic flux in activated CD8+ T cells over a time course of 7 days (Fig. 4d) .", [["CD8+", "ANATOMY", 52, 56], ["T cells", "ANATOMY", 57, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 52, 55], ["T cells", "CELL", 57, 64], ["CD8", "PROTEIN", 52, 55], ["T cells", "CELL_TYPE", 57, 64], ["diminishes", "OBSERVATION_MODIFIER", 8, 18], ["autophagic flux", "OBSERVATION", 23, 38]]], ["We then tested whetherFigure 4 Spermidine's mode of action is via eIF5A and TFEB in human CD8+ T cells (a) Human T cell line Jurkat was cultured for 24h with 100 \u00b5M GC7, then eIF5A and hypusinated eIF5A were measured by WB. (b) Jurkat cell line was stimulated with increasing concentrations of GC7 and cell lysates blotted for LC3B.", [["CD8+ T cells", "ANATOMY", 90, 102], ["T cell line Jurkat", "ANATOMY", 113, 131], ["WB. (b) Jurkat cell line", "ANATOMY", 220, 244], ["cell lysates", "ANATOMY", 302, 314], ["Spermidine", "CHEMICAL", 31, 41], ["Spermidine", "SIMPLE_CHEMICAL", 31, 41], ["eIF5A", "GENE_OR_GENE_PRODUCT", 66, 71], ["TFEB", "GENE_OR_GENE_PRODUCT", 76, 80], ["human", "ORGANISM", 84, 89], ["CD8", "GENE_OR_GENE_PRODUCT", 90, 93], ["Human", "ORGANISM", 107, 112], ["T cell line Jurkat", "CELL", 113, 131], ["GC7", "SIMPLE_CHEMICAL", 165, 168], ["eIF5A", "GENE_OR_GENE_PRODUCT", 175, 180], ["eIF5A", "GENE_OR_GENE_PRODUCT", 197, 202], ["Jurkat cell line", "CELL", 228, 244], ["GC7", "SIMPLE_CHEMICAL", 294, 297], ["cell", "CELL", 302, 306], ["LC3B", "GENE_OR_GENE_PRODUCT", 327, 331], ["eIF5A", "PROTEIN", 66, 71], ["TFEB", "PROTEIN", 76, 80], ["human CD8+ T cells", "CELL_TYPE", 84, 102], ["Human T cell line Jurkat", "CELL_LINE", 107, 131], ["eIF5A", "PROTEIN", 175, 180], ["hypusinated eIF5A", "PROTEIN", 185, 202], ["WB", "CELL_LINE", 220, 222], ["Jurkat cell line", "CELL_LINE", 228, 244], ["GC7", "PROTEIN", 294, 297], ["LC3B", "PROTEIN", 327, 331], ["human", "SPECIES", 84, 89], ["Human", "SPECIES", 107, 112], ["human", "SPECIES", 84, 89], ["Spermidine", "TREATMENT", 31, 41], ["a) Human T cell line Jurkat", "TREATMENT", 104, 131], ["eIF5A", "TEST", 175, 180], ["hypusinated eIF5A", "PROBLEM", 185, 202], ["Jurkat cell line", "TREATMENT", 228, 244], ["increasing concentrations of GC7", "PROBLEM", 265, 297], ["cell lysates", "PROBLEM", 302, 314], ["LC3B", "PROBLEM", 327, 331], ["Jurkat cell line", "OBSERVATION", 228, 244]]], ["(C, D) PBMC from young human donors were cultured with anti-CD3/CD28 for 7 days and treated with GC7.", [["PBMC", "ANATOMY", 7, 11], ["PBMC", "CELL", 7, 11], ["human", "ORGANISM", 23, 28], ["donors", "ORGANISM", 29, 35], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 55, 63], ["CD28", "GENE_OR_GENE_PRODUCT", 64, 68], ["PBMC", "CELL_TYPE", 7, 11], ["anti-CD3", "PROTEIN", 55, 63], ["CD28", "PROTEIN", 64, 68], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["PBMC", "PROBLEM", 7, 11], ["young human donors", "TREATMENT", 17, 35], ["anti-CD3/CD28", "TREATMENT", 55, 68], ["GC7", "TREATMENT", 97, 100]]], ["The protein levels of TFEB and eIF5A hypusination were measured in CD8+ cells by Western blot on day 4 (c)and autophagic flux was determined as in Fig 1 (d) response.", [["CD8+ cells", "ANATOMY", 67, 77], ["TFEB", "GENE_OR_GENE_PRODUCT", 22, 26], ["eIF5A", "GENE_OR_GENE_PRODUCT", 31, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["TFEB", "PROTEIN", 22, 26], ["eIF5A", "PROTEIN", 31, 36], ["CD8", "PROTEIN", 67, 70], ["The protein levels", "TEST", 0, 18], ["TFEB", "TEST", 22, 26], ["eIF5A hypusination", "TEST", 31, 49], ["Western blot", "TEST", 81, 93], ["autophagic flux", "TEST", 110, 125], ["autophagic flux", "OBSERVATION", 110, 125]]], ["In addition, to be active, TFEB needs to be dephosphorylated for its translocation into the nucleus, which mTOR inhibition facilitates [32] [33] [34] .", [["nucleus", "ANATOMY", 92, 99], ["TFEB", "GENE_OR_GENE_PRODUCT", 27, 31], ["nucleus", "CELLULAR_COMPONENT", 92, 99], ["mTOR", "GENE_OR_GENE_PRODUCT", 107, 111], ["[32] [33] [34]", "SIMPLE_CHEMICAL", 135, 149], ["TFEB", "PROTEIN", 27, 31], ["mTOR", "PROTEIN", 107, 111], ["its translocation into the nucleus", "PROBLEM", 65, 99], ["active", "OBSERVATION", 19, 25], ["nucleus", "ANATOMY", 92, 99]]], ["Therefore, spermidine and an mTOR inhibitor may have to be combined to optimally restore immune responses in the older adults.Figure 4 Spermidine's mode of action is via eIF5A and TFEB in human CD8+ T cells (a) Human T cell line Jurkat was cultured for 24h with 100 \u00b5M GC7, then eIF5A and hypusinated eIF5A were measured by WB. (b) Jurkat cell line was stimulated with increasing concentrations of GC7 and cell lysates blotted for LC3B.", [["CD8+ T cells", "ANATOMY", 194, 206], ["T cell line Jurkat", "ANATOMY", 217, 235], ["WB. (b) Jurkat cell line", "ANATOMY", 324, 348], ["cell lysates", "ANATOMY", 406, 418], ["spermidine", "CHEMICAL", 11, 21], ["Spermidine", "CHEMICAL", 135, 145], ["spermidine", "CHEMICAL", 11, 21], ["Spermidine", "CHEMICAL", 135, 145], ["spermidine", "SIMPLE_CHEMICAL", 11, 21], ["mTOR", "GENE_OR_GENE_PRODUCT", 29, 33], ["Spermidine", "SIMPLE_CHEMICAL", 135, 145], ["eIF5A", "GENE_OR_GENE_PRODUCT", 170, 175], ["TFEB", "GENE_OR_GENE_PRODUCT", 180, 184], ["human", "ORGANISM", 188, 193], ["CD8", "GENE_OR_GENE_PRODUCT", 194, 197], ["Human", "ORGANISM", 211, 216], ["T cell line Jurkat", "CELL", 217, 235], ["GC7", "SIMPLE_CHEMICAL", 269, 272], ["eIF5A", "GENE_OR_GENE_PRODUCT", 279, 284], ["eIF5A", "GENE_OR_GENE_PRODUCT", 301, 306], ["Jurkat cell line", "CELL", 332, 348], ["GC7", "SIMPLE_CHEMICAL", 398, 401], ["cell", "CELL", 406, 410], ["LC3B", "GENE_OR_GENE_PRODUCT", 431, 435], ["eIF5A", "PROTEIN", 170, 175], ["TFEB", "PROTEIN", 180, 184], ["human CD8+ T cells", "CELL_TYPE", 188, 206], ["Human T cell line Jurkat", "CELL_LINE", 211, 235], ["eIF5A", "PROTEIN", 279, 284], ["hypusinated eIF5A", "PROTEIN", 289, 306], ["WB", "CELL_LINE", 324, 326], ["Jurkat cell line", "CELL_LINE", 332, 348], ["GC7", "PROTEIN", 398, 401], ["LC3B", "PROTEIN", 431, 435], ["human", "SPECIES", 188, 193], ["Human", "SPECIES", 211, 216], ["human", "SPECIES", 188, 193], ["spermidine", "TREATMENT", 11, 21], ["an mTOR inhibitor", "TREATMENT", 26, 43], ["Figure", "TEST", 126, 132], ["Spermidine", "TREATMENT", 135, 145], ["Human T cell line Jurkat", "TREATMENT", 211, 235], ["eIF5A", "TEST", 279, 284], ["hypusinated eIF5A", "PROBLEM", 289, 306], ["Jurkat cell line", "TREATMENT", 332, 348], ["increasing concentrations of GC7", "PROBLEM", 369, 401], ["cell lysates", "PROBLEM", 406, 418], ["LC3B", "PROBLEM", 431, 435], ["Jurkat cell line", "OBSERVATION", 332, 348]]], ["(C, D) PBMC from young human donors were cultured with anti-CD3/CD28 for 7 days and treated with GC7.", [["PBMC", "ANATOMY", 7, 11], ["PBMC", "CELL", 7, 11], ["human", "ORGANISM", 23, 28], ["donors", "ORGANISM", 29, 35], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 55, 63], ["CD28", "GENE_OR_GENE_PRODUCT", 64, 68], ["PBMC", "CELL_TYPE", 7, 11], ["anti-CD3", "PROTEIN", 55, 63], ["CD28", "PROTEIN", 64, 68], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["PBMC", "PROBLEM", 7, 11], ["young human donors", "TREATMENT", 17, 35], ["anti-CD3/CD28", "TREATMENT", 55, 68], ["GC7", "TREATMENT", 97, 100]]], ["The protein levels of TFEB and eIF5A hypusination were measured in CD8+ cells by Western blot on day 4 (c)We find that spermidine levels decline in PBMCs in the older humans.", [["CD8+ cells", "ANATOMY", 67, 77], ["PBMCs", "ANATOMY", 148, 153], ["spermidine", "CHEMICAL", 119, 129], ["spermidine", "CHEMICAL", 119, 129], ["TFEB", "GENE_OR_GENE_PRODUCT", 22, 26], ["eIF5A", "GENE_OR_GENE_PRODUCT", 31, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["spermidine", "SIMPLE_CHEMICAL", 119, 129], ["PBMCs", "CELL", 148, 153], ["humans", "ORGANISM", 167, 173], ["TFEB", "PROTEIN", 22, 26], ["eIF5A", "PROTEIN", 31, 36], ["CD8", "PROTEIN", 67, 70], ["PBMCs", "CELL_TYPE", 148, 153], ["humans", "SPECIES", 167, 173], ["humans", "SPECIES", 167, 173], ["The protein levels", "TEST", 0, 18], ["TFEB", "TEST", 22, 26], ["eIF5A hypusination", "TEST", 31, 49], ["spermidine levels decline", "PROBLEM", 119, 144]]], ["This confirms earlier study in plasma in which spermidine levels were found to be low in the >65 age group and rising again in centenarians 35 .", [["plasma", "ANATOMY", 31, 37], ["spermidine", "CHEMICAL", 47, 57], ["spermidine", "CHEMICAL", 47, 57], ["plasma", "ORGANISM_SUBSTANCE", 31, 37], ["spermidine", "SIMPLE_CHEMICAL", 47, 57], ["earlier study", "TEST", 14, 27], ["spermidine levels", "TEST", 47, 64], ["low", "OBSERVATION_MODIFIER", 82, 85]]], ["However, the reasons for the age-related decline in spermidine in blood cells are not clear, and currently under investigation.Figure 4 Spermidine's mode of action is via eIF5A and TFEB in human CD8+ T cells (a) Human T cell line Jurkat was cultured for 24h with 100 \u00b5M GC7, then eIF5A and hypusinated eIF5A were measured by WB. (b) Jurkat cell line was stimulated with increasing concentrations of GC7 and cell lysates blotted for LC3B.", [["blood cells", "ANATOMY", 66, 77], ["CD8+ T cells", "ANATOMY", 195, 207], ["T cell line Jurkat", "ANATOMY", 218, 236], ["WB. (b) Jurkat cell line", "ANATOMY", 325, 349], ["cell lysates", "ANATOMY", 407, 419], ["spermidine", "CHEMICAL", 52, 62], ["Spermidine", "CHEMICAL", 136, 146], ["spermidine", "CHEMICAL", 52, 62], ["Spermidine", "CHEMICAL", 136, 146], ["spermidine", "SIMPLE_CHEMICAL", 52, 62], ["blood cells", "CELL", 66, 77], ["Spermidine", "SIMPLE_CHEMICAL", 136, 146], ["eIF5A", "GENE_OR_GENE_PRODUCT", 171, 176], ["TFEB", "GENE_OR_GENE_PRODUCT", 181, 185], ["human", "ORGANISM", 189, 194], ["CD8", "GENE_OR_GENE_PRODUCT", 195, 198], ["Human", "ORGANISM", 212, 217], ["T cell line Jurkat", "CELL", 218, 236], ["GC7", "SIMPLE_CHEMICAL", 270, 273], ["eIF5A", "GENE_OR_GENE_PRODUCT", 280, 285], ["eIF5A", "GENE_OR_GENE_PRODUCT", 302, 307], ["Jurkat cell line", "CELL", 333, 349], ["GC7", "SIMPLE_CHEMICAL", 399, 402], ["cell", "CELL", 407, 411], ["LC3B", "GENE_OR_GENE_PRODUCT", 432, 436], ["blood cells", "CELL_TYPE", 66, 77], ["eIF5A", "PROTEIN", 171, 176], ["TFEB", "PROTEIN", 181, 185], ["human CD8+ T cells", "CELL_TYPE", 189, 207], ["Human T cell line Jurkat", "CELL_LINE", 212, 236], ["eIF5A", "PROTEIN", 280, 285], ["hypusinated eIF5A", "PROTEIN", 290, 307], ["WB", "CELL_LINE", 325, 327], ["Jurkat cell line", "CELL_LINE", 333, 349], ["GC7", "PROTEIN", 399, 402], ["LC3B", "PROTEIN", 432, 436], ["human", "SPECIES", 189, 194], ["Human", "SPECIES", 212, 217], ["human", "SPECIES", 189, 194], ["related decline in spermidine in blood cells", "PROBLEM", 33, 77], ["Figure", "TEST", 127, 133], ["Spermidine", "TREATMENT", 136, 146], ["Human T cell line Jurkat", "TREATMENT", 212, 236], ["eIF5A", "TEST", 280, 285], ["hypusinated eIF5A", "PROBLEM", 290, 307], ["Jurkat cell line", "TREATMENT", 333, 349], ["increasing concentrations of GC7", "PROBLEM", 370, 402], ["cell lysates", "PROBLEM", 407, 419], ["LC3B", "PROBLEM", 432, 436], ["Jurkat cell line", "OBSERVATION", 333, 349]]], ["(C, D) PBMC from young human donors were cultured with anti-CD3/CD28 for 7 days and treated with GC7.", [["PBMC", "ANATOMY", 7, 11], ["PBMC", "CELL", 7, 11], ["human", "ORGANISM", 23, 28], ["donors", "ORGANISM", 29, 35], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 55, 63], ["CD28", "GENE_OR_GENE_PRODUCT", 64, 68], ["PBMC", "CELL_TYPE", 7, 11], ["anti-CD3", "PROTEIN", 55, 63], ["CD28", "PROTEIN", 64, 68], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["PBMC", "PROBLEM", 7, 11], ["young human donors", "TREATMENT", 17, 35], ["anti-CD3/CD28", "TREATMENT", 55, 68], ["GC7", "TREATMENT", 97, 100]]], ["The protein levels of TFEB and eIF5A hypusination were measured in CD8+ cells by Western blot on day 4 (c)Overall it is evident that endogenous spermidine maintains autophagy in human T cells, a novel metabolic pathway that has not been investigated before.Figure 4 Spermidine's mode of action is via eIF5A and TFEB in human CD8+ T cells (a) Human T cell line Jurkat was cultured for 24h with 100 \u00b5M GC7, then eIF5A and hypusinated eIF5A were measured by WB. (b) Jurkat cell line was stimulated with increasing concentrations of GC7 and cell lysates blotted for LC3B.", [["CD8+ cells", "ANATOMY", 67, 77], ["T cells", "ANATOMY", 184, 191], ["CD8+ T cells", "ANATOMY", 325, 337], ["T cell line Jurkat", "ANATOMY", 348, 366], ["WB. (b) Jurkat cell line", "ANATOMY", 455, 479], ["cell lysates", "ANATOMY", 537, 549], ["spermidine", "CHEMICAL", 144, 154], ["Spermidine", "CHEMICAL", 266, 276], ["spermidine", "CHEMICAL", 144, 154], ["Spermidine", "CHEMICAL", 266, 276], ["TFEB", "GENE_OR_GENE_PRODUCT", 22, 26], ["eIF5A", "GENE_OR_GENE_PRODUCT", 31, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["spermidine", "SIMPLE_CHEMICAL", 144, 154], ["human", "ORGANISM", 178, 183], ["T cells", "CELL", 184, 191], ["Spermidine", "SIMPLE_CHEMICAL", 266, 276], ["eIF5A", "GENE_OR_GENE_PRODUCT", 301, 306], ["TFEB", "GENE_OR_GENE_PRODUCT", 311, 315], ["human", "ORGANISM", 319, 324], ["CD8", "GENE_OR_GENE_PRODUCT", 325, 328], ["Human", "ORGANISM", 342, 347], ["T cell line Jurkat", "CELL", 348, 366], ["GC7", "SIMPLE_CHEMICAL", 400, 403], ["eIF5A", "GENE_OR_GENE_PRODUCT", 410, 415], ["eIF5A", "GENE_OR_GENE_PRODUCT", 432, 437], ["Jurkat cell line", "CELL", 463, 479], ["GC7", "SIMPLE_CHEMICAL", 529, 532], ["cell", "CELL", 537, 541], ["LC3B", "GENE_OR_GENE_PRODUCT", 562, 566], ["TFEB", "PROTEIN", 22, 26], ["eIF5A", "PROTEIN", 31, 36], ["CD8", "PROTEIN", 67, 70], ["human T cells", "CELL_TYPE", 178, 191], ["eIF5A", "PROTEIN", 301, 306], ["TFEB", "PROTEIN", 311, 315], ["human CD8+ T cells", "CELL_TYPE", 319, 337], ["Human T cell line Jurkat", "CELL_LINE", 342, 366], ["eIF5A", "PROTEIN", 410, 415], ["hypusinated eIF5A", "PROTEIN", 420, 437], ["WB", "CELL_LINE", 455, 457], ["Jurkat cell line", "CELL_LINE", 463, 479], ["GC7", "PROTEIN", 529, 532], ["LC3B", "PROTEIN", 562, 566], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 319, 324], ["Human", "SPECIES", 342, 347], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 319, 324], ["The protein levels", "TEST", 0, 18], ["TFEB", "TEST", 22, 26], ["eIF5A hypusination", "TEST", 31, 49], ["endogenous spermidine", "PROBLEM", 133, 154], ["Figure", "TEST", 257, 263], ["Spermidine", "TREATMENT", 266, 276], ["Human T cell line Jurkat", "TREATMENT", 342, 366], ["eIF5A", "TEST", 410, 415], ["hypusinated eIF5A", "PROBLEM", 420, 437], ["Jurkat cell line", "TREATMENT", 463, 479], ["increasing concentrations of GC7", "PROBLEM", 500, 532], ["cell lysates", "PROBLEM", 537, 549], ["LC3B", "PROBLEM", 562, 566], ["endogenous spermidine", "OBSERVATION", 133, 154], ["Jurkat cell line", "OBSERVATION", 463, 479]]], ["(C, D) PBMC from young human donors were cultured with anti-CD3/CD28 for 7 days and treated with GC7.", [["PBMC", "ANATOMY", 7, 11], ["PBMC", "CELL", 7, 11], ["human", "ORGANISM", 23, 28], ["donors", "ORGANISM", 29, 35], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 55, 63], ["CD28", "GENE_OR_GENE_PRODUCT", 64, 68], ["PBMC", "CELL_TYPE", 7, 11], ["anti-CD3", "PROTEIN", 55, 63], ["CD28", "PROTEIN", 64, 68], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["PBMC", "PROBLEM", 7, 11], ["young human donors", "TREATMENT", 17, 35], ["anti-CD3/CD28", "TREATMENT", 55, 68], ["GC7", "TREATMENT", 97, 100]]], ["The protein levels of TFEB and eIF5A hypusination were measured in CD8+ cells by Western blot on day 4 (c)Spermidine has recently been administered to humans in a small experimental trial with a beneficial effect on cognitive function without adverse effects 36, 37 .", [["CD8+ cells", "ANATOMY", 67, 77], ["Spermidine", "CHEMICAL", 106, 116], ["Spermidine", "CHEMICAL", 106, 116], ["TFEB", "GENE_OR_GENE_PRODUCT", 22, 26], ["eIF5A", "GENE_OR_GENE_PRODUCT", 31, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["c)Spermidine", "SIMPLE_CHEMICAL", 104, 116], ["humans", "ORGANISM", 151, 157], ["TFEB", "PROTEIN", 22, 26], ["eIF5A", "PROTEIN", 31, 36], ["CD8", "PROTEIN", 67, 70], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 151, 157], ["The protein levels", "TEST", 0, 18], ["TFEB", "TEST", 22, 26], ["eIF5A hypusination", "TEST", 31, 49], ["Spermidine", "TREATMENT", 106, 116], ["a small experimental trial", "TREATMENT", 161, 187], ["adverse effects", "PROBLEM", 243, 258]]], ["It remains to be shown whether at such low doses it has an effect on autophagy.", [["autophagy", "PROBLEM", 69, 78]]], ["Our study strongly suggests that a small experimental trial should be conducted to test whether spermidine can be used to improve vaccination efficiency in older adults -eIF5A, TFEB and autophagy in PBMCs could be used as biomarkers to determine dose, duration and biomarkers for the anti-immune senescence effect.Figure 4 Spermidine's mode of action is via eIF5A and TFEB in human CD8+ T cells (a) Human T cell line Jurkat was cultured for 24h with 100 \u00b5M GC7, then eIF5A and hypusinated eIF5A were measured by WB. (b) Jurkat cell line was stimulated with increasing concentrations of GC7 and cell lysates blotted for LC3B.", [["PBMCs", "ANATOMY", 199, 204], ["CD8+ T cells", "ANATOMY", 382, 394], ["T cell line Jurkat", "ANATOMY", 405, 423], ["WB. (b) Jurkat cell line", "ANATOMY", 512, 536], ["cell lysates", "ANATOMY", 594, 606], ["spermidine", "CHEMICAL", 96, 106], ["Spermidine", "CHEMICAL", 323, 333], ["spermidine", "CHEMICAL", 96, 106], ["Spermidine", "CHEMICAL", 323, 333], ["spermidine", "SIMPLE_CHEMICAL", 96, 106], ["IF5A", "GENE_OR_GENE_PRODUCT", 171, 175], ["TFEB", "GENE_OR_GENE_PRODUCT", 177, 181], ["PBMCs", "CELL", 199, 204], ["Spermidine", "SIMPLE_CHEMICAL", 323, 333], ["eIF5A", "GENE_OR_GENE_PRODUCT", 358, 363], ["TFEB", "GENE_OR_GENE_PRODUCT", 368, 372], ["human", "ORGANISM", 376, 381], ["CD8", "GENE_OR_GENE_PRODUCT", 382, 385], ["Human", "ORGANISM", 399, 404], ["T cell line Jurkat", "CELL", 405, 423], ["GC7", "SIMPLE_CHEMICAL", 457, 460], ["eIF5A", "GENE_OR_GENE_PRODUCT", 467, 472], ["eIF5A", "GENE_OR_GENE_PRODUCT", 489, 494], ["Jurkat cell line", "CELL", 520, 536], ["GC7", "SIMPLE_CHEMICAL", 586, 589], ["cell", "CELL", 594, 598], ["LC3B", "GENE_OR_GENE_PRODUCT", 619, 623], ["PBMCs", "CELL_TYPE", 199, 204], ["eIF5A", "PROTEIN", 358, 363], ["TFEB", "PROTEIN", 368, 372], ["human CD8+ T cells", "CELL_TYPE", 376, 394], ["Human T cell line Jurkat", "CELL_LINE", 399, 423], ["eIF5A", "PROTEIN", 467, 472], ["hypusinated eIF5A", "PROTEIN", 477, 494], ["WB", "CELL_LINE", 512, 514], ["Jurkat cell line", "CELL_LINE", 520, 536], ["GC7", "PROTEIN", 586, 589], ["LC3B", "PROTEIN", 619, 623], ["human", "SPECIES", 376, 381], ["Human", "SPECIES", 399, 404], ["human", "SPECIES", 376, 381], ["Our study", "TEST", 0, 9], ["a small experimental trial", "TREATMENT", 33, 59], ["spermidine", "TREATMENT", 96, 106], ["vaccination efficiency", "PROBLEM", 130, 152], ["TFEB", "TREATMENT", 177, 181], ["biomarkers", "TEST", 222, 232], ["biomarkers", "TEST", 265, 275], ["the anti-immune senescence effect", "PROBLEM", 280, 313], ["Figure", "TEST", 314, 320], ["Spermidine", "TREATMENT", 323, 333], ["Human T cell line Jurkat", "TREATMENT", 399, 423], ["eIF5A", "TEST", 467, 472], ["hypusinated eIF5A", "PROBLEM", 477, 494], ["Jurkat cell line", "TREATMENT", 520, 536], ["increasing concentrations of GC7", "PROBLEM", 557, 589], ["cell lysates", "PROBLEM", 594, 606], ["LC3B", "PROBLEM", 619, 623], ["small", "OBSERVATION_MODIFIER", 35, 40], ["Jurkat cell line", "OBSERVATION", 520, 536]]], ["(C, D) PBMC from young human donors were cultured with anti-CD3/CD28 for 7 days and treated with GC7.", [["PBMC", "ANATOMY", 7, 11], ["PBMC", "CELL", 7, 11], ["human", "ORGANISM", 23, 28], ["donors", "ORGANISM", 29, 35], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 55, 63], ["CD28", "GENE_OR_GENE_PRODUCT", 64, 68], ["PBMC", "CELL_TYPE", 7, 11], ["anti-CD3", "PROTEIN", 55, 63], ["CD28", "PROTEIN", 64, 68], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["PBMC", "PROBLEM", 7, 11], ["young human donors", "TREATMENT", 17, 35], ["anti-CD3/CD28", "TREATMENT", 55, 68], ["GC7", "TREATMENT", 97, 100]]], ["The protein levels of TFEB and eIF5A hypusination were measured in CD8+ cells by Western blot on day 4 (c)In conclusion we validated a novel anti-immune senescence pathway in humans with druggable targets and biomarkers, which could also be used for other broader antiaging drug trials.Human Samples Human peripheral blood mononuclear cells (PBMC) wereobtained under the ethics reference NRES Berkshire 13/SC/0023, from phase I clinical trials of novel viral-vectored vaccines for hepatitis-C virus (HCV; NCT01070407 and NCT01296451) or respiratory syncytial virus (RSV), described in more detail elsewhere 16,17 38 39 40 .", [["CD8+ cells", "ANATOMY", 67, 77], ["Samples", "ANATOMY", 292, 299], ["peripheral blood mononuclear cells", "ANATOMY", 306, 340], ["PBMC", "ANATOMY", 342, 346], ["hepatitis-C", "DISEASE", 481, 492], ["respiratory syncytial virus", "DISEASE", 537, 564], ["TFEB", "GENE_OR_GENE_PRODUCT", 22, 26], ["eIF5A", "GENE_OR_GENE_PRODUCT", 31, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["humans", "ORGANISM", 175, 181], ["Human", "ORGANISM", 286, 291], ["Human", "ORGANISM", 300, 305], ["peripheral blood mononuclear cells", "CELL", 306, 340], ["PBMC", "CELL", 342, 346], ["hepatitis-C virus", "ORGANISM", 481, 498], ["HCV", "ORGANISM", 500, 503], ["respiratory syncytial virus", "ORGANISM", 537, 564], ["RSV", "ORGANISM", 566, 569], ["TFEB", "PROTEIN", 22, 26], ["eIF5A", "PROTEIN", 31, 36], ["CD8", "PROTEIN", 67, 70], ["Human peripheral blood mononuclear cells", "CELL_TYPE", 300, 340], ["PBMC", "CELL_TYPE", 342, 346], ["humans", "SPECIES", 175, 181], ["Human", "SPECIES", 286, 291], ["Human", "SPECIES", 300, 305], ["hepatitis-C virus", "SPECIES", 481, 498], ["respiratory syncytial virus", "SPECIES", 537, 564], ["humans", "SPECIES", 175, 181], ["Human", "SPECIES", 286, 291], ["hepatitis-C virus", "SPECIES", 481, 498], ["HCV", "SPECIES", 500, 503], ["respiratory syncytial virus", "SPECIES", 537, 564], ["RSV", "SPECIES", 566, 569], ["The protein levels", "TEST", 0, 18], ["TFEB", "TEST", 22, 26], ["eIF5A hypusination", "TEST", 31, 49], ["a novel anti-immune senescence pathway", "TREATMENT", 133, 171], ["biomarkers", "TEST", 209, 219], ["broader antiaging drug trials", "TREATMENT", 256, 285], ["Human Samples", "TEST", 286, 299], ["novel viral-vectored vaccines", "TREATMENT", 447, 476], ["hepatitis", "PROBLEM", 481, 490], ["C virus", "PROBLEM", 491, 498], ["HCV", "PROBLEM", 500, 503], ["NCT01070407", "TEST", 505, 516], ["respiratory syncytial virus", "PROBLEM", 537, 564], ["mononuclear cells", "OBSERVATION", 323, 340], ["respiratory", "ANATOMY", 537, 548], ["syncytial virus", "OBSERVATION", 549, 564]]], ["Volunteers were self-selected adults who provided written informed consent and who were carefully screened for being healthy before vaccination.", [["Volunteers", "ORGANISM", 0, 10], ["adults", "ORGANISM", 30, 36]]], ["The vaccine schedules are described in Diagrams ( Fig S4 A and B) .", [["The vaccine schedules", "TREATMENT", 0, 21]]], ["Blood samples were collected in heparinised tubes for assays that required PBMC.", [["Blood samples", "ANATOMY", 0, 13], ["PBMC", "ANATOMY", 75, 79], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["PBMC", "CELL", 75, 79], ["PBMC", "CELL_TYPE", 75, 79], ["Blood samples", "TEST", 0, 13], ["heparinised tubes", "TREATMENT", 32, 49], ["assays", "TEST", 54, 60], ["PBMC", "TREATMENT", 75, 79]]], ["PBMC were isolated within 6 h of sample collection.", [["PBMC", "ANATOMY", 0, 4], ["sample", "ANATOMY", 33, 39], ["PBMC", "CELL", 0, 4], ["PBMC", "CELL_TYPE", 0, 4], ["PBMC", "TREATMENT", 0, 4], ["sample collection", "TEST", 33, 50]]], ["Table 2 .Human Samples Human peripheral blood mononuclear cells (PBMC) wereFollowing incubation cells were washed with FACS buffer and immediately analysed on a four-laser LSR Fortessa X-20 flow cytometer.", [["Samples", "ANATOMY", 15, 22], ["peripheral blood mononuclear cells", "ANATOMY", 29, 63], ["PBMC", "ANATOMY", 65, 69], ["cells", "ANATOMY", 96, 101], ["Human", "ORGANISM", 9, 14], ["Human", "ORGANISM", 23, 28], ["peripheral blood mononuclear cells", "CELL", 29, 63], ["PBMC", "CELL", 65, 69], ["cells", "CELL", 96, 101], ["Human peripheral blood mononuclear cells", "CELL_TYPE", 23, 63], ["PBMC", "CELL_TYPE", 65, 69], ["Human", "SPECIES", 9, 14], ["Human", "SPECIES", 23, 28], ["Human", "SPECIES", 9, 14], ["Human Samples", "TEST", 9, 22], ["Human peripheral blood mononuclear cells (PBMC)", "TREATMENT", 23, 70], ["incubation cells", "TREATMENT", 85, 101], ["FACS buffer", "TREATMENT", 119, 130], ["peripheral", "ANATOMY_MODIFIER", 29, 39], ["blood", "ANATOMY", 40, 45], ["mononuclear cells", "OBSERVATION", 46, 63]]], ["Acquired data were analyzed using FlowJo 10.2.Intracellular Staining for Flow CytometryFor intracellular staining, PBMC were stimulated in R10 with anti-CD3 (1 \u03bcg/ml,MHC class I pentamer staining to identify antigen-specific T cellsAn HCV-specific HLA-AP\u22640.05, ***P\u22640.0001, ns, not significant.", [["Intracellular", "ANATOMY", 46, 59], ["intracellular", "ANATOMY", 91, 104], ["PBMC", "ANATOMY", 115, 119], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 59], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 104], ["PBMC", "CELL", 115, 119], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 148, 156], ["T cellsAn", "GENE_OR_GENE_PRODUCT", 225, 234], ["PBMC", "CELL_TYPE", 115, 119], ["anti-CD3", "PROTEIN", 148, 156], ["MHC class I pentamer", "PROTEIN", 166, 186], ["HLA", "PROTEIN", 248, 251], ["T cellsAn HCV", "SPECIES", 225, 238], ["Acquired data", "TEST", 0, 13], ["FlowJo", "TEST", 34, 40], ["Intracellular Staining", "TEST", 46, 68], ["Flow Cytometry", "TEST", 73, 87], ["intracellular staining", "PROBLEM", 91, 113], ["PBMC", "TEST", 115, 119], ["anti-CD3", "TREATMENT", 148, 156], ["antigen", "TEST", 208, 215], ["HCV", "TEST", 235, 238], ["HLA", "TEST", 248, 251], ["AP", "TEST", 252, 254], ["P", "TEST", 264, 265], ["ns", "TEST", 274, 276], ["Staining", "OBSERVATION", 60, 68], ["Flow Cytometry", "OBSERVATION", 73, 87], ["staining", "OBSERVATION", 105, 113]]]], "194e558786013e0e61b4905fe2a36a3d60db56a6": [["SARS-CoV-2-related atypical thyroiditisThe COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1,2 has seriously affected northern Italy.", [["SARS", "DISEASE", 0, 4], ["thyroiditis", "DISEASE", 28, 39], ["acute respiratory syndrome coronavirus", "DISEASE", 82, 120], ["SARS-CoV-2", "ORGANISM", 0, 10], ["severe acute respiratory syndrome coronavirus", "SPECIES", 75, 120], ["SARS-CoV-2", "SPECIES", 124, 134], ["SARS", "PROBLEM", 0, 4], ["atypical thyroiditis", "PROBLEM", 19, 39], ["The COVID", "TEST", 39, 48], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 71, 120], ["atypical", "OBSERVATION_MODIFIER", 19, 27], ["thyroiditis", "OBSERVATION", 28, 39], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["respiratory syndrome coronavirus", "OBSERVATION", 88, 120]]], ["Preliminary data analysis of patients with COVID-19 who required high intensity of care at our institution (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy) showed that these individuals commonly had low or suppressed serum thyroid stimulating hormone, with and without elevated free thyroxine concentrations, which suggests thyrotoxicosis.", [["serum", "ANATOMY", 242, 247], ["thyroxine", "CHEMICAL", 308, 317], ["thyrotoxicosis", "DISEASE", 349, 363], ["thyroxine", "CHEMICAL", 308, 317], ["patients", "ORGANISM", 29, 37], ["individuals", "ORGANISM", 199, 210], ["serum", "ORGANISM_SUBSTANCE", 242, 247], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 248, 275], ["thyroxine", "SIMPLE_CHEMICAL", 308, 317], ["patients", "SPECIES", 29, 37], ["Preliminary data analysis", "TEST", 0, 25], ["COVID", "TEST", 43, 48], ["Fondazione", "TREATMENT", 108, 118], ["low or suppressed serum thyroid stimulating hormone", "PROBLEM", 224, 275], ["elevated free thyroxine concentrations", "PROBLEM", 294, 332], ["thyrotoxicosis", "PROBLEM", 349, 363], ["suggests", "UNCERTAINTY", 340, 348], ["thyrotoxicosis", "OBSERVATION", 349, 363]]], ["Patients who are critically ill can have alterations of thyroid function tests, known as non-thyroidal illness syndrome.", [["thyroid", "ANATOMY", 56, 63], ["critically ill", "DISEASE", 17, 31], ["non-thyroidal illness syndrome", "DISEASE", 89, 119], ["Patients", "ORGANISM", 0, 8], ["thyroid", "ORGAN", 56, 63], ["Patients", "SPECIES", 0, 8], ["critically ill", "PROBLEM", 17, 31], ["thyroid function tests", "TEST", 56, 78], ["non-thyroidal illness syndrome", "PROBLEM", 89, 119], ["thyroid", "ANATOMY", 56, 63]]], ["3, 4 Alternatively, thyrotoxicosis could result from SARS-CoV-2 directly infecting the thyroid gland, as described in other viral infections.", [["thyroid gland", "ANATOMY", 87, 100], ["thyrotoxicosis", "DISEASE", 20, 34], ["viral infections", "DISEASE", 124, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 63], ["thyroid gland", "ORGAN", 87, 100], ["SARS-CoV", "SPECIES", 53, 61], ["thyrotoxicosis", "PROBLEM", 20, 34], ["SARS", "PROBLEM", 53, 57], ["CoV", "TEST", 58, 61], ["other viral infections", "PROBLEM", 118, 140], ["thyrotoxicosis", "OBSERVATION", 20, 34], ["thyroid gland", "ANATOMY", 87, 100], ["viral", "OBSERVATION_MODIFIER", 124, 129], ["infections", "OBSERVATION", 130, 140]]], ["Infection of the thyroid gland is known as subacute thyroiditis and is characterised by self-limiting thyrotoxicosis of variable durationlasting a period of weeks or monthsfollowed by hypothyroidism with final restoration of euthyroidism.", [["thyroid gland", "ANATOMY", 17, 30], ["Infection of the thyroid gland", "DISEASE", 0, 30], ["thyroiditis", "DISEASE", 52, 63], ["thyrotoxicosis", "DISEASE", 102, 116], ["hypothyroidism", "DISEASE", 184, 198], ["euthyroidism", "DISEASE", 225, 237], ["thyroid gland", "ORGAN", 17, 30], ["Infection of the thyroid gland", "PROBLEM", 0, 30], ["subacute thyroiditis", "PROBLEM", 43, 63], ["self-limiting thyrotoxicosis", "PROBLEM", 88, 116], ["hypothyroidism", "PROBLEM", 184, 198], ["euthyroidism", "PROBLEM", 225, 237], ["thyroid gland", "ANATOMY", 17, 30], ["subacute", "OBSERVATION_MODIFIER", 43, 51], ["thyroiditis", "OBSERVATION", 52, 63], ["self-limiting", "OBSERVATION_MODIFIER", 88, 101], ["thyrotoxicosis", "OBSERVATION", 102, 116], ["hypothyroidism", "OBSERVATION", 184, 198], ["euthyroidism", "OBSERVATION", 225, 237]]], ["5, 6 We aimed to assess the prevalence of thyrotoxicosis, suggestive for subacute thyroiditis, in patients admitted to high intensity of care units (HICUs) in relation to the presence or absence of COVID-19.", [["thyrotoxicosis", "DISEASE", 42, 56], ["thyroiditis", "DISEASE", 82, 93], ["COVID-19", "CHEMICAL", 198, 206], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["thyrotoxicosis", "PROBLEM", 42, 56], ["subacute thyroiditis", "PROBLEM", 73, 93], ["COVID", "TEST", 198, 203], ["thyrotoxicosis", "OBSERVATION", 42, 56], ["suggestive for", "UNCERTAINTY", 58, 72], ["subacute", "OBSERVATION_MODIFIER", 73, 81], ["thyroiditis", "OBSERVATION", 82, 93]]], ["To this end, we compared patients admitted to HICUs in 2020 because of COVID-19 (HICU-20 group), with those admitted to the same HICUs in 2019, thus SARS-CoV-2 negative (HICU-19 group).", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["COVID", "TEST", 71, 76], ["SARS", "TEST", 149, 153], ["CoV", "TEST", 154, 157]]], ["Estimating a prevalence of subacute thyroiditis of 0\u00b75% in the HICU-19 group, in line with the general population, 5 and of 10% in the HICU-20 group, a total of 166 patients were needed to obtain a 80% statistical power and a significance of 0\u00b705 (two tails).SARS-CoV-2-related atypical thyroiditisThyroid function was assessed at hospital admittance (within an average of 2 days) in 93 consecutive patients in the HICU-20 group and 101 consecutive patients in the HICU-19 group.", [["Thyroid", "ANATOMY", 298, 305], ["thyroiditis", "DISEASE", 36, 47], ["SARS", "DISEASE", 259, 263], ["thyroiditis", "DISEASE", 287, 298], ["patients", "ORGANISM", 165, 173], ["SARS-CoV-2", "ORGANISM", 259, 269], ["Thyroid", "ORGAN", 298, 305], ["patients", "ORGANISM", 399, 407], ["patients", "ORGANISM", 449, 457], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 399, 407], ["patients", "SPECIES", 449, 457], ["subacute thyroiditis", "PROBLEM", 27, 47], ["SARS", "TEST", 259, 263], ["atypical thyroiditis", "PROBLEM", 278, 298], ["subacute", "OBSERVATION_MODIFIER", 27, 35], ["thyroiditis", "OBSERVATION", 36, 47], ["atypical", "OBSERVATION_MODIFIER", 278, 286], ["thyroiditis", "OBSERVATION", 287, 298], ["Thyroid", "ANATOMY", 298, 305]]], ["52 patients with COVID-19 who were admitted to low intensity of care units (LICU-20 group) were also studied (appendix p 4).", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11]]], ["Patients in the HICU-20 group were younger than those in the other two groups ( .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Thyroid diseases are more common in women, which was reflected in the number of patients with pre-existing thyroid disorders: 23 (23%) of 101 in the HICU-19 group, 11 (21%) of 52 in the LICU-20 group, and 8 (9%) of 93 in the HICU-20 group (p=0\u00b7017).", [["Thyroid", "ANATOMY", 0, 7], ["thyroid", "ANATOMY", 107, 114], ["Thyroid diseases", "DISEASE", 0, 16], ["thyroid disorders", "DISEASE", 107, 124], ["Thyroid", "ORGAN", 0, 7], ["women", "ORGANISM", 36, 41], ["patients", "ORGANISM", 80, 88], ["thyroid", "ORGAN", 107, 114], ["women", "SPECIES", 36, 41], ["patients", "SPECIES", 80, 88], ["Thyroid diseases", "PROBLEM", 0, 16], ["pre-existing thyroid disorders", "PROBLEM", 94, 124], ["diseases", "OBSERVATION", 8, 16], ["thyroid", "ANATOMY", 107, 114]]], ["These patients were excluded from the thyroid function analysis (appendix p 4).", [["thyroid", "ANATOMY", 38, 45], ["patients", "ORGANISM", 6, 14], ["thyroid", "ORGAN", 38, 45], ["patients", "SPECIES", 6, 14], ["the thyroid function analysis", "TEST", 34, 63], ["thyroid", "ANATOMY", 38, 45]]], ["As many as 13 (15%) of 85 patients in the HICU-20 group were thyrotoxic, compared with one (1%) of 78 patients in the HICU-19 group (p=0\u00b7002) and one (2%) of 41 patients in the LICU-20 group (p=0\u00b7025).", [["thyrotoxic", "DISEASE", 61, 71], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 161, 169], ["thyrotoxic", "PROBLEM", 61, 71]]], ["Of the 14 patients with COVID-19 and thyrotoxicosis, more were men (nine [64%] men and five [36%] women; p=0\u00b7017).", [["thyrotoxicosis", "DISEASE", 37, 51], ["patients", "ORGANISM", 10, 18], ["men", "ORGANISM", 63, 66], ["men", "ORGANISM", 79, 82], ["women", "ORGANISM", 98, 103], ["patients", "SPECIES", 10, 18], ["men", "SPECIES", 63, 66], ["men", "SPECIES", 79, 82], ["women", "SPECIES", 98, 103], ["COVID", "TEST", 24, 29], ["thyrotoxicosis", "PROBLEM", 37, 51]]], ["Patients in the HICU-20 group had lower serum thyroid stimulating hormone concentrations than did patients in the HICU-19 and LICU-20 groups (p=0\u00b7018; figure 1A ).", [["serum", "ANATOMY", 40, 45], ["Patients", "ORGANISM", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 46, 73], ["patients", "ORGANISM", 98, 106], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 98, 106], ["lower serum thyroid stimulating hormone concentrations", "PROBLEM", 34, 88], ["LICU", "TEST", 126, 130], ["thyroid", "ANATOMY", 46, 53]]], ["Mean serum free thyroxine concentrations were higher in the HICU-20 group than in the LICU-20 group (p=0\u00b7016), but not the HICU-19 group (p=0\u00b738; appendix p 4).", [["serum", "ANATOMY", 5, 10], ["thyroxine", "CHEMICAL", 16, 25], ["thyroxine", "CHEMICAL", 16, 25], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["thyroxine", "SIMPLE_CHEMICAL", 16, 25], ["Mean serum free thyroxine concentrations", "TEST", 0, 40]]], ["Stratification for sex and age did not affect the results (data not shown).SARS-CoV-2-related atypical thyroiditisAlthough the dramatic increase in the number of patients requiring hospitalisation because of the COVID-19 pandemic emergency might have meant that patients in the HICU-20 group were admitted in more critical conditions compared with those in the HICU-19 group, the thyroid dysfunction observed in the HICU-20 group is unlikely to be related to non-thyroidal illness syndrome only.", [["thyroid", "ANATOMY", 380, 387], ["SARS", "DISEASE", 75, 79], ["thyroiditis", "DISEASE", 103, 114], ["thyroid dysfunction", "DISEASE", 380, 399], ["HICU-20", "CHEMICAL", 416, 423], ["non-thyroidal illness syndrome", "DISEASE", 459, 489], ["HICU-20", "CHEMICAL", 416, 423], ["SARS-CoV-2", "ORGANISM", 75, 85], ["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 262, 270], ["HICU-20", "ORGANISM", 278, 285], ["thyroid", "ORGAN", 380, 387], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 262, 270], ["SARS", "PROBLEM", 75, 79], ["atypical thyroiditis", "PROBLEM", 94, 114], ["the dramatic increase", "PROBLEM", 123, 144], ["the thyroid dysfunction", "PROBLEM", 376, 399], ["non-thyroidal illness syndrome", "PROBLEM", 459, 489], ["atypical", "OBSERVATION_MODIFIER", 94, 102], ["thyroiditis", "OBSERVATION", 103, 114], ["dramatic", "OBSERVATION_MODIFIER", 127, 135], ["increase", "OBSERVATION_MODIFIER", 136, 144], ["number", "OBSERVATION_MODIFIER", 152, 158], ["thyroid", "ANATOMY", 380, 387], ["dysfunction", "OBSERVATION", 388, 399], ["unlikely to be related to", "UNCERTAINTY", 433, 458], ["non-thyroidal illness", "OBSERVATION", 459, 480]]], ["There was no significant difference between the free tri-iodothyronine concentrations, the main non-thyroidal illness syndrome indicator, which were low in all groups (p=0\u00b771; appendix p 4).", [["tri-iodothyronine", "CHEMICAL", 53, 70], ["tri-iodothyronine", "CHEMICAL", 53, 70], ["tri-iodothyronine", "SIMPLE_CHEMICAL", 53, 70], ["the free tri-iodothyronine concentrations", "PROBLEM", 44, 85], ["the main non-thyroidal illness syndrome", "PROBLEM", 87, 126], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["free tri-iodothyronine concentrations", "OBSERVATION", 48, 85], ["main", "OBSERVATION_MODIFIER", 91, 95], ["non-thyroidal", "OBSERVATION_MODIFIER", 96, 109], ["illness syndrome", "OBSERVATION", 110, 126], ["low", "OBSERVATION_MODIFIER", 149, 152], ["appendix", "ANATOMY", 176, 184]]], ["In patients with non-thyroidal illness syndrome, normal or low serum concentrations of thyroid stimulating hormone and low concentrations of tri-iodothyronine are usually associated with low concentrations of thyroxine; 3,4 however, in our cohort of patients See Online for appendix correlates with signatures of immune cell enrichment.", [["serum", "ANATOMY", 63, 68], ["immune cell", "ANATOMY", 313, 324], ["non-thyroidal illness syndrome", "DISEASE", 17, 47], ["tri-iodothyronine", "CHEMICAL", 141, 158], ["thyroxine", "CHEMICAL", 209, 218], ["tri-iodothyronine", "CHEMICAL", 141, 158], ["thyroxine", "CHEMICAL", 209, 218], ["patients", "ORGANISM", 3, 11], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 87, 114], ["tri-iodothyronine", "SIMPLE_CHEMICAL", 141, 158], ["thyroxine", "SIMPLE_CHEMICAL", 209, 218], ["patients", "ORGANISM", 250, 258], ["appendix", "ORGAN", 274, 282], ["immune cell", "CELL", 313, 324], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 250, 258], ["non-thyroidal illness syndrome", "PROBLEM", 17, 47], ["low serum concentrations of thyroid stimulating hormone", "PROBLEM", 59, 114], ["low concentrations of tri-iodothyronine", "PROBLEM", 119, 158], ["thyroxine", "TREATMENT", 209, 218], ["immune cell enrichment", "TREATMENT", 313, 335], ["non-thyroidal", "ANATOMY", 17, 30], ["illness", "OBSERVATION", 31, 38], ["thyroid", "ANATOMY", 87, 94], ["low concentrations", "OBSERVATION_MODIFIER", 119, 137], ["appendix", "ANATOMY", 274, 282], ["immune cell enrichment", "OBSERVATION", 313, 335]]], ["9 This expression profile might explain why in this study the most severe forms of COVID-19 pneumonia 2 and associated thyroid dysfunction were predominantly reported in men in the HICU-20 group, but not women as in the classic viral subacute thyroiditis.", [["thyroid", "ANATOMY", 119, 126], ["COVID", "DISEASE", 83, 88], ["pneumonia", "DISEASE", 92, 101], ["thyroid dysfunction", "DISEASE", 119, 138], ["viral subacute thyroiditis", "DISEASE", 228, 254], ["thyroid", "ORGAN", 119, 126], ["men", "ORGANISM", 170, 173], ["women", "ORGANISM", 204, 209], ["men", "SPECIES", 170, 173], ["women", "SPECIES", 204, 209], ["this study", "TEST", 47, 57], ["COVID", "TEST", 83, 88], ["pneumonia 2", "PROBLEM", 92, 103], ["thyroid dysfunction", "PROBLEM", 119, 138], ["the classic viral subacute thyroiditis", "PROBLEM", 216, 254], ["pneumonia", "OBSERVATION", 92, 101], ["thyroid", "ANATOMY", 119, 126], ["dysfunction", "OBSERVATION", 127, 138], ["viral", "OBSERVATION_MODIFIER", 228, 233], ["subacute", "OBSERVATION_MODIFIER", 234, 242], ["thyroiditis", "OBSERVATION", 243, 254]]], ["6 Serum C-reactive protein concentration is a general non-specific marker of inflammation, subacute thyroiditis, 10 and COVID-19 disease severity.", [["Serum", "ANATOMY", 2, 7], ["inflammation", "DISEASE", 77, 89], ["thyroiditis", "DISEASE", 100, 111], ["Serum C-reactive protein", "GENE_OR_GENE_PRODUCT", 2, 26], ["Serum C-reactive protein", "PROTEIN", 2, 26], ["Serum C-reactive protein concentration", "TEST", 2, 40], ["a general non-specific marker of inflammation", "PROBLEM", 44, 89], ["subacute thyroiditis", "PROBLEM", 91, 111], ["COVID-19 disease severity", "PROBLEM", 120, 145], ["-reactive protein concentration", "OBSERVATION", 9, 40], ["non-specific", "OBSERVATION_MODIFIER", 54, 66], ["inflammation", "OBSERVATION", 77, 89], ["subacute", "OBSERVATION_MODIFIER", 91, 99], ["thyroiditis", "OBSERVATION", 100, 111], ["19 disease", "OBSERVATION_MODIFIER", 126, 136], ["severity", "OBSERVATION_MODIFIER", 137, 145]]], ["2 Median serum C-reactive protein concentrations were significantly higher in the HICU-20 group compared with the HICU-19 ad LICU-20 groups (p=0\u00b70038; figure 1B ; appendix p 4).", [["serum", "ANATOMY", 9, 14], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 15, 33], ["serum C-reactive protein", "PROTEIN", 9, 33], ["Median serum C", "TEST", 2, 16], ["reactive protein concentrations", "TEST", 17, 48]]], ["In patients with COVID-19, median serum C-reactive protein, but not median thyroid stimulating hormone and mean free thyroxine concentrations, were significantly higher in patients that died than in survivors (median 190 mg/L [IQR 94-256] in patients that died vs 73 mg/L [33-133] mg/L in patients that survived; p=0\u00b70052; not shown).", [["serum", "ANATOMY", 34, 39], ["thyroxine", "CHEMICAL", 117, 126], ["thyroxine", "CHEMICAL", 117, 126], ["patients", "ORGANISM", 3, 11], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["C-reactive", "GENE_OR_GENE_PRODUCT", 40, 50], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 75, 102], ["thyroxine", "SIMPLE_CHEMICAL", 117, 126], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 289, 297], ["serum C-reactive protein", "PROTEIN", 34, 58], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 242, 250], ["patients", "SPECIES", 289, 297], ["COVID", "TEST", 17, 22], ["median serum C-reactive protein", "PROBLEM", 27, 58], ["median thyroid stimulating hormone", "PROBLEM", 68, 102], ["mean free thyroxine concentrations", "PROBLEM", 107, 141], ["reactive protein", "OBSERVATION", 42, 58], ["thyroid", "ANATOMY", 75, 82]]], ["This difference was not observed in the HICU-19 group (p=0\u00b727).", [["HICU-19", "CHEMICAL", 40, 47]]], ["It could be speculated that patients with higher serum C-reactive protein concentrations might have a systemic spread of SARS-CoV-2 that is more likely to affect the thyroid gland.", [["serum", "ANATOMY", 49, 54], ["thyroid gland", "ANATOMY", 166, 179], ["SARS", "DISEASE", 121, 125], ["patients", "ORGANISM", 28, 36], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 55, 73], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 121, 131], ["thyroid gland", "ORGAN", 166, 179], ["serum C", "PROTEIN", 49, 56], ["patients", "SPECIES", 28, 36], ["SARS-CoV", "SPECIES", 121, 129], ["higher serum C-reactive protein concentrations", "PROBLEM", 42, 88], ["SARS", "PROBLEM", 121, 125], ["systemic", "OBSERVATION_MODIFIER", 102, 110], ["spread", "OBSERVATION_MODIFIER", 111, 117], ["SARS", "OBSERVATION", 121, 125], ["more likely", "UNCERTAINTY", 140, 151], ["thyroid gland", "ANATOMY", 166, 179]]], ["This is the first comprehensive description of thyroid alterations in hospitalised patients with COVID-19 with initial longitudinal follow-up available; however, this work has limitations.", [["thyroid", "ANATOMY", 47, 54], ["thyroid alterations", "DISEASE", 47, 66], ["thyroid", "ORGAN", 47, 54], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["thyroid alterations", "PROBLEM", 47, 66], ["COVID", "TEST", 97, 102], ["thyroid", "ANATOMY", 47, 54]]], ["Serum free thyroxine and free tri-iodothyronine concentrations were measured when thyroid stimulating hormone concentrations were less than 0\u00b745 mIU/L and thyroxine concentrations were measured when thyroid stimulating hormone concentrations were more than 3\u00b750 mIU/L (appendix p 2), thyroid imaging was done nearly two months after baseline thyroid stimulating hormone measurement because of prolonged post-discharge persistence of SARS-CoV-2 positivity, COVID-19, requiring high intensity of care, present with thyrotoxicosis and low serum thyroid stimulating hormone concentrations, possibly as a consequence of subacute thyroiditis induced by SARS-CoV-2, in an underlying setting of nonthyroidal illness syndrome.", [["Serum", "ANATOMY", 0, 5], ["thyroid", "ANATOMY", 284, 291], ["serum", "ANATOMY", 536, 541], ["thyroxine", "CHEMICAL", 11, 20], ["tri-iodothyronine", "CHEMICAL", 30, 47], ["thyroxine", "CHEMICAL", 155, 164], ["SARS", "DISEASE", 433, 437], ["thyrotoxicosis", "DISEASE", 513, 527], ["thyroiditis", "DISEASE", 624, 635], ["nonthyroidal illness syndrome", "DISEASE", 687, 716], ["thyroxine", "CHEMICAL", 11, 20], ["tri-iodothyronine", "CHEMICAL", 30, 47], ["thyroxine", "CHEMICAL", 155, 164], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["thyroxine", "SIMPLE_CHEMICAL", 11, 20], ["tri-iodothyronine", "SIMPLE_CHEMICAL", 30, 47], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 82, 109], ["thyroxine", "SIMPLE_CHEMICAL", 155, 164], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 199, 226], ["thyroid", "ORGAN", 284, 291], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 342, 369], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 433, 443], ["serum", "ORGANISM_SUBSTANCE", 536, 541], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 542, 569], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 647, 657], ["Serum free thyroxine", "TREATMENT", 0, 20], ["free tri-iodothyronine concentrations", "TREATMENT", 25, 62], ["thyroid stimulating hormone concentrations", "TEST", 82, 124], ["thyroxine concentrations", "TEST", 155, 179], ["thyroid stimulating hormone concentrations", "TEST", 199, 241], ["thyroid imaging", "TEST", 284, 299], ["baseline thyroid stimulating hormone measurement", "TEST", 333, 381], ["SARS", "PROBLEM", 433, 437], ["CoV", "TEST", 438, 441], ["COVID", "TEST", 456, 461], ["high intensity of care", "TREATMENT", 476, 498], ["thyrotoxicosis", "PROBLEM", 513, 527], ["low serum thyroid stimulating hormone concentrations", "PROBLEM", 532, 584], ["subacute thyroiditis", "PROBLEM", 615, 635], ["SARS", "PROBLEM", 647, 651], ["CoV", "TEST", 652, 655], ["nonthyroidal illness syndrome", "PROBLEM", 687, 716], ["thyroid", "ANATOMY", 284, 291], ["high intensity", "OBSERVATION_MODIFIER", 476, 490], ["thyrotoxicosis", "OBSERVATION", 513, 527], ["subacute", "OBSERVATION_MODIFIER", 615, 623], ["thyroiditis", "OBSERVATION", 624, 635], ["nonthyroidal illness", "OBSERVATION", 687, 707]]], ["Patients in the HICU-20 group also had a lower prevalence of both autoimmune and non-autoimmune pre-existing thyroid disorders compared with the HICU-19 group; this suggests that such conditions are not a risk factor for SARS-CoV-2 infection or severity of COVID-19.", [["thyroid", "ANATOMY", 109, 116], ["thyroid disorders", "DISEASE", 109, 126], ["SARS", "DISEASE", 221, 225], ["infection", "DISEASE", 232, 241], ["Patients", "ORGANISM", 0, 8], ["thyroid", "ORGAN", 109, 116], ["SARS-CoV-2", "ORGANISM", 221, 231], ["Patients", "SPECIES", 0, 8], ["both autoimmune", "PROBLEM", 61, 76], ["non-autoimmune pre-existing thyroid disorders", "PROBLEM", 81, 126], ["such conditions", "PROBLEM", 179, 194], ["a risk factor", "PROBLEM", 203, 216], ["SARS", "PROBLEM", 221, 225], ["CoV-2 infection", "PROBLEM", 226, 241], ["COVID", "TEST", 257, 262], ["autoimmune", "OBSERVATION", 66, 76], ["thyroid", "ANATOMY", 109, 116]]], ["In patients with COVID-19 requiring high intensity of care and presenting with subacute thyroiditis, serum free thyroxine concentrations were not as elevated and serum thyroid stimulating hormone concentrations not as suppressed, as described in the classic subacute thyroiditis.", [["serum", "ANATOMY", 101, 106], ["serum", "ANATOMY", 162, 167], ["thyroiditis", "DISEASE", 88, 99], ["thyroxine", "CHEMICAL", 112, 121], ["thyroiditis", "DISEASE", 267, 278], ["thyroxine", "CHEMICAL", 112, 121], ["patients", "ORGANISM", 3, 11], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["thyroxine", "SIMPLE_CHEMICAL", 112, 121], ["serum", "ORGANISM_SUBSTANCE", 162, 167], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 168, 195], ["patients", "SPECIES", 3, 11], ["COVID", "TEST", 17, 22], ["high intensity of care", "TREATMENT", 36, 58], ["subacute thyroiditis", "PROBLEM", 79, 99], ["serum free thyroxine concentrations", "TEST", 101, 136], ["elevated", "PROBLEM", 149, 157], ["serum thyroid stimulating hormone concentrations", "TEST", 162, 210], ["the classic subacute thyroiditis", "PROBLEM", 246, 278], ["subacute", "OBSERVATION_MODIFIER", 79, 87], ["thyroiditis", "OBSERVATION", 88, 99], ["subacute", "OBSERVATION_MODIFIER", 258, 266], ["thyroiditis", "OBSERVATION", 267, 278]]], ["6 These patients also did not complain of neck pain (consistent with silent thyroiditis), did not have leucocytosis, but did have lymphopenia, as observed with COVID-19 infection (appendix p 6).", [["neck", "ANATOMY", 42, 46], ["neck pain", "DISEASE", 42, 51], ["thyroiditis", "DISEASE", 76, 87], ["leucocytosis", "DISEASE", 103, 115], ["lymphopenia", "DISEASE", 130, 141], ["COVID-19", "CHEMICAL", 160, 168], ["infection", "DISEASE", 169, 178], ["patients", "ORGANISM", 8, 16], ["neck", "ORGANISM_SUBDIVISION", 42, 46], ["patients", "SPECIES", 8, 16], ["neck pain", "PROBLEM", 42, 51], ["silent thyroiditis", "PROBLEM", 69, 87], ["leucocytosis", "PROBLEM", 103, 115], ["lymphopenia", "PROBLEM", 130, 141], ["COVID", "TEST", 160, 165], ["infection", "PROBLEM", 169, 178], ["neck", "ANATOMY", 42, 46], ["pain", "OBSERVATION", 47, 51], ["consistent with", "UNCERTAINTY", 53, 68], ["thyroiditis", "OBSERVATION", 76, 87], ["leucocytosis", "OBSERVATION", 103, 115], ["lymphopenia", "OBSERVATION", 130, 141], ["infection", "OBSERVATION", 169, 178]]], ["2 These features differ from those described in the first case report of late-onset thyroiditis after mild SARS-CoV-2 infection, 7 and reports of classic subacute thyroiditis, characterised by a pathognomonic infiltration of giant cells (congregates of lymphocytes, histiocytes, and colloid), with swelling of thyroid follicles, stretching of the thyroid capsule, and consequent neck pain.", [["giant cells", "ANATOMY", 225, 236], ["congregates", "ANATOMY", 238, 249], ["lymphocytes", "ANATOMY", 253, 264], ["histiocytes", "ANATOMY", 266, 277], ["colloid", "ANATOMY", 283, 290], ["thyroid follicles", "ANATOMY", 310, 327], ["thyroid capsule", "ANATOMY", 347, 362], ["neck", "ANATOMY", 379, 383], ["thyroiditis", "DISEASE", 84, 95], ["SARS-CoV-2 infection", "DISEASE", 107, 127], ["thyroiditis", "DISEASE", 163, 174], ["swelling of thyroid follicles", "DISEASE", 298, 327], ["neck pain", "DISEASE", 379, 388], ["giant cells", "CELL", 225, 236], ["lymphocytes", "CELL", 253, 264], ["histiocytes", "TISSUE", 266, 277], ["thyroid follicles", "MULTI-TISSUE_STRUCTURE", 310, 327], ["thyroid capsule", "CANCER", 347, 362], ["neck", "ORGANISM_SUBDIVISION", 379, 383], ["giant cells", "CELL_TYPE", 225, 236], ["lymphocytes", "CELL_TYPE", 253, 264], ["histiocytes", "CELL_TYPE", 266, 277], ["late-onset thyroiditis", "PROBLEM", 73, 95], ["mild SARS", "PROBLEM", 102, 111], ["CoV-2 infection", "PROBLEM", 112, 127], ["classic subacute thyroiditis", "PROBLEM", 146, 174], ["a pathognomonic infiltration of giant cells", "PROBLEM", 193, 236], ["lymphocytes", "PROBLEM", 253, 264], ["histiocytes", "PROBLEM", 266, 277], ["colloid", "TEST", 283, 290], ["swelling of thyroid follicles", "PROBLEM", 298, 327], ["stretching of the thyroid capsule", "PROBLEM", 329, 362], ["consequent neck pain", "PROBLEM", 368, 388], ["thyroiditis", "OBSERVATION", 84, 95], ["mild", "OBSERVATION_MODIFIER", 102, 106], ["SARS", "OBSERVATION", 107, 111], ["subacute", "OBSERVATION_MODIFIER", 154, 162], ["thyroiditis", "OBSERVATION", 163, 174], ["pathognomonic", "OBSERVATION_MODIFIER", 195, 208], ["infiltration", "OBSERVATION", 209, 221], ["giant cells", "OBSERVATION", 225, 236], ["lymphocytes", "ANATOMY", 253, 264], ["swelling", "OBSERVATION", 298, 306], ["thyroid", "ANATOMY", 310, 317], ["follicles", "OBSERVATION", 318, 327], ["stretching", "OBSERVATION_MODIFIER", 329, 339], ["thyroid", "ANATOMY", 347, 354], ["capsule", "ANATOMY_MODIFIER", 355, 362], ["neck", "ANATOMY", 379, 383], ["pain", "OBSERVATION", 384, 388]]], ["6 In SARS-CoV-2 related thyroiditis, giant cells might not form because of lymphopenia and thyroid cells might be damaged by apoptosis, as observed with severe acute respiratory syndrome coronavirus (SARS-CoV).", [["giant cells", "ANATOMY", 37, 48], ["thyroid cells", "ANATOMY", 91, 104], ["thyroiditis", "DISEASE", 24, 35], ["lymphopenia", "DISEASE", 75, 86], ["acute respiratory syndrome coronavirus", "DISEASE", 160, 198], ["SARS", "DISEASE", 200, 204], ["SARS-CoV-2", "ORGANISM", 5, 15], ["giant cells", "CELL", 37, 48], ["thyroid cells", "CELL", 91, 104], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 153, 198], ["SARS-CoV", "ORGANISM", 200, 208], ["giant cells", "CELL_TYPE", 37, 48], ["thyroid cells", "CELL_TYPE", 91, 104], ["SARS-CoV", "SPECIES", 5, 13], ["severe acute respiratory syndrome coronavirus", "SPECIES", 153, 198], ["SARS-CoV", "SPECIES", 200, 208], ["SARS", "PROBLEM", 5, 9], ["CoV", "PROBLEM", 10, 13], ["thyroiditis", "PROBLEM", 24, 35], ["giant cells", "PROBLEM", 37, 48], ["lymphopenia", "PROBLEM", 75, 86], ["thyroid cells", "PROBLEM", 91, 104], ["apoptosis", "PROBLEM", 125, 134], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 153, 198], ["thyroiditis", "OBSERVATION", 24, 35], ["giant cells", "OBSERVATION", 37, 48], ["lymphopenia", "OBSERVATION", 75, 86], ["thyroid", "ANATOMY", 91, 98], ["apoptosis", "OBSERVATION", 125, 134], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["respiratory syndrome coronavirus", "OBSERVATION", 166, 198]]], ["8 The angiotensin-converting enzyme 2 (ACE2) is a host-cell entry receptor for both SARS-CoV and SARS-CoV-2, 1 and it might be partly responsible for a common pathogenic pathway.", [["cell", "ANATOMY", 55, 59], ["angiotensin", "CHEMICAL", 6, 17], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 6, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["cell", "CELL", 55, 59], ["SARS-CoV", "ORGANISM", 84, 92], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["1", "GENE_OR_GENE_PRODUCT", 109, 110], ["angiotensin-converting enzyme 2", "PROTEIN", 6, 37], ["ACE2", "PROTEIN", 39, 43], ["host-cell entry receptor", "PROTEIN", 50, 74], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 97, 105], ["The angiotensin-converting enzyme", "TEST", 2, 35], ["ACE2", "TEST", 39, 43], ["both SARS", "TEST", 79, 88], ["CoV", "TEST", 89, 92], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105]]], ["ACE2 is more highly expressed in thyroid cells than in lung cells, and in women such expression negatively with COVID-19, low concentrations of thyroid stimulating hormone and triiodothyronine were associated with normal or elevated concentrations of thyroxine.", [["thyroid cells", "ANATOMY", 33, 46], ["lung cells", "ANATOMY", 55, 65], ["triiodothyronine", "CHEMICAL", 176, 192], ["thyroxine", "CHEMICAL", 251, 260], ["triiodothyronine", "CHEMICAL", 176, 192], ["thyroxine", "CHEMICAL", 251, 260], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["thyroid cells", "CELL", 33, 46], ["lung cells", "CELL", 55, 65], ["women", "ORGANISM", 74, 79], ["COVID-19", "GENE_OR_GENE_PRODUCT", 112, 120], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 144, 171], ["triiodothyronine", "SIMPLE_CHEMICAL", 176, 192], ["thyroxine", "SIMPLE_CHEMICAL", 251, 260], ["ACE2", "PROTEIN", 0, 4], ["thyroid cells", "CELL_TYPE", 33, 46], ["lung cells", "CELL_TYPE", 55, 65], ["COVID", "PROTEIN", 112, 117], ["women", "SPECIES", 74, 79], ["ACE2", "PROBLEM", 0, 4], ["COVID", "TEST", 112, 117], ["thyroid stimulating hormone", "TREATMENT", 144, 171], ["triiodothyronine", "TREATMENT", 176, 192], ["elevated concentrations of thyroxine", "PROBLEM", 224, 260], ["more highly", "OBSERVATION_MODIFIER", 8, 19], ["thyroid cells", "OBSERVATION", 33, 46], ["lung", "ANATOMY", 55, 59], ["thyroid", "ANATOMY", 144, 151]]], ["A transient thyroxine increase over a period of hours can occur in acute conditions, usually associated with normal or high serum thyroid stimulating hormone concentrations, 3 but not low concentrations as observed in this study.", [["serum", "ANATOMY", 124, 129], ["thyroxine", "CHEMICAL", 12, 21], ["thyroxine", "CHEMICAL", 12, 21], ["thyroxine", "SIMPLE_CHEMICAL", 12, 21], ["serum", "ORGANISM_SUBSTANCE", 124, 129], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 130, 157], ["A transient thyroxine increase", "PROBLEM", 0, 30], ["acute conditions", "PROBLEM", 67, 83], ["high serum thyroid stimulating hormone concentrations", "PROBLEM", 119, 172], ["low concentrations", "PROBLEM", 184, 202], ["this study", "TEST", 218, 228], ["transient", "OBSERVATION_MODIFIER", 2, 11], ["thyroxine", "OBSERVATION", 12, 21], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["conditions", "OBSERVATION", 73, 83], ["low concentrations", "OBSERVATION_MODIFIER", 184, 202]]], ["It is plausible that our patients might have had a combination of thyrotoxicosis and non-thyroidal illness syndrome, described as thyroxine thyrotoxicosis.", [["thyrotoxicosis", "DISEASE", 66, 80], ["non-thyroidal illness syndrome", "DISEASE", 85, 115], ["thyroxine", "CHEMICAL", 130, 139], ["thyrotoxicosis", "DISEASE", 140, 154], ["thyroxine", "CHEMICAL", 130, 139], ["patients", "ORGANISM", 25, 33], ["thyroxine", "SIMPLE_CHEMICAL", 130, 139], ["patients", "SPECIES", 25, 33], ["thyrotoxicosis", "PROBLEM", 66, 80], ["non-thyroidal illness syndrome", "PROBLEM", 85, 115], ["thyroxine thyrotoxicosis", "PROBLEM", 130, 154], ["thyrotoxicosis", "OBSERVATION", 66, 80], ["non-thyroidal illness", "OBSERVATION", 85, 106]]], ["4 To test this hypothesis, eight patients with COVID-19 and any thyroid dysfunction observed at hospital admission were followedup after a mean of 55 (SD 8) days following discharge when negative for SARS-CoV-2 (appendix p 6).", [["thyroid", "ANATOMY", 64, 71], ["thyroid dysfunction", "DISEASE", 64, 83], ["SARS", "DISEASE", 200, 204], ["patients", "ORGANISM", 33, 41], ["thyroid", "ORGAN", 64, 71], ["patients", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 200, 208], ["COVID", "TEST", 47, 52], ["any thyroid dysfunction", "PROBLEM", 60, 83], ["SARS", "PROBLEM", 200, 204], ["CoV", "TEST", 205, 208], ["thyroid", "ANATOMY", 64, 71], ["dysfunction", "OBSERVATION", 72, 83], ["appendix", "ANATOMY", 212, 220]]], ["Two (25%) patients were confirmed to have hypothyroidism and had marked diffuse hypoechogenicity and heterogeneity at thyroid ultrasound, characteristic features of autoimmune thyroiditis.", [["thyroid", "ANATOMY", 118, 125], ["hypothyroidism", "DISEASE", 42, 56], ["hypoechogenicity", "DISEASE", 80, 96], ["autoimmune thyroiditis", "DISEASE", 165, 187], ["patients", "ORGANISM", 10, 18], ["thyroid", "ORGAN", 118, 125], ["patients", "SPECIES", 10, 18], ["hypothyroidism", "PROBLEM", 42, 56], ["marked diffuse hypoechogenicity", "PROBLEM", 65, 96], ["heterogeneity at thyroid ultrasound", "PROBLEM", 101, 136], ["autoimmune thyroiditis", "PROBLEM", 165, 187], ["hypothyroidism", "OBSERVATION", 42, 56], ["marked", "OBSERVATION_MODIFIER", 65, 71], ["diffuse", "OBSERVATION_MODIFIER", 72, 79], ["hypoechogenicity", "OBSERVATION", 80, 96], ["heterogeneity", "OBSERVATION_MODIFIER", 101, 114], ["thyroid", "ANATOMY", 118, 125], ["autoimmune thyroiditis", "OBSERVATION", 165, 187]]], ["The six (75%) patients with low or suppressed thyroid stimulating hormone concentrations or thyrotoxicosis at baseline had normal thyroid function and were negative for thyroid autoantibodies at follow-up; none reported neck pain ever.", [["thyroid", "ANATOMY", 130, 137], ["thyroid", "ANATOMY", 169, 176], ["neck", "ANATOMY", 220, 224], ["thyrotoxicosis", "DISEASE", 92, 106], ["thyroid autoantibodies", "DISEASE", 169, 191], ["neck pain", "DISEASE", 220, 229], ["patients", "ORGANISM", 14, 22], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 46, 73], ["thyroid", "ORGAN", 130, 137], ["thyroid", "ORGAN", 169, 176], ["neck", "ORGANISM_SUBDIVISION", 220, 224], ["thyroid autoantibodies", "PROTEIN", 169, 191], ["patients", "SPECIES", 14, 22], ["low or suppressed thyroid stimulating hormone concentrations", "PROBLEM", 28, 88], ["thyrotoxicosis", "PROBLEM", 92, 106], ["thyroid autoantibodies", "PROBLEM", 169, 191], ["neck pain", "PROBLEM", 220, 229], ["thyroid", "ANATOMY", 46, 53], ["thyroid", "ANATOMY", 130, 137], ["thyroid", "ANATOMY", 169, 176], ["neck", "ANATOMY", 220, 224], ["pain", "OBSERVATION", 225, 229]]], ["The six patients had a diffuse mild hypoechoic pattern at thyroid ultrasound.", [["thyroid", "ANATOMY", 58, 65], ["patients", "ORGANISM", 8, 16], ["thyroid", "ORGAN", 58, 65], ["patients", "SPECIES", 8, 16], ["a diffuse mild hypoechoic pattern", "PROBLEM", 21, 54], ["thyroid ultrasound", "TEST", 58, 76], ["diffuse", "OBSERVATION_MODIFIER", 23, 30], ["mild", "OBSERVATION_MODIFIER", 31, 35], ["hypoechoic", "OBSERVATION", 36, 46], ["thyroid", "ANATOMY", 58, 65]]], ["Three patients had focal markedly hypoechoic areas.", [["patients", "ORGANISM", 6, 14], ["hypoechoic areas", "PATHOLOGICAL_FORMATION", 34, 50], ["patients", "SPECIES", 6, 14], ["focal markedly hypoechoic areas", "PROBLEM", 19, 50], ["focal", "OBSERVATION_MODIFIER", 19, 24], ["markedly", "OBSERVATION_MODIFIER", 25, 33], ["hypoechoic", "OBSERVATION_MODIFIER", 34, 44], ["areas", "OBSERVATION", 45, 50]]], ["Such areas corresponded to focal reduced Technetium-99m uptake at single-photon emission CT imaging, and the thyroid gland showed a general low to normal or reduced Technetium-99m uptake, which suggested subacute thyroiditis (appendix p 7).", [["thyroid gland", "ANATOMY", 109, 122], ["thyroiditis", "DISEASE", 213, 224], ["Technetium-99m", "SIMPLE_CHEMICAL", 41, 55], ["thyroid gland", "ORGAN", 109, 122], ["focal reduced Technetium", "PROBLEM", 27, 51], ["single-photon emission CT imaging", "TEST", 66, 99], ["the thyroid gland", "TEST", 105, 122], ["reduced Technetium", "PROBLEM", 157, 175], ["subacute thyroiditis", "PROBLEM", 204, 224], ["focal", "OBSERVATION_MODIFIER", 27, 32], ["reduced", "OBSERVATION_MODIFIER", 33, 40], ["thyroid gland", "ANATOMY", 109, 122], ["subacute", "OBSERVATION_MODIFIER", 204, 212], ["thyroiditis", "OBSERVATION", 213, 224], ["appendix", "ANATOMY", 226, 234]]], ["It is plausible that we might have missed some typical imaging features of subacute thyroiditis in the other three patients because of the time elapsed between hospital admission and follow-up and the anti-inflammatory treatments received.SARS-CoV-2-related atypical thyroiditisOur work suggests that a substantial pro por tion of patients with and serum thyroid stimulating hormone analysis was not available in all patients in the LICU-20 group.SARS-CoV-2-related atypical thyroiditisIn conclusion, we suggest routine assess ment of thyroid function in patients with COVID-19 requiring high intensity care, because they frequently present with thyrotoxicosis due to a form of subacute thyroiditis related to SARS-CoV-2.", [["serum", "ANATOMY", 349, 354], ["thyroid", "ANATOMY", 535, 542], ["thyroiditis", "DISEASE", 84, 95], ["SARS", "DISEASE", 239, 243], ["thyroiditis", "DISEASE", 267, 278], ["SARS", "DISEASE", 447, 451], ["thyroiditis", "DISEASE", 475, 486], ["thyrotoxicosis", "DISEASE", 646, 660], ["thyroiditis", "DISEASE", 687, 698], ["SARS", "DISEASE", 710, 714], ["LICU-20", "CHEMICAL", 433, 440], ["patients", "ORGANISM", 115, 123], ["SARS-CoV-2", "ORGANISM", 239, 249], ["patients", "ORGANISM", 331, 339], ["serum", "ORGANISM_SUBSTANCE", 349, 354], ["thyroid stimulating hormone", "GENE_OR_GENE_PRODUCT", 355, 382], ["patients", "ORGANISM", 417, 425], ["SARS-CoV-2", "ORGANISM", 447, 457], ["thyroid", "ORGAN", 535, 542], ["patients", "ORGANISM", 555, 563], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 710, 720], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 331, 339], ["patients", "SPECIES", 417, 425], ["patients", "SPECIES", 555, 563], ["subacute thyroiditis", "PROBLEM", 75, 95], ["the anti-inflammatory treatments", "TREATMENT", 197, 229], ["SARS", "PROBLEM", 239, 243], ["atypical thyroiditis", "PROBLEM", 258, 278], ["serum thyroid stimulating hormone analysis", "TEST", 349, 391], ["SARS", "PROBLEM", 447, 451], ["atypical thyroiditis", "PROBLEM", 466, 486], ["COVID", "TEST", 569, 574], ["high intensity care", "TREATMENT", 588, 607], ["thyrotoxicosis", "PROBLEM", 646, 660], ["subacute thyroiditis", "PROBLEM", 678, 698], ["SARS", "PROBLEM", 710, 714], ["subacute", "OBSERVATION_MODIFIER", 75, 83], ["thyroiditis", "OBSERVATION", 84, 95], ["atypical", "OBSERVATION_MODIFIER", 258, 266], ["thyroiditis", "OBSERVATION", 267, 278], ["atypical", "OBSERVATION_MODIFIER", 466, 474], ["thyroiditis", "OBSERVATION", 475, 486], ["thyroid", "ANATOMY", 535, 542], ["subacute", "OBSERVATION_MODIFIER", 678, 686], ["thyroiditis", "OBSERVATION", 687, 698]]], ["Considering the currently ongoing pandemic emer gency, future studies are encouraged to confirm, or counter, these results.", [["future studies", "TEST", 55, 69]]], ["Thyroid cytology or histology and longitudinal studies of thyroid (dys)function in these patients would be particularly informative.", [["Thyroid", "ANATOMY", 0, 7], ["thyroid", "ANATOMY", 58, 65], ["Thyroid", "ORGAN", 0, 7], ["thyroid", "ORGAN", 58, 65], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Thyroid cytology", "TEST", 0, 16], ["histology", "TEST", 20, 29], ["longitudinal studies", "TEST", 34, 54], ["thyroid", "ANATOMY", 58, 65]]]], "PMC7273900": [["Study design & participants ::: Materials & methodsIn this retrospective study, we included discharged patients, including deaths,hospitalized with COVID-19 pneumonia in the Central Hospital of Wuhan from 1January to 20 February 2020.", [["deaths", "DISEASE", 123, 129], ["pneumonia", "DISEASE", 157, 166], ["patients", "ORGANISM", 103, 111], ["participants", "SPECIES", 15, 27], ["patients", "SPECIES", 103, 111], ["this retrospective study", "TEST", 54, 78], ["COVID", "TEST", 148, 153], ["pneumonia", "PROBLEM", 157, 166], ["pneumonia", "OBSERVATION", 157, 166]]], ["COVID-19 was defined as a positive result onreal time reverse transcriptase PCR and \u2018ground-glassopacity\u2019 on computed tomography (CT).", [["COVID-19", "DNA", 0, 8], ["reverse transcriptase", "PROTEIN", 54, 75], ["COVID", "TEST", 0, 5], ["transcriptase PCR", "TEST", 62, 79], ["computed tomography", "TEST", 109, 128], ["CT", "TEST", 130, 132]]], ["This study was approved by theEthics Commission of the Central Hospital of Wuhan.", [["This study", "TEST", 0, 10]]], ["Written informed consent waswaived by the Ethics Commission of the designated hospital under the criteria ofemerging infectious diseases.", [["infectious diseases", "DISEASE", 117, 136], ["infectious", "OBSERVATION", 117, 127]]], ["The classification of diseases used is asdescribed previously [10,11].Participants\u2019\u00a0characteristics & data collection ::: Materials & methodsThis study retrospectively analyzed the patients\u2019 medical history,epidemiological data (including workplace), history of disease exposure, fever,cough, headache, diarrhea and chest pain, etc. The laboratory tests includedliver function, kidney function, blood cell count, COVID-19 nucleic acid andtests for other respiratory viruses etc. Data regarding medical expenses, lungCT image, drugs prescribed and comorbidities were also analyzed [12].Clinical outcomes ::: Materials & methodsThis study focused on discharged patients.", [["chest", "ANATOMY", 316, 321], ["kidney", "ANATOMY", 378, 384], ["blood cell", "ANATOMY", 395, 405], ["fever", "DISEASE", 280, 285], ["cough", "DISEASE", 286, 291], ["headache", "DISEASE", 293, 301], ["diarrhea", "DISEASE", 303, 311], ["chest pain", "DISEASE", 316, 326], ["nucleic acid", "CHEMICAL", 422, 434], ["respiratory viruses", "DISEASE", 454, 473], ["patients", "ORGANISM", 181, 189], ["chest", "ORGANISM_SUBDIVISION", 316, 321], ["kidney", "ORGAN", 378, 384], ["blood cell", "CELL", 395, 405], ["patients", "ORGANISM", 659, 667], ["COVID", "PROTEIN", 413, 418], ["Participants", "SPECIES", 70, 82], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 659, 667], ["diseases", "PROBLEM", 22, 30], ["This study", "TEST", 141, 151], ["disease exposure", "PROBLEM", 262, 278], ["fever", "PROBLEM", 280, 285], ["cough", "PROBLEM", 286, 291], ["headache", "PROBLEM", 293, 301], ["diarrhea", "PROBLEM", 303, 311], ["chest pain", "PROBLEM", 316, 326], ["The laboratory tests", "TEST", 333, 353], ["kidney function", "TEST", 378, 393], ["blood cell count", "TEST", 395, 411], ["COVID", "TEST", 413, 418], ["nucleic acid andtests", "TEST", 422, 443], ["other respiratory viruses etc", "PROBLEM", 448, 477], ["lungCT image", "TEST", 512, 524], ["drugs", "TREATMENT", 526, 531], ["comorbidities", "PROBLEM", 547, 560], ["This study", "TEST", 626, 636], ["diseases", "OBSERVATION", 22, 30], ["disease", "OBSERVATION", 262, 269], ["chest", "ANATOMY", 316, 321], ["kidney", "ANATOMY", 378, 384], ["respiratory viruses", "OBSERVATION", 454, 473]]], ["The two patient subtypes includedrehabilitation discharges and death cases.Statistical analysis ::: Materials & methodsAll data were expressed as median interquartile range (IQR), or percentages(%).", [["death", "DISEASE", 63, 68], ["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15], ["All data", "TEST", 119, 127], ["percentages", "TEST", 183, 194]]], ["Categorical data were tested using Fisher\u2019s exact testor x2 test.", [["Categorical data", "TEST", 0, 16]]], ["Normal distribution datawere tested by independent t-test, while non-normaldistribution data were tested by nonparametric Mann\u2013WhitneyU test.", [["non-normaldistribution data", "TEST", 65, 92], ["nonparametric Mann\u2013WhitneyU test", "TEST", 108, 140], ["distribution", "OBSERVATION_MODIFIER", 7, 19]]], ["A binary logistic regression analysis wasused to assess the independent predictors for the risk of nonsurvivors.", [["A binary logistic regression analysis", "TEST", 0, 37], ["nonsurvivors", "PROBLEM", 99, 111]]], ["Topredict the risk of nonsurvivors, a receiver operatingcharacteristic curve was plotted to determine the cut-off point foralbumin.", [["foralbumin", "CHEMICAL", 120, 130], ["foralbumin", "CHEMICAL", 120, 130], ["foralbumin", "SIMPLE_CHEMICAL", 120, 130], ["nonsurvivors", "PROBLEM", 22, 34], ["a receiver operatingcharacteristic curve", "TEST", 36, 76]]], ["The data were analyzed using SPSS 20.0.", [["The data", "TEST", 0, 8], ["SPSS", "TEST", 29, 33]]], ["A two-sided \u03b1 score<0.05 was considered statistically significant.ResultsIn this retrospective study, we included 134 discharged patients, including deaths.Patient demographics, characteristics, outcomes and medical expenses are summarizedin Table 1.", [["deaths", "DISEASE", 149, 155], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["Patient", "SPECIES", 156, 163], ["A two-sided \u03b1 score", "TEST", 0, 19], ["this retrospective study", "TEST", 76, 100], ["sided", "ANATOMY_MODIFIER", 6, 11]]], ["The median age of all thepatients was 61.00 years, 69 (51.49%) of the patients were>60 years of age, 65 (48.51%) were <60 years of age and75 (55.97%) of them were males.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["A total of 83.58, 96.27 and 100.00%had no history of smoking, drinking or a history of exposure to the Huanan seafoodmarket, respectively.", [["smoking", "CHEMICAL", 53, 60], ["A total", "TEST", 0, 7], ["the Huanan seafoodmarket", "TREATMENT", 99, 123], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["A total of 15 (11.19%) of the patients withCOVID-19 were medical staff.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["the patients withCOVID", "TEST", 26, 48]]], ["Some patients had comorbidities includingcardiovascular disease (44.03%), endocrine disorder (diabetes)(25.37%), digestive disorder (14.93%), respiratory disease(8.21%), neurological disease (17.16%) and solid tumor(9.70%).", [["endocrine", "ANATOMY", 74, 83], ["digestive", "ANATOMY", 113, 122], ["respiratory", "ANATOMY", 142, 153], ["neurological", "ANATOMY", 170, 182], ["solid tumor", "ANATOMY", 204, 215], ["comorbidities includingcardiovascular disease", "DISEASE", 18, 63], ["endocrine disorder", "DISEASE", 74, 92], ["diabetes", "DISEASE", 94, 102], ["digestive disorder", "DISEASE", 113, 131], ["respiratory disease", "DISEASE", 142, 161], ["neurological disease", "DISEASE", 170, 190], ["tumor", "DISEASE", 210, 215], ["patients", "ORGANISM", 5, 13], ["digestive", "ORGAN", 113, 122], ["solid tumor", "CANCER", 204, 215], ["patients", "SPECIES", 5, 13], ["comorbidities includingcardiovascular disease", "PROBLEM", 18, 63], ["endocrine disorder (diabetes)", "PROBLEM", 74, 103], ["digestive disorder", "PROBLEM", 113, 131], ["respiratory disease", "PROBLEM", 142, 161], ["neurological disease", "PROBLEM", 170, 190], ["solid tumor", "PROBLEM", 204, 215], ["digestive", "ANATOMY", 113, 122], ["respiratory disease", "OBSERVATION", 142, 161], ["solid", "ANATOMY", 204, 209], ["tumor", "OBSERVATION", 210, 215]]], ["The median hospital stays and medical expenses for all the patientswere 13.00 days and 24,093.38 yuan, respectively.", [["median", "OBSERVATION_MODIFIER", 4, 10]]], ["Forty two (31.34%)patients died due to COVID-19 pneumonia.ResultsAccording to the severity of COVID-19 pneumonia (Table 1), the increase in the median age, percentage of patients\u226560 years, percentage of patients with cardiovascular disease, and the medianmedical expenses occurred concomitantly with the severity of COVID-19 pneumonia (allp-values <0.05).", [["cardiovascular", "ANATOMY", 217, 231], ["COVID", "DISEASE", 39, 44], ["pneumonia", "DISEASE", 48, 57], ["COVID", "DISEASE", 94, 99], ["pneumonia", "DISEASE", 103, 112], ["cardiovascular disease", "DISEASE", 217, 239], ["pneumonia", "DISEASE", 325, 334], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 170, 178], ["patients", "ORGANISM", 203, 211], ["cardiovascular", "ANATOMICAL_SYSTEM", 217, 231], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 170, 178], ["patients", "SPECIES", 203, 211], ["COVID", "TEST", 39, 44], ["pneumonia", "PROBLEM", 48, 57], ["COVID", "TEST", 94, 99], ["pneumonia", "PROBLEM", 103, 112], ["cardiovascular disease", "PROBLEM", 217, 239], ["the medianmedical expenses", "PROBLEM", 245, 271], ["COVID", "TEST", 316, 321], ["pneumonia", "PROBLEM", 325, 334], ["allp", "TEST", 336, 340], ["pneumonia", "OBSERVATION", 48, 57], ["pneumonia", "OBSERVATION", 103, 112], ["increase", "OBSERVATION_MODIFIER", 128, 136], ["cardiovascular", "ANATOMY", 217, 231], ["disease", "OBSERVATION", 232, 239], ["pneumonia", "OBSERVATION", 325, 334]]], ["However, the median hospital stay was the shortest in thecritical group, as this may have been due to the quick disease progression and earlypatient death.ResultsThe clinical characteristics of the patients are summarized in Table 2.", [["death", "DISEASE", 149, 154], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["the quick disease progression", "PROBLEM", 102, 131], ["earlypatient death", "PROBLEM", 136, 154]]], ["The most common symptoms were fever(84.33%), cough (76.87%), diarrhea (20.15%), muscle pain(19.40%), generally feeling sick and vomiting (11.19%), as well as96.27% experiencing more than one symptom.", [["muscle", "ANATOMY", 80, 86], ["fever", "DISEASE", 30, 35], ["cough", "DISEASE", 45, 50], ["diarrhea", "DISEASE", 61, 69], ["muscle pain", "DISEASE", 80, 91], ["vomiting", "DISEASE", 128, 136], ["muscle", "ORGAN", 80, 86], ["The most common symptoms", "PROBLEM", 0, 24], ["fever", "PROBLEM", 30, 35], ["cough", "PROBLEM", 45, 50], ["diarrhea", "PROBLEM", 61, 69], ["muscle pain", "PROBLEM", 80, 91], ["generally feeling sick", "PROBLEM", 101, 123], ["vomiting", "PROBLEM", 128, 136], ["muscle", "ANATOMY", 80, 86]]], ["Out of the 134 patients, 62(46.27%) developed ARDS and 120 (89.55%) had bilateral pneumonia.", [["ARDS", "DISEASE", 46, 50], ["pneumonia", "DISEASE", 82, 91], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["ARDS", "PROBLEM", 46, 50], ["bilateral pneumonia", "PROBLEM", 72, 91], ["ARDS", "OBSERVATION", 46, 50], ["bilateral", "ANATOMY_MODIFIER", 72, 81], ["pneumonia", "OBSERVATION", 82, 91]]], ["Mostwere treated with oxygen (66.42%), antibiotics (97.76%), antiviraldrugs (97.76%), hormones (66.42%) and immunoglobulin (59.70%).An increase in the percentage of patients with bilateral pneumonia and hormones usedoccurred concomitantly with an increase in the severity of COVID-19 pneumonia (all p< 0.05).ResultsThe laboratory results of the patients with COVID-19 are summarized in Table 3.", [["oxygen", "CHEMICAL", 22, 28], ["pneumonia", "DISEASE", 189, 198], ["pneumonia", "DISEASE", 284, 293], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "SIMPLE_CHEMICAL", 22, 28], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 108, 122], ["patients", "ORGANISM", 165, 173], ["patients", "ORGANISM", 345, 353], ["immunoglobulin", "PROTEIN", 108, 122], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 345, 353], ["oxygen", "TREATMENT", 22, 28], ["antibiotics", "TREATMENT", 39, 50], ["antiviraldrugs", "TREATMENT", 61, 75], ["hormones", "TEST", 86, 94], ["immunoglobulin", "TEST", 108, 122], ["bilateral pneumonia and hormones", "PROBLEM", 179, 211], ["COVID", "TEST", 275, 280], ["pneumonia", "PROBLEM", 284, 293], ["COVID", "TEST", 359, 364], ["increase", "OBSERVATION_MODIFIER", 135, 143], ["percentage", "OBSERVATION_MODIFIER", 151, 161], ["bilateral", "ANATOMY_MODIFIER", 179, 188], ["pneumonia", "OBSERVATION", 189, 198], ["increase", "OBSERVATION_MODIFIER", 247, 255], ["severity", "OBSERVATION_MODIFIER", 263, 271], ["pneumonia", "OBSERVATION", 284, 293]]], ["An increase in the severity ofCOVID-19 pneumonia was associated with higher median values of leukocytes (p< 0.001), neutrophils (p < 0.001), D-dimer (p = 0.005),aspartate aminotransferase (p = 0.010), serum urea (p = 0.009),lactate dehydrogenase (p < 0.001), myoglobin (p = 0.026), glucose (p< 0.001), procalcitonin (p = 0.022) and C-reactive protein (p <0.001), lower platelets count (p = 0.005), lower albumin (p < 0.001)and lower sodium (p = 0.03).", [["leukocytes", "ANATOMY", 93, 103], ["neutrophils", "ANATOMY", 116, 127], ["serum", "ANATOMY", 201, 206], ["platelets", "ANATOMY", 369, 378], ["pneumonia", "DISEASE", 39, 48], ["aspartate", "CHEMICAL", 161, 170], ["urea", "CHEMICAL", 207, 211], ["lactate", "CHEMICAL", 224, 231], ["glucose", "CHEMICAL", 282, 289], ["sodium", "CHEMICAL", 433, 439], ["aspartate", "CHEMICAL", 161, 170], ["urea", "CHEMICAL", 207, 211], ["lactate", "CHEMICAL", 224, 231], ["glucose", "CHEMICAL", 282, 289], ["sodium", "CHEMICAL", 433, 439], ["leukocytes", "CELL", 93, 103], ["neutrophils", "CELL", 116, 127], ["D-dimer", "GENE_OR_GENE_PRODUCT", 141, 148], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 161, 187], ["serum", "ORGANISM_SUBSTANCE", 201, 206], ["urea", "SIMPLE_CHEMICAL", 207, 211], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 224, 245], ["myoglobin", "GENE_OR_GENE_PRODUCT", 259, 268], ["glucose", "SIMPLE_CHEMICAL", 282, 289], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 302, 315], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 332, 350], ["platelets", "CELL", 369, 378], ["albumin", "GENE_OR_GENE_PRODUCT", 404, 411], ["sodium", "SIMPLE_CHEMICAL", 433, 439], ["leukocytes", "CELL_TYPE", 93, 103], ["neutrophils", "CELL_TYPE", 116, 127], ["D-dimer", "PROTEIN", 141, 148], ["aspartate aminotransferase", "PROTEIN", 161, 187], ["lactate dehydrogenase", "PROTEIN", 224, 245], ["myoglobin", "PROTEIN", 259, 268], ["procalcitonin", "PROTEIN", 302, 315], ["C-reactive protein", "PROTEIN", 332, 350], ["platelets", "CELL_TYPE", 369, 378], ["the severity ofCOVID", "TEST", 15, 35], ["pneumonia", "PROBLEM", 39, 48], ["leukocytes", "TEST", 93, 103], ["neutrophils", "TEST", 116, 127], ["D-dimer", "TEST", 141, 148], ["p", "TEST", 150, 151], ["aspartate aminotransferase", "TEST", 161, 187], ["p", "TEST", 189, 190], ["serum urea", "TEST", 201, 211], ["lactate dehydrogenase", "TEST", 224, 245], ["myoglobin", "TEST", 259, 268], ["glucose", "TEST", 282, 289], ["procalcitonin", "TEST", 302, 315], ["p", "TEST", 317, 318], ["C-reactive protein", "TEST", 332, 350], ["lower platelets count", "TEST", 363, 384], ["p", "TEST", 386, 387], ["lower albumin", "TEST", 398, 411], ["lower sodium", "TEST", 427, 439], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["severity", "OBSERVATION_MODIFIER", 19, 27], ["pneumonia", "OBSERVATION", 39, 48], ["leukocytes", "ANATOMY", 93, 103]]], ["The lymphocyte counts were lower in the criticalgroup (p = 0.046).", [["lymphocyte", "ANATOMY", 4, 14], ["lymphocyte", "CELL", 4, 14], ["The lymphocyte counts", "TEST", 0, 21], ["lymphocyte counts", "OBSERVATION", 4, 21], ["lower", "OBSERVATION_MODIFIER", 27, 32]]], ["Few patients had co-infections with other viruses,bacteria, etc. The positivity rate of the first test for viral nucleic acid was33.58%.", [["co-infections", "DISEASE", 17, 30], ["nucleic acid", "CHEMICAL", 113, 125], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["co-infections", "PROBLEM", 17, 30], ["other viruses", "PROBLEM", 36, 49], ["bacteria", "PROBLEM", 50, 58], ["The positivity rate", "TEST", 65, 84], ["the first test", "TEST", 88, 102], ["viral nucleic acid", "TEST", 107, 125], ["co-infections", "OBSERVATION", 17, 30], ["bacteria", "OBSERVATION", 50, 58]]], ["Furthermore, with an increase in the severity of COVID-19 pneumonia,the positivity rate of the first test for viral nucleic acid increased accordingly(p = 0.010).ResultsA 51-year-old female medical staff tested positive for COVID-19, possibly due toexposure in the hospital and she developed fever and cough that lasted for 3 days.Her chest CT (Figure 1) showed little groundglass opacities below the right lung (Figure1A).", [["right lung", "ANATOMY", 401, 411], ["pneumonia", "DISEASE", 58, 67], ["nucleic acid", "CHEMICAL", 116, 128], ["fever", "DISEASE", 292, 297], ["cough", "DISEASE", 302, 307], ["female", "ORGANISM", 183, 189], ["lung", "ORGAN", 407, 411], ["COVID-19 pneumonia", "PROBLEM", 49, 67], ["the first test", "TEST", 91, 105], ["viral nucleic acid", "TEST", 110, 128], ["COVID", "TEST", 224, 229], ["fever", "PROBLEM", 292, 297], ["cough", "PROBLEM", 302, 307], ["Her chest CT", "TEST", 331, 343], ["little groundglass opacities", "PROBLEM", 362, 390], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["pneumonia", "OBSERVATION", 58, 67], ["fever", "OBSERVATION", 292, 297], ["cough", "OBSERVATION", 302, 307], ["chest", "ANATOMY", 335, 340], ["little", "OBSERVATION_MODIFIER", 362, 368], ["groundglass opacities", "OBSERVATION", 369, 390], ["right", "ANATOMY_MODIFIER", 401, 406], ["lung", "ANATOMY", 407, 411]]], ["On the 5th day of her admission (Figure1B), the area of ground glass opacities below the right lung increased.On the 15th (Figure 1C) and 23rd (Figure 1D) days after treatment, the ground glassopacities in the right lung gradually reduced and the lung inflammation slowlyresolved.", [["right lung", "ANATOMY", 89, 99], ["right lung", "ANATOMY", 210, 220], ["lung", "ANATOMY", 247, 251], ["inflammation", "DISEASE", 252, 264], ["lung", "ORGAN", 95, 99], ["lung", "ORGAN", 216, 220], ["lung", "ORGAN", 247, 251], ["ground glass opacities", "PROBLEM", 56, 78], ["treatment", "TREATMENT", 166, 175], ["the ground glassopacities in the right lung", "PROBLEM", 177, 220], ["the lung inflammation", "PROBLEM", 243, 264], ["area", "OBSERVATION_MODIFIER", 48, 52], ["ground glass opacities", "OBSERVATION", 56, 78], ["right", "ANATOMY_MODIFIER", 89, 94], ["lung", "ANATOMY", 95, 99], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["ground glassopacities", "OBSERVATION", 181, 202], ["right", "ANATOMY_MODIFIER", 210, 215], ["lung", "ANATOMY", 216, 220], ["gradually", "OBSERVATION_MODIFIER", 221, 230], ["reduced", "OBSERVATION_MODIFIER", 231, 238], ["lung", "ANATOMY", 247, 251], ["inflammation", "OBSERVATION", 252, 264]]], ["A 66-year-old man infected with COVID-19 due to a meal, presented withfever, cough and shortness of breath for 6 days.", [["cough", "DISEASE", 77, 82], ["shortness of breath", "DISEASE", 87, 106], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["COVID", "TREATMENT", 32, 37], ["cough", "PROBLEM", 77, 82], ["shortness of breath", "PROBLEM", 87, 106], ["infected", "OBSERVATION", 18, 26], ["cough", "OBSERVATION", 77, 82]]], ["His chest CT showed multiple,ground-glass turbidity (Figure 1E).", [["chest", "ANATOMY", 4, 9], ["His chest CT", "TEST", 0, 12], ["multiple,ground-glass turbidity", "PROBLEM", 20, 51], ["chest", "ANATOMY", 4, 9], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["glass turbidity", "OBSERVATION", 36, 51]]], ["On the 5th(Figure 1F), 9th (Figure 1G) and 20th (Figure1H) day of admission after active treatment, the ground glass opacitiesin the lungs gradually reduced and the clinical symptoms improved.ResultsThe patients in the critical group were divided into group 1 (dead) and group 2(surviving).", [["lungs", "ANATOMY", 133, 138], ["lungs", "ORGAN", 133, 138], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["active treatment", "TREATMENT", 82, 98], ["the ground glass opacitiesin the lungs", "PROBLEM", 100, 138], ["the clinical symptoms", "PROBLEM", 161, 182], ["ground glass opacitiesin", "OBSERVATION", 104, 128], ["lungs", "ANATOMY", 133, 138], ["gradually", "OBSERVATION_MODIFIER", 139, 148], ["reduced", "OBSERVATION_MODIFIER", 149, 156]]], ["The parameters affecting disease progression (p < 0.05) as inTables 1\u20133 were included in Table 4 to further explore whether disease progressionwas closely related to the risk of nonsurvivors.", [["disease progression", "PROBLEM", 25, 44], ["disease progressionwas", "PROBLEM", 124, 146], ["nonsurvivors", "PROBLEM", 178, 190], ["disease", "OBSERVATION_MODIFIER", 25, 32], ["progression", "OBSERVATION_MODIFIER", 33, 44]]], ["The clinical and laboratoryindicators, closely related to the severity of patients with COVID-19 are summarizedin Table 4.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["COVID", "TEST", 88, 93]]], ["In group 1 and group 2,the median ages were 70.00 and 55.00 years, respectively (p < 0.001).More cases of cardiovascular disease (64.29 vs 35.29%; p = 0.042),ARDS (100.00 vs 52.94%; p < 0.001) and higher median values of D-dimer(1.67 vs 0.49; p = 0.017), lactate dehydrogenase (337.50 vs 258.00; p= 0.026) and glucose (7.85 vs 7.05; p = 0.031), along with lowercounts of platelets (median, 134.00 vs 182.00; p = 0.028) and albumin(median, 33.45 vs 39.20; p < 0.001) were found in group 1, as compared withgroup 2.ResultsTaking nonsurvivors as the dependent variable, the significant risk factors (Table 4) were analyzed using a binarylogistic regression.", [["cardiovascular", "ANATOMY", 106, 120], ["platelets", "ANATOMY", 371, 380], ["cardiovascular disease", "DISEASE", 106, 128], ["ARDS", "DISEASE", 158, 162], ["lactate", "CHEMICAL", 255, 262], ["glucose", "CHEMICAL", 310, 317], ["lactate", "CHEMICAL", 255, 262], ["glucose", "CHEMICAL", 310, 317], ["cardiovascular", "ANATOMICAL_SYSTEM", 106, 120], ["D-dimer", "GENE_OR_GENE_PRODUCT", 221, 228], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 255, 276], ["glucose", "SIMPLE_CHEMICAL", 310, 317], ["platelets", "CELL", 371, 380], ["albumin", "GENE_OR_GENE_PRODUCT", 423, 430], ["lactate dehydrogenase", "PROTEIN", 255, 276], ["platelets", "CELL_TYPE", 371, 380], ["albumin", "PROTEIN", 423, 430], ["cardiovascular disease", "PROBLEM", 106, 128], ["vs", "TEST", 136, 138], ["p", "TEST", 147, 148], ["ARDS", "TEST", 158, 162], ["vs", "TEST", 171, 173], ["p", "TEST", 182, 183], ["higher median values of D-dimer", "PROBLEM", 197, 228], ["p", "TEST", 243, 244], ["lactate dehydrogenase", "TEST", 255, 276], ["vs", "TEST", 285, 287], ["p", "TEST", 296, 297], ["glucose", "TEST", 310, 317], ["p", "TEST", 333, 334], ["platelets", "TEST", 371, 380], ["vs", "TEST", 397, 399], ["p", "TEST", 408, 409], ["albumin", "TEST", 423, 430], ["vs", "TEST", 445, 447], ["p", "TEST", 455, 456], ["a binarylogistic regression", "TREATMENT", 626, 653], ["cardiovascular", "ANATOMY", 106, 120], ["ARDS", "OBSERVATION", 158, 162]]], ["Even after adjusting for age, cardiovascular disease and ARDS,plasma platelets and albumin levels were still associated with the risk ofnonsurvivors in the critical group (all p < 0.05; Table 5).ResultsA receiver operating characteristic curve analysis was performed to verify thediagnostic accuracy of the platelets and albumin levels for the risk of nonsurvivorsin the critical group.", [["cardiovascular", "ANATOMY", 30, 44], ["plasma platelets", "ANATOMY", 62, 78], ["platelets", "ANATOMY", 307, 316], ["cardiovascular disease", "DISEASE", 30, 52], ["ARDS", "DISEASE", 57, 61], ["plasma", "ORGANISM_SUBSTANCE", 62, 68], ["platelets", "CELL", 69, 78], ["albumin", "GENE_OR_GENE_PRODUCT", 83, 90], ["platelets", "CELL", 307, 316], ["albumin", "GENE_OR_GENE_PRODUCT", 321, 328], ["plasma platelets", "CELL_TYPE", 62, 78], ["albumin", "PROTEIN", 83, 90], ["platelets", "CELL_TYPE", 307, 316], ["albumin", "PROTEIN", 321, 328], ["cardiovascular disease", "PROBLEM", 30, 52], ["ARDS", "PROBLEM", 57, 61], ["plasma platelets", "TEST", 62, 78], ["albumin levels", "TEST", 83, 97], ["the risk ofnonsurvivors", "PROBLEM", 125, 148], ["characteristic curve analysis", "TEST", 223, 252], ["the platelets", "TEST", 303, 316], ["albumin levels", "TEST", 321, 335], ["cardiovascular", "ANATOMY", 30, 44], ["disease", "OBSERVATION", 45, 52], ["ARDS", "OBSERVATION", 57, 61]]], ["The area under the curve for platelets and albuminwere 0.67 (95% CI: 0.50\u20130.83; p < 0.05) and 0.79 (95%CI: 0.64\u20130.93; p < 0.001), respectively.", [["platelets", "ANATOMY", 29, 38], ["platelets", "CELL", 29, 38], ["platelets", "CELL_TYPE", 29, 38], ["the curve", "TEST", 15, 24], ["platelets", "TEST", 29, 38], ["albuminwere", "TEST", 43, 54], ["CI", "TEST", 65, 67], ["p", "TEST", 80, 81], ["CI", "TEST", 103, 105], ["p", "TEST", 118, 119]]], ["The optimal cut-off pointsfor platelet and albumin were 155.00 109/l and35.1 g/l, respectively.", [["platelet", "ANATOMY", 30, 38], ["platelet", "CELL", 30, 38], ["albumin", "GENE_OR_GENE_PRODUCT", 43, 50], ["platelet", "TEST", 30, 38], ["albumin", "TEST", 43, 50]]], ["At this level, the Youden index was: 0.36(platelet), 0.51 (albumin); sensitivity: 70.59% (platelet, 95% CI:0.44\u20130.90), 76.47% (albumin, 95% CI: 0.50\u20130.93);specificity: 65.00% (platelet, 95% CI: 0.48\u20130.79),73.81% (albumin, 95% CI: 0.58\u20130.85).", [["platelet", "ANATOMY", 42, 50], ["platelet", "ANATOMY", 90, 98], ["platelet", "ANATOMY", 176, 184], ["platelet", "CELL", 42, 50], ["albumin", "GENE_OR_GENE_PRODUCT", 59, 66], ["platelet", "CELL", 90, 98], ["albumin", "GENE_OR_GENE_PRODUCT", 127, 134], ["platelet", "CELL", 176, 184], ["albumin", "GENE_OR_GENE_PRODUCT", 213, 220], ["albumin", "PROTEIN", 127, 134], ["albumin", "PROTEIN", 213, 220], ["the Youden index", "TEST", 15, 31], ["platelet", "TEST", 42, 50], ["albumin", "TEST", 59, 66], ["sensitivity", "TEST", 69, 80], ["platelet", "TEST", 90, 98], ["CI", "TEST", 104, 106], ["albumin", "TEST", 127, 134], ["CI", "TEST", 140, 142], ["specificity", "TEST", 155, 166], ["platelet", "TEST", 176, 184], ["CI", "TEST", 190, 192], ["albumin", "TEST", 213, 220], ["CI", "TEST", 226, 228]]], ["The area under the curvefor albumin was higher than that for platelets (Figure2).", [["platelets", "ANATOMY", 61, 70], ["albumin", "GENE_OR_GENE_PRODUCT", 28, 35], ["platelets", "CELL", 61, 70], ["platelets", "CELL_TYPE", 61, 70], ["the curvefor albumin", "TEST", 15, 35], ["platelets (Figure2)", "TREATMENT", 61, 80], ["area", "OBSERVATION_MODIFIER", 4, 8]]], ["Therefore, albumin may be a better predictive marker (cut-off point:35.1 g/l) for the risk of nonsurvivors in the critical group.DiscussionIn this study, we identified differences in clinical manifestations, laboratorytests, therapeutic interventions with severity and the risk of nonsurvivors inpatients with confirmed COVID-19.", [["albumin", "GENE_OR_GENE_PRODUCT", 11, 18], ["albumin", "PROTEIN", 11, 18], ["albumin", "TREATMENT", 11, 18], ["nonsurvivors", "PROBLEM", 94, 106], ["this study", "TEST", 142, 152], ["therapeutic interventions", "TREATMENT", 225, 250], ["COVID", "TEST", 320, 325]]], ["We found that albumin may be an independentpredictive marker (cut-off point: 35.1 g/l) for the risk ofnonsurvivors in critically ill patients with confirmed COVID-19.", [["critically ill", "DISEASE", 118, 132], ["albumin", "GENE_OR_GENE_PRODUCT", 14, 21], ["patients", "ORGANISM", 133, 141], ["albumin", "PROTEIN", 14, 21], ["patients", "SPECIES", 133, 141], ["albumin", "TEST", 14, 21], ["an independentpredictive marker", "TEST", 29, 60], ["COVID", "TEST", 157, 162], ["albumin", "OBSERVATION", 14, 21], ["may be", "UNCERTAINTY", 22, 28]]], ["Our findingshighlight the clinical significance of focusing on the levels of albumin as apredictor of a high risk of nonsurvivors in critically ill patients withCOVID-19.DiscussionAlbumin is synthesized by the liver, which plays an important role in maintainingbody nutrition and osmotic pressure [13].", [["liver", "ANATOMY", 210, 215], ["maintainingbody", "ANATOMY", 250, 265], ["critically ill", "DISEASE", 133, 147], ["DiscussionAlbumin", "CHEMICAL", 170, 187], ["albumin", "GENE_OR_GENE_PRODUCT", 77, 84], ["patients", "ORGANISM", 148, 156], ["DiscussionAlbumin", "SIMPLE_CHEMICAL", 170, 187], ["liver", "ORGAN", 210, 215], ["albumin", "PROTEIN", 77, 84], ["patients", "SPECIES", 148, 156], ["albumin", "TREATMENT", 77, 84], ["withCOVID", "TEST", 157, 166], ["osmotic pressure", "TEST", 280, 296], ["liver", "ANATOMY", 210, 215]]], ["Adecrease in the levels of albumin is most likely due to liver damage and is likelyto be caused by adverse drug reactions and systemic inflammation in critically illpatients with COVID-19.", [["liver", "ANATOMY", 57, 62], ["liver damage", "DISEASE", 57, 69], ["adverse drug reactions", "DISEASE", 99, 121], ["inflammation", "DISEASE", 135, 147], ["COVID-19", "CHEMICAL", 179, 187], ["albumin", "GENE_OR_GENE_PRODUCT", 27, 34], ["liver", "ORGAN", 57, 62], ["albumin", "PROTEIN", 27, 34], ["the levels of albumin", "PROBLEM", 13, 34], ["liver damage", "PROBLEM", 57, 69], ["adverse drug reactions", "PROBLEM", 99, 121], ["systemic inflammation", "PROBLEM", 126, 147], ["COVID", "TEST", 179, 184], ["albumin", "OBSERVATION", 27, 34], ["most likely due to", "UNCERTAINTY", 38, 56], ["liver", "ANATOMY", 57, 62], ["damage", "OBSERVATION", 63, 69], ["adverse", "OBSERVATION_MODIFIER", 99, 106], ["drug reactions", "OBSERVATION", 107, 121], ["systemic", "OBSERVATION_MODIFIER", 126, 134], ["inflammation", "OBSERVATION", 135, 147]]], ["Although, several studies have reported that albumin maypredict disease severity in patients with COVID-19 [14,15], we found that incritically ill patients, if the albumin level was less than 35.1 g/l,the risk of nonsurvivors is higher (sensitivity: 76.47%, 95% CI:0.50\u20130.93; specificity: 73.81%, 95% CI: 0.58\u20130.85).However, as hypoproteinemia is defined as blood albumin <25 g/l[16], it will be too late to add albuminat this stage, as the risk of nonsurvivors would be greatly increased.", [["blood", "ANATOMY", 358, 363], ["incritically ill", "DISEASE", 130, 146], ["hypoproteinemia", "DISEASE", 328, 343], ["COVID-19", "CHEMICAL", 98, 106], ["albumin", "GENE_OR_GENE_PRODUCT", 45, 52], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 147, 155], ["albumin", "GENE_OR_GENE_PRODUCT", 164, 171], ["blood", "ORGANISM_SUBSTANCE", 358, 363], ["albumin", "GENE_OR_GENE_PRODUCT", 364, 371], ["albumin", "PROTEIN", 164, 171], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 147, 155], ["several studies", "TEST", 10, 25], ["albumin maypredict disease severity", "PROBLEM", 45, 80], ["COVID", "TEST", 98, 103], ["the albumin level", "TEST", 160, 177], ["nonsurvivors", "TEST", 213, 225], ["sensitivity", "TEST", 237, 248], ["CI", "TEST", 262, 264], ["specificity", "TEST", 276, 287], ["CI", "TEST", 301, 303], ["hypoproteinemia", "PROBLEM", 328, 343], ["blood albumin", "TEST", 358, 371], ["nonsurvivors", "PROBLEM", 449, 461], ["hypoproteinemia", "OBSERVATION", 328, 343], ["increased", "OBSERVATION_MODIFIER", 479, 488]]], ["Therefore, werecommend using drugs such as human albumin (that raise levels of albumin) to reducerisk of nonsurvivors, due to decreased levels of albumin (less than35.1 g/l) in critically ill patients.", [["critically ill", "DISEASE", 177, 191], ["human", "ORGANISM", 43, 48], ["albumin", "GENE_OR_GENE_PRODUCT", 49, 56], ["albumin", "GENE_OR_GENE_PRODUCT", 79, 86], ["albumin", "GENE_OR_GENE_PRODUCT", 146, 153], ["patients", "ORGANISM", 192, 200], ["human albumin", "PROTEIN", 43, 56], ["albumin", "PROTEIN", 79, 86], ["albumin", "PROTEIN", 146, 153], ["human", "SPECIES", 43, 48], ["patients", "SPECIES", 192, 200], ["human", "SPECIES", 43, 48], ["drugs", "TREATMENT", 29, 34], ["human albumin", "TREATMENT", 43, 56], ["levels of albumin", "TREATMENT", 69, 86], ["decreased levels of albumin", "PROBLEM", 126, 153]]], ["This may also help cliniciansidentify patients with high risk of nonsurvivors at an early stage.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["nonsurvivors", "PROBLEM", 65, 77]]], ["Low levels ofalbumin also indicate that the patient\u2019s nutritional status is poor and thebody\u2019s immunity is reduced.", [["ofalbumin", "CHEMICAL", 11, 20], ["ofalbumin", "GENE_OR_GENE_PRODUCT", 11, 20], ["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["Low levels ofalbumin", "PROBLEM", 0, 20], ["reduced", "OBSERVATION_MODIFIER", 107, 114]]], ["However, the host\u2019s immune responseagainst RNA viral infection is often weakened due to nutritional deficiencies, whichmay be overlooked during clinical diagnosis and treatment.", [["viral infection", "DISEASE", 47, 62], ["RNA viral infection", "PROBLEM", 43, 62], ["nutritional deficiencies", "PROBLEM", 88, 112], ["treatment", "TREATMENT", 167, 176], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["infection", "OBSERVATION", 53, 62], ["nutritional deficiencies", "OBSERVATION", 88, 112]]], ["Therefore, we recommendverifying the nutritional status of patients with COVID-19 before giving generaltreatments.DiscussionSimilar to previous studies [8,10,11],the elderly and male patients with cardiovascular disease had higher morbidity andmortality.", [["cardiovascular", "ANATOMY", 197, 211], ["cardiovascular disease", "DISEASE", 197, 219], ["COVID-19", "CHEMICAL", 73, 81], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 183, 191], ["COVID", "TREATMENT", 73, 78], ["previous studies", "TEST", 135, 151], ["cardiovascular disease", "PROBLEM", 197, 219], ["higher morbidity andmortality", "PROBLEM", 224, 253], ["cardiovascular", "ANATOMY", 197, 211], ["disease", "OBSERVATION", 212, 219]]], ["Fever and cough were the main symptoms.", [["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 10, 15], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 10, 15], ["the main symptoms", "PROBLEM", 21, 38], ["cough", "OBSERVATION", 10, 15]]], ["Elevated levels of neutrophils,D-dimer, lactate dehydrogenase, procalcitonin, C-reactive protein and decreasedlymphocyte count were found.", [["neutrophils", "ANATOMY", 19, 30], ["lactate", "CHEMICAL", 40, 47], ["lactate", "CHEMICAL", 40, 47], ["neutrophils", "CELL", 19, 30], ["D-dimer", "GENE_OR_GENE_PRODUCT", 31, 38], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 40, 61], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 63, 76], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 78, 96], ["neutrophils", "CELL_TYPE", 19, 30], ["D-dimer", "PROTEIN", 31, 38], ["lactate dehydrogenase", "PROTEIN", 40, 61], ["procalcitonin", "PROTEIN", 63, 76], ["C-reactive protein", "PROTEIN", 78, 96], ["Elevated levels", "PROBLEM", 0, 15], ["neutrophils", "TEST", 19, 30], ["D-dimer", "TEST", 31, 38], ["lactate dehydrogenase", "TEST", 40, 61], ["procalcitonin", "TEST", 63, 76], ["C-reactive protein", "TEST", 78, 96], ["decreasedlymphocyte count", "TEST", 101, 126], ["neutrophils", "ANATOMY", 19, 30], ["reactive protein", "OBSERVATION", 80, 96]]], ["However, the elevation of D-dimer was not shown theindependent risk factor of a nonsurvivor.", [["D-dimer", "CHEMICAL", 26, 33], ["D-dimer", "GENE_OR_GENE_PRODUCT", 26, 33], ["D-dimer", "PROTEIN", 26, 33], ["the elevation of D-dimer", "PROBLEM", 9, 33], ["elevation", "OBSERVATION_MODIFIER", 13, 22]]], ["In the critical group, there was one casewith myocardial infarction, two cases with pulmonary thromboembolism and five caseswith ischemic stroke in a group of nonsurvivors, however, there was only one casewith ischemic stroke in the group of survivors; after analysis, there was nostatistical difference between survivors and nonsurvivors in these three diseases.The proportion of patients without fever with COVID-19 was higher than that found insevere acute respiratory syndrome (SARS) coronavirus (1%) and Middle Eastrespiratory syndrome (MERS) coronavirus infection (2%) [17].", [["myocardial", "ANATOMY", 46, 56], ["pulmonary", "ANATOMY", 84, 93], ["myocardial infarction", "DISEASE", 46, 67], ["pulmonary thromboembolism", "DISEASE", 84, 109], ["ischemic stroke", "DISEASE", 129, 144], ["ischemic stroke", "DISEASE", 210, 225], ["fever", "DISEASE", 398, 403], ["COVID-19", "CHEMICAL", 409, 417], ["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 454, 499], ["Middle Eastrespiratory syndrome", "DISEASE", 509, 540], ["coronavirus infection", "DISEASE", 548, 569], ["myocardial", "MULTI-TISSUE_STRUCTURE", 46, 56], ["pulmonary", "ORGAN", 84, 93], ["patients", "ORGANISM", 381, 389], ["patients", "SPECIES", 381, 389], ["SARS) coronavirus", "SPECIES", 482, 499], ["Middle Eastrespiratory syndrome (MERS) coronavirus", "SPECIES", 509, 559], ["myocardial infarction", "PROBLEM", 46, 67], ["pulmonary thromboembolism", "PROBLEM", 84, 109], ["five caseswith ischemic stroke", "PROBLEM", 114, 144], ["ischemic stroke", "PROBLEM", 210, 225], ["analysis", "TEST", 259, 267], ["these three diseases", "PROBLEM", 342, 362], ["fever", "PROBLEM", 398, 403], ["COVID", "TEST", 409, 414], ["acute respiratory syndrome", "PROBLEM", 454, 480], ["SARS) coronavirus", "PROBLEM", 482, 499], ["Middle Eastrespiratory syndrome (MERS) coronavirus infection", "PROBLEM", 509, 569], ["myocardial", "ANATOMY", 46, 56], ["infarction", "OBSERVATION", 57, 67], ["pulmonary", "ANATOMY", 84, 93], ["thromboembolism", "OBSERVATION", 94, 109], ["ischemic", "OBSERVATION_MODIFIER", 129, 137], ["stroke", "OBSERVATION", 138, 144], ["ischemic", "OBSERVATION_MODIFIER", 210, 218], ["stroke", "OBSERVATION", 219, 225], ["acute", "OBSERVATION_MODIFIER", 454, 459], ["respiratory syndrome", "OBSERVATION", 460, 480], ["Middle", "ANATOMY_MODIFIER", 509, 515], ["Eastrespiratory syndrome", "OBSERVATION", 516, 540]]], ["Therefore, if surveillance teams focus on fever detection,patients with COVID-19 may be missed.DiscussionThe case fatality rate (31.34%) of this study was similar to that by Prof Yu(28.4%), but significantly higher than that from other studies (1.4, 3.2, 11and 15%) [1,3,8].", [["fever", "DISEASE", 42, 47], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["fever detection", "TEST", 42, 57], ["COVID", "TEST", 72, 77], ["this study", "TEST", 140, 150], ["other studies", "TEST", 230, 243]]], ["Inaddition, mortality rate in the critically ill was as high as 71.19%,probably because of the difference in sample sizes and case inclusion criteria.", [["critically ill", "DISEASE", 34, 48], ["mortality rate", "TEST", 12, 26]]], ["Thisstudy focused on discharged patients (including rehabilitation discharge and deathcases) and no inpatients were included.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["The patients studied were infected with thefirst-generation of the virus, but the virus might be more virulent now.DiscussionThe median hospital stay in the critical group was 1.5 days longer than that in themoderate group.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["infected", "PROBLEM", 26, 34], ["thefirst", "TREATMENT", 40, 48], ["the virus", "PROBLEM", 63, 72], ["the virus", "PROBLEM", 78, 87], ["virus", "OBSERVATION", 67, 72]]], ["Recently, studies have found that four patients with COVID-19 whomet criteria for the discharge requirements had positive real time reversetranscriptase PCR results after 5\u201313 days in China.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["COVID", "TEST", 53, 58], ["the discharge requirements", "PROBLEM", 82, 108], ["reversetranscriptase PCR", "TEST", 132, 156]]], ["This suggests that at aproportion of the recovered patients may still be virus carriers [18].", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["virus carriers", "PROBLEM", 73, 87]]], ["Therefore, we recommend that recoveringpatients from the severe and critical groups should have to extend the duration oftheir hospital stay, so that they can get better rehabilitation services in thehospital.DiscussionIn this study, the positivity rate for the first test for viral nucleic acid was33.58%, however, similar to previous studies, the positivity rate increasedto 78.36% after multiple tests [19].These viral nucleic acid test results were inconsistent with the patient\u2019sclinical symptoms and lung CT imaging.", [["lung", "ANATOMY", 506, 510], ["nucleic acid", "CHEMICAL", 283, 295], ["nucleic acid", "CHEMICAL", 422, 434], ["patient", "ORGANISM", 475, 482], ["lung", "ORGAN", 506, 510], ["patient", "SPECIES", 475, 482], ["this study", "TEST", 222, 232], ["the positivity rate", "TEST", 234, 253], ["the first test", "TEST", 258, 272], ["viral nucleic acid", "TEST", 277, 295], ["previous studies", "TEST", 327, 343], ["the positivity rate", "TEST", 345, 364], ["multiple tests", "TEST", 390, 404], ["These viral nucleic acid test", "TEST", 410, 439], ["the patient\u2019sclinical symptoms", "PROBLEM", 471, 501], ["lung CT imaging", "TEST", 506, 521], ["lung", "ANATOMY", 506, 510]]], ["This may have been caused by irregularsampling, incorrect PCR amplification and interpretation as well as unstablekits.", [["irregularsampling", "PROBLEM", 29, 46], ["incorrect PCR amplification", "PROBLEM", 48, 75]]], ["Therefore, rapidly optimizing the sampling site, ensuring quality of testingkits and standard operating procedure should be done urgently to provide the bestinfrastructure for the testing of COVID-19.DiscussionPrevious studies have shown that SARS and Middle East respiratory syndromecoronavirus (MERS-CoV) infection increased the levels of serum proinflammatorycytokines [20,21].", [["serum", "ANATOMY", 341, 346], ["SARS", "DISEASE", 243, 247], ["respiratory syndromecoronavirus", "DISEASE", 264, 295], ["infection", "DISEASE", 307, 316], ["COVID-19", "CHEMICAL", 191, 199], ["Middle East respiratory syndromecoronavirus", "ORGANISM", 252, 295], ["MERS-CoV", "ORGANISM", 297, 305], ["serum", "ORGANISM_SUBSTANCE", 341, 346], ["proinflammatorycytokines", "GENE_OR_GENE_PRODUCT", 347, 371], ["serum proinflammatorycytokines", "PROTEIN", 341, 371], ["Middle East respiratory syndromecoronavirus (MERS-CoV", "SPECIES", 252, 305], ["standard operating procedure", "TREATMENT", 85, 113], ["the testing", "TEST", 176, 187], ["COVID", "TEST", 191, 196], ["DiscussionPrevious studies", "TEST", 200, 226], ["SARS", "PROBLEM", 243, 247], ["Middle East respiratory syndromecoronavirus", "PROBLEM", 252, 295], ["CoV) infection", "PROBLEM", 302, 316], ["serum proinflammatorycytokines", "TEST", 341, 371], ["Middle", "ANATOMY_MODIFIER", 252, 258]]], ["In this study, we noted that higher median values of leukocytes,neutrophils and C-reactive protein were associated with the increased severity ofCOVID-19 pneumonia, which suggests that a cytokine storm is associated with diseaseseverity.", [["leukocytes", "ANATOMY", 53, 63], ["neutrophils", "ANATOMY", 64, 75], ["pneumonia", "DISEASE", 154, 163], ["leukocytes", "CELL", 53, 63], ["neutrophils", "CELL", 64, 75], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 80, 98], ["leukocytes", "CELL_TYPE", 53, 63], ["neutrophils", "CELL_TYPE", 64, 75], ["C-reactive protein", "PROTEIN", 80, 98], ["cytokine", "PROTEIN", 187, 195], ["this study", "TEST", 3, 13], ["leukocytes", "TEST", 53, 63], ["neutrophils", "TEST", 64, 75], ["C-reactive protein", "PROBLEM", 80, 98], ["the increased severity ofCOVID", "PROBLEM", 120, 150], ["19 pneumonia", "PROBLEM", 151, 163], ["a cytokine storm", "PROBLEM", 185, 201], ["diseaseseverity", "PROBLEM", 221, 236], ["leukocytes", "ANATOMY", 53, 63], ["reactive protein", "OBSERVATION", 82, 98], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["severity", "OBSERVATION_MODIFIER", 134, 142], ["pneumonia", "OBSERVATION", 154, 163], ["cytokine storm", "OBSERVATION", 187, 201]]], ["In this study, most patients were prescribed corticosteroids to reduce theinflammatory-induced lung injury.", [["lung", "ANATOMY", 95, 99], ["lung injury", "DISEASE", 95, 106], ["corticosteroids", "CHEMICAL", 45, 60], ["patients", "ORGANISM", 20, 28], ["lung", "ORGAN", 95, 99], ["patients", "SPECIES", 20, 28], ["this study", "TEST", 3, 13], ["corticosteroids", "TREATMENT", 45, 60], ["theinflammatory-induced lung injury", "PROBLEM", 71, 106], ["lung", "ANATOMY", 95, 99], ["injury", "OBSERVATION", 100, 106]]], ["However, previous studies have reported thatadministering corticosteroids in patients with SARS and MERS did not affectmortality [22,23].", [["corticosteroids", "CHEMICAL", 58, 73], ["SARS", "DISEASE", 91, 95], ["MERS", "DISEASE", 100, 104], ["corticosteroids", "CHEMICAL", 58, 73], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["previous studies", "TEST", 9, 25], ["thatadministering corticosteroids", "TREATMENT", 40, 73], ["SARS", "PROBLEM", 91, 95]]], ["Therefore, we recommend low- and moderate-dose corticosteroids forcritically ill COVID-19-positive patients.", [["corticosteroids", "CHEMICAL", 47, 62], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["moderate-dose corticosteroids", "TREATMENT", 33, 62], ["ill COVID", "TEST", 77, 86]]], ["However, the efficacy and adversereactions need to be further studied.", [["adversereactions", "TREATMENT", 26, 42]]], ["Although immunoglobulins were used extensivelyfor COVID-19, it should be noted that a third of all critically ill SARS patientsdeveloped venous thrombo-embolism including pulmonary embolism during the outbreakin Singapore in 2003 [24], due to animmunoglobulin-induced increase of viscosity in hypercoagulable states.", [["venous", "ANATOMY", 137, 143], ["pulmonary", "ANATOMY", 171, 180], ["critically ill", "DISEASE", 99, 113], ["SARS", "DISEASE", 114, 118], ["venous thrombo-embolism", "DISEASE", 137, 160], ["pulmonary embolism", "DISEASE", 171, 189], ["animmunoglobulin", "CHEMICAL", 243, 259], ["increase of viscosity", "DISEASE", 268, 289], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 9, 24], ["venous", "PATHOLOGICAL_FORMATION", 137, 143], ["pulmonary", "ORGAN", 171, 180], ["animmunoglobulin", "SIMPLE_CHEMICAL", 243, 259], ["immunoglobulins", "PROTEIN", 9, 24], ["immunoglobulins", "TREATMENT", 9, 24], ["COVID", "TEST", 50, 55], ["venous thrombo-embolism", "PROBLEM", 137, 160], ["pulmonary embolism", "PROBLEM", 171, 189], ["animmunoglobulin", "TEST", 243, 259], ["viscosity in hypercoagulable states", "PROBLEM", 280, 315], ["venous", "ANATOMY", 137, 143], ["thrombo-embolism", "OBSERVATION", 144, 160], ["pulmonary", "ANATOMY", 171, 180], ["embolism", "OBSERVATION", 181, 189], ["increase", "OBSERVATION_MODIFIER", 268, 276], ["viscosity", "OBSERVATION_MODIFIER", 280, 289], ["hypercoagulable states", "OBSERVATION", 293, 315]]], ["Therefore,immunoglobulins should be used with caution in critically ill patients withsignificantly elevated D-dimer or decreased platelets to prevent nonsurvivors frompulmonary embolism.DiscussionCurrently, there are no studies on the beneficial effects of antiviral drugs[10].", [["platelets", "ANATOMY", 129, 138], ["critically ill", "DISEASE", 57, 71], ["embolism", "DISEASE", 177, 185], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 10, 25], ["patients", "ORGANISM", 72, 80], ["D-dimer", "GENE_OR_GENE_PRODUCT", 108, 115], ["platelets", "CELL", 129, 138], ["immunoglobulins", "PROTEIN", 10, 25], ["D-dimer", "PROTEIN", 108, 115], ["platelets", "CELL_TYPE", 129, 138], ["patients", "SPECIES", 72, 80], ["immunoglobulins", "TREATMENT", 10, 25], ["elevated D-dimer", "PROBLEM", 99, 115], ["decreased platelets", "PROBLEM", 119, 138], ["nonsurvivors frompulmonary embolism", "PROBLEM", 150, 185], ["antiviral drugs", "TREATMENT", 257, 272], ["frompulmonary embolism", "OBSERVATION", 163, 185]]], ["Arbidol, oseltamivir, lopinavir andritonavir treatments are not effective.", [["Arbidol", "CHEMICAL", 0, 7], ["oseltamivir", "CHEMICAL", 9, 20], ["lopinavir andritonavir", "CHEMICAL", 22, 44], ["Arbidol", "CHEMICAL", 0, 7], ["oseltamivir", "CHEMICAL", 9, 20], ["lopinavir", "CHEMICAL", 22, 31], ["andritonavir", "CHEMICAL", 32, 44], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["oseltamivir", "SIMPLE_CHEMICAL", 9, 20], ["lopinavir andritonavir", "SIMPLE_CHEMICAL", 22, 44], ["Arbidol", "TREATMENT", 0, 7], ["oseltamivir", "TREATMENT", 9, 20], ["lopinavir andritonavir treatments", "TREATMENT", 22, 55]]], ["However, remdesivir is currently in PhaseIII clinical trials and its efficacy is unknown.", [["remdesivir", "CHEMICAL", 9, 19], ["remdesivir", "CHEMICAL", 9, 19], ["remdesivir", "SIMPLE_CHEMICAL", 9, 19]]], ["At present, some traditionalChinese medicine decoctions were used clinically, as their main action is to improvelung function and enhance host immunity against COVID-19 infection [25].DiscussionThere were some limitations in this study.", [["COVID-19", "CHEMICAL", 160, 168], ["infection", "DISEASE", 169, 178], ["COVID-19", "ORGANISM", 160, 168], ["Chinese medicine decoctions", "TREATMENT", 28, 55], ["COVID-19 infection", "PROBLEM", 160, 178], ["this study", "TEST", 225, 235]]], ["First, some cases were incompletelyrecorded and laboratory testing indicators were not complete, which will cause somedeviations.", [["laboratory testing indicators", "TEST", 48, 77], ["somedeviations", "PROBLEM", 114, 128]]], ["In addition, the sample size may not be large enough and some bias mayhave occurred.", [["the sample size", "TEST", 13, 28], ["size", "OBSERVATION_MODIFIER", 24, 28], ["may not be", "UNCERTAINTY", 29, 39], ["large", "OBSERVATION", 40, 45]]], ["Also, we undoubtedly missed asymptomatic cases, so our study cohortmay represent only the more serious COVID-19 cases.", [["our study cohortmay", "TEST", 51, 70]]], ["Finally, this is a single-centerretrospective study, so these results need further confirmation with a multicentricstudy.ConclusionAlbumin levels decreased with the progression of the disease and could be used as anindependent predictor (cut-off point: 35.1 g/l) of the risk ofnonsurvivors in critically ill patients with COVID-19.", [["ConclusionAlbumin", "CHEMICAL", 121, 138], ["critically ill", "DISEASE", 293, 307], ["COVID-19", "CHEMICAL", 322, 330], ["ConclusionAlbumin", "SIMPLE_CHEMICAL", 121, 138], ["patients", "ORGANISM", 308, 316], ["patients", "SPECIES", 308, 316], ["a single-centerretrospective study", "TEST", 17, 51], ["further confirmation", "TEST", 75, 95], ["a multicentricstudy", "TEST", 101, 120], ["ConclusionAlbumin levels", "TEST", 121, 145], ["the disease", "PROBLEM", 180, 191], ["COVID", "TEST", 322, 327], ["decreased", "OBSERVATION_MODIFIER", 146, 155], ["progression", "OBSERVATION_MODIFIER", 165, 176], ["disease", "OBSERVATION", 184, 191]]], ["This may help clinicians toidentify high risk of nonsurvivors among critically ill patients at an earlystage.", [["critically ill", "DISEASE", 68, 82], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91]]]], "PMC7152904": [["IntroductionThe World Health Organization has now declared a global emergency and pandemic for the coronavirus disease (COVID-19) that has been actively spreading around the globe.", [["coronavirus disease", "DISEASE", 99, 118], ["COVID-19", "CHEMICAL", 120, 128], ["coronavirus", "ORGANISM", 99, 110], ["pandemic", "PROBLEM", 82, 90], ["the coronavirus disease", "PROBLEM", 95, 118], ["COVID", "TEST", 120, 125], ["coronavirus disease", "OBSERVATION", 99, 118], ["actively", "OBSERVATION_MODIFIER", 144, 152], ["spreading", "OBSERVATION_MODIFIER", 153, 162], ["globe", "ANATOMY", 174, 179]]], ["COVID-19 which is caused by the virus SARS-CoV-2; can cause symptoms such as fever, cough, pneumonia, nausea, and fatigue.", [["fever", "DISEASE", 77, 82], ["cough", "DISEASE", 84, 89], ["pneumonia", "DISEASE", 91, 100], ["nausea", "DISEASE", 102, 108], ["fatigue", "DISEASE", 114, 121], ["SARS-CoV-2", "ORGANISM", 38, 48], ["COVID", "TEST", 0, 5], ["the virus SARS", "PROBLEM", 28, 42], ["symptoms", "PROBLEM", 60, 68], ["fever", "PROBLEM", 77, 82], ["cough", "PROBLEM", 84, 89], ["pneumonia", "PROBLEM", 91, 100], ["nausea", "PROBLEM", 102, 108], ["fatigue", "PROBLEM", 114, 121], ["pneumonia", "OBSERVATION", 91, 100], ["nausea", "OBSERVATION", 102, 108]]], ["As of now SARS-CoV-2 has reached 24 countries around the globe, with more than 190,000 cases confirmed as of March 18, 2020[1].IntroductionThe epidemiological background of the virus was thought to stem from a seafood market in Wuhan, China [2].", [["SARS", "DISEASE", 10, 14], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "PROBLEM", 10, 14], ["CoV", "TEST", 15, 18], ["the virus", "PROBLEM", 173, 182], ["globe", "ANATOMY", 57, 62]]], ["However, the true epicenter of the initial transfer to humans is still unknown.", [["humans", "ORGANISM", 55, 61], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 55, 61]]], ["Currently, there are >100 complete genome sequences known in the NCBI GenBank, from over 10 countries.", [["genome sequences", "DNA", 35, 51], ["NCBI GenBank", "DNA", 65, 77]]], ["The variation between these sequences is less than 1%.IntroductionThis virus is closely related to the SARS-CoV and this allows utilization of the known protein structures to quickly build a model for drug discovery on this new SARS-CoV-2 [3].", [["SARS", "DISEASE", 103, 107], ["SARS-CoV", "ORGANISM", 103, 111], ["SARS-CoV", "SPECIES", 103, 111], ["these sequences", "TEST", 22, 37], ["This virus", "PROBLEM", 66, 76], ["the SARS-CoV", "PROBLEM", 99, 111], ["the known protein structures", "PROBLEM", 143, 171], ["variation", "OBSERVATION_MODIFIER", 4, 13]]], ["While traditional methods of drug discovery could take years, the approach taken here to search for possible medications for the SARS-CoV-2 is in silico docking models from the most variable proteins in the SARS-CoV-2, the spike glycoprotein, and the SARS-CoV-2 3CL main protease.IntroductionThe CoV spike protein binds to a host cell membrane through a receptor-mediated interaction which allows entrance to the host cell.", [["cell membrane", "ANATOMY", 330, 343], ["cell", "ANATOMY", 418, 422], ["SARS", "DISEASE", 129, 133], ["SARS-CoV-2", "ORGANISM", 129, 139], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 207, 217], ["CoV", "ORGANISM", 296, 299], ["cell membrane", "CELLULAR_COMPONENT", 330, 343], ["host cell", "CELL", 413, 422], ["spike glycoprotein", "PROTEIN", 223, 241], ["SARS-CoV-2 3CL main protease", "PROTEIN", 251, 279], ["CoV spike protein", "PROTEIN", 296, 313], ["host cell", "CELL_TYPE", 413, 422], ["medications", "TREATMENT", 109, 120], ["the SARS", "PROBLEM", 125, 133], ["the SARS", "TEST", 203, 211], ["CoV", "TEST", 212, 215], ["the spike glycoprotein", "PROBLEM", 219, 241], ["the SARS", "TEST", 247, 255], ["The CoV spike protein binds", "PROBLEM", 292, 319], ["host cell membrane", "OBSERVATION", 325, 343], ["host cell", "OBSERVATION", 413, 422]]], ["It has been computationally determined that the SARS-CoV-2 has similar mechanism to that of the SARS virus and the receptor to which it has the highest affinity is ACE2 (angiotensin-converting enzyme 2) [4].", [["SARS", "DISEASE", 48, 52], ["SARS", "DISEASE", 96, 100], ["angiotensin", "CHEMICAL", 170, 181], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["SARS virus", "ORGANISM", 96, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 164, 168], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 170, 201], ["ACE2", "PROTEIN", 164, 168], ["angiotensin-converting enzyme 2", "PROTEIN", 170, 201], ["SARS virus", "SPECIES", 96, 106], ["the SARS-CoV-2", "PROBLEM", 44, 58], ["the SARS virus", "PROBLEM", 92, 106], ["ACE2 (angiotensin-converting enzyme", "TREATMENT", 164, 199]]], ["While there are structural similarities between the SARS-CoV-2 spike protein and the SARS spike protein, the conservation is only 73% with most of the variability being in the host cell interaction region of the protein.", [["cell", "ANATOMY", 181, 185], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["cell", "CELL", 181, 185], ["SARS-CoV-2 spike protein", "PROTEIN", 52, 76], ["SARS spike protein", "PROTEIN", 85, 103], ["host cell interaction region", "PROTEIN", 176, 204], ["SARS-CoV", "SPECIES", 52, 60], ["the SARS", "TEST", 48, 56], ["the SARS spike protein", "PROBLEM", 81, 103], ["host cell", "OBSERVATION", 176, 185]]], ["Currently, there is no crystal structure available for the SARS-CoV-2 spike protein, so we employed homology modeling of the SARS-CoV-2 utilizing the SARS spike protein (PDB: 2GHV) as a template.IntroductionThe second in silico docking model is the 3CLPRO main protease, which is responsible for controlling several major functions of the virus and has a highly conserved catalytic domain from the SARS virus [5].", [["SARS", "DISEASE", 398, 402], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["PDB: 2GHV", "GENE_OR_GENE_PRODUCT", 170, 179], ["SARS virus", "ORGANISM", 398, 408], ["SARS-CoV-2 spike protein", "PROTEIN", 59, 83], ["SARS spike protein", "PROTEIN", 150, 168], ["PDB", "PROTEIN", 170, 173], ["2GHV", "PROTEIN", 175, 179], ["3CLPRO main protease", "PROTEIN", 249, 269], ["catalytic domain", "PROTEIN", 372, 388], ["SARS virus", "SPECIES", 398, 408], ["crystal structure", "PROBLEM", 23, 40], ["the SARS", "TEST", 55, 63], ["2 spike protein", "PROBLEM", 68, 83], ["the SARS", "TEST", 121, 129], ["CoV", "TEST", 130, 133], ["the SARS spike protein", "PROBLEM", 146, 168], ["a template", "TREATMENT", 184, 194], ["the 3CLPRO main protease", "TREATMENT", 245, 269], ["the virus", "PROBLEM", 335, 344], ["a highly conserved catalytic domain", "PROBLEM", 353, 388], ["the SARS virus", "PROBLEM", 394, 408], ["no", "UNCERTAINTY", 20, 22], ["crystal structure", "OBSERVATION", 23, 40]]], ["Some of its functions include the replication processes of the virus which makes it an ideal target for drug development [6].", [["the virus", "PROBLEM", 59, 68]]], ["The SARS-CoV-2 main protease was determined by Ref.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2 main protease", "PROTEIN", 4, 28], ["The SARS", "TEST", 0, 8]]], ["[7] (PDB: 6LU7).IntroductionBoth these proteins, spike and protease, are essential to the transmission and virulence of the virus.", [["protease", "PROTEIN", 59, 67], ["these proteins", "TEST", 33, 47], ["spike", "PROBLEM", 49, 54], ["protease", "TREATMENT", 59, 67], ["the virus", "PROBLEM", 120, 129]]], ["By inhibiting anyone of these two proteins or both for a higher active therapy, the severity of the infection will be reduced.", [["infection", "DISEASE", 100, 109], ["a higher active therapy", "TREATMENT", 55, 78], ["the infection", "PROBLEM", 96, 109], ["infection", "OBSERVATION", 100, 109]]], ["A library of known bioactive compounds has been run against several sites on the spike protein and the catalytic site of the SARS-CoV-2 main protease.IntroductionBy utilizing an approved compound database, quick trials of these compounds, with minimal effort of approval by food and drug agencies, could be carried out.", [["spike protein", "PROTEIN", 81, 94], ["catalytic site", "PROTEIN", 103, 117], ["SARS-CoV-2 main protease", "PROTEIN", 125, 149], ["A library of known bioactive compounds", "PROBLEM", 0, 38], ["the spike protein", "TEST", 77, 94], ["the SARS", "PROBLEM", 121, 129], ["CoV", "TEST", 130, 133], ["these compounds", "TREATMENT", 222, 237], ["bioactive compounds", "OBSERVATION", 19, 38]]], ["We have chosen to run the Zinc15 database which is classified by Zinc15 [8] as \u201cApproved drugs in major jurisdictions, including the FDA, i.e DrugBank approved\u201d.", [["Zinc15", "GENE_OR_GENE_PRODUCT", 26, 32]]], ["This database covers all major bioactive pharmaceutical compounds utilized around the globe, and currently has 3447 entries.Molecular docking ::: MethodsMolecular docking calculations were completed using Schrodinger\u00ae docking suits (Schr\u00f6dinger Maestro, New York, NY, USA.", [["MethodsMolecular docking calculations", "TREATMENT", 146, 183], ["major", "OBSERVATION_MODIFIER", 25, 30], ["bioactive", "OBSERVATION_MODIFIER", 31, 40], ["pharmaceutical compounds", "OBSERVATION", 41, 65], ["globe", "ANATOMY", 86, 91]]], ["Version 11.9.011, MMshare Version 4.5.011, Release 2019\u20131, Platform Windows-x64) using a virtual screening workflow.", [["Version", "TEST", 0, 7], ["Platform Windows", "TEST", 59, 75], ["a virtual screening workflow", "TEST", 87, 115]]], ["This workflow utilized three docking precisions, HTVS, SP, and XP, which yielded the top 10% of hits for each binding site.", [["SP", "PROTEIN", 55, 57], ["HTVS", "TEST", 49, 53], ["XP", "TREATMENT", 63, 65]]], ["Both proteins were prepared by restrained minimization using force field OPLS3e.", [["force field OPLS3e", "TREATMENT", 61, 79]]], ["The grid sites were created using Glide\u00ae receptor grid generator with docking length of 20 \u00c5.", [["grid sites", "ANATOMY", 4, 14], ["grid sites", "MULTI-TISSUE_STRUCTURE", 4, 14], ["grid sites", "DNA", 4, 14], ["The grid sites", "TREATMENT", 0, 14], ["Glide\u00ae receptor grid generator", "TREATMENT", 34, 64]]], ["Grids centers were determined from active resides on target protein.", [["target protein", "PROTEIN", 53, 67], ["active", "OBSERVATION_MODIFIER", 35, 41]]], ["Ligands were prepared using force field OPLS3e and possible states were generated from pH 7.0\u00b12.0.", [["force field OPLS3e", "TEST", 28, 46], ["pH", "TEST", 87, 89]]], ["Docking scores are reported in kcal/mol, the more negative the number, the better binding.Homology modeling of spike protein ::: MethodsThe surface glycoprotein [Wuhan seafood market pneumonia virus] (Sequence ID: YP_009724390.1) structure was modeled using ModBase [9] which utilized Modeller [10] for the structural modeling.", [["surface", "ANATOMY", 140, 147], ["pneumonia", "DISEASE", 183, 192], ["spike protein", "PROTEIN", 111, 124], ["surface glycoprotein", "PROTEIN", 140, 160], ["Wuhan seafood market pneumonia virus", "SPECIES", 162, 198], ["Docking scores", "TEST", 0, 14], ["Methods", "TREATMENT", 129, 136], ["The surface glycoprotein", "TREATMENT", 136, 160], ["pneumonia virus", "PROBLEM", 183, 198], ["the structural modeling", "PROBLEM", 303, 326]]], ["The sequence (NCBI Accession: YP_009724390) was uploaded to the ModBase interface and was run with the template being SARS spike protein receptor binding domain (PDB: 2GHV, Chain E).", [["SARS spike protein receptor binding domain", "PROTEIN", 118, 160], ["2GHV", "PROTEIN", 167, 171], ["Chain E", "PROTEIN", 173, 180], ["the template", "TREATMENT", 99, 111], ["SARS spike protein receptor binding domain", "PROBLEM", 118, 160]]], ["The sequence identity was found to be 73% (Fig. 1A).", [["The sequence identity", "TEST", 0, 21]]], ["The calculation was completed and imported into Schr\u00f6dinger Maestro\u00ae.", [["The calculation", "TEST", 0, 15]]], ["The structure was then minimized using the force field OPLS3e, the overlay of the pre and post minimized structure can be seen in Fig. S2.Spike glycoprotein ::: ResultsSequencing has revealed that the SARS-CoV-2 is similar to that of the SARS-CoV virus which allows for genomic and proteomic homology comparison.", [["SARS", "DISEASE", 201, 205], ["SARS", "DISEASE", 238, 242], ["S2", "GENE_OR_GENE_PRODUCT", 135, 137], ["SARS-CoV-2", "ORGANISM", 201, 211], ["SARS-CoV virus", "ORGANISM", 238, 252], ["S2", "PROTEIN", 135, 137], ["Spike glycoprotein", "PROTEIN", 138, 156], ["SARS-CoV-2", "DNA", 201, 211], ["CoV virus", "SPECIES", 243, 252], ["SARS-CoV", "SPECIES", 201, 209], ["SARS-CoV virus", "SPECIES", 238, 252], ["the force field OPLS3e", "TEST", 39, 61], ["the SARS", "TEST", 197, 205], ["the SARS-CoV virus", "PROBLEM", 234, 252], ["genomic and proteomic homology comparison", "TEST", 270, 311]]], ["Using the homology modeling we have been able to develop a model of the Spike glycoprotein (Fig. 1).", [["Spike glycoprotein", "GENE_OR_GENE_PRODUCT", 72, 90], ["Spike glycoprotein", "PROTEIN", 72, 90], ["the Spike glycoprotein (Fig", "TREATMENT", 68, 95]]], ["This model has allowed us to perform docking calculations utilizing a database of known bioactive and approved compounds.Spike glycoprotein ::: ResultsThe MODELLER and ModBase programs were able to use a homologue SARS spike protein (PDB: 2GHV) and the original SARS-CoV-2 sequence (GenBank: MN908947) and construct the SARS-CoV-2 spike protein.", [["PDB: 2GHV", "GENE_OR_GENE_PRODUCT", 234, 243], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 320, 330], ["Spike glycoprotein", "PROTEIN", 121, 139], ["homologue SARS spike protein", "PROTEIN", 204, 232], ["2GHV", "PROTEIN", 239, 243], ["SARS-CoV-2 sequence", "DNA", 262, 281], ["SARS-CoV-2 spike protein", "PROTEIN", 320, 344], ["SARS-CoV", "SPECIES", 262, 270], ["SARS-CoV", "SPECIES", 320, 328], ["docking calculations", "TEST", 37, 57], ["ModBase programs", "TREATMENT", 168, 184], ["a homologue SARS spike protein", "TEST", 202, 232], ["the original SARS", "TEST", 249, 266], ["the SARS", "TEST", 316, 324], ["CoV", "TEST", 325, 328]]], ["The protein was then run through a restriction minimization process utilizing Schrodinger Docking Suits\u00ae Protein Preparation which allows side chains to be placed in the most energetically favorable conformation (Fig. 1B).Spike glycoprotein ::: ResultsIn an effort to stop the Spike-ACE2 interaction, several sites have been determined and targeted on the Spike protein for docking studies.", [["Spike", "GENE_OR_GENE_PRODUCT", 277, 282], ["ACE2", "GENE_OR_GENE_PRODUCT", 283, 287], ["Spike glycoprotein", "PROTEIN", 222, 240], ["Spike", "PROTEIN", 277, 282], ["ACE2", "PROTEIN", 283, 287], ["Spike protein", "PROTEIN", 356, 369], ["a restriction minimization process", "TREATMENT", 33, 67], ["Schrodinger Docking Suits", "TREATMENT", 78, 103], ["Protein Preparation", "TREATMENT", 105, 124], ["side chains", "TREATMENT", 138, 149], ["ACE2 interaction", "PROBLEM", 283, 299], ["docking studies", "TEST", 374, 389]]], ["Three of these sites are located at the interaction points specifically where hydrogen bonding is calculated as the main intermolecular force of the Spike-ACE2 interaction and a fourth allosteric site has been determined by surface mapping of the protein.Spike glycoprotein ::: ResultsThe locations of the binding sites have been chosen as these would cause the most destruction in ACE2 interactions.", [["surface", "ANATOMY", 224, 231], ["hydrogen", "CHEMICAL", 78, 86], ["hydrogen", "SIMPLE_CHEMICAL", 78, 86], ["Spike", "GENE_OR_GENE_PRODUCT", 149, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 155, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 382, 386], ["Spike", "PROTEIN", 149, 154], ["ACE2", "PROTEIN", 155, 159], ["fourth allosteric site", "PROTEIN", 178, 200], ["Spike glycoprotein", "PROTEIN", 255, 273], ["binding sites", "DNA", 306, 319], ["ACE2", "PROTEIN", 382, 386], ["hydrogen bonding", "PROBLEM", 78, 94], ["ACE2 interaction", "PROBLEM", 155, 171], ["a fourth allosteric site", "PROBLEM", 176, 200], ["the binding sites", "PROBLEM", 302, 319], ["the most destruction in ACE2 interactions", "PROBLEM", 358, 399], ["sites", "OBSERVATION_MODIFIER", 15, 20], ["hydrogen bonding", "OBSERVATION", 78, 94], ["Spike", "OBSERVATION_MODIFIER", 149, 154], ["most", "OBSERVATION_MODIFIER", 362, 366], ["destruction", "OBSERVATION", 367, 378]]], ["The sites are labeled as site 1\u20134 and information on the sites can be seen in Supplemental (Table S1, Fig. S1).", [["sites", "ANATOMY", 4, 9], ["S1", "GENE_OR_GENE_PRODUCT", 107, 109], ["site 1\u20134", "DNA", 25, 33], ["S1", "PROTEIN", 107, 109]]], ["The results from the SARS-CoV-2 spike glycoprotein are reported in Table 1.3CLPRO main protease ::: ResultsStructural alignments have revealed that the SARS-CoV-2 protease is highly conserved for that of the SARS (PDB: 1LVO) main protease at 98% ID [11].", [["SARS", "DISEASE", 21, 25], ["SARS", "DISEASE", 152, 156], ["SARS", "DISEASE", 208, 212], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 152, 162], ["SARS-CoV-2 spike glycoprotein", "PROTEIN", 21, 50], ["protease", "PROTEIN", 87, 95], ["SARS-CoV-2 protease", "PROTEIN", 152, 171], ["SARS (PDB: 1LVO) main protease", "PROTEIN", 208, 238], ["SARS-CoV", "SPECIES", 21, 29], ["the SARS", "TEST", 17, 25], ["CoV", "TEST", 26, 29], ["ResultsStructural alignments", "TEST", 100, 128], ["the SARS", "TEST", 148, 156], ["the SARS", "PROBLEM", 204, 212], ["main protease", "TREATMENT", 225, 238]]], ["The 3CLPRO main protease was run through a restriction minimization process utilizing Schrodinger Docking Suits\u00ae (Fig. S3A).", [["3CLPRO main protease", "PROTEIN", 4, 24], ["The 3CLPRO main protease", "TREATMENT", 0, 24], ["a restriction minimization process", "TREATMENT", 41, 75], ["Schrodinger Docking Suits", "TREATMENT", 86, 111]]], ["Previous studies have revealed in the SARS protease mutation of the residue His162 renders the enzyme inactive.", [["SARS", "DISEASE", 38, 42], ["His", "CHEMICAL", 76, 79], ["His162", "AMINO_ACID", 76, 82], ["SARS protease", "PROTEIN", 38, 51], ["Previous studies", "TEST", 0, 16], ["the SARS protease mutation", "PROBLEM", 34, 60], ["the residue", "TEST", 64, 75], ["the enzyme", "TEST", 91, 101]]], ["The SARS-CoV-2 homologous residue is His163 (Site 1 center: x = \u221217.59, y = 15.81, z = 63.53) (Fig. S3B) which has been used as the central point for molecular docking calculations.", [["SARS", "DISEASE", 4, 8], ["His", "CHEMICAL", 37, 40], ["SARS-CoV-2 homologous residue", "DNA", 4, 33], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["z", "TEST", 83, 84]]], ["The active site also revealed a second Histidine (center: His41 Site 2 center: x = \u221213.81, y = 19.72, z = 71.91) (Fig. S3C) that seems to play a role in the interactions of the bound ligand in the 6LU7 structure, so this was targeted as a second center point for the molecular docking calculations.", [["Histidine", "CHEMICAL", 39, 48], ["Histidine", "CHEMICAL", 39, 48], ["Histidine", "AMINO_ACID", 39, 48], ["6LU7 structure", "PROTEIN", 197, 211], ["y", "TEST", 91, 92], ["z", "TEST", 102, 103]]], ["The results from the SARS-CoV-2 3CL protease are reported in Table 2.ConclusionMolecular docking has been employed for the search of possible medications that are contained in the approved bioactive compound database.", [["SARS", "DISEASE", 21, 25], ["SARS-CoV-2 3CL protease", "PROTEIN", 21, 44], ["SARS-CoV", "SPECIES", 21, 29], ["the SARS", "TEST", 17, 25], ["CoV", "TEST", 26, 29], ["3CL protease", "TREATMENT", 32, 44], ["medications", "TREATMENT", 142, 153]]], ["The hit compounds reported here have potential to inhibit the SARS-CoV-2 spike protein and the 3CLPRO main protease but are not guaranteed to have any activity; however, this lays the groundwork for computational drug discovery for new compounds to reduce transmission and symptoms of SARS-CoV-2.", [["SARS", "DISEASE", 285, 289], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 62, 72], ["SARS-CoV-2", "ORGANISM", 285, 295], ["SARS-CoV-2 spike protein", "PROTEIN", 62, 86], ["3CLPRO main protease", "PROTEIN", 95, 115], ["SARS-CoV", "SPECIES", 285, 293], ["The hit compounds", "PROBLEM", 0, 17], ["the SARS", "TEST", 58, 66], ["CoV", "TEST", 67, 70], ["2 spike protein", "PROBLEM", 71, 86], ["the 3CLPRO main protease", "TREATMENT", 91, 115], ["new compounds", "PROBLEM", 232, 245], ["symptoms", "PROBLEM", 273, 281], ["SARS", "PROBLEM", 285, 289], ["CoV", "TEST", 290, 293]]], ["We have used structural homology modeling to determine a dock-able target for the SARS-CoV-2 spike protein and have utilized the newly characterized 3CLPRO main protease in our docking models.ConclusionWe have several exciting hits on the 3CLPRO main proteinase.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 82, 92], ["SARS-CoV-2 spike protein", "PROTEIN", 82, 106], ["3CLPRO main protease", "PROTEIN", 149, 169], ["3CLPRO main proteinase", "PROTEIN", 239, 261], ["structural homology modeling", "TEST", 13, 41], ["the SARS", "TEST", 78, 86], ["the 3CLPRO main proteinase", "TREATMENT", 235, 261], ["several", "OBSERVATION_MODIFIER", 210, 217], ["exciting", "OBSERVATION_MODIFIER", 218, 226], ["hits", "OBSERVATION", 227, 231]]], ["Zanamivir is an approved medication for the treatment of influenza A and B viruses [12].", [["Zanamivir", "CHEMICAL", 0, 9], ["influenza A and B viruses", "DISEASE", 57, 82], ["Zanamivir", "CHEMICAL", 0, 9], ["Zanamivir", "SIMPLE_CHEMICAL", 0, 9], ["influenza A", "ORGANISM", 57, 68], ["B viruses", "ORGANISM", 73, 82], ["Zanamivir", "TREATMENT", 0, 9], ["an approved medication", "TREATMENT", 13, 35], ["the treatment", "TREATMENT", 40, 53], ["influenza A and B viruses", "PROBLEM", 57, 82]]], ["Indinavir and Saquinavir have been shown to treat and prevent HIV.", [["Indinavir", "CHEMICAL", 0, 9], ["Saquinavir", "CHEMICAL", 14, 24], ["Indinavir", "CHEMICAL", 0, 9], ["Saquinavir", "CHEMICAL", 14, 24], ["Indinavir", "SIMPLE_CHEMICAL", 0, 9], ["Saquinavir", "SIMPLE_CHEMICAL", 14, 24], ["HIV", "ORGANISM", 62, 65], ["HIV", "SPECIES", 62, 65], ["HIV", "SPECIES", 62, 65], ["Indinavir", "TREATMENT", 0, 9], ["Saquinavir", "TREATMENT", 14, 24], ["HIV", "PROBLEM", 62, 65]]], ["Remdesivir is an antiviral compound in experimental stages that has shown activity against the SARS-coronavirus, Ebola virus, and possibly the SARS-CoV-2 [[13], [14], [15]].", [["Remdesivir", "CHEMICAL", 0, 10], ["SARS-coronavirus", "DISEASE", 95, 111], ["Ebola virus", "DISEASE", 113, 124], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["SARS-coronavirus", "ORGANISM", 95, 111], ["Ebola virus", "ORGANISM", 113, 124], ["[13], [14], [15]]", "SIMPLE_CHEMICAL", 155, 172], ["SARS-coronavirus", "SPECIES", 95, 111], ["Ebola virus", "SPECIES", 113, 124], ["SARS-coronavirus", "SPECIES", 95, 111], ["Ebola virus", "SPECIES", 113, 124], ["SARS-CoV", "SPECIES", 143, 151], ["Remdesivir", "TREATMENT", 0, 10], ["an antiviral compound", "TREATMENT", 14, 35], ["the SARS", "PROBLEM", 91, 99], ["coronavirus", "PROBLEM", 100, 111], ["Ebola virus", "PROBLEM", 113, 124], ["the SARS", "TEST", 139, 147], ["CoV", "TEST", 148, 151], ["antiviral compound", "OBSERVATION", 17, 35]]], ["It is also exciting to uncover that Flavin Adenine Dinucleotide (FAD) Adeflavin, B2 Deficiency medicine, and Coenzyme A, a coenzyme, may also be potentially used for the treatment of SARS-CoV-2 infections.CRediT authorship contribution statement", [["Flavin Adenine Dinucleotide", "CHEMICAL", 36, 63], ["FAD", "CHEMICAL", 65, 68], ["Adeflavin", "CHEMICAL", 70, 79], ["Coenzyme A", "CHEMICAL", 109, 119], ["SARS-CoV-2 infections", "DISEASE", 183, 204], ["Flavin Adenine Dinucleotide", "CHEMICAL", 36, 63], ["FAD", "CHEMICAL", 65, 68], ["Adeflavin", "CHEMICAL", 70, 79], ["Coenzyme A", "CHEMICAL", 109, 119], ["Flavin Adenine Dinucleotide", "SIMPLE_CHEMICAL", 36, 63], ["FAD", "SIMPLE_CHEMICAL", 65, 68], ["Adeflavin", "SIMPLE_CHEMICAL", 70, 79], ["B2", "SIMPLE_CHEMICAL", 81, 83], ["Coenzyme A", "SIMPLE_CHEMICAL", 109, 119], ["coenzyme", "SIMPLE_CHEMICAL", 123, 131], ["SARS-CoV-2", "ORGANISM", 183, 193], ["SARS-CoV", "SPECIES", 183, 191], ["Flavin Adenine Dinucleotide (FAD) Adeflavin", "TREATMENT", 36, 79], ["B2 Deficiency medicine", "TREATMENT", 81, 103], ["Coenzyme", "TREATMENT", 109, 117], ["a coenzyme", "TREATMENT", 121, 131], ["SARS", "PROBLEM", 183, 187], ["CoV-2 infections", "PROBLEM", 188, 204]]]], "PMC7365051": [["Guarantor statementDR takes responsibility for the content of the manuscript, including the data.Individual contributionsCLB and DR designed the study.", [["the data", "TEST", 88, 96], ["the study", "TEST", 141, 150]]], ["CLB and DR collected and interpreted the data.", [["CLB", "CHEMICAL", 0, 3], ["CLB", "SIMPLE_CHEMICAL", 0, 3]]], ["All authors participated to patient care and ECMO management.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["ECMO management", "TREATMENT", 45, 60]]], ["CLB, DD, JDR and DR wrote the manuscript.", [["CLB", "CHEMICAL", 0, 3], ["CLB", "PROBLEM", 0, 3], ["DD", "PROBLEM", 5, 7]]], ["All authors critically read and modified the manuscript.FundingNone.Author contributionsCLB and DR designed the study.", [["the study", "TEST", 108, 117]]], ["CLB and DR collected and interpreted the data.", [["CLB", "CHEMICAL", 0, 3], ["CLB", "SIMPLE_CHEMICAL", 0, 3]]], ["All authors participated to patient care and ECMO management.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["ECMO management", "TREATMENT", 45, 60]]], ["CLB, DD, JDR and DR wrote the manuscript.", [["CLB", "CHEMICAL", 0, 3], ["CLB", "PROBLEM", 0, 3], ["DD", "PROBLEM", 5, 7]]], ["JDR received travel support form Fisher and Paykel Healthcare.", [["travel support", "TREATMENT", 13, 27]]]], "9791652bce8752738f1bfb75305fd5faa6e30374": [["IntroductionInfluenza contributes significantly to worldwide morbidity and mortality [1] .", [["IntroductionInfluenza", "DISEASE", 0, 21]]], ["Periodically, influenza viruses mutate into antigenically-different strains leading to global pandemics [2] .", [["influenza viruses", "DISEASE", 14, 31], ["influenza viruses", "ORGANISM", 14, 31], ["influenza viruses", "PROBLEM", 14, 31], ["different strains", "PROBLEM", 58, 75], ["global pandemics", "PROBLEM", 87, 103]]], ["The 2009 influenza pandemic (pH1N1) was caused by a triple reassortment of human, swine and avian influenza viruses [3] .", [["influenza pandemic", "DISEASE", 9, 27], ["influenza viruses", "DISEASE", 98, 115], ["human", "ORGANISM", 75, 80], ["swine", "ORGANISM", 82, 87], ["avian influenza viruses", "ORGANISM", 92, 115], ["human", "SPECIES", 75, 80], ["swine", "SPECIES", 82, 87], ["avian influenza viruses", "SPECIES", 92, 115], ["human", "SPECIES", 75, 80], ["swine", "SPECIES", 82, 87], ["The 2009 influenza pandemic", "PROBLEM", 0, 27], ["H1N1", "PROBLEM", 30, 34], ["a triple reassortment of human", "TREATMENT", 50, 80], ["avian influenza viruses", "PROBLEM", 92, 115]]], ["Vaccination is the most effective intervention for preventing influenza [4] and a core part of national pandemic plans for pandemic mitigation.", [["influenza", "DISEASE", 62, 71], ["pandemic", "DISEASE", 123, 131], ["Vaccination", "TREATMENT", 0, 11], ["influenza", "PROBLEM", 62, 71], ["pandemic mitigation", "TREATMENT", 123, 142]]], ["Lead times of at least 6 months in producing a vaccine against a novel strain means that while vaccines may be unavailable in time to prevent the first wave of a pandemic [5, 6] , effective public uptake of a vaccine may mitigate subsequent waves [7] .BackgroundSignificant health promotion activities regarding influenza prevention have been prominent in Hong Kong since well before the onset of pH1N1, arising largely from the Severe Acute Respiratory Infection (SARS) epidemic and A/H5N1 Bird Flu outbreaks.", [["influenza", "DISEASE", 312, 321], ["pH1N1", "DISEASE", 397, 402], ["Acute Respiratory Infection", "DISEASE", 436, 463], ["SARS", "DISEASE", 465, 469], ["H5N1 Bird Flu", "ORGANISM", 486, 499], ["A/H5N1 Bird Flu", "SPECIES", 484, 499], ["a vaccine", "TREATMENT", 45, 54], ["vaccines", "TREATMENT", 95, 103], ["a pandemic", "PROBLEM", 160, 170], ["a vaccine", "TREATMENT", 207, 216], ["influenza prevention", "TREATMENT", 312, 332], ["pH1N1", "PROBLEM", 397, 402], ["the Severe Acute Respiratory Infection", "PROBLEM", 425, 463], ["epidemic", "PROBLEM", 471, 479], ["Significant", "OBSERVATION_MODIFIER", 262, 273], ["prominent", "OBSERVATION_MODIFIER", 343, 352], ["pH1N1", "OBSERVATION", 397, 402], ["Severe", "OBSERVATION_MODIFIER", 429, 435], ["Acute", "OBSERVATION_MODIFIER", 436, 441], ["Respiratory", "ANATOMY", 442, 453], ["Infection", "OBSERVATION", 454, 463]]], ["Seasonal influenza vaccination is widely promoted each year.", [["influenza", "DISEASE", 9, 18], ["Seasonal influenza vaccination", "TREATMENT", 0, 30]]], ["Hong Kong's pH1N1 epidemic started on 11 June 2009, peaking in September, and by early November had petered out ( Figure 1 ).", [["Hong Kong's pH1N1", "SPECIES", 0, 17]]], ["By the end of December 2009, the Hong Kong government had recorded 37,174 human pH1N1 cases [8] in a population of ,7 million.", [["human", "ORGANISM", 74, 79], ["human", "SPECIES", 74, 79], ["human pH1N1", "SPECIES", 74, 85]]], ["To minimize any potential second wave, significant televised and other publicity was given to the launch of a pH1N1 vaccination programme on 21 December 2009, initially for five priority groups: healthcare workers, persons with chronic illness and pregnant women, children aged 6 months to 6 years, adults aged 65 years or above, and pig farmers and slaughtering industry personnel [9] .", [["chronic illness", "DISEASE", 228, 243], ["persons", "ORGANISM", 215, 222], ["women", "ORGANISM", 257, 262], ["children", "ORGANISM", 264, 272], ["pig", "ORGANISM", 334, 337], ["persons", "SPECIES", 215, 222], ["women", "SPECIES", 257, 262], ["children", "SPECIES", 264, 272], ["pig", "SPECIES", 334, 337], ["pig", "SPECIES", 334, 337], ["a pH1N1 vaccination programme", "TREATMENT", 108, 137]]], ["On 26 January 2010 pH1N1 vaccination was extended to the general public.", [["pH1N1 vaccination", "TREATMENT", 19, 36]]], ["The vaccination was free for priority group members [10] , but cost HK$100-150 (US$13-20, 1-1.5% of Hong Kong's median monthly income of HK$10,000/ US$1,286/J991) per dose for the general population.", [["US", "TEST", 80, 82], ["HK", "TEST", 137, 139], ["US", "TEST", 148, 150], ["population", "OBSERVATION", 188, 198]]], ["A study in July 2009 of 301 respondents projected that vaccine uptake would be influenced by end-user cost, with 45%, of Hong Kong's general population being ''highly likely'' to take up pH1N1 vaccine if free, and 24% if costing HK [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [11, 12] .BackgroundFrom November 2009 onwards, television, radio, newspaper and official websites strongly encouraged priority groups to have pH1N1 vaccination [13] .", [["HK [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25]", "CHEMICAL", 229, 296], ["HK [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25]", "SIMPLE_CHEMICAL", 229, 296], ["A study", "TEST", 0, 7], ["H1N1 vaccine", "TREATMENT", 188, 200], ["costing HK", "TEST", 221, 231], ["pH1N1 vaccination", "TREATMENT", 440, 457]]], ["Shortly after the vaccine launch for priority groups, local media prominently attributed several adverse events to pH1N1 vaccination, including, a case of Guillain-Barre Syndrome (GBS) diagnosed a week after pH1N1 vaccination, reported on 6th January 2010, and an intrauterine death (IUD) 3 weeks following the mother's vaccination, reported on 20th January 2010 ( Figure 2 ).", [["intrauterine", "ANATOMY", 264, 276], ["pH1N1", "DISEASE", 115, 120], ["Guillain-Barre Syndrome", "DISEASE", 155, 178], ["GBS", "DISEASE", 180, 183], ["intrauterine death", "DISEASE", 264, 282], ["pH1N1", "ORGANISM", 115, 120], ["Guillain-Barre Syndrome", "ORGANISM", 155, 178], ["the vaccine", "TREATMENT", 14, 25], ["priority groups", "TREATMENT", 37, 52], ["local media", "TREATMENT", 54, 65], ["several adverse events", "PROBLEM", 89, 111], ["pH1N1 vaccination", "TREATMENT", 115, 132], ["Guillain-Barre Syndrome", "PROBLEM", 155, 178], ["GBS", "PROBLEM", 180, 183], ["pH1N1 vaccination", "TREATMENT", 208, 225], ["an intrauterine death", "PROBLEM", 261, 282], ["the mother's vaccination", "TREATMENT", 307, 331], ["Barre Syndrome", "OBSERVATION", 164, 178]]], ["In both cases local health agencies presented convincing evidence challenging the link between vaccination and the two adverse events but were largely ignored.", [["vaccination", "TREATMENT", 95, 106], ["the two adverse events", "PROBLEM", 111, 133]]], ["Retrospectively, a drop in pH1N1 vaccination uptake among priority groups was observed [14] .", [["a drop in pH1N1 vaccination uptake", "PROBLEM", 17, 51], ["drop", "OBSERVATION_MODIFIER", 19, 23]]], ["It seems probable that the adverse media reports had impeded vaccination uptake among general population.", [["the adverse media", "PROBLEM", 23, 40], ["seems probable", "UNCERTAINTY", 3, 17]]], ["We collected baseline data between 12-25 January, 2010, immediately before pH1N1 vaccine was made available to the general population and then two months later (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) March 2010) we recorded their reported vaccination status ( Figure 2 ) with the intention of modelling how general population decision-making regarding pH1N1 vaccination might predict subsequent vaccine uptake.Previous findings and knowledge gapEmpirical studies have found that history of seasonal influenza vaccination [12, [15] [16] [17] [18] , perceived risk of pandemic influenza [17, [19] [20] [21] [22] [23] [24] [25] [26] , worry [17, 22, 26, 27] , and attitudes towards vaccine, such as vaccine efficacy and side-effects [12, 15, 20, [24] [25] [26] were significantly associated with intention to receive a vaccine against the influenza pandemic.", [["influenza", "DISEASE", 539, 548], ["influenza", "DISEASE", 615, 624], ["influenza pandemic", "DISEASE", 876, 894], ["pH1N1", "ORGANISM", 392, 397], ["pH1N1 vaccine", "TREATMENT", 75, 88], ["pH1N1 vaccination", "TREATMENT", 392, 409], ["knowledge gapEmpirical studies", "TEST", 472, 502], ["seasonal influenza vaccination", "PROBLEM", 530, 560], ["pandemic influenza", "PROBLEM", 606, 624], ["worry", "TEST", 672, 677], ["vaccine", "TREATMENT", 719, 726], ["a vaccine", "TREATMENT", 854, 863], ["the influenza pandemic", "PROBLEM", 872, 894]]], ["This is consistent with the findings related to determinants of vaccination against seasonal influenza [28] [29] [30] [31] [32] .", [["influenza", "DISEASE", 93, 102], ["[28] [29] [30] [31", "SIMPLE_CHEMICAL", 103, 121], ["vaccination", "TREATMENT", 64, 75], ["seasonal influenza", "PROBLEM", 84, 102], ["consistent with", "UNCERTAINTY", 8, 23]]], ["However, there are some common and significant limitations to these empirical studies.", [["these empirical studies", "TEST", 62, 85], ["some", "OBSERVATION_MODIFIER", 19, 23], ["common", "OBSERVATION_MODIFIER", 24, 30], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["limitations", "OBSERVATION", 47, 58]]], ["First, all except one [24] relied on vaccination intention to predict the actual vaccination uptake.", [["vaccination intention", "TREATMENT", 37, 58]]], ["In one study, since only a few respondents reported having received the pH1N1 vaccine, the authors combined those intending to get vaccinated with those who had already received the vaccine into one ''intending'' group and examined factors associated with this 'vaccination intention' [20] .", [["the pH1N1 vaccine", "TREATMENT", 68, 85], ["the vaccine", "TREATMENT", 178, 189], ["this 'vaccination intention", "TREATMENT", 256, 283]]], ["This is problematic because factors associated with vaccination intention and actual vaccination receipt probably differ.", [["vaccination intention", "TREATMENT", 52, 73], ["actual vaccination receipt", "TREATMENT", 78, 104]]], ["Harris et al. found that only about half of ''intending'' recipients of seasonal influenza vaccination actually take it and almost all those who do not intend to take it remained unvaccinated [33] .", [["influenza", "DISEASE", 81, 90], ["recipients", "ORGANISM", 58, 68], ["seasonal influenza vaccination", "TREATMENT", 72, 102]]], ["Moreover, most studies conducted before the pandemic occurred or before the vaccine was available [11, 12, [16] [17] [18] [19] 21, 23] of Dutch respondents reported intending to take pH1N1 vaccination prior to or at the onset of the (potential) pandemic phase, respectively [23] .", [["most studies", "TEST", 10, 22], ["the pandemic", "PROBLEM", 40, 52], ["the vaccine", "TREATMENT", 72, 83], ["pH1N1 vaccination", "TREATMENT", 183, 200]]], ["Similarly, in Hong Kong 45% of 301 respondents in July 2009 reported being ''highly likely'' to receive pH1N1 vaccine if offered for free [11, 12] .", [["H1N1 vaccine", "TREATMENT", 105, 117]]], ["However, by the time vaccination became available intention appeared much lower with only 10-15% of study respondents in France and in Turkey intending to take the pH1N1 vaccine [20, 24] .", [["the pH1N1 vaccine", "TREATMENT", 160, 177]]], ["Second, all the studies are cross-sectional rather than longitudinal; none assessed subsequent actual vaccination status.", [["all the studies", "TEST", 8, 23]]], ["Thus, although associations have been identified, there is no way to infer causality.", [["no way", "UNCERTAINTY", 59, 65]]], ["Third, most of the studies are atheoretical.", [["the studies", "TEST", 15, 26]]], ["Although some of the studies developed their study questions based on theoretical framework such as HBM [17, 23, 24] , none have conducted model analysis and evaluated the model fit.", [["the studies", "TEST", 17, 28], ["their study", "TEST", 39, 50], ["HBM", "TEST", 100, 103], ["conducted model analysis", "TEST", 129, 153]]], ["Therefore, due to these three reasons, there remains a significant concern about how valid such results are and a significant knowledge gap about how the observed pattern of influences could be explained.Intention-behaviour relationA major limitation of previous empirical studies [12, [15] [16] [17] [18] [19] [20] [21] [22] [23] 25, 26] is failure to accommodate the intention-behaviour gap.", [["15] [16] [17] [18] [19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 287, 330], ["previous empirical studies", "TEST", 254, 280], ["failure", "PROBLEM", 342, 349], ["behaviour gap", "PROBLEM", 379, 392], ["failure", "OBSERVATION", 342, 349]]], ["Empirical studies of the intention-behavior relationship showed that intention had a medium effect (a correlation of ,0.4-0.5) on behavior [40] [41] [42] , but a recent review including 47 experimental studies found that a medium-to-large change in intention induced by manipulated interventions caused only a small-to-medium change in behavior [43] , where an effect size of 0.5 is medium and one of 0.2 is small [44] .", [["Empirical studies", "TEST", 0, 17], ["a medium effect", "PROBLEM", 83, 98], ["experimental studies", "TEST", 189, 209], ["a small-to-medium change in behavior", "PROBLEM", 308, 344], ["an effect size", "TEST", 358, 372], ["small-to-medium change", "OBSERVATION_MODIFIER", 310, 332], ["size", "OBSERVATION_MODIFIER", 368, 372], ["small", "OBSERVATION_MODIFIER", 408, 413]]], ["Factors that are prime contenders to moderate/ mediate the relationship between intention and behaviour include behavioural control/efficacy, action planning and anticipation of consequences [41] [42] [43] .Intention-behaviour relationPerceived behavioural control/self-efficacy.", [["behavioural control", "TREATMENT", 112, 131]]], ["The TPB is an extension of the TRA incorporating the concept of perceived behavioural control (PBC) as an intervening variable predicting both intention and also actual behavioural change directly [38, 39] .", [["PBC", "DISEASE", 95, 98], ["the TRA", "TREATMENT", 27, 34], ["perceived behavioural control", "TREATMENT", 64, 93]]], ["The direct effect of PBC on actual behavioural change partly explains why not all intention translates into behaviour.", [["PBC", "DISEASE", 21, 24], ["PBC on actual behavioural change", "PROBLEM", 21, 53], ["PBC", "OBSERVATION", 21, 24]]], ["Previous reviews suggested that intention-behaviour relationships could be moderated by perceived behavioral control, with higher levels of perceived behavioural control improving prediction of intention on behaviour [42, 43] .", [["perceived behavioural control", "TREATMENT", 140, 169]]], ["Although some researchers suggested that PBC differs from self-efficacy because selfefficacy emphasized perceived internal control more while PBC also considers external control factors [45] , a systemic review on the efficacy of TBP found that PBC and self-efficacy had comparable effects on intention and behaviour [41] .", [["PBC", "DISEASE", 41, 44], ["PBC", "DISEASE", 142, 145], ["PBC", "DISEASE", 245, 248], ["PBC", "CANCER", 41, 44], ["TBP", "GENE_OR_GENE_PRODUCT", 230, 233], ["TBP", "PROTEIN", 230, 233], ["PBC", "PROBLEM", 41, 44], ["selfefficacy", "PROBLEM", 80, 92], ["internal control", "TREATMENT", 114, 130], ["TBP", "PROBLEM", 230, 233], ["PBC", "PROBLEM", 245, 248]]], ["Despite being a dominant theory of behavioural change, because the TPB is limited in predicting behaviour we sought to enhance its predictive power by replacing PBC with self-efficacy and incorporating enhanced social effects to accommodate external control factors.Intention-behaviour relationImplementation of intention/planning.", [["PBC", "DISEASE", 161, 164], ["behavioural change", "PROBLEM", 35, 53], ["the TPB", "TEST", 63, 70], ["external control factors", "TREATMENT", 241, 265]]], ["A meta-analytic review showed that implementation of intention as planning consistently caused a medium-to-large effect on behavioural change [47] .Intention-behaviour relationAnticipated regret.", [["A meta-analytic review", "TEST", 0, 22], ["behavioural change", "PROBLEM", 123, 141]]], ["Anticipated regret has been found to be a strong predictor of vaccine uptake against seasonal influenza [31, 32] , playing the lottery [48] and exercise [49] .", [["influenza", "DISEASE", 94, 103], ["seasonal influenza", "PROBLEM", 85, 103]]], ["Anticipated regret might also moderate the intention-behavior relationship: the higher anticipated regret for inaction, the better the prediction of intention on behaviour [48, 49] .Our conceptual modelA robust theoretical framework comprehensively explaining behavior change that elucidates population decision-making for health protective and promoting behaviour has long been sought.", [["health protective", "TREATMENT", 323, 340], ["moderate", "OBSERVATION_MODIFIER", 30, 38]]], ["As the main contender, the TPB explains ,34% of variance in health behavioural change related to addictive behaviour, automobile-related behaviours, clinical and screening behaviour, eating behaviour, exercising behaivour, HIV/AIDS-related behaviour and oral hygiene behaivour [40] .", [["oral", "ANATOMY", 254, 258], ["eating behaviour", "DISEASE", 183, 199], ["HIV/AIDS", "DISEASE", 223, 231], ["oral", "ORGANISM_SUBDIVISION", 254, 258], ["HIV", "SPECIES", 223, 226], ["HIV", "SPECIES", 223, 226], ["variance in health behavioural change", "PROBLEM", 48, 85], ["HIV/AIDS", "PROBLEM", 223, 231], ["main", "OBSERVATION_MODIFIER", 7, 11]]], ["The standard version of TPB proposes that attitudes towards the behaviour, subjective norm and PBC predict behavioral intention while intention and PBC predict the actual behavioural change [38, 39] .", [["PBC", "DISEASE", 95, 98], ["PBC", "DISEASE", 148, 151], ["The standard version of TPB", "TREATMENT", 0, 27], ["subjective norm and PBC", "PROBLEM", 75, 98], ["PBC", "TEST", 148, 151]]], ["Two previous studies have examined modified versions of TPB to predict vaccination uptake against seasonal influenza [50, 51] .", [["influenza", "DISEASE", 107, 116], ["Two previous studies", "TEST", 0, 20], ["TPB", "TREATMENT", 56, 59], ["vaccination uptake", "TEST", 71, 89], ["seasonal influenza", "PROBLEM", 98, 116]]], ["One study used TPB plus two additional factors: influenza vaccination history and anticipated regret, to predict intention to receive vaccine against seasonal influenza among elderly from social clubs [50] : vaccination history and anticipated regret respectively accounted for an additional 10.7% and 13.7% of total variance in influenza vaccination intention [50] .", [["influenza", "DISEASE", 159, 168], ["One study", "TEST", 0, 9], ["TPB", "TREATMENT", 15, 18], ["influenza vaccination", "TREATMENT", 48, 69], ["vaccine", "TREATMENT", 134, 141], ["seasonal influenza", "PROBLEM", 150, 168], ["total variance in influenza vaccination intention", "TREATMENT", 311, 360]]], ["However, again the study was cross-sectional and actual vaccination uptake was not assessed.", [["the study", "TEST", 15, 24], ["actual vaccination uptake", "TEST", 49, 74]]], ["A second study of healthcare workers [51] adopted an extended version of TPB that included additional elements of anticipated regret, moral norm, descriptive norm and professional norm.", [["an extended version of TPB", "TREATMENT", 50, 76]]], ["The study found that controlling for the original TPB variables, moral norm and anticipated regret were significant determinants of actual receipt of seasonal influenza vaccine [51] .", [["influenza", "DISEASE", 159, 168], ["The study", "TEST", 0, 9], ["the original TPB variables", "TEST", 37, 63], ["seasonal influenza vaccine", "TREATMENT", 150, 176]]], ["The study provides useful information for future application of the extended version of TPB.", [["The study", "TEST", 0, 9], ["the extended version of TPB", "TREATMENT", 64, 91]]], ["However, since the study was conducted among healthcare workers, some of the variables such as moral norm and professional norm which emphasize obligation and professional convictions may not be applicable among the general population.Our conceptual modelFactors influencing pH1N1 vaccine uptake at the later stage of a pandemic might be more cognitively driven unlike behavioral responses during the early stage of a pandemic which might be more affect driven [52] .", [["pH1N1", "ORGANISM", 275, 280], ["the study", "TEST", 15, 24], ["pH1N1 vaccine uptake", "PROBLEM", 275, 295], ["a pandemic", "PROBLEM", 318, 328], ["a pandemic", "PROBLEM", 416, 426]]], ["Therefore, taking into account prior work on seasonal influenza vaccination uptake [50, 51] , extending the TPB could provide theoretical utility for understanding public decision on taking pH1N1 vaccination.", [["influenza", "DISEASE", 54, 63], ["pH1N1", "ORGANISM", 190, 195], ["seasonal influenza vaccination uptake", "PROBLEM", 45, 82], ["pH1N1 vaccination", "TREATMENT", 190, 207]]], ["Starting with TPB and existing literature, we therefore built a conceptual model of public decision-making for pH1N1 vaccination ( Figure 3 ).", [["pH1N1", "DISEASE", 111, 116], ["pH1N1", "ORGANISM", 111, 116], ["TPB", "TREATMENT", 14, 17], ["pH1N1 vaccination", "TREATMENT", 111, 128]]], ["In addition to the original TPB components, seasonal influenza vaccination history, anticipated regret and vaccination planning were included in the model.", [["the original TPB components", "TREATMENT", 15, 42], ["seasonal influenza vaccination history", "TREATMENT", 44, 82], ["anticipated regret", "TREATMENT", 84, 102], ["vaccination planning", "TREATMENT", 107, 127]]], ["The model proposed that attitudes towards vaccination (perceived benefits of pH1N1 vaccination and concerns regarding possible adverse effects of pH1N1 vaccination), perceived social pressures from significant others and other people around regarding pH1N1 vaccination (social norms regarding pH1N1 vaccination), perceived self-efficacy in taking vaccination (perceived self-efficacy), anticipated regret for not taking the pH1N1 vaccination (anticipated regret) and seasonal influenza vaccination history would predict vaccination intention, which in turn predicts vaccination planning and future vaccination uptake; anticipated regret and perceived self-efficacy could also predict vaccination status directly; finally, vaccination planning was proposed to bridge the intention-behavior gap and predict vaccination status directly ( Figure 3 ).Our conceptual modelWe conducted a longitudinal study of influences on pH1N1 vaccination behaviour in Hong Kong to test this model ( Figure 3) , and subsequently followed up participants to record their selfreported receipt of pH1N1 vaccine.", [["pH1N1", "DISEASE", 1073, 1078], ["people", "ORGANISM", 227, 233], ["pH1N1", "ORGANISM", 917, 922], ["pH1N1", "ORGANISM", 1073, 1078], ["people", "SPECIES", 227, 233], ["participants", "SPECIES", 1020, 1032], ["vaccination", "TREATMENT", 42, 53], ["pH1N1 vaccination", "TREATMENT", 77, 94], ["pH1N1 vaccination", "TREATMENT", 146, 163], ["pH1N1 vaccination", "TREATMENT", 251, 268], ["H1N1 vaccination", "TREATMENT", 294, 310], ["the pH1N1 vaccination", "TREATMENT", 420, 441], ["seasonal influenza vaccination", "TREATMENT", 467, 497], ["vaccination planning", "TREATMENT", 566, 586], ["future vaccination uptake", "TREATMENT", 591, 616], ["vaccination planning", "TREATMENT", 722, 742], ["behavior gap", "PROBLEM", 780, 792], ["a longitudinal study", "TEST", 879, 899], ["pH1N1 vaccination", "TREATMENT", 917, 934], ["pH1N1 vaccine", "TREATMENT", 1073, 1086]]], ["In this study, we aimed to answer the following research questions: How well does intention predict future uptake of pH1N1 vaccine?", [["pH1N1", "DISEASE", 117, 122], ["pH1N1", "ORGANISM", 117, 122], ["this study", "TEST", 3, 13], ["pH1N1 vaccine", "TREATMENT", 117, 130]]], ["And do the original TPB components and the additional components (extended social norms, anticipated regret and seasonal influenza vaccination history) contribute to peoples' decisions on vaccination uptake?Ethics statementThe study obtained ethics approval from the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.", [["the original TPB components", "TREATMENT", 7, 34], ["seasonal influenza vaccination history", "TREATMENT", 112, 150], ["vaccination uptake", "PROBLEM", 188, 206], ["The study", "TEST", 223, 232]]], ["Written informed consent was waived by the IRB because all the data were analyzed anonymously, but verbal consent was obtained from all the subjects before the interview started.SamplingHong Kong has 99% landline telephone penetration, local calls are free and telephone interviews are common and representative methods of survey data collection [53] .", [["survey data collection", "TEST", 323, 345]]], ["We conducted 13 main cross-sectional telephone surveys of psychological and behavioural responses to the first wave of the 2009 influenza A/H1N1 pandemic in Hong Kong from April through November 2009 (the parent study) [53] in order to monitor these variables.", [["influenza A/H1N1 pandemic", "DISEASE", 128, 153], ["H1N1 pandemic", "SPECIES", 140, 153], ["H1N1", "PROBLEM", 140, 144], ["the parent study", "TEST", 201, 217]]], ["As an extension, the present study re-contacted subjects from some of these surveys and sought to understand public decision-making regarding pH1N1 vaccine uptake for mitigating the potential second wave of the pandemic.", [["pH1N1", "ORGANISM", 142, 147], ["the present study", "TEST", 17, 34], ["pH1N1 vaccine uptake", "TREATMENT", 142, 162], ["the pandemic", "PROBLEM", 207, 219], ["pandemic", "OBSERVATION", 211, 219]]], ["Between 12-25 January, 2010 a baseline assessment for the present study was performed, immediately prior the local pH1N1 vaccination campaign extending to the general community (vaccination for high risk groups started from December 21, 2009), and we again contacted participants for follow-up two months later, between 15-30 March 2010.SamplingSample size determination.", [["participants", "SPECIES", 267, 279], ["a baseline assessment", "TEST", 28, 49], ["the present study", "TEST", 54, 71], ["the local pH1N1 vaccination campaign", "TREATMENT", 105, 141], ["SamplingSample size determination", "TEST", 337, 370], ["size", "OBSERVATION_MODIFIER", 352, 356]]], ["We estimated that a sample of at least 500 was required to achieve 80% power at an a = 0.05 to reject a model of the specified complexity ( Figure 3 ) if the model fit index Root Mean Square Error of Approximation (RMSEA) exceeded 0.08 [54, 55] .", [["a sample", "TEST", 18, 26]]], ["To allow for a response rate ,60% in the follow-up and the baseline surveys, we need to target at least 1,389 subjects in the baseline survey.SamplingSubject selection and inclusion criteria.", [["a response rate", "TEST", 13, 28], ["inclusion criteria", "TEST", 172, 190]]], ["A flow chart showing subject selection is provided in Figure 4 .", [["A flow chart", "TEST", 0, 12]]], ["A total of 12,965 subjects participated in the parent study [53] .", [["the parent study", "TEST", 43, 59], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["All these subjects were Cantonese-speaking adults (aged$18) selected within households using a Kish Grid methodology, who were capable of and willing to answer a telephone interview.", [["adults", "ORGANISM", 43, 49]]], ["Respondents in the 7 th , 9-12 th surveys of the 13 surveys comprising the parent study who, in the parent study agreed to be re-contacted and who had not received pH1N1 vaccine were invited to complete the baseline assessment for the present study.", [["the parent study", "TEST", 71, 87], ["pH1N1 vaccine", "TREATMENT", 164, 177], ["the baseline assessment", "TEST", 203, 226], ["the present study", "TEST", 231, 248]]], ["These five surveys (the 7 th , 9-12 th surveys) were selected because participants in these surveys had not had any follow-up contact either in the parent study or otherwise.", [["participants", "SPECIES", 70, 82], ["the parent study", "TEST", 144, 160]]], ["This minimizes interview fatigue thereby improving response rates.", [["fatigue", "DISEASE", 25, 32], ["fatigue", "PROBLEM", 25, 32]]], ["These surveys were all of a comparable sample size, between 1,000-1,007 [53] .", [["These surveys", "TEST", 0, 13], ["a comparable sample size", "TEST", 26, 50], ["size", "OBSERVATION_MODIFIER", 46, 50]]], ["Of these 78 (5%, 78/1,511) reported already having received pH1N1 vaccination and were therefore excluded as ineligible, leaving 1,433 respondents who completed baseline interviews.Data collectionThe interview questionnaire for the baseline survey was derived from literature review, our previous cross-sectional surveys [53] and the theoretical framework constructed for this study (Figure 3 ).", [["pH1N1 vaccination", "TREATMENT", 60, 77], ["Data collection", "TEST", 181, 196], ["this study", "TEST", 372, 382]]], ["Specialists in health psychology, statistics, infectious disease and public health jointly determined the measures comprising the final questionnaire, guided by the need to maintain low assessment load and parsimony to ensure good response rates.", [["infectious disease", "DISEASE", 46, 64], ["good response", "OBSERVATION", 226, 239]]], ["The finalized questionnaire consisted of five sections: Section 1 addressed respondents' self-rated health and their experience of influenzalike illness in the past six months; Section 2 addressed risk perceptions regarding pH1N1; Section 3 addressed perceived trust in information related to pH1N1 and pH1N1 vaccination from different information sources; Section 4 addressed attitudes, beliefs and social norms regarding pH1N1 vaccine/vaccination, vaccination intention and planning; Section 5 addressed key respondent demographics.", [["influenzalike illness", "DISEASE", 131, 152], ["pH1N1", "DISEASE", 224, 229], ["pH1N1", "ORGANISM", 303, 308], ["pH1N1", "ORGANISM", 423, 428], ["influenzalike illness", "PROBLEM", 131, 152], ["H1N1", "PROBLEM", 294, 298], ["pH1N1 vaccination", "TREATMENT", 303, 320], ["pH1N1 vaccine", "TREATMENT", 423, 436], ["vaccination", "TREATMENT", 437, 448]]], ["Overall, the baseline assessment consisted of 44 questions, which took less than 15 minutes to complete.", [["the baseline assessment", "TEST", 9, 32]]], ["Other demographic data were obtained from the parent study [53] .", [["Other demographic data", "TEST", 0, 22], ["the parent study", "TEST", 42, 58]]], ["Prior to baseline assessment for the present study, subjects were reminded of their prior participation and that they had agreed to participate in a further study.", [["baseline assessment", "TEST", 9, 28], ["the present study", "TEST", 33, 50], ["a further study", "TEST", 147, 162]]], ["The study was introduced as a survey of attitudes towards swine flu vaccination.", [["swine", "ORGANISM", 58, 63], ["swine", "SPECIES", 58, 63], ["swine flu", "SPECIES", 58, 67], ["The study", "TEST", 0, 9], ["swine flu vaccination", "TREATMENT", 58, 79]]], ["Subjects who reported that they had already received pH1N1 vaccination were excluded.", [["Subjects", "ORGANISM", 0, 8], ["pH1N1 vaccination", "TREATMENT", 53, 70]]], ["All the data were collected through telephone interview in both Baseline and Follow-up surveys.MeasuresThe measures comprising the study instruments were used to build the conceptual model ( Figure 3 ) and are described below and in Table 1 .MeasuresPerceived benefits of pH1N1 vaccination, and, Concerns regarding adverse effects of pH1N1 vaccination.", [["pH1N1", "ORGANISM", 272, 277], ["pH1N1", "ORGANISM", 334, 339], ["the study instruments", "TEST", 127, 148], ["pH1N1 vaccination", "TREATMENT", 272, 289], ["pH1N1 vaccination", "TREATMENT", 334, 351]]], ["These two constructs assessed attitudes towards pH1N1 vaccination.", [["pH1N1", "DISEASE", 48, 53], ["pH1N1", "ORGANISM", 48, 53], ["pH1N1 vaccination", "TREATMENT", 48, 65]]], ["Perceived benefits of pH1N1 vaccination was assessed by measuring agreement on five-point ordinal scales (from 1 ''strongly disagree'' to 5 ''strongly agree'') with three statements (Table 1) .", [["pH1N1", "ORGANISM", 22, 27], ["pH1N1 vaccination", "TREATMENT", 22, 39]]], ["A Cronbach's alpha (a) of 0.71 indicated an acceptable internal consistency for this scale and these two items were treated as the indicators of a latent scale (Perceived benefits of pH1N1 vaccination).", [["A Cronbach's alpha", "TEST", 0, 18], ["this scale", "TREATMENT", 80, 90], ["a latent scale", "TREATMENT", 145, 159], ["pH1N1 vaccination", "TREATMENT", 183, 200]]], ["Concerns regarding adverse effects of pH1N1 vaccination were assessed by measuring agreement, using fivepoint scales, with two statements.", [["pH1N1", "ORGANISM", 38, 43], ["pH1N1 vaccination", "TREATMENT", 38, 55], ["fivepoint scales", "TREATMENT", 100, 116]]], ["We therefore treated the items as reflecting a latent variable (Concerns regarding adverse effects of pH1N1 vaccination).", [["a latent variable", "PROBLEM", 45, 62], ["pH1N1 vaccination", "TREATMENT", 102, 119], ["latent", "OBSERVATION_MODIFIER", 47, 53]]], ["Social norms regarding pH1N1 vaccination.", [["pH1N1", "ORGANISM", 23, 28], ["pH1N1 vaccination", "TREATMENT", 23, 40]]], ["While TBP considers the influence of solely coercive social pressure from significant others to perform a behaviour, previous studies suggest that it is also important to consider the generalized tendency to adopt behaviours demonstrated by others encountered in daily life for imitative reasons [48, 57] .", [["TBP", "GENE_OR_GENE_PRODUCT", 6, 9], ["TBP", "PROTEIN", 6, 9], ["previous studies", "TEST", 117, 133]]], ["The internal consistency for these two items was weaker, with a = 0.53, which suggests each item appropriately measures different social influences.", [["internal", "ANATOMY_MODIFIER", 4, 12]]], ["Responses of these two items were on a 7-point categorical scale (from 1 ''definitely not'' to 7 ''certain'').", [["a 7-point categorical scale", "TREATMENT", 37, 64]]], ["The internal consistency a for these two items was 0.68.", [["internal", "ANATOMY_MODIFIER", 4, 12]]], ["The two items were used to indicate the latent variable ''anticipated regret'' in the modeling analysis.MeasuresPerceived self-efficacy.", [["the latent variable ''anticipated regret", "PROBLEM", 36, 76], ["the modeling analysis", "TEST", 82, 103]]], ["One item was used to measure selfefficacy, asking about respondents' agreement on a 5-point scale with the statement ''I am confident that I can go independently to get human swine flu vaccination''.", [["human", "ORGANISM", 169, 174], ["human", "SPECIES", 169, 174], ["swine", "SPECIES", 175, 180], ["human swine flu", "SPECIES", 169, 184], ["human swine flu vaccination", "TREATMENT", 169, 196]]], ["A standard scale of self-efficacy was not adopted to minimize assessment load.", [["A standard scale of self-efficacy", "TREATMENT", 0, 33], ["assessment load", "TEST", 62, 77]]], ["However, a single item for self-efficacy has been shown elsewhere to have validity in predicting behavioural change [59, 60] .MeasuresSeasonal influenza vaccination history.", [["validity in predicting behavioural change", "PROBLEM", 74, 115], ["MeasuresSeasonal influenza vaccination history", "TREATMENT", 126, 172]]], ["Respondents were asked whether they had received any seasonal influenza vaccination in the past three years (Yes/no/don't know).MeasuresVaccination intention.", [["any seasonal influenza vaccination", "TREATMENT", 49, 83]]], ["Respondents were asked how likely it was that they would get vaccinated against pH1N1 during the winter flu season, using a 7-point Likert scale (from 1 ''definitely not'' to 7 ''certain'').MeasuresVaccination planning.", [["pH1N1", "DISEASE", 80, 85], ["pH1N1", "ORGANISM", 80, 85], ["pH1N1", "PROBLEM", 80, 85], ["MeasuresVaccination planning", "TREATMENT", 190, 218]]], ["We measured vaccination planning by assessing respondents' agreement on a 5-point scale with three statement items, such as ''I have planned when and where to get my human swine flu vaccination this winter''.", [["human", "ORGANISM", 166, 171], ["human", "SPECIES", 166, 171], ["swine", "SPECIES", 172, 177], ["human swine flu", "SPECIES", 166, 181], ["vaccination planning", "TREATMENT", 12, 32], ["a 5-point scale", "TREATMENT", 72, 87], ["my human swine flu vaccination", "TREATMENT", 163, 193]]], ["The internal consistency a for these three items was 0.59, though less than the most common acceptable level of above 0.7, remaining at the minimal acceptable level (a ranged between 0.5-0.6) of reliability for preliminary research [56] .", [["internal", "ANATOMY_MODIFIER", 4, 12], ["minimal", "OBSERVATION_MODIFIER", 140, 147]]], ["These items were also treated as indicators of a latent variable for modeling purposes.MeasuresReported vaccination uptake.", [["modeling purposes", "TEST", 69, 86]]], ["In the follow-up survey, respondents were asked to confirm if they had received pH1N1 vaccine within the past three months.", [["pH1N1 vaccine", "TREATMENT", 80, 93]]], ["Respondents were also asked to indicate their major reasons for having or not having taken the pH1N1 vaccination using open-ended questions.", [["the pH1N1 vaccination", "TREATMENT", 91, 112]]], ["Multiple reasons could be given by each respondent.Statistical analysisWe first compared demographic differences between follow-up and lost-to-follow-up respondents with Pearson chi-square test while demographic differences of the respondents who completed both the baseline and follow-up survey and the general population [61] were assessed using Cohen's effect sizes [44] .", [["Pearson chi-square test", "TEST", 170, 193]]], ["Proportions were calculated to describe patterns of vaccination intention, reported vaccination uptake, and major reasons for taking or not taking pH1N1 vaccination.", [["vaccination intention", "PROBLEM", 52, 73], ["vaccination uptake", "PROBLEM", 84, 102], ["pH1N1 vaccination", "TREATMENT", 147, 164]]], ["Structural equation modeling was then applied to examine the determinants of pH1N1 vaccination, vaccination intention and vaccination planning based on the extension of TBP.", [["pH1N1", "ORGANISM", 77, 82], ["TBP", "GENE_OR_GENE_PRODUCT", 169, 172], ["TBP", "PROTEIN", 169, 172], ["Structural equation modeling", "TEST", 0, 28], ["pH1N1 vaccination", "TREATMENT", 77, 94], ["vaccination intention", "TREATMENT", 96, 117], ["vaccination planning", "TREATMENT", 122, 142], ["TBP", "PROBLEM", 169, 172]]], ["Mplus 6.0 for Windows (Muth\u00e9n & Muth\u00e9n, 1998 -2010 was employed because the model comprised dichotomous (vaccination status) and ordinal (vaccination intention) outcome variables.", [["the model comprised dichotomous (vaccination status)", "TREATMENT", 72, 124], ["ordinal (vaccination intention", "TREATMENT", 129, 159]]], ["Confirmatory factor analysis was performed to assess the adequacy of the measurement model including perceived benefits of pH1N1 vaccination, concerns regarding adverse effects of pH1N1 vaccination, social norms regarding pH1N1 vaccination, anticipated regret and vaccination planning.", [["pH1N1", "DISEASE", 123, 128], ["Confirmatory factor analysis", "TEST", 0, 28], ["the measurement model", "TEST", 69, 90], ["pH1N1 vaccination", "TREATMENT", 123, 140], ["pH1N1 vaccination", "TREATMENT", 180, 197], ["pH1N1 vaccination", "TREATMENT", 222, 239], ["vaccination planning", "TREATMENT", 264, 284]]], ["Mean and variance adjusted weighted least squares estimation was applied to evaluate the standardized parameters (beta, b).", [["Mean", "TEST", 0, 4], ["the standardized parameters", "TEST", 85, 112]]], ["Since chi-square test is very sensitive to sample size and non-normally distributed data, several other model fit indices were evaluated including the Comparative Fit index (CFI), the Tucker Lewis index (TLI), and RMSEA.", [["chi-square test", "TEST", 6, 21], ["sample size", "TEST", 43, 54], ["the Tucker Lewis index", "TEST", 180, 202]]], ["A CFI.0.90 and TLI.0.90 indicates a good fit.", [["A CFI", "TEST", 0, 5], ["TLI", "ANATOMY", 15, 18], ["good fit", "OBSERVATION", 36, 44]]], ["RMSEA less than 0.05 and one ranging between 0.05-0.08 respectively indicate a good and acceptable model fit [55] .", [["RMSEA", "TEST", 0, 5]]], ["Misfitting models were respecified guided by theoretical soundness and modification indices [55] .", [["modification indices", "TEST", 71, 91]]], ["Missing proportions ranged from 0.1% for seasonal flu vaccination history to 5.5% for the item ''I have planned when and where to get my pH1N1 vaccination this winter''.", [["Missing proportions", "PROBLEM", 0, 19], ["seasonal flu vaccination history", "TREATMENT", 41, 73], ["my pH1N1 vaccination", "TREATMENT", 134, 154]]], ["There was no missing data for reported vaccination uptake.", [["missing data", "PROBLEM", 13, 25], ["reported vaccination uptake", "PROBLEM", 30, 57]]], ["Missing data were handled with multiple imputation [62] .ParticipantsOf the 1433 respondents who completed the baseline assessment, 896/1433 (63%) respondents agreed to participate and completed the March follow-up survey (Figure 4 ).", [["the baseline assessment", "TEST", 107, 130]]], ["Demographic characteristics of respondents in the baseline and followup surveys are shown in Table 2 .", [["followup surveys", "TEST", 63, 79]]], ["Overall, the low Cohen effect sizes (,0.3) showed that the demographics of respondents who completed both the baseline and follow-up surveys were comparable to those of the general population of Hong Kong [61] .Vaccination intention at baseline and vaccination status at follow-upOf the 1,433 respondents who completed the baseline survey, 36% (510/1,433) reported that they would ''definitely not'' take pH1N1 vaccination during the winter flu season; 36% (521/1,433) reported being ''very unlikely/unlikely'' to take it; 19% (278/ 1,433) reported their pH1N1 vaccination likelihood as ''evens'' (50:50/equal likelihood); and only 8% (119/1,433) reported vaccination likelihood as ''likely/very likely/certain''.", [["vaccination status", "TEST", 249, 267], ["pH1N1 vaccination", "TREATMENT", 405, 422], ["low Cohen effect", "OBSERVATION_MODIFIER", 13, 29], ["sizes", "OBSERVATION_MODIFIER", 30, 35]]], ["Within the subset of 896/1,433 respondents who completed both baseline and follow-up surveys, 7% (67/896) had reported at baseline that they would be ''likely/very likely/certain'' to receive pH1N1 vaccination.", [["follow-up surveys", "TEST", 75, 92], ["H1N1 vaccination", "TREATMENT", 193, 209]]], ["However, in the follow-up survey, only 7/896 (0.8%) respondents reported having received pH1N1 vaccination in the intervening period, 4 of whom had reported being ''likely/very likely/certain'' to receive pH1N1 vaccination at baseline.Vaccination intention at baseline and vaccination status at follow-upReporting higher intention to receive pH1N1 vaccination in the baseline was associated with greater likelihood to vaccinate by follow-up (Fisher's exact test, x 2 = 24.24, p,0.001).Major reasons for receiving pH1N1 vaccineThe 7 respondents who reported taking pH1N1 vaccination gave the major reasons for deciding on vaccination as follows: Three choose vaccination because of the 'high risk of swine influenza' characterized by statements like ''swine flu is serious'', ''I am worried that swine flu will become more serious'', and ''I feel vulnerable to swine flu''; two reported that their decision was due to 'doctors' advice' and two reported 'belief of the vaccine efficacy'.", [["influenza", "DISEASE", 705, 714], ["swine", "SPECIES", 699, 704], ["swine", "SPECIES", 751, 756], ["swine", "SPECIES", 795, 800], ["swine", "SPECIES", 860, 865], ["swine", "SPECIES", 699, 704], ["swine flu", "SPECIES", 751, 760], ["swine flu", "SPECIES", 795, 804], ["swine flu", "SPECIES", 860, 869], ["pH1N1 vaccination", "TREATMENT", 89, 106], ["pH1N1 vaccination", "TREATMENT", 205, 222], ["vaccination status", "TEST", 273, 291], ["pH1N1 vaccination", "TREATMENT", 342, 359], ["Fisher's exact test", "TEST", 442, 461], ["pH1N1 vaccine", "TREATMENT", 513, 526], ["pH1N1 vaccination", "TREATMENT", 564, 581], ["Three choose vaccination", "TREATMENT", 645, 669], ["swine influenza'", "PROBLEM", 699, 715], ["the vaccine efficacy", "TREATMENT", 963, 983]]], ["Other reasons provided by one respondent only were 'belief in the vaccine's safety', 'government recommendation', 'convenient availability', and 'protection of patients'.Major reasons for not receiving pH1N1 vaccineReasons for not having vaccination given by the 889 respondents who did not receive pH1N1 vaccination ( Figure 5) were, most frequently 'low risk of or from swine influenza' (529/889, 60%) and 'concerns regarding adverse effects of the vaccine' (328/889, 37%).", [["influenza", "DISEASE", 378, 387], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["swine", "SPECIES", 372, 377], ["swine", "SPECIES", 372, 377], ["pH1N1 vaccineReasons", "TREATMENT", 202, 222], ["vaccination", "TREATMENT", 238, 249], ["pH1N1 vaccination", "TREATMENT", 299, 316], ["swine influenza'", "PROBLEM", 372, 388], ["the vaccine", "TREATMENT", 447, 458]]], ["Around 11% (100/889) of the respondents reported both 'low risk of/from swine influenza' and 'concerns regarding adverse effects of the vaccine'.", [["influenza", "DISEASE", 78, 87], ["swine", "SPECIES", 72, 77], ["swine", "SPECIES", 72, 77], ["swine influenza'", "PROBLEM", 72, 88], ["the vaccine'", "TREATMENT", 132, 144]]], ["Table 3 For the final full structural model (Figure 6 ), two additional paths were added and estimated based on the modification indices including a path from social norms to vaccination planning and path from anticipated regret to vaccination planning while the path from perceived self-efficacy to vaccination and the path from anticipated regret to vaccination were removed, coefficients for these two paths being nonsignificant and too small to be meaningful.", [["the modification indices", "TEST", 112, 136], ["vaccination planning", "TREATMENT", 175, 195], ["vaccination planning", "TREATMENT", 232, 252], ["vaccination", "TREATMENT", 300, 311], ["vaccination", "TREATMENT", 352, 363], ["too small", "OBSERVATION_MODIFIER", 436, 445]]], ["The final model indicated a good fit with CFI = 0.96, TLI = 0.93 and RMSEA = 0.06 ( Figure 6) .Structural equation model for receipt of pH1N1 vaccineThe model showed that respondents perceiving greater pH1N1vaccination benefits (b = 0.15), less concerns regarding vaccine adverse effects (b = 20.20), greater sensitivity to social norms b = 0.39), higher anticipated regret if not vaccinated (b = 0.47), higher perceived self-efficacy in taking pH1N1 vaccination (b = 0.12) and receiving seasonal influenza vaccination in the past three years (b = 0.12) reported greater intention to take pH1N1 vaccination, and accounted for 59% of variance in vaccination intention scores.", [["influenza", "DISEASE", 497, 506], ["pH1N1", "ORGANISM", 136, 141], ["CFI", "TEST", 42, 45], ["TLI", "TEST", 54, 57], ["RMSEA", "TEST", 69, 74], ["pH1N1 vaccine", "TREATMENT", 136, 149], ["vaccine adverse effects", "PROBLEM", 264, 287], ["pH1N1 vaccination", "TREATMENT", 445, 462], ["seasonal influenza vaccination", "TREATMENT", 488, 518], ["pH1N1 vaccination", "TREATMENT", 589, 606], ["good", "OBSERVATION_MODIFIER", 28, 32]]], ["Greater adherence to social norms (b = 0.70), higher vaccination intention (b = 0.31) and higher anticipated regret (b = 0.19) were associated with more vaccination planning, together accounting for 67% of variance in vaccination planning.", [["vaccination planning", "TREATMENT", 218, 238]]], ["Both vaccination intention (b = 0.30) and vaccination planning (b = 0.36) significantly predicted actual pH1N1 vaccination, accounting for 36% of variance in pH1N1 vaccination ( Figure 6 ).DiscussionThe World Health Organization recommended a stepwise use of pH1N1 vaccines for protecting people against the pH1N1 influenza pandemic in July 2009 [63] .", [["pH1N1", "DISEASE", 158, 163], ["influenza", "DISEASE", 314, 323], ["pH1N1", "ORGANISM", 259, 264], ["people", "ORGANISM", 289, 295], ["people", "SPECIES", 289, 295], ["vaccination planning", "TREATMENT", 42, 62], ["actual pH1N1 vaccination", "TREATMENT", 98, 122], ["pH1N1 vaccination", "TREATMENT", 158, 175], ["pH1N1 vaccines", "TREATMENT", 259, 273], ["the pH1N1 influenza pandemic", "PROBLEM", 304, 332]]], ["However, a vaccination program's efficacy largely depends on the public's compliance.", [["a vaccination program", "TREATMENT", 9, 30]]], ["Our study found that only 5% of 1,511 subjects reported having received pH1N1vaccination and of 1,433 subjects remaining unvaccinated, only 8% reported intending (being likely/very likely/certain) to take the pH1N1 vaccine.", [["subjects", "ORGANISM", 38, 46], ["Our study", "TEST", 0, 9], ["pH1N1vaccination", "TREATMENT", 72, 88], ["the pH1N1 vaccine", "TREATMENT", 205, 222]]], ["Two months later in the follow-up survey, an even smaller proportion, 0.8% of the respondents who completed both the baseline and follow-up survey reported having been vaccinated against pH1N1.", [["pH1N1", "SPECIES", 187, 192], ["H1N1", "PROBLEM", 188, 192], ["smaller", "OBSERVATION_MODIFIER", 50, 57]]], ["Perceived low risk of pH1N1 and concerns regarding vaccine-related adverse effects were the two most frequently cited reasons for refusing the vaccination.", [["pH1N1", "DISEASE", 22, 27], ["pH1N1", "PROBLEM", 22, 27], ["vaccine", "TREATMENT", 51, 58], ["adverse effects", "PROBLEM", 67, 82], ["the vaccination", "TREATMENT", 139, 154], ["pH1N1", "OBSERVATION", 22, 27]]], ["The extended TPB model suggests that both the original TPB components and the additional components contribute to people's decisions on vaccination uptake but that social norms and anticipated regret for not taking vaccination were the strongest determinants of vaccination intention and vaccination planning.", [["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120], ["The extended TPB model", "TREATMENT", 0, 22], ["the original TPB components", "TREATMENT", 42, 69], ["vaccination uptake", "TREATMENT", 136, 154], ["vaccination", "TREATMENT", 215, 226], ["vaccination intention", "TREATMENT", 262, 283], ["vaccination planning", "TREATMENT", 288, 308]]], ["Finally vaccination planning partially-mediated the relation between intention and reported vaccination uptake.DiscussionCompared to previous studies, vaccination intention was much lower in our study than that found in surveys conducted prior to the influenza pandemic [23] or before the vaccine was available [11] , but was comparable to the findings of surveys conducted in France [20] and Turkey [24] after pH1N1 vaccination programmes were launched there.", [["influenza", "DISEASE", 251, 260], ["pH1N1", "ORGANISM", 411, 416], ["vaccination planning", "TREATMENT", 8, 28], ["previous studies", "TEST", 133, 149], ["our study", "TEST", 191, 200], ["the influenza pandemic", "PROBLEM", 247, 269], ["the vaccine", "TREATMENT", 285, 296], ["pH1N1 vaccination programmes", "TREATMENT", 411, 439]]], ["An earlier Hong Kong study that relied on expressed intent to predict vaccination uptake [11] failed to accurately predict the subsequent meager population uptake of pH1N1 vaccination by, at best, an order of magnitude [64] , suggesting that intention alone is insufficient for predicting future vaccination uptake, consistent with empirical findings in other areas [33, 42] .DiscussionDespite predictions that intended pH1N1 vaccination uptake would decline if there was insufficient data on novel vaccine safety and efficacy [11] , safety issues were not the predominant barrier to vaccination in the present study.", [["pH1N1", "DISEASE", 166, 171], ["pH1N1", "ORGANISM", 420, 425], ["Kong study", "TEST", 16, 26], ["pH1N1 vaccination", "TREATMENT", 166, 183], ["vaccination uptake", "PROBLEM", 296, 314], ["pH1N1 vaccination uptake", "TREATMENT", 420, 444], ["novel vaccine safety", "TREATMENT", 493, 513], ["the present study", "TEST", 599, 616], ["consistent with", "UNCERTAINTY", 316, 331]]], ["While 37% of our study respondents who remained unvaccinated cited vaccine safety concerns, despite good evidence that the vaccine is effective with a risk profile similar to that of seasonal influenza vaccine [65] , almost twice as many, 60%, cited 'low risk of/from swine influenza' as their reason for not getting vaccinated, suggesting that these respondents felt no advantage would be gained by vaccination.", [["influenza", "DISEASE", 192, 201], ["influenza", "DISEASE", 274, 283], ["swine", "SPECIES", 268, 273], ["swine", "SPECIES", 268, 273], ["our study", "TEST", 13, 22], ["the vaccine", "TREATMENT", 119, 130], ["a risk profile", "PROBLEM", 149, 163], ["seasonal influenza vaccine", "TREATMENT", 183, 209], ["swine influenza'", "PROBLEM", 268, 284]]], ["Around 11% of respondents, cited both 'low risk of/ from swine influenza' and 'concerns regarding adverse effects of vaccine' as the reasons for not getting vaccinated, seemingly adopting a risk-benefit approach to vaccination decision-making.", [["influenza", "DISEASE", 63, 72], ["swine", "SPECIES", 57, 62], ["swine", "SPECIES", 57, 62], ["swine influenza'", "PROBLEM", 57, 73], ["vaccine'", "TREATMENT", 117, 125], ["vaccination decision", "TREATMENT", 215, 235]]], ["However, in the setting of low influenza risk, with the reports of vaccine related adverse events in the media after the vaccine was available for the priority groups (Figure 2) , people may shift their perceived risks away from influenza and towards vaccination, suggestive of availability bias (risk distortion by easily recalled events) [66] .", [["influenza", "DISEASE", 31, 40], ["influenza", "DISEASE", 229, 238], ["people", "ORGANISM", 180, 186], ["people", "SPECIES", 180, 186], ["low influenza risk", "PROBLEM", 27, 45], ["vaccine", "TREATMENT", 67, 74], ["adverse events", "PROBLEM", 83, 97], ["the vaccine", "TREATMENT", 117, 128], ["influenza", "PROBLEM", 229, 238], ["low", "OBSERVATION_MODIFIER", 27, 30], ["influenza", "OBSERVATION", 31, 40]]], ["We believe that perceived vaccine risk would become progressively less of a barrier to vaccination as perceived influenza risk increases, and vice versa.DiscussionMoreover, despite recent reports that Hong Kong residents would be sensitive to vaccination pricing when considering whether to vaccinate [11, 12] , only 2.5% of our respondents cited high vaccine cost as the reason for rejecting vaccination.DiscussionMajor reasons for taking pH1N1 vaccination corresponded to reasons for not taking it, with perception of pH1N1 risk most frequently cited.", [["influenza", "DISEASE", 112, 121], ["pH1N1", "DISEASE", 440, 445], ["pH1N1", "ORGANISM", 440, 445], ["perceived vaccine risk", "PROBLEM", 16, 38], ["a barrier to vaccination", "TREATMENT", 74, 98], ["perceived influenza risk", "PROBLEM", 102, 126], ["vaccination pricing", "TREATMENT", 243, 262], ["rejecting vaccination", "TREATMENT", 383, 404], ["pH1N1 vaccination", "TREATMENT", 440, 457], ["pH1N1 risk", "PROBLEM", 520, 530]]], ["However, the few respondents receiving pH1N1 vaccination prohibited meaningful comparison.DiscussionThe extended version of TPB model fits well to the survey data.", [["pH1N1", "ORGANISM", 39, 44], ["pH1N1 vaccination", "TREATMENT", 39, 56], ["The extended version of TPB model", "TREATMENT", 100, 133], ["the survey data", "TEST", 147, 162], ["few", "OBSERVATION_MODIFIER", 13, 16]]], ["The model showed that an expanded social norms and anticipated regret accounted for most of the variance in vaccination intention, rather than the more core elements of TPB.", [["TPB", "TREATMENT", 169, 172]]], ["In turn, social norms independently accounted for more than twice the variance in vaccination planning than did intention, and vaccination planning accounted for more variance in vaccination uptake than did intention.", [["vaccination planning", "TREATMENT", 82, 102], ["vaccination planning", "TREATMENT", 127, 147]]], ["Thus it seems that social norms comprise the major influences on vaccination uptake through modifying vaccination intention and planning.", [["vaccination uptake", "TREATMENT", 65, 83]]], ["A meta-analytic review of TPB efficacy concluded that the TPB variable subjective norm (perceived coercive social pressure from significant others) weakly predicted intention compared to other TPB components, mainly due to poor measurement [41] .", [["TPB efficacy", "TREATMENT", 26, 38], ["the TPB variable subjective norm", "PROBLEM", 54, 86]]], ["''Descriptive norm'' (perception of what other people do, imitation or conformity behaviour) is reportedly a more important predictor for intention [48, 57] .", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53]]], ["Correlations, means, standard deviations, and standardized factor loadings for the measurement model. measures of subjective and descriptive norms, treated as a latent variable (social norms), because they were found to have much the same predictive direction and weight.", [["standardized factor loadings", "TREATMENT", 46, 74], ["the measurement model", "TEST", 79, 100], ["weight", "TEST", 264, 270]]], ["This model importantly informs public health approaches to population behaviour during respiratory epidemics.", [["respiratory epidemics", "DISEASE", 87, 108], ["respiratory epidemics", "PROBLEM", 87, 108]]], ["First, information uncertainty or untrustworthiness, for example regarding vaccine safety, is likely to prompt people look to others for their cues to action: the social environment, namely what other people believe and do powerfully influences decisions to action [45, 67] .", [["people", "ORGANISM", 111, 117], ["people", "ORGANISM", 201, 207], ["people", "SPECIES", 111, 117], ["people", "SPECIES", 201, 207], ["untrustworthiness", "PROBLEM", 34, 51]]], ["People often tend to imitate others, so establishing a ''vaccination trend'' may help uptake.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["a ''vaccination", "TREATMENT", 53, 68]]], ["Second, encouraging uptake of a new vaccine will be problematic if the associated threat element is low, irrespective of vaccine pricing, particularly for novel and untested vaccines.", [["a new vaccine", "TREATMENT", 30, 43], ["vaccine pricing", "TREATMENT", 121, 136], ["novel and untested vaccines", "TREATMENT", 155, 182]]], ["Vaccine safety and efficacy data should be provided wherever possible at all levels including through health-care providers, media and the general public.", [["Vaccine", "TREATMENT", 0, 7], ["efficacy data", "TEST", 19, 32]]], ["To effectively communicate the risk and benefit of a novel vaccine, it is important to establish an effective surveillance system to monitor vaccination progammes and rapidly respond to any reported adverse events [70] .", [["a novel vaccine", "TREATMENT", 51, 66], ["vaccination progammes", "TREATMENT", 141, 162], ["any reported adverse events", "PROBLEM", 186, 213]]], ["Public health agencies need to improve their liaison with influential media outlets to minimize this, where possible.", [["influential media outlets", "TREATMENT", 58, 83]]], ["Third, omission bias, a phenomenon where people view vaccination as more risky than remaining unvaccinated, could be a barrier for vaccination [71] .", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["a phenomenon", "PROBLEM", 22, 34], ["people view vaccination", "TREATMENT", 41, 64]]], ["Omission bias arises when there is anticipation of greater regret about adverse effects of vaccination, if taken, than the regret about being infected with influenza if vaccination is rejected [72] .", [["influenza", "DISEASE", 156, 165], ["vaccination", "TREATMENT", 91, 102], ["influenza", "PROBLEM", 156, 165]]], ["Therefore, social marketing emphasizing the far greater likelihood of regret for consequences due to refusing vaccination than the regret over an improbably low adverse event due to taking vaccination may help to reduce this bias.", [["vaccination", "TREATMENT", 110, 121], ["an improbably low adverse event", "PROBLEM", 143, 174], ["vaccination", "TREATMENT", 189, 200]]], ["For example, previous studies found that simply asking two questions about feeling regret for inaction could increase respondents' intention to play a lottery or do exercise [48, 49] .", [["previous studies", "TEST", 13, 29]]], ["Finally, vaccination planning is a key intervening variable between vaccination intention and actual vaccination.", [["vaccination planning", "TREATMENT", 9, 29], ["vaccination intention", "TREATMENT", 68, 89], ["actual vaccination", "TREATMENT", 94, 112]]], ["This could include suggesting where, when and how to get vaccination, improving and publicizing accessibility of vaccination centres and opening times.", [["vaccination", "TREATMENT", 57, 68], ["vaccination centres", "TREATMENT", 113, 132]]], ["Even so, intention and planning explained only 36% of the variance in the reported vaccination behaviour, suggesting that other factors, such as intention stability [42] , influencing vaccination behaviour await identification.DiscussionStudy limitations include baseline attitudes/beliefs, vaccination intention and planning being measured at the same time point, prohibiting exploration of causality in observed associations.", [["vaccination intention", "TREATMENT", 291, 312]]], ["Some study measures were constrained due to length of telephone interviewing, and while sub-optimal were necessary methodological compromises.", [["Some study measures", "TEST", 0, 19], ["methodological compromises", "PROBLEM", 115, 141]]], ["Although most researchers recommended Cronbach's a of 0.7 as the minimal acceptable for internal consistency of multi-item scales, others accept 0.6 or 0.5-0.6 for preliminary research as the cut-off point [56] .", [["Cronbach's a", "TEST", 38, 50]]], ["Other than dimensionality concerns, lower a can reflect too few items comprising the putative scale [73] .", [["too few items", "PROBLEM", 56, 69]]], ["This is more likely for complex variables, such as social norms which have a broad spectrum of elements.", [["complex variables", "PROBLEM", 24, 41], ["more likely for", "UNCERTAINTY", 8, 23]]], ["Additionally, collinearity between exogenous indicators, such as social norms and perceived benefit can be potentially problematic, perhaps lowering the accuracy of SEM estimation.", [["SEM estimation", "TEST", 165, 179]]], ["However, since high associations between measures of the constructs were not observed (Table 3) then collinearity-related error is probably small [74] .", [["probably", "UNCERTAINTY", 131, 139], ["small", "OBSERVATION_MODIFIER", 140, 145]]], ["Despite being randomly selected for the parent study, subjects of this study were not randomly selected from the general population, although demographics suggest the current sample is comparable to the Hong Kong general population [61] (Table 2 ).", [["the parent study", "TEST", 36, 52], ["this study", "TEST", 66, 76]]], ["Moreover, subject recruitment was based on voluntariness and all data were selfreported.", [["voluntariness", "PROBLEM", 43, 56], ["all data", "TEST", 61, 69]]], ["Our study examined public decision-making regarding a novel influenza pandemic vaccine.", [["influenza pandemic", "DISEASE", 60, 78], ["Our study", "TEST", 0, 9], ["a novel influenza pandemic vaccine", "TREATMENT", 52, 86]]], ["Our findings may not apply to vaccination against seasonal influenza due to numerous differences in beliefs towards the vaccination.", [["influenza", "DISEASE", 59, 68], ["vaccination", "TREATMENT", 30, 41], ["seasonal influenza", "PROBLEM", 50, 68], ["the vaccination", "TREATMENT", 116, 131]]], ["For example, although perceived low risk remains the major reasons for refusing vaccination against seasonal influenza as in our study, vaccine safety is seldom cited as a barrier [28, 29] whereas we found that about one third of respondents had vaccine safety concerns.", [["influenza", "DISEASE", 109, 118], ["perceived low risk", "PROBLEM", 22, 40], ["refusing vaccination", "TREATMENT", 71, 91], ["seasonal influenza", "PROBLEM", 100, 118], ["our study", "TEST", 125, 134], ["vaccine", "TREATMENT", 136, 143]]], ["Cultural differences in influenza and vaccination-related beliefs are possible [75] , but these differences may gradually diminish with the increasing identical news information available through the three dominant news agencies and common public health strategies being increasingly universal.", [["influenza", "DISEASE", 24, 33], ["Cultural differences", "PROBLEM", 0, 20], ["influenza", "PROBLEM", 24, 33], ["vaccination", "TREATMENT", 38, 49], ["influenza", "OBSERVATION", 24, 33]]], ["Related stories, such as use of preservatives and adjuvants in vaccine manufacture may enhance knowledge and reduce trust in product safety [76] .", [["preservatives", "TREATMENT", 32, 45], ["adjuvants in vaccine manufacture", "TREATMENT", 50, 82]]], ["Finally, data was insufficient to reliably report the reasons for pH1N1 vaccination uptake among the population.DiscussionNonetheless, compared with other cross-sectional studies [12, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , the longitudinal design of this study strengthens understanding of influences on population decision-making for pandemic influenza vaccination uptake and represents a step forward in this area of research.", [["[15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26]", "CHEMICAL", 184, 243], ["influenza", "DISEASE", 372, 381], ["[15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27]", "SIMPLE_CHEMICAL", 184, 248], ["pH1N1 vaccination uptake", "TREATMENT", 66, 90], ["other cross-sectional studies", "TEST", 149, 178], ["pandemic influenza vaccination uptake", "PROBLEM", 363, 400]]], ["This study is novel in linking theoretically derived, vaccination-related cognitions to subsequent influenza vaccination behaviour, and exemplifies that within the Hong Kong Chinese culture, social norms and action planning are far more influential than intention in predicting vaccination behaviour.", [["influenza", "DISEASE", 99, 108], ["This study", "TEST", 0, 10], ["vaccination", "TREATMENT", 54, 65], ["subsequent influenza vaccination behaviour", "PROBLEM", 88, 130], ["Chinese culture", "TEST", 174, 189], ["action planning", "TREATMENT", 208, 223]]]], "709daf5bc174d7a1680ab08bee0f6850ff7265f4": [["preexposure prophylaxis appointments have been canceled.", [["preexposure prophylaxis", "TREATMENT", 0, 23]]], ["If you have had a recent exposure, need postexposure prophylaxis, or have an urgent question, please call the triage nurse.\" 4 The NYC Planned Parenthood clinics moved to a virtual appointment only model: \"All services will be virtual, except for abortion services and select in-person visits.\" 5 Finally, New York-Presbyterian Hospital's human immunodeficiency virus (HIV) Prevention Program began tapering services starting March 19, 2020, limiting onsite visits to only urgent cases, such as postexposure prophylaxis.", [["human immunodeficiency virus (HIV)", "DISEASE", 339, 373], ["human immunodeficiency virus", "ORGANISM", 339, 367], ["human", "SPECIES", 339, 344], ["immunodeficiency virus", "SPECIES", 345, 367], ["human immunodeficiency virus", "SPECIES", 339, 367], ["HIV", "SPECIES", 369, 372], ["postexposure prophylaxis", "TREATMENT", 40, 64], ["postexposure prophylaxis", "TREATMENT", 495, 519]]], ["Those patients with symptomatic STIs were discouraged from coming into clinic to avoid their risk of COVID-19 exposure and were treated presumptively with a corresponding telehealth visit.", [["STIs", "DISEASE", 32, 36], ["COVID-19", "CHEMICAL", 101, 109], ["COVID-19", "CHEMICAL", 101, 109], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["symptomatic STIs", "PROBLEM", 20, 36]]], ["Preexposure prophylaxis prescriptions were refilled without quarterly STI and HIV screening. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf.", [["HIV", "SPECIES", 78, 81], ["HIV", "SPECIES", 78, 81], ["Preexposure prophylaxis prescriptions", "TREATMENT", 0, 37], ["HIV screening", "TEST", 78, 91]]]], "PMC7119199": [["IntroductionAn increasing body of evidences in the last two decades have been reported on the presence of autoantibodies directed to a heterogeneous family of structural endothelial proteins, as well as antigens adhering to endothelial cells (ECs) in patients with diseases characterized by endothelial damage (Fig. 1).", [["body", "ANATOMY", 26, 30], ["endothelial", "ANATOMY", 170, 181], ["endothelial cells", "ANATOMY", 224, 241], ["ECs", "ANATOMY", 243, 246], ["endothelial", "ANATOMY", 291, 302], ["endothelial damage", "DISEASE", 291, 309], ["endothelial", "CELL", 170, 181], ["endothelial cells", "CELL", 224, 241], ["ECs", "CELL", 243, 246], ["patients", "ORGANISM", 251, 259], ["endothelial", "TISSUE", 291, 302], ["autoantibodies", "PROTEIN", 106, 120], ["structural endothelial proteins", "PROTEIN", 159, 190], ["antigens", "PROTEIN", 203, 211], ["endothelial cells", "CELL_TYPE", 224, 241], ["ECs", "CELL_TYPE", 243, 246], ["patients", "SPECIES", 251, 259], ["autoantibodies", "PROBLEM", 106, 120], ["structural endothelial proteins", "PROBLEM", 159, 190], ["diseases", "PROBLEM", 265, 273], ["endothelial damage", "PROBLEM", 291, 309], ["structural endothelial proteins", "OBSERVATION", 159, 190], ["endothelial cells", "OBSERVATION", 224, 241], ["endothelial", "ANATOMY", 291, 302], ["damage", "OBSERVATION", 303, 309]]], ["Vascular ECs play an important role in many processes such as blood pressure regulation, coagulation, fibrinolysis, angiogenesis, and blood cell activation during physiological and pathological processes [1].", [["Vascular ECs", "ANATOMY", 0, 12], ["blood", "ANATOMY", 62, 67], ["blood cell", "ANATOMY", 134, 144], ["Vascular ECs", "CELL", 0, 12], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["blood cell", "CELL", 134, 144], ["Vascular ECs", "CELL_TYPE", 0, 12], ["blood pressure regulation", "TEST", 62, 87], ["fibrinolysis", "PROBLEM", 102, 114], ["angiogenesis", "PROBLEM", 116, 128], ["blood cell activation", "TEST", 134, 155]]], ["So far, anti\u2010endothelial cell antibodies (AECA) have been correlated with both disease activity and vascular involvement in several diseases.", [["anti\u2010endothelial cell", "ANATOMY", 8, 29], ["vascular", "ANATOMY", 100, 108], ["anti\u2010endothelial cell antibodies", "GENE_OR_GENE_PRODUCT", 8, 40], ["AECA", "GENE_OR_GENE_PRODUCT", 42, 46], ["vascular", "MULTI-TISSUE_STRUCTURE", 100, 108], ["anti\u2010endothelial cell antibodies", "PROTEIN", 8, 40], ["AECA", "PROTEIN", 42, 46], ["anti\u2010endothelial cell antibodies", "TEST", 8, 40], ["AECA", "TEST", 42, 46], ["both disease activity", "PROBLEM", 74, 95], ["several diseases", "PROBLEM", 124, 140], ["both", "OBSERVATION_MODIFIER", 74, 78], ["disease", "OBSERVATION", 79, 86], ["vascular", "ANATOMY", 100, 108], ["several", "OBSERVATION_MODIFIER", 124, 131], ["diseases", "OBSERVATION", 132, 140]]], ["Much effort has been made to determine whether AECA mediated\u2010mechanisms underlie the development of diseases or merely represent markers of vascular damage.", [["vascular", "ANATOMY", 140, 148], ["vascular damage", "DISEASE", 140, 155], ["AECA", "GENE_OR_GENE_PRODUCT", 47, 51], ["vascular", "MULTI-TISSUE_STRUCTURE", 140, 148], ["AECA", "PROBLEM", 47, 51], ["diseases", "PROBLEM", 100, 108], ["vascular damage", "PROBLEM", 140, 155], ["diseases", "OBSERVATION", 100, 108], ["vascular", "ANATOMY", 140, 148], ["damage", "OBSERVATION", 149, 155]]], ["Intriguingly, endothelial antigens are readily accessible to circulating antibodies and a pathogenic role of AECA has been suggested by several authors.", [["endothelial", "ANATOMY", 14, 25], ["endothelial antigens", "GENE_OR_GENE_PRODUCT", 14, 34], ["AECA", "GENE_OR_GENE_PRODUCT", 109, 113], ["endothelial antigens", "PROTEIN", 14, 34], ["circulating antibodies", "PROTEIN", 61, 83], ["AECA", "PROTEIN", 109, 113], ["circulating antibodies", "TEST", 61, 83], ["AECA", "PROBLEM", 109, 113], ["endothelial", "ANATOMY", 14, 25], ["AECA", "OBSERVATION", 109, 113]]], ["In particular, recent findings suggest that AECA may activate ECs by an upregulation of the cell adhesion molecule (CAM), or by inducing the secretion of proinflammatory cytokines.", [["ECs", "ANATOMY", 62, 65], ["cell", "ANATOMY", 92, 96], ["AECA", "GENE_OR_GENE_PRODUCT", 44, 48], ["ECs", "CELL", 62, 65], ["cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 92, 114], ["CAM", "MULTI-TISSUE_STRUCTURE", 116, 119], ["AECA", "PROTEIN", 44, 48], ["ECs", "CELL_TYPE", 62, 65], ["cell adhesion molecule", "PROTEIN", 92, 114], ["CAM", "PROTEIN", 116, 119], ["proinflammatory cytokines", "PROTEIN", 154, 179], ["AECA", "PROBLEM", 44, 48], ["the cell adhesion molecule", "PROBLEM", 88, 114], ["proinflammatory cytokines", "PROBLEM", 154, 179], ["AECA", "OBSERVATION", 44, 48], ["cell adhesion", "OBSERVATION", 92, 105], ["proinflammatory cytokines", "OBSERVATION", 154, 179]]], ["It has been suggested that AECA might also activate ECs through an interaction with toll\u2010like receptor 4 (TLR4) because of the molecular mimicry between beta2\u2010glycoprotein I (\u03b22\u2010GPI) and microbial structures that represent the natural ligand of TLR4.", [["ECs", "ANATOMY", 52, 55], ["AECA", "SIMPLE_CHEMICAL", 27, 31], ["ECs", "CELL", 52, 55], ["toll\u2010like receptor 4", "GENE_OR_GENE_PRODUCT", 84, 104], ["TLR4", "GENE_OR_GENE_PRODUCT", 106, 110], ["beta2\u2010glycoprotein I", "GENE_OR_GENE_PRODUCT", 153, 173], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 175, 181], ["TLR4", "GENE_OR_GENE_PRODUCT", 245, 249], ["AECA", "PROTEIN", 27, 31], ["ECs", "CELL_TYPE", 52, 55], ["toll\u2010like receptor 4", "PROTEIN", 84, 104], ["TLR4", "PROTEIN", 106, 110], ["beta2\u2010glycoprotein I", "PROTEIN", 153, 173], ["\u03b22\u2010GPI", "PROTEIN", 175, 181], ["TLR4", "PROTEIN", 245, 249], ["AECA", "PROBLEM", 27, 31], ["toll\u2010like receptor", "TREATMENT", 84, 102], ["AECA", "OBSERVATION", 27, 31]]], ["Finally, controversial results have been reported regarding the induction of ECs apoptosis by AECA, although it is well known that these autoantibodies bind to apoptotic ECs, thus increasing phagocytosis by macrophages and clearance of apoptotic cells [[2], [3], [4]].IntroductionIn this chapter, we analyze the knowledge about AECA in autoimmune diseases focusing in particular on their pathogenic role in systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis (SSc), and vasculitis.Methods of AECA DetectionSince the discovery of AECA, several studies have focused on their role as diagnostic tools for diseases characterized by an inflammation of blood vessels.", [["ECs", "ANATOMY", 77, 80], ["ECs", "ANATOMY", 170, 173], ["macrophages", "ANATOMY", 207, 218], ["cells", "ANATOMY", 246, 251], ["blood vessels", "ANATOMY", 683, 696], ["autoimmune diseases", "DISEASE", 336, 355], ["systemic lupus erythematosus", "DISEASE", 407, 435], ["SLE", "DISEASE", 437, 440], ["antiphospholipid syndrome", "DISEASE", 443, 468], ["APS", "DISEASE", 470, 473], ["systemic sclerosis", "DISEASE", 476, 494], ["SSc", "DISEASE", 496, 499], ["vasculitis", "DISEASE", 506, 516], ["ECs", "CELL", 77, 80], ["AECA", "GENE_OR_GENE_PRODUCT", 94, 98], ["ECs", "CELL", 170, 173], ["macrophages", "CELL", 207, 218], ["cells", "CELL", 246, 251], ["[3], [4]", "SIMPLE_CHEMICAL", 258, 266], ["AECA", "SIMPLE_CHEMICAL", 328, 332], ["AECA", "CANCER", 565, 569], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 683, 696], ["ECs", "CELL_TYPE", 77, 80], ["AECA", "PROTEIN", 94, 98], ["autoantibodies", "PROTEIN", 137, 151], ["apoptotic ECs", "CELL_TYPE", 160, 173], ["macrophages", "CELL_TYPE", 207, 218], ["apoptotic cells", "CELL_TYPE", 236, 251], ["ECs apoptosis", "PROBLEM", 77, 90], ["AECA", "TEST", 94, 98], ["these autoantibodies bind", "PROBLEM", 131, 156], ["apoptotic ECs", "TEST", 160, 173], ["increasing phagocytosis", "PROBLEM", 180, 203], ["apoptotic cells", "TEST", 236, 251], ["AECA in autoimmune diseases", "PROBLEM", 328, 355], ["systemic lupus erythematosus", "PROBLEM", 407, 435], ["SLE)", "PROBLEM", 437, 441], ["antiphospholipid syndrome", "PROBLEM", 443, 468], ["APS)", "PROBLEM", 470, 474], ["systemic sclerosis (SSc)", "PROBLEM", 476, 500], ["vasculitis", "PROBLEM", 506, 516], ["AECA", "PROBLEM", 565, 569], ["several studies", "TEST", 571, 586], ["diagnostic tools", "TEST", 617, 633], ["diseases", "PROBLEM", 638, 646], ["an inflammation of blood vessels", "PROBLEM", 664, 696], ["apoptotic cells", "OBSERVATION", 236, 251], ["autoimmune diseases", "OBSERVATION", 336, 355], ["systemic", "ANATOMY", 407, 415], ["lupus erythematosus", "OBSERVATION", 416, 435], ["antiphospholipid syndrome", "OBSERVATION", 443, 468], ["systemic", "ANATOMY", 476, 484], ["sclerosis", "OBSERVATION", 485, 494], ["SSc", "ANATOMY", 496, 499], ["vasculitis", "OBSERVATION", 506, 516], ["AECA", "OBSERVATION", 528, 532], ["AECA", "OBSERVATION", 565, 569], ["inflammation", "OBSERVATION", 667, 679], ["blood vessels", "ANATOMY", 683, 696]]], ["Despite the growing interest in this field, AECA immunoassays still show a high\u2010interlaboratory variability, most probably due to the lack of international standardization.", [["AECA immunoassays", "TEST", 44, 61], ["a high\u2010interlaboratory variability", "PROBLEM", 73, 107], ["high\u2010interlaboratory variability", "OBSERVATION", 75, 107], ["most probably due to", "UNCERTAINTY", 109, 129]]], ["Many methods have been developed to detect AECA, including immunofluorescence, immunoassays (ELISA and RIA) using fixed cells, Western blot (WB), and fluorescence\u2010activated cell sorter analysis (FACS).", [["cells", "ANATOMY", 120, 125], ["cell", "ANATOMY", 173, 177], ["AECA", "CANCER", 43, 47], ["cells", "CELL", 120, 125], ["cell", "CELL", 173, 177], ["AECA", "PROTEIN", 43, 47], ["AECA", "TEST", 43, 47], ["immunofluorescence", "TEST", 59, 77], ["immunoassays", "TEST", 79, 91], ["ELISA", "TEST", 93, 98], ["RIA", "TEST", 103, 106], ["fixed cells", "TEST", 114, 125], ["Western blot", "TEST", 127, 139], ["fluorescence\u2010activated cell sorter analysis", "TEST", 150, 193]]], ["Nevertheless, only a small number of comparative studies have been done and data concerning sensitivity and specificity of methods to detect AECA are frequently variable and inconclusive (reviewed in Ref.", [["AECA", "CANCER", 141, 145], ["comparative studies", "TEST", 37, 56], ["sensitivity", "TEST", 92, 103], ["methods", "TEST", 123, 130], ["AECA", "TEST", 141, 145], ["small", "OBSERVATION_MODIFIER", 21, 26]]], ["The major part of our knowledge on AECA reactivity comes from in vitro experiments with human umbilical vein ECs (HUVECs).", [["human umbilical vein ECs", "ANATOMY", 88, 112], ["HUVECs", "ANATOMY", 114, 120], ["AECA", "SIMPLE_CHEMICAL", 35, 39], ["human umbilical vein ECs", "CELL", 88, 112], ["HUVECs", "CELL", 114, 120], ["human umbilical vein ECs", "CELL_TYPE", 88, 112], ["HUVECs", "CELL_LINE", 114, 120], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["AECA reactivity", "TEST", 35, 50], ["human umbilical vein ECs", "TREATMENT", 88, 112], ["umbilical vein", "ANATOMY", 94, 108]]], ["Nevertheless, the isolation of primary HUVECs is laborious and the AECA reactivity obtained with different donors cannot easily be compared to each other because of their different origin.", [["HUVECs", "ANATOMY", 39, 45], ["HUVECs", "CELL", 39, 45], ["AECA", "SIMPLE_CHEMICAL", 67, 71], ["donors", "ORGANISM", 107, 113], ["primary HUVECs", "CELL_LINE", 31, 45], ["primary HUVECs", "PROBLEM", 31, 45], ["laborious", "PROBLEM", 49, 58], ["the AECA reactivity", "TEST", 63, 82], ["different donors", "TREATMENT", 97, 113], ["primary HUVECs", "OBSERVATION", 31, 45]]], ["Moreover, HUVECs present a short life span and can be kept in culture only for short periods.", [["HUVECs", "ANATOMY", 10, 16], ["HUVECs", "CELL", 10, 16], ["HUVECs", "CELL_LINE", 10, 16], ["a short life span", "PROBLEM", 25, 42], ["culture", "TEST", 62, 69], ["HUVECs", "ANATOMY", 10, 16]]], ["Another point of debate is the fixation procedure of HUVECs, which may influence the AECA reactivity against intracytoplasmic or membrane antigens.", [["HUVECs", "ANATOMY", 53, 59], ["intracytoplasmic", "ANATOMY", 109, 125], ["membrane", "ANATOMY", 129, 137], ["HUVECs", "CELL", 53, 59], ["AECA", "SIMPLE_CHEMICAL", 85, 89], ["intracytoplasmic", "ORGANISM_SUBSTANCE", 109, 125], ["or membrane antigens", "GENE_OR_GENE_PRODUCT", 126, 146], ["HUVECs", "CELL_LINE", 53, 59], ["intracytoplasmic or membrane antigens", "PROTEIN", 109, 146], ["the fixation procedure of HUVECs", "TREATMENT", 27, 59], ["the AECA reactivity", "TEST", 81, 100], ["intracytoplasmic or membrane antigens", "PROBLEM", 109, 146], ["fixation", "OBSERVATION", 31, 39], ["HUVECs", "ANATOMY", 53, 59]]], ["Interference from heterophilic antibodies, which recognize fetal calf serum (FCS) proteins, may be avoided by adding FCS to the dilution buffer [6].", [["fetal calf serum", "ANATOMY", 59, 75], ["calf", "ORGANISM_SUBSTANCE", 65, 69], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["FCS", "ORGANISM_SUBSTANCE", 77, 80], ["heterophilic antibodies", "PROTEIN", 18, 41], ["fetal calf serum (FCS) proteins", "PROTEIN", 59, 90], ["calf", "SPECIES", 65, 69], ["Interference from heterophilic antibodies", "PROBLEM", 0, 41], ["fetal calf serum", "TEST", 59, 75], ["the dilution buffer", "TREATMENT", 124, 143], ["heterophilic antibodies", "OBSERVATION", 18, 41], ["fetal", "ANATOMY_MODIFIER", 59, 64], ["calf", "ANATOMY", 65, 69]]], ["Finally, different ECs from macro\u2010 and microvasculature have been used for AECA detection with different results.", [["ECs", "ANATOMY", 19, 22], ["macro\u2010", "ANATOMY", 28, 34], ["microvasculature", "ANATOMY", 39, 55], ["ECs", "CELL", 19, 22], ["microvasculature", "TISSUE", 39, 55], ["AECA", "CANCER", 75, 79], ["ECs", "CELL_TYPE", 19, 22], ["AECA detection", "TEST", 75, 89], ["microvasculature", "ANATOMY", 39, 55]]], ["ECs from diverse tissues are also heterogeneous not only in respect to small vs large vessels but also in respect to their surface phenotype and protein expression.", [["ECs", "ANATOMY", 0, 3], ["tissues", "ANATOMY", 17, 24], ["vessels", "ANATOMY", 86, 93], ["surface", "ANATOMY", 123, 130], ["ECs", "CELL", 0, 3], ["tissues", "TISSUE", 17, 24], ["large vessels", "MULTI-TISSUE_STRUCTURE", 80, 93], ["surface", "CELLULAR_COMPONENT", 123, 130], ["ECs", "CELL_TYPE", 0, 3], ["small vs large vessels", "PROBLEM", 71, 93], ["diverse tissues", "OBSERVATION", 9, 24], ["heterogeneous", "OBSERVATION_MODIFIER", 34, 47], ["small", "OBSERVATION_MODIFIER", 71, 76], ["large", "OBSERVATION", 80, 85], ["vessels", "ANATOMY", 86, 93], ["protein expression", "OBSERVATION", 145, 163]]], ["For instance, Renaudineau et al. [7] showed the highest prevalence of AECA reactivity in a large series of patients with SSc using microvascular bone marrow ECs in comparison to HUVECs.", [["microvascular bone marrow ECs", "ANATOMY", 131, 160], ["HUVECs", "ANATOMY", 178, 184], ["SSc", "DISEASE", 121, 124], ["AECA", "SIMPLE_CHEMICAL", 70, 74], ["patients", "ORGANISM", 107, 115], ["microvascular bone marrow ECs", "CELL", 131, 160], ["HUVECs", "CELL", 178, 184], ["AECA", "PROTEIN", 70, 74], ["microvascular bone marrow ECs", "CELL_TYPE", 131, 160], ["HUVECs", "CELL_TYPE", 178, 184], ["patients", "SPECIES", 107, 115], ["AECA reactivity", "PROBLEM", 70, 85], ["SSc using microvascular bone marrow ECs", "TREATMENT", 121, 160], ["HUVECs", "TEST", 178, 184], ["AECA reactivity", "OBSERVATION", 70, 85], ["large", "OBSERVATION_MODIFIER", 91, 96], ["SSc", "ANATOMY", 121, 124], ["microvascular bone", "ANATOMY", 131, 149], ["marrow ECs", "OBSERVATION", 150, 160]]], ["The need for reproducible results has increased the demand for immortalized EC lines, such as EA.hy926, generated by fusion of HUVECs with the human lung carcinoma cell line A549 [8], or the immortalized human microvascular EC line (HMEC\u20101) [9].", [["EC lines", "ANATOMY", 76, 84], ["HUVECs", "ANATOMY", 127, 133], ["lung carcinoma cell line A549", "ANATOMY", 149, 178], ["microvascular EC line", "ANATOMY", 210, 231], ["HMEC", "ANATOMY", 233, 237], ["hy926", "CHEMICAL", 97, 102], ["lung carcinoma", "DISEASE", 149, 163], ["EC lines", "CELL", 76, 84], ["hy926", "CELL", 97, 102], ["HUVECs", "CELL", 127, 133], ["human", "ORGANISM", 143, 148], ["lung carcinoma cell line A549 [8", "CELL", 149, 181], ["human", "ORGANISM", 204, 209], ["microvascular EC line", "CELL", 210, 231], ["HMEC\u20101", "CELL", 233, 239], ["immortalized EC lines", "CELL_LINE", 63, 84], ["EA.", "CELL_LINE", 94, 97], ["HUVECs", "CELL_LINE", 127, 133], ["human lung carcinoma cell line A549 [8", "CELL_LINE", 143, 181], ["immortalized human microvascular EC line", "CELL_LINE", 191, 231], ["HMEC\u20101", "CELL_LINE", 233, 239], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 204, 209], ["immortalized EC lines", "TREATMENT", 63, 84], ["the human lung carcinoma", "PROBLEM", 139, 163], ["the immortalized human microvascular EC line", "TREATMENT", 187, 231], ["EC lines", "OBSERVATION", 76, 84], ["lung", "ANATOMY", 149, 153], ["carcinoma", "OBSERVATION", 154, 163], ["microvascular", "ANATOMY", 210, 223], ["EC line", "OBSERVATION", 224, 231]]], ["ECs derived from human umbilical and iliac veins and arteries transfected with a plasmid containing the Simian Virus 40 large T\u2010antigen, may also be useful for the detection of AECA [10].", [["ECs", "ANATOMY", 0, 3], ["umbilical", "ANATOMY", 23, 32], ["iliac veins", "ANATOMY", 37, 48], ["arteries", "ANATOMY", 53, 61], ["plasmid", "ANATOMY", 81, 88], ["ECs", "CELL", 0, 3], ["human", "ORGANISM", 17, 22], ["umbilical", "TISSUE", 23, 32], ["iliac veins", "MULTI-TISSUE_STRUCTURE", 37, 48], ["arteries", "MULTI-TISSUE_STRUCTURE", 53, 61], ["Simian Virus 40", "ORGANISM", 104, 119], ["ECs", "CELL_TYPE", 0, 3], ["human", "SPECIES", 17, 22], ["Simian Virus", "SPECIES", 104, 116], ["human", "SPECIES", 17, 22], ["Simian Virus 40", "SPECIES", 104, 119], ["ECs", "TEST", 0, 3], ["a plasmid", "TREATMENT", 79, 88], ["the Simian Virus", "TREATMENT", 100, 116], ["AECA", "TEST", 177, 181], ["umbilical", "ANATOMY_MODIFIER", 23, 32], ["iliac veins", "ANATOMY", 37, 48], ["arteries", "ANATOMY", 53, 61]]], ["Immortalized human glomerular endothelial cell (HGEC) lines were also generated [11].", [["glomerular endothelial cell", "ANATOMY", 19, 46], ["HGEC) lines", "ANATOMY", 48, 59], ["human", "ORGANISM", 13, 18], ["glomerular endothelial cell (HGEC) lines", "CELL", 19, 59], ["Immortalized human glomerular endothelial cell (HGEC) lines", "CELL_LINE", 0, 59], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["Immortalized human glomerular endothelial cell (HGEC) lines", "TREATMENT", 0, 59], ["glomerular endothelial cell", "OBSERVATION", 19, 46]]], ["These cell lines maintain the morphologic and functional characteristics of HGECs even after several weeks in culture, thus providing a standardized substrate for AECA detection.", [["cell lines", "ANATOMY", 6, 16], ["HGECs", "ANATOMY", 76, 81], ["cell lines", "CELL", 6, 16], ["HGECs", "CELL", 76, 81], ["AECA", "CANCER", 163, 167], ["cell lines", "CELL_LINE", 6, 16], ["HGECs", "CELL_TYPE", 76, 81], ["AECA", "PROTEIN", 163, 167], ["culture", "TEST", 110, 117], ["AECA detection", "TEST", 163, 177], ["cell lines", "OBSERVATION", 6, 16], ["morphologic", "OBSERVATION_MODIFIER", 30, 41]]], ["Nevertheless, AECA detection on immortalized ECs may be subject to great variability and scientists interested in autoimmunity against ECs would prefer primary EC lines as substrate because these cells probably present more primary endothelial traits.", [["ECs", "ANATOMY", 45, 48], ["ECs", "ANATOMY", 135, 138], ["primary EC lines", "ANATOMY", 152, 168], ["cells", "ANATOMY", 196, 201], ["endothelial", "ANATOMY", 232, 243], ["autoimmunity", "DISEASE", 114, 126], ["AECA", "GENE_OR_GENE_PRODUCT", 14, 18], ["ECs", "CELL", 45, 48], ["ECs", "CELL", 135, 138], ["EC lines", "CELL", 160, 168], ["cells", "CELL", 196, 201], ["endothelial", "CELL", 232, 243], ["AECA", "PROTEIN", 14, 18], ["ECs", "CELL_TYPE", 45, 48], ["ECs", "CELL_TYPE", 135, 138], ["primary EC lines", "CELL_LINE", 152, 168], ["AECA detection", "TEST", 14, 28], ["immortalized ECs", "TEST", 32, 48], ["primary EC lines", "TREATMENT", 152, 168], ["these cells", "PROBLEM", 190, 201], ["primary endothelial traits", "OBSERVATION", 224, 250]]], ["Although the original cyto\u2010ELISA remains the most widely used method for the detection of AECA, it is advisable to confirm a positive result using other methods, such as flow cytometry, immunoprecipitation, or WB, which appear to be difficult to use on a routine basis [12].", [["AECA", "CANCER", 90, 94], ["AECA", "PROBLEM", 90, 94], ["other methods", "TREATMENT", 147, 160], ["flow cytometry", "TEST", 170, 184], ["immunoprecipitation", "TEST", 186, 205], ["WB", "TEST", 210, 212], ["AECA", "OBSERVATION", 90, 94]]], ["It is important to point out that heating sera should be avoided because this treatment increases AECA binding by a nonspecific mechanism in sera from both patients and healthy individuals [13].", [["sera", "ANATOMY", 42, 46], ["sera", "ANATOMY", 141, 145], ["sera", "ORGANISM_SUBSTANCE", 42, 46], ["AECA", "SIMPLE_CHEMICAL", 98, 102], ["sera", "ORGANISM_SUBSTANCE", 141, 145], ["patients", "ORGANISM", 156, 164], ["AECA", "PROTEIN", 98, 102], ["patients", "SPECIES", 156, 164], ["heating sera", "TREATMENT", 34, 46], ["this treatment", "TREATMENT", 73, 87], ["AECA binding", "PROBLEM", 98, 110], ["a nonspecific mechanism in sera", "PROBLEM", 114, 145]]], ["ANA or RF in serum samples have been shown not to interfere with AECA detection by ELISA with nucleus\u2010depleted lysates prepared from EA.hy926 [14].Methods of AECA DetectionFinally, because it has been reported that different AECA isotypes may be prevalent in different autoimmune disorders, as discussed elsewhere in this chapter, it should be pointed out that the AECA test should include determination of both IgG and IgM in most disorders with the addition of IgA in patients with Henoch\u2010Schonlein purpura (HSP).", [["serum samples", "ANATOMY", 13, 26], ["lysates", "ANATOMY", 111, 118], ["autoimmune disorders", "DISEASE", 269, 289], ["purpura", "DISEASE", 501, 508], ["HSP", "DISEASE", 510, 513], ["ANA", "GENE_OR_GENE_PRODUCT", 0, 3], ["serum samples", "ORGANISM_SUBSTANCE", 13, 26], ["AECA", "GENE_OR_GENE_PRODUCT", 65, 69], ["lysates", "ORGANISM_SUBSTANCE", 111, 118], ["AECA isotypes", "GENE_OR_GENE_PRODUCT", 225, 238], ["AECA", "CANCER", 365, 369], ["IgG", "GENE_OR_GENE_PRODUCT", 412, 415], ["IgM", "GENE_OR_GENE_PRODUCT", 420, 423], ["IgA", "GENE_OR_GENE_PRODUCT", 463, 466], ["patients", "ORGANISM", 470, 478], ["ANA", "PROTEIN", 0, 3], ["RF", "PROTEIN", 7, 9], ["AECA", "PROTEIN", 65, 69], ["AECA isotypes", "PROTEIN", 225, 238], ["IgG", "PROTEIN", 412, 415], ["IgM", "PROTEIN", 420, 423], ["IgA", "PROTEIN", 463, 466], ["patients", "SPECIES", 470, 478], ["ANA or RF in serum samples", "TEST", 0, 26], ["AECA detection", "TEST", 65, 79], ["AECA DetectionFinally", "TEST", 158, 179], ["different AECA isotypes", "PROBLEM", 215, 238], ["different autoimmune disorders", "PROBLEM", 259, 289], ["the AECA test", "TEST", 361, 374], ["both IgG and IgM in most disorders", "PROBLEM", 407, 441], ["Henoch", "TREATMENT", 484, 490], ["Schonlein purpura", "PROBLEM", 491, 508], ["AECA", "OBSERVATION", 158, 162], ["AECA isotypes", "OBSERVATION", 225, 238], ["may be", "UNCERTAINTY", 239, 245], ["autoimmune disorders", "OBSERVATION", 269, 289], ["purpura", "OBSERVATION", 501, 508]]], ["In fact, while IgG AECA are predominant in most autoimmune conditions, IgM AECA have been shown to be particularly increased in Kawasaki disease (KD) probably reflecting the acute nature of this disorder.", [["Kawasaki disease", "DISEASE", 128, 144], ["KD", "DISEASE", 146, 148], ["IgG", "GENE_OR_GENE_PRODUCT", 15, 18], ["AECA", "GENE_OR_GENE_PRODUCT", 19, 23], ["IgM AECA", "GENE_OR_GENE_PRODUCT", 71, 79], ["IgG AECA", "PROTEIN", 15, 23], ["IgM AECA", "PROTEIN", 71, 79], ["IgG AECA", "TEST", 15, 23], ["most autoimmune conditions", "PROBLEM", 43, 69], ["IgM AECA", "TEST", 71, 79], ["Kawasaki disease", "PROBLEM", 128, 144], ["this disorder", "PROBLEM", 190, 203], ["predominant", "OBSERVATION_MODIFIER", 28, 39], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["Kawasaki disease", "OBSERVATION", 128, 144], ["probably reflecting the", "UNCERTAINTY", 150, 173], ["acute", "OBSERVATION_MODIFIER", 174, 179]]], ["In addition, IgG and IgM AECA may exert diverse pathogenic role due to their differential ability to fix and activate the complement cascade as well as to induce ECs damage via antibody\u2010dependent cytotoxicity.AECA in Systemic Lupus Erythematosus and Antiphospholipid Syndrome ::: AECA in Autoimmune DiseasesSLE is a protean autoimmune disease characterized by the largest number of detectable autoantibodies reactive with antigens localized in the nucleus, cytoplasm, or on the cell membrane (reviewed in Ref.", [["ECs", "ANATOMY", 162, 165], ["nucleus", "ANATOMY", 448, 455], ["cytoplasm", "ANATOMY", 457, 466], ["cell membrane", "ANATOMY", 478, 491], ["AECA", "DISEASE", 209, 213], ["Systemic Lupus Erythematosus", "DISEASE", 217, 245], ["Antiphospholipid Syndrome", "DISEASE", 250, 275], ["AECA", "DISEASE", 280, 284], ["Autoimmune DiseasesSLE", "DISEASE", 288, 310], ["autoimmune disease", "DISEASE", 324, 342], ["IgG", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgM AECA", "GENE_OR_GENE_PRODUCT", 21, 29], ["ECs", "CELL", 162, 165], ["nucleus", "CELLULAR_COMPONENT", 448, 455], ["cytoplasm", "ORGANISM_SUBSTANCE", 457, 466], ["cell membrane", "CELLULAR_COMPONENT", 478, 491], ["IgG", "PROTEIN", 13, 16], ["IgM", "PROTEIN", 21, 24], ["AECA", "PROTEIN", 25, 29], ["ECs", "CELL_TYPE", 162, 165], ["autoantibodies", "PROTEIN", 393, 407], ["antigens", "PROTEIN", 422, 430], ["IgG", "TEST", 13, 16], ["IgM AECA", "TEST", 21, 29], ["the complement cascade", "TREATMENT", 118, 140], ["ECs damage", "PROBLEM", 162, 172], ["antibody\u2010dependent cytotoxicity", "PROBLEM", 177, 208], ["AECA", "TEST", 209, 213], ["Systemic Lupus Erythematosus", "PROBLEM", 217, 245], ["Antiphospholipid Syndrome", "PROBLEM", 250, 275], ["AECA", "TEST", 280, 284], ["a protean autoimmune disease", "PROBLEM", 314, 342], ["detectable autoantibodies reactive", "PROBLEM", 382, 416], ["Systemic Lupus Erythematosus", "OBSERVATION", 217, 245], ["Antiphospholipid Syndrome", "OBSERVATION", 250, 275], ["Autoimmune", "OBSERVATION", 288, 298], ["largest", "OBSERVATION_MODIFIER", 364, 371], ["detectable", "OBSERVATION_MODIFIER", 382, 392], ["autoantibodies", "OBSERVATION", 393, 407], ["reactive", "OBSERVATION_MODIFIER", 408, 416], ["nucleus", "ANATOMY", 448, 455], ["cytoplasm", "OBSERVATION_MODIFIER", 457, 466], ["cell membrane", "OBSERVATION", 478, 491]]], ["Anti\u2010dsDNA antibodies, and complement consumption are established markers of disease activity.", [["Anti\u2010dsDNA antibodies", "GENE_OR_GENE_PRODUCT", 0, 21], ["Anti\u2010dsDNA antibodies", "PROTEIN", 0, 21], ["Anti\u2010dsDNA antibodies", "TEST", 0, 21], ["disease activity", "PROBLEM", 77, 93]]], ["A large number of studies have focused on the association of autoantibodies with specific symptoms of SLE: for example, it is well known that anti\u2010dsDNA antibodies, as well as antibodies to the collagen\u2010like region of the complement component C1q (anti\u2010C1q), are associated with renal involvement in SLE [16].", [["renal", "ANATOMY", 279, 284], ["SLE", "DISEASE", 102, 105], ["SLE", "DISEASE", 300, 303], ["SLE", "CANCER", 102, 105], ["anti\u2010dsDNA antibodies", "GENE_OR_GENE_PRODUCT", 142, 163], ["complement component C1q", "GENE_OR_GENE_PRODUCT", 222, 246], ["anti\u2010C1q", "GENE_OR_GENE_PRODUCT", 248, 256], ["renal", "ORGAN", 279, 284], ["autoantibodies", "PROTEIN", 61, 75], ["anti\u2010dsDNA antibodies", "PROTEIN", 142, 163], ["antibodies", "PROTEIN", 176, 186], ["collagen\u2010like region", "PROTEIN", 194, 214], ["complement component", "PROTEIN", 222, 242], ["C1q", "PROTEIN", 243, 246], ["anti\u2010C1q", "PROTEIN", 248, 256], ["autoantibodies", "PROBLEM", 61, 75], ["specific symptoms", "PROBLEM", 81, 98], ["SLE", "PROBLEM", 102, 105], ["anti\u2010dsDNA antibodies", "PROBLEM", 142, 163], ["renal involvement in SLE", "PROBLEM", 279, 303], ["large", "OBSERVATION_MODIFIER", 2, 7], ["renal", "ANATOMY", 279, 284], ["involvement", "OBSERVATION", 285, 296]]], ["Moreover, anti\u2010Ro antibodies have been found to be a marker of neonatal lupus and subacute cutaneous lupus, and anti\u2010\u03b22\u2010glycoprotein I (anti\u2010\u03b22\u2010GPI) and anti\u2010cardiolipin (aCL) antibodies were significantly correlated with clinical thrombosis, abortion, and fetal loss.", [["fetal", "ANATOMY", 257, 262], ["lupus", "DISEASE", 72, 77], ["lupus", "DISEASE", 101, 106], ["thrombosis", "DISEASE", 231, 241], ["abortion", "DISEASE", 243, 251], ["fetal loss", "DISEASE", 257, 267], ["anti\u2010Ro antibodies", "GENE_OR_GENE_PRODUCT", 10, 28], ["anti\u2010\u03b22\u2010glycoprotein I", "GENE_OR_GENE_PRODUCT", 112, 134], ["anti\u2010\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 136, 147], ["anti\u2010cardiolipin", "GENE_OR_GENE_PRODUCT", 153, 169], ["aCL", "GENE_OR_GENE_PRODUCT", 171, 174], ["fetal", "ORGANISM_SUBDIVISION", 257, 262], ["anti\u2010Ro antibodies", "PROTEIN", 10, 28], ["anti\u2010\u03b22\u2010glycoprotein I", "PROTEIN", 112, 134], ["anti\u2010\u03b22", "PROTEIN", 136, 143], ["GPI", "PROTEIN", 144, 147], ["anti\u2010cardiolipin (aCL) antibodies", "PROTEIN", 153, 186], ["anti\u2010Ro antibodies", "TEST", 10, 28], ["neonatal lupus", "PROBLEM", 63, 77], ["subacute cutaneous lupus", "PROBLEM", 82, 106], ["anti\u2010\u03b22\u2010glycoprotein I", "TREATMENT", 112, 134], ["anti\u2010cardiolipin (aCL) antibodies", "TEST", 153, 186], ["clinical thrombosis", "PROBLEM", 222, 241], ["abortion", "PROBLEM", 243, 251], ["fetal loss", "PROBLEM", 257, 267], ["neonatal", "OBSERVATION_MODIFIER", 63, 71], ["lupus", "OBSERVATION", 72, 77], ["subacute", "OBSERVATION_MODIFIER", 82, 90], ["cutaneous lupus", "OBSERVATION", 91, 106], ["thrombosis", "OBSERVATION", 231, 241], ["fetal loss", "OBSERVATION", 257, 267]]], ["Despite the fact that most studies have shown a higher prevalence of AECA in SLE, the clinical relevance of these autoantibodies is still a matter of debate.AECA in Systemic Lupus Erythematosus and Antiphospholipid Syndrome ::: AECA in Autoimmune DiseasesThe prevalence of AECA in SLE largely range from 15% to 80%, depending on the method and patient selection.", [["AECA", "DISEASE", 69, 73], ["SLE", "DISEASE", 77, 80], ["AECA", "DISEASE", 157, 161], ["Systemic Lupus Erythematosus", "DISEASE", 165, 193], ["Antiphospholipid Syndrome", "DISEASE", 198, 223], ["AECA", "DISEASE", 228, 232], ["Autoimmune Diseases", "DISEASE", 236, 255], ["AECA", "DISEASE", 273, 277], ["SLE", "DISEASE", 281, 284], ["AECA", "CANCER", 69, 73], ["AECA", "CANCER", 273, 277], ["patient", "ORGANISM", 344, 351], ["autoantibodies", "PROTEIN", 114, 128], ["patient", "SPECIES", 344, 351], ["most studies", "TEST", 22, 34], ["AECA in SLE", "PROBLEM", 69, 80], ["these autoantibodies", "PROBLEM", 108, 128], ["AECA", "TEST", 157, 161], ["Systemic Lupus Erythematosus", "PROBLEM", 165, 193], ["Antiphospholipid Syndrome", "PROBLEM", 198, 223], ["AECA", "TEST", 228, 232], ["Autoimmune Diseases", "PROBLEM", 236, 255], ["AECA", "TEST", 273, 277], ["AECA", "OBSERVATION", 69, 73], ["Systemic Lupus Erythematosus", "OBSERVATION", 165, 193], ["Antiphospholipid Syndrome", "OBSERVATION", 198, 223], ["Autoimmune Diseases", "OBSERVATION", 236, 255], ["AECA", "OBSERVATION", 273, 277]]], ["Nonetheless, the presence of vasculitis in SLE is frequently associated with AECA although these autoantibodies have been correlated with several other clinical manifestations of the disease such as lupus nephritis, pleurisy, thrombocytopenia, and neuropsychiatric symptoms [[17], [18], [19]].", [["vasculitis", "DISEASE", 29, 39], ["SLE", "DISEASE", 43, 46], ["lupus nephritis", "DISEASE", 199, 214], ["pleurisy", "DISEASE", 216, 224], ["thrombocytopenia", "DISEASE", 226, 242], ["neuropsychiatric symptoms", "DISEASE", 248, 273], ["SLE", "CANCER", 43, 46], ["AECA", "CANCER", 77, 81], ["[17], [18], [19]]", "SIMPLE_CHEMICAL", 275, 292], ["autoantibodies", "PROTEIN", 97, 111], ["vasculitis in SLE", "PROBLEM", 29, 46], ["AECA", "PROBLEM", 77, 81], ["these autoantibodies", "PROBLEM", 91, 111], ["the disease", "PROBLEM", 179, 190], ["lupus nephritis", "PROBLEM", 199, 214], ["pleurisy", "PROBLEM", 216, 224], ["thrombocytopenia", "PROBLEM", 226, 242], ["neuropsychiatric symptoms", "PROBLEM", 248, 273], ["vasculitis", "OBSERVATION", 29, 39], ["disease", "OBSERVATION", 183, 190], ["lupus nephritis", "OBSERVATION", 199, 214], ["pleurisy", "OBSERVATION", 216, 224], ["thrombocytopenia", "OBSERVATION", 226, 242]]], ["Inflammatory or thrombotic vascular injury represents one of the most frequent lesions in SLE and endothelial perturbation induced by AECA may be involved in the earliest events in the pathophysiology of vascular tissue damage.", [["vascular", "ANATOMY", 27, 35], ["lesions", "ANATOMY", 79, 86], ["endothelial", "ANATOMY", 98, 109], ["vascular tissue", "ANATOMY", 204, 219], ["thrombotic vascular injury", "DISEASE", 16, 42], ["SLE", "DISEASE", 90, 93], ["vascular tissue damage", "DISEASE", 204, 226], ["vascular", "MULTI-TISSUE_STRUCTURE", 27, 35], ["lesions", "PATHOLOGICAL_FORMATION", 79, 86], ["SLE", "CANCER", 90, 93], ["endothelial", "CELL", 98, 109], ["AECA", "GENE_OR_GENE_PRODUCT", 134, 138], ["vascular tissue", "TISSUE", 204, 219], ["AECA", "PROTEIN", 134, 138], ["Inflammatory or thrombotic vascular injury", "PROBLEM", 0, 42], ["the most frequent lesions in SLE", "PROBLEM", 61, 93], ["endothelial perturbation", "PROBLEM", 98, 122], ["AECA", "PROBLEM", 134, 138], ["vascular tissue damage", "PROBLEM", 204, 226], ["thrombotic", "OBSERVATION_MODIFIER", 16, 26], ["vascular", "ANATOMY", 27, 35], ["injury", "OBSERVATION", 36, 42], ["most", "OBSERVATION_MODIFIER", 65, 69], ["frequent", "OBSERVATION_MODIFIER", 70, 78], ["lesions", "OBSERVATION", 79, 86], ["SLE", "OBSERVATION", 90, 93], ["endothelial", "ANATOMY", 98, 109], ["AECA", "OBSERVATION", 134, 138], ["vascular tissue", "ANATOMY", 204, 219], ["damage", "OBSERVATION", 220, 226]]], ["Vessels of any size may be affected and therefore the clinical scenario of vasculitis in SLE is extremely wide.", [["Vessels", "ANATOMY", 0, 7], ["vasculitis", "DISEASE", 75, 85], ["SLE", "DISEASE", 89, 92], ["Vessels", "MULTI-TISSUE_STRUCTURE", 0, 7], ["vasculitis in SLE", "PROBLEM", 75, 92], ["size", "OBSERVATION_MODIFIER", 15, 19], ["may be", "UNCERTAINTY", 20, 26], ["affected", "OBSERVATION", 27, 35], ["vasculitis", "OBSERVATION", 75, 85], ["wide", "OBSERVATION_MODIFIER", 106, 110]]], ["In 1987, Hashemi and coworkers described an association between AECA and vasculitis [20].", [["vasculitis", "DISEASE", 73, 83], ["AECA", "CANCER", 64, 68], ["vasculitis", "PROBLEM", 73, 83], ["vasculitis", "OBSERVATION", 73, 83]]], ["Thereafter, Del Papa et al. [21] showed that sera from SLE patients with vasculitis immunoprecipitated EC surface proteins ranging from 200 to 25 kDa.", [["sera", "ANATOMY", 45, 49], ["EC surface", "ANATOMY", 103, 113], ["SLE", "DISEASE", 55, 58], ["vasculitis", "DISEASE", 73, 83], ["sera", "ORGANISM_SUBSTANCE", 45, 49], ["patients", "ORGANISM", 59, 67], ["EC surface proteins", "GENE_OR_GENE_PRODUCT", 103, 122], ["vasculitis immunoprecipitated EC surface proteins", "PROTEIN", 73, 122], ["patients", "SPECIES", 59, 67], ["Del Papa et al.", "TEST", 12, 27], ["vasculitis", "PROBLEM", 73, 83], ["EC surface proteins", "TEST", 103, 122], ["vasculitis", "OBSERVATION", 73, 83]]], ["Song and coworkers described a higher positivity rate of AECA in patients with digital vasculitis as previously reported [[19], [22]].", [["AECA", "DISEASE", 57, 61], ["vasculitis", "DISEASE", 87, 97], ["AECA", "CANCER", 57, 61], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["digital vasculitis", "PROBLEM", 79, 97], ["vasculitis", "OBSERVATION", 87, 97]]], ["In this study IgG\u2010AECA showed a positive correlation with disease activity in SLE patients.", [["SLE", "DISEASE", 78, 81], ["IgG\u2010AECA", "GENE_OR_GENE_PRODUCT", 14, 22], ["patients", "ORGANISM", 82, 90], ["IgG\u2010AECA", "PROTEIN", 14, 22], ["patients", "SPECIES", 82, 90], ["this study IgG\u2010AECA", "TEST", 3, 22], ["disease activity in SLE patients", "PROBLEM", 58, 90]]], ["Moreover, a significant correlation between the IgG\u2010AECA titer and SLE disease activity index (SLEDAI) score modification was also observed in SLE patients after treatment [19].", [["SLE", "DISEASE", 67, 70], ["SLE", "DISEASE", 143, 146], ["IgG", "GENE_OR_GENE_PRODUCT", 48, 51], ["AECA", "GENE_OR_GENE_PRODUCT", 52, 56], ["patients", "ORGANISM", 147, 155], ["IgG", "PROTEIN", 48, 51], ["AECA", "PROTEIN", 52, 56], ["patients", "SPECIES", 147, 155], ["the IgG", "TEST", 44, 51], ["AECA titer", "TEST", 52, 62], ["SLE disease activity index (SLEDAI) score modification", "PROBLEM", 67, 121]]], ["Thus, AECA may be useful in the follow\u2010up of patients; other soluble markers of EC dysfunction, such as von Willebrand factor, thrombomodulin, and soluble E\u2010selectin, seem to be surrogate markers (an epiphenomenon) related to EC damage [23].", [["EC", "ANATOMY", 80, 82], ["EC", "ANATOMY", 226, 228], ["AECA", "GENE_OR_GENE_PRODUCT", 6, 10], ["patients", "ORGANISM", 45, 53], ["EC", "CELL", 80, 82], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 104, 125], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 127, 141], ["E\u2010selectin", "GENE_OR_GENE_PRODUCT", 155, 165], ["EC", "CELL", 226, 228], ["AECA", "PROTEIN", 6, 10], ["EC", "CELL_TYPE", 80, 82], ["von Willebrand factor", "PROTEIN", 104, 125], ["thrombomodulin", "PROTEIN", 127, 141], ["E\u2010selectin", "PROTEIN", 155, 165], ["EC", "CELL_TYPE", 226, 228], ["patients", "SPECIES", 45, 53], ["AECA", "TEST", 6, 10], ["EC dysfunction", "PROBLEM", 80, 94], ["von Willebrand factor", "TEST", 104, 125], ["thrombomodulin", "PROBLEM", 127, 141], ["soluble E\u2010selectin", "TREATMENT", 147, 165], ["an epiphenomenon)", "PROBLEM", 197, 214], ["EC damage", "PROBLEM", 226, 235]]], ["It is possible that AECA may represent a marker of cell injury or a sign of polyclonal activation of humoral immune responses in other diseases such as in liver transplantation where AECA correlate with cytomegalovirus (CMV) infection [[24], [25]] and are associated with higher frequency of humoral allograft rejection [25].", [["cell", "ANATOMY", 51, 55], ["liver", "ANATOMY", 155, 160], ["allograft", "ANATOMY", 300, 309], ["cytomegalovirus (CMV) infection", "DISEASE", 203, 234], ["AECA", "GENE_OR_GENE_PRODUCT", 20, 24], ["cell", "CELL", 51, 55], ["liver", "ORGAN", 155, 160], ["AECA", "CANCER", 183, 187], ["cytomegalovirus", "ORGANISM", 203, 218], ["CMV", "ORGANISM", 220, 223], ["allograft", "ORGAN", 300, 309], ["AECA", "PROTEIN", 20, 24], ["CMV", "SPECIES", 220, 223], ["AECA", "PROBLEM", 20, 24], ["cell injury", "PROBLEM", 51, 62], ["polyclonal activation", "PROBLEM", 76, 97], ["humoral immune responses", "PROBLEM", 101, 125], ["other diseases", "PROBLEM", 129, 143], ["liver transplantation", "TREATMENT", 155, 176], ["AECA", "TEST", 183, 187], ["cytomegalovirus (CMV) infection", "PROBLEM", 203, 234], ["humoral allograft rejection", "PROBLEM", 292, 319], ["AECA", "OBSERVATION", 20, 24], ["may represent", "UNCERTAINTY", 25, 38], ["cell injury", "OBSERVATION", 51, 62], ["polyclonal activation", "OBSERVATION", 76, 97], ["humoral immune responses", "OBSERVATION", 101, 125], ["liver", "ANATOMY", 155, 160], ["transplantation", "OBSERVATION", 161, 176], ["cytomegalovirus", "OBSERVATION", 203, 218], ["humoral allograft rejection", "OBSERVATION", 292, 319]]], ["AECA have been found in patients with SLE and urticarial vasculitis (UV) as well as in hypocomplementemic urticarial vasculitis syndrome (HUVS) [26].", [["SLE", "DISEASE", 38, 41], ["urticarial vasculitis", "DISEASE", 46, 67], ["urticarial vasculitis syndrome", "DISEASE", 106, 136], ["HUVS", "DISEASE", 138, 142], ["AECA", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 24, 32], ["AECA", "PROTEIN", 0, 4], ["patients", "SPECIES", 24, 32], ["AECA", "TEST", 0, 4], ["SLE", "PROBLEM", 38, 41], ["urticarial vasculitis", "PROBLEM", 46, 67], ["hypocomplementemic urticarial vasculitis syndrome", "PROBLEM", 87, 136], ["urticarial", "OBSERVATION_MODIFIER", 46, 56], ["vasculitis", "OBSERVATION", 57, 67], ["urticarial", "OBSERVATION_MODIFIER", 106, 116], ["vasculitis", "OBSERVATION", 117, 127]]], ["D'Cruz and colleagues described a high prevalence of AECA, associated with reduced serum levels of complement, in SLE patients with UV, but not in primary UV or in SLE patients without UV [26].", [["serum", "ANATOMY", 83, 88], ["AECA", "DISEASE", 53, 57], ["SLE", "DISEASE", 114, 117], ["SLE", "DISEASE", 164, 167], ["AECA", "CANCER", 53, 57], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["complement", "GENE_OR_GENE_PRODUCT", 99, 109], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 168, 176], ["AECA", "PROBLEM", 53, 57], ["reduced serum levels of complement", "PROBLEM", 75, 109], ["UV", "PROBLEM", 132, 134], ["AECA", "OBSERVATION", 53, 57]]], ["The binding of AECA to ECs may be accompanied by the formation of immune complexes and complement fixation resulting in tissue damage.", [["ECs", "ANATOMY", 23, 26], ["tissue", "ANATOMY", 120, 126], ["tissue damage", "DISEASE", 120, 133], ["AECA", "GENE_OR_GENE_PRODUCT", 15, 19], ["ECs", "CELL", 23, 26], ["tissue", "TISSUE", 120, 126], ["AECA", "PROTEIN", 15, 19], ["ECs", "CELL_TYPE", 23, 26], ["immune complexes", "PROTEIN", 66, 82], ["immune complexes", "PROBLEM", 66, 82], ["complement fixation", "TREATMENT", 87, 106], ["tissue damage", "PROBLEM", 120, 133], ["AECA", "OBSERVATION", 15, 19], ["immune complexes", "OBSERVATION", 66, 82], ["fixation", "OBSERVATION", 98, 106], ["tissue", "ANATOMY", 120, 126], ["damage", "OBSERVATION", 127, 133]]], ["The anti\u2010C1q antibodies seem to be a specific marker for HUVS [[26], [27]], but they may also be detected occasionally in SLE patients (with or without UV).", [["SLE", "DISEASE", 122, 125], ["anti\u2010C1q antibodies", "GENE_OR_GENE_PRODUCT", 4, 23], ["[27]", "SIMPLE_CHEMICAL", 69, 73], ["patients", "ORGANISM", 126, 134], ["anti\u2010C1q antibodies", "PROTEIN", 4, 23], ["patients", "SPECIES", 126, 134], ["The anti\u2010C1q antibodies", "TREATMENT", 0, 23], ["may also be", "UNCERTAINTY", 85, 96]]], ["It has been suggested that anti\u2010C1q antibodies could contribute to EC damage by cross\u2010linking C1q bound to the immune complexes on the surface of ECs [28].AECA in Systemic Lupus Erythematosus and Antiphospholipid Syndrome ::: AECA in Autoimmune DiseasesThe presence of AECA has also been associated with thrombotic vascular damage in patients with SLE as well as in primary or secondary APS [29].", [["EC", "ANATOMY", 67, 69], ["surface", "ANATOMY", 135, 142], ["ECs", "ANATOMY", 146, 149], ["vascular", "ANATOMY", 315, 323], ["AECA", "DISEASE", 155, 159], ["Systemic Lupus Erythematosus", "DISEASE", 163, 191], ["Antiphospholipid Syndrome", "DISEASE", 196, 221], ["AECA", "DISEASE", 226, 230], ["Autoimmune Diseases", "DISEASE", 234, 253], ["thrombotic vascular damage", "DISEASE", 304, 330], ["SLE", "DISEASE", 348, 351], ["APS", "DISEASE", 387, 390], ["anti\u2010C1q antibodies", "GENE_OR_GENE_PRODUCT", 27, 46], ["EC", "CELL", 67, 69], ["C1q", "GENE_OR_GENE_PRODUCT", 94, 97], ["surface", "CELLULAR_COMPONENT", 135, 142], ["ECs", "CELL", 146, 149], ["AECA", "GENE_OR_GENE_PRODUCT", 269, 273], ["vascular", "MULTI-TISSUE_STRUCTURE", 315, 323], ["patients", "ORGANISM", 334, 342], ["anti\u2010C1q antibodies", "PROTEIN", 27, 46], ["EC", "CELL_TYPE", 67, 69], ["C1q", "PROTEIN", 94, 97], ["immune complexes", "PROTEIN", 111, 127], ["ECs", "CELL_TYPE", 146, 149], ["AECA", "PROTEIN", 269, 273], ["patients", "SPECIES", 334, 342], ["anti\u2010C1q antibodies", "TREATMENT", 27, 46], ["EC damage", "PROBLEM", 67, 76], ["cross\u2010linking C1q bound", "PROBLEM", 80, 103], ["AECA", "TEST", 155, 159], ["Systemic Lupus Erythematosus", "PROBLEM", 163, 191], ["Antiphospholipid Syndrome", "PROBLEM", 196, 221], ["AECA in Autoimmune Diseases", "PROBLEM", 226, 253], ["AECA", "PROBLEM", 269, 273], ["thrombotic vascular damage", "PROBLEM", 304, 330], ["SLE", "PROBLEM", 348, 351], ["Systemic Lupus Erythematosus", "OBSERVATION", 163, 191], ["Antiphospholipid Syndrome", "OBSERVATION", 196, 221], ["Autoimmune Diseases", "OBSERVATION", 234, 253], ["AECA", "OBSERVATION", 269, 273], ["associated with", "UNCERTAINTY", 288, 303], ["thrombotic", "OBSERVATION_MODIFIER", 304, 314], ["vascular", "ANATOMY", 315, 323], ["damage", "OBSERVATION", 324, 330]]], ["In this regard, Dieude et al. showed that AECA from SLE patients recognized heat\u2010shock protein 60 (HSP60) on the surface of HUVECs and induced apoptosis.", [["surface", "ANATOMY", 113, 120], ["HUVECs", "ANATOMY", 124, 130], ["AECA", "CHEMICAL", 42, 46], ["SLE", "DISEASE", 52, 55], ["AECA", "SIMPLE_CHEMICAL", 42, 46], ["patients", "ORGANISM", 56, 64], ["heat\u2010shock protein 60", "GENE_OR_GENE_PRODUCT", 76, 97], ["HSP60", "GENE_OR_GENE_PRODUCT", 99, 104], ["surface", "CELLULAR_COMPONENT", 113, 120], ["HUVECs", "CELL", 124, 130], ["AECA", "PROTEIN", 42, 46], ["heat\u2010shock protein 60", "PROTEIN", 76, 97], ["HSP60", "PROTEIN", 99, 104], ["HUVECs", "CELL_TYPE", 124, 130], ["patients", "SPECIES", 56, 64], ["AECA", "PROBLEM", 42, 46], ["heat\u2010shock protein", "TEST", 76, 94], ["HSP60", "TEST", 99, 104], ["induced apoptosis", "PROBLEM", 135, 152], ["AECA", "OBSERVATION", 42, 46], ["HUVECs", "ANATOMY", 124, 130], ["apoptosis", "OBSERVATION", 143, 152]]], ["A relationship between a high titer of anti\u2010HSP60, the presence of lupus anticoagulant (LAC), and thrombosis in SLE patients was also observed [3].", [["lupus", "DISEASE", 67, 72], ["thrombosis", "DISEASE", 98, 108], ["SLE", "DISEASE", 112, 115], ["anti\u2010HSP60", "GENE_OR_GENE_PRODUCT", 39, 49], ["lupus anticoagulant", "GENE_OR_GENE_PRODUCT", 67, 86], ["LAC", "CANCER", 88, 91], ["patients", "ORGANISM", 116, 124], ["anti\u2010HSP60", "PROTEIN", 39, 49], ["patients", "SPECIES", 116, 124], ["lupus anticoagulant", "PROBLEM", 67, 86], ["thrombosis in SLE patients", "PROBLEM", 98, 124], ["high titer", "OBSERVATION_MODIFIER", 25, 35], ["lupus anticoagulant", "OBSERVATION", 67, 86], ["thrombosis", "OBSERVATION", 98, 108]]], ["Thus, the authors suggest that, in the pathophysiologic pathway of thrombosis, the induction of apoptosis by anti\u2010HSP60 may represent the initial event that leads to aPL binding to the anionic phospholipid on the EC surface which may initiate the thrombotic cascade [3].AECA in Systemic Lupus Erythematosus and Antiphospholipid Syndrome ::: AECA in Autoimmune DiseasesAnti\u2010endothelial protein C receptor (EPCR) autoantibodies can be detected in APS patients and represent a novel risk factor for fetal death [30].", [["EC surface", "ANATOMY", 213, 223], ["fetal", "ANATOMY", 496, 501], ["thrombosis", "DISEASE", 67, 77], ["aPL", "DISEASE", 166, 169], ["thrombotic", "DISEASE", 247, 257], ["AECA", "DISEASE", 270, 274], ["Systemic Lupus Erythematosus", "DISEASE", 278, 306], ["Antiphospholipid Syndrome", "DISEASE", 311, 336], ["AECA", "DISEASE", 341, 345], ["APS", "DISEASE", 445, 448], ["fetal death", "DISEASE", 496, 507], ["anti\u2010HSP60", "GENE_OR_GENE_PRODUCT", 109, 119], ["aPL", "GENE_OR_GENE_PRODUCT", 166, 169], ["phospholipid", "SIMPLE_CHEMICAL", 193, 205], ["EC surface", "CELLULAR_COMPONENT", 213, 223], ["Anti\u2010endothelial protein C receptor", "GENE_OR_GENE_PRODUCT", 368, 403], ["EPCR", "GENE_OR_GENE_PRODUCT", 405, 409], ["patients", "ORGANISM", 449, 457], ["fetal", "ANATOMICAL_SYSTEM", 496, 501], ["anti\u2010HSP60", "PROTEIN", 109, 119], ["aPL", "PROTEIN", 166, 169], ["AECA", "PROTEIN", 341, 345], ["Anti\u2010endothelial protein C receptor", "PROTEIN", 368, 403], ["EPCR", "PROTEIN", 405, 409], ["autoantibodies", "PROTEIN", 411, 425], ["patients", "SPECIES", 449, 457], ["thrombosis", "PROBLEM", 67, 77], ["apoptosis", "PROBLEM", 96, 105], ["aPL binding", "PROBLEM", 166, 177], ["the anionic phospholipid on the EC surface", "TREATMENT", 181, 223], ["the thrombotic cascade", "TREATMENT", 243, 265], ["AECA", "TEST", 270, 274], ["Systemic Lupus Erythematosus", "PROBLEM", 278, 306], ["Antiphospholipid Syndrome", "PROBLEM", 311, 336], ["AECA", "TEST", 341, 345], ["Autoimmune Diseases", "PROBLEM", 349, 368], ["Anti\u2010endothelial protein C receptor (EPCR)", "TREATMENT", 368, 410], ["autoantibodies", "PROBLEM", 411, 425], ["fetal death", "PROBLEM", 496, 507], ["thrombosis", "OBSERVATION", 67, 77], ["thrombotic", "OBSERVATION", 247, 257], ["Systemic Lupus Erythematosus", "OBSERVATION", 278, 306], ["Antiphospholipid Syndrome", "OBSERVATION", 311, 336], ["Autoimmune Diseases", "OBSERVATION", 349, 368]]], ["A higher percentage of AECA positivity was also observed in Sneddon's syndrome, a disease characterized by livedo reticularis and ischemic cerebral vascular disease [31].AECA in Systemic Lupus Erythematosus and Antiphospholipid Syndrome ::: AECA in Autoimmune DiseasesIt has been suggested that AECA of various isotypes may be associated with lupus nephritis in SLE [[17], [32], [33]]; in particular, the highest AECA levels have been detected in a large series of SLE patients with diffuse proliferative glomerulonephritis at the time of renal biopsy or with proteinuria and nephrotic syndrome [17].", [["livedo reticularis", "ANATOMY", 107, 125], ["cerebral vascular", "ANATOMY", 139, 156], ["renal", "ANATOMY", 539, 544], ["Sneddon's syndrome", "DISEASE", 60, 78], ["cerebral vascular disease", "DISEASE", 139, 164], ["AECA", "DISEASE", 170, 174], ["Systemic Lupus Erythematosus", "DISEASE", 178, 206], ["Antiphospholipid Syndrome", "DISEASE", 211, 236], ["AECA", "DISEASE", 241, 245], ["Autoimmune Diseases", "DISEASE", 249, 268], ["lupus nephritis", "DISEASE", 343, 358], ["SLE", "DISEASE", 362, 365], ["SLE", "DISEASE", 465, 468], ["glomerulonephritis", "DISEASE", 505, 523], ["proteinuria", "DISEASE", 560, 571], ["nephrotic syndrome", "DISEASE", 576, 594], ["AECA", "GENE_OR_GENE_PRODUCT", 23, 27], ["cerebral vascular", "MULTI-TISSUE_STRUCTURE", 139, 156], ["AECA", "GENE_OR_GENE_PRODUCT", 295, 299], ["AECA", "GENE_OR_GENE_PRODUCT", 413, 417], ["patients", "ORGANISM", 469, 477], ["renal biopsy", "MULTI-TISSUE_STRUCTURE", 539, 551], ["AECA", "PROTEIN", 23, 27], ["AECA", "PROTEIN", 295, 299], ["AECA", "PROTEIN", 413, 417], ["patients", "SPECIES", 469, 477], ["A higher percentage of AECA positivity", "PROBLEM", 0, 38], ["Sneddon's syndrome", "PROBLEM", 60, 78], ["a disease", "PROBLEM", 80, 89], ["livedo reticularis", "PROBLEM", 107, 125], ["ischemic cerebral vascular disease", "PROBLEM", 130, 164], ["AECA", "TEST", 170, 174], ["Systemic Lupus Erythematosus", "PROBLEM", 178, 206], ["Antiphospholipid Syndrome", "PROBLEM", 211, 236], ["AECA in Autoimmune Diseases", "PROBLEM", 241, 268], ["AECA of various isotypes", "PROBLEM", 295, 319], ["lupus nephritis", "PROBLEM", 343, 358], ["the highest AECA levels", "TEST", 401, 424], ["diffuse proliferative glomerulonephritis", "PROBLEM", 483, 523], ["renal biopsy", "TEST", 539, 551], ["proteinuria", "PROBLEM", 560, 571], ["nephrotic syndrome", "PROBLEM", 576, 594], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["percentage", "OBSERVATION_MODIFIER", 9, 19], ["AECA positivity", "OBSERVATION", 23, 38], ["livedo reticularis", "OBSERVATION", 107, 125], ["ischemic", "OBSERVATION_MODIFIER", 130, 138], ["cerebral", "ANATOMY_MODIFIER", 139, 147], ["vascular", "ANATOMY", 148, 156], ["Systemic Lupus Erythematosus", "OBSERVATION", 178, 206], ["Antiphospholipid Syndrome", "OBSERVATION", 211, 236], ["Autoimmune Diseases", "OBSERVATION", 249, 268], ["may be associated with", "UNCERTAINTY", 320, 342], ["lupus", "OBSERVATION_MODIFIER", 343, 348], ["nephritis", "OBSERVATION", 349, 358], ["diffuse", "OBSERVATION_MODIFIER", 483, 490], ["proliferative", "OBSERVATION_MODIFIER", 491, 504], ["glomerulonephritis", "OBSERVATION", 505, 523], ["renal", "ANATOMY", 539, 544], ["biopsy", "OBSERVATION", 545, 551], ["proteinuria", "OBSERVATION", 560, 571], ["nephrotic syndrome", "OBSERVATION", 576, 594]]], ["AECA showed the highest titer in active lupus, whereas the mean antibody titer fell significantly as patients entered remission [34].", [["lupus", "DISEASE", 40, 45], ["AECA", "GENE_OR_GENE_PRODUCT", 0, 4], ["lupus", "CANCER", 40, 45], ["patients", "ORGANISM", 101, 109], ["AECA", "PROTEIN", 0, 4], ["patients", "SPECIES", 101, 109], ["AECA", "TEST", 0, 4], ["active lupus", "PROBLEM", 33, 45], ["the mean antibody titer", "TEST", 55, 78], ["highest", "OBSERVATION_MODIFIER", 16, 23], ["titer", "OBSERVATION_MODIFIER", 24, 29], ["active", "OBSERVATION_MODIFIER", 33, 39], ["lupus", "OBSERVATION", 40, 45]]], ["These findings have been further validated by a prospective study that suggested a role for AECA, in association with other laboratory parameters, as a marker of disease activity in SLE [35].", [["SLE", "DISEASE", 182, 185], ["AECA", "GENE_OR_GENE_PRODUCT", 92, 96], ["AECA", "PROTEIN", 92, 96], ["a prospective study", "TEST", 46, 65], ["AECA", "PROBLEM", 92, 96], ["disease activity", "PROBLEM", 162, 178]]], ["Autoantibodies reacting in immunoblot analysis with both 27\u2010 and 29\u2010kDa endothelial cell antigens were correlated to the presence of glomerular capillary thrombi and heavy proteinuria [36].", [["endothelial cell", "ANATOMY", 72, 88], ["glomerular capillary thrombi", "ANATOMY", 133, 161], ["proteinuria", "DISEASE", 172, 183], ["\u2010kDa endothelial cell antigens", "GENE_OR_GENE_PRODUCT", 67, 97], ["glomerular capillary thrombi", "TISSUE", 133, 161], ["27\u2010 and 29\u2010kDa endothelial cell antigens", "PROTEIN", 57, 97], ["Autoantibodies", "TEST", 0, 14], ["immunoblot analysis", "TEST", 27, 46], ["endothelial cell antigens", "TEST", 72, 97], ["glomerular capillary thrombi", "PROBLEM", 133, 161], ["heavy proteinuria", "PROBLEM", 166, 183], ["glomerular", "OBSERVATION_MODIFIER", 133, 143], ["capillary thrombi", "OBSERVATION", 144, 161], ["heavy", "OBSERVATION_MODIFIER", 166, 171], ["proteinuria", "OBSERVATION", 172, 183]]], ["In another study, patients with lupus nephritis, vasculitis, and hypocomplementemia showed IgG\u2010AECA against a 66\u2010kDa membrane antigen [18].", [["lupus nephritis", "DISEASE", 32, 47], ["vasculitis", "DISEASE", 49, 59], ["hypocomplementemia", "DISEASE", 65, 83], ["patients", "ORGANISM", 18, 26], ["IgG\u2010AECA", "GENE_OR_GENE_PRODUCT", 91, 99], ["IgG\u2010AECA", "PROTEIN", 91, 99], ["patients", "SPECIES", 18, 26], ["another study", "TEST", 3, 16], ["lupus nephritis", "PROBLEM", 32, 47], ["vasculitis", "PROBLEM", 49, 59], ["hypocomplementemia", "PROBLEM", 65, 83], ["IgG\u2010AECA", "TEST", 91, 99], ["Da membrane antigen", "TEST", 114, 133], ["lupus", "OBSERVATION_MODIFIER", 32, 37], ["nephritis", "OBSERVATION", 38, 47], ["vasculitis", "OBSERVATION", 49, 59], ["hypocomplementemia", "OBSERVATION", 65, 83]]], ["Antibodies against ribosomal P protein P0 have been identified by a molecular cloning strategy in SLE patients with active disease and nephritis [37].", [["ribosomal", "ANATOMY", 19, 28], ["SLE", "DISEASE", 98, 101], ["active disease", "DISEASE", 116, 130], ["nephritis", "DISEASE", 135, 144], ["ribosomal P protein P0", "GENE_OR_GENE_PRODUCT", 19, 41], ["patients", "ORGANISM", 102, 110], ["ribosomal P protein P0", "PROTEIN", 19, 41], ["patients", "SPECIES", 102, 110], ["Antibodies", "TEST", 0, 10], ["ribosomal P protein P0", "PROBLEM", 19, 41], ["active disease", "PROBLEM", 116, 130], ["nephritis", "PROBLEM", 135, 144], ["active", "OBSERVATION_MODIFIER", 116, 122], ["disease", "OBSERVATION", 123, 130], ["nephritis", "OBSERVATION", 135, 144]]], ["In one patient, these autoantibodies correlated with total AECA levels as well as with anti\u2010DNA antibody, disease activity, and renal involvement in a longitudinal follow\u2010up.", [["renal", "ANATOMY", 128, 133], ["patient", "ORGANISM", 7, 14], ["AECA", "GENE_OR_GENE_PRODUCT", 59, 63], ["anti\u2010DNA antibody", "GENE_OR_GENE_PRODUCT", 87, 104], ["renal", "ORGAN", 128, 133], ["autoantibodies", "PROTEIN", 22, 36], ["AECA", "PROTEIN", 59, 63], ["anti\u2010DNA antibody", "PROTEIN", 87, 104], ["patient", "SPECIES", 7, 14], ["these autoantibodies", "TEST", 16, 36], ["total AECA levels", "TEST", 53, 70], ["anti\u2010DNA antibody", "TREATMENT", 87, 104], ["disease activity", "PROBLEM", 106, 122], ["renal involvement", "PROBLEM", 128, 145], ["renal", "ANATOMY", 128, 133], ["involvement", "OBSERVATION", 134, 145]]], ["Nevertheless, to date, positive findings of both anti\u2010dsDNA and anti\u2010C1q antibodies are of higher specificity for active nephritis in SLE patients [16].AECA in Systemic Lupus Erythematosus and Antiphospholipid Syndrome ::: AECA in Autoimmune DiseasesaPL, anti\u2010\u03b22\u2010GPI, and AECA have been associated with various neurological manifestations in patients with SLE.", [["neurological", "ANATOMY", 311, 323], ["nephritis", "DISEASE", 121, 130], ["SLE", "DISEASE", 134, 137], ["AECA", "DISEASE", 152, 156], ["Systemic Lupus Erythematosus", "DISEASE", 160, 188], ["Antiphospholipid Syndrome", "DISEASE", 193, 218], ["SLE", "DISEASE", 356, 359], ["anti\u2010dsDNA", "GENE_OR_GENE_PRODUCT", 49, 59], ["anti\u2010C1q antibodies", "GENE_OR_GENE_PRODUCT", 64, 83], ["patients", "ORGANISM", 138, 146], ["anti\u2010\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 255, 266], ["AECA", "GENE_OR_GENE_PRODUCT", 272, 276], ["patients", "ORGANISM", 342, 350], ["anti\u2010dsDNA", "PROTEIN", 49, 59], ["anti\u2010C1q antibodies", "PROTEIN", 64, 83], ["anti\u2010\u03b22", "PROTEIN", 255, 262], ["GPI", "PROTEIN", 263, 266], ["AECA", "PROTEIN", 272, 276], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 342, 350], ["both anti\u2010dsDNA", "TREATMENT", 44, 59], ["anti\u2010C1q antibodies", "TREATMENT", 64, 83], ["active nephritis", "PROBLEM", 114, 130], ["AECA", "TEST", 152, 156], ["Systemic Lupus Erythematosus", "PROBLEM", 160, 188], ["Antiphospholipid Syndrome", "PROBLEM", 193, 218], ["AECA", "PROBLEM", 223, 227], ["Autoimmune DiseasesaPL", "PROBLEM", 231, 253], ["anti\u2010\u03b22\u2010GPI", "TREATMENT", 255, 266], ["AECA", "TREATMENT", 272, 276], ["various neurological manifestations", "PROBLEM", 303, 338], ["SLE", "PROBLEM", 356, 359], ["active", "OBSERVATION_MODIFIER", 114, 120], ["nephritis", "OBSERVATION", 121, 130], ["Systemic Lupus Erythematosus", "OBSERVATION", 160, 188], ["Antiphospholipid Syndrome", "OBSERVATION", 193, 218], ["AECA", "ANATOMY", 223, 227], ["Autoimmune DiseasesaPL", "OBSERVATION", 231, 253]]], ["These in vivo observations were further validated by a mouse model of APS, which developed neurological dysfunction and hyperactive behavior associated with aPL, anti\u2010\u03b22\u2010GPI, and AECA after passive immunization with human aCL mAb [38].", [["neurological", "ANATOMY", 91, 103], ["APS", "DISEASE", 70, 73], ["neurological dysfunction", "DISEASE", 91, 115], ["hyperactive behavior", "DISEASE", 120, 140], ["aPL", "DISEASE", 157, 160], ["mouse", "ORGANISM", 55, 60], ["aPL", "GENE_OR_GENE_PRODUCT", 157, 160], ["anti\u2010\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 162, 173], ["AECA", "GENE_OR_GENE_PRODUCT", 179, 183], ["human", "ORGANISM", 216, 221], ["aPL", "PROTEIN", 157, 160], ["anti\u2010\u03b22", "PROTEIN", 162, 169], ["GPI", "PROTEIN", 170, 173], ["AECA", "PROTEIN", 179, 183], ["human aCL mAb", "PROTEIN", 216, 229], ["mouse", "SPECIES", 55, 60], ["human", "SPECIES", 216, 221], ["mouse", "SPECIES", 55, 60], ["human", "SPECIES", 216, 221], ["neurological dysfunction", "PROBLEM", 91, 115], ["hyperactive behavior", "PROBLEM", 120, 140], ["aPL", "TEST", 157, 160], ["anti\u2010\u03b22\u2010GPI", "TREATMENT", 162, 173], ["AECA", "TREATMENT", 179, 183], ["passive immunization", "TREATMENT", 190, 210], ["human aCL mAb", "TREATMENT", 216, 229], ["hyperactive", "OBSERVATION", 120, 131]]], ["We demonstrated an association between the presence of AECA and psychiatric manifestations, such as psychosis and depression in SLE, suggesting a possible organic mechanism underlying the psychiatric symptoms [39].", [["AECA", "DISEASE", 55, 59], ["psychiatric", "DISEASE", 64, 75], ["psychosis", "DISEASE", 100, 109], ["depression", "DISEASE", 114, 124], ["SLE", "DISEASE", 128, 131], ["psychiatric", "DISEASE", 188, 199], ["AECA", "CANCER", 55, 59], ["AECA and psychiatric manifestations", "PROBLEM", 55, 90], ["psychosis", "PROBLEM", 100, 109], ["depression in SLE", "PROBLEM", 114, 131], ["organic mechanism", "PROBLEM", 155, 172], ["the psychiatric symptoms", "PROBLEM", 184, 208], ["AECA", "OBSERVATION", 55, 59], ["psychiatric manifestations", "OBSERVATION", 64, 90]]], ["In our study no significant correlation was found between aCL, anti\u2010\u03b22\u2010GPI, anti\u2010Ro, antiglial fibrillary acidic protein, antiribosomal P protein, anti\u2010dsDNA, and anti\u2010nucleosome antibodies and psychiatric involvement in SLE patients.", [["psychiatric", "DISEASE", 194, 205], ["SLE", "DISEASE", 221, 224], ["aCL", "GENE_OR_GENE_PRODUCT", 58, 61], ["anti\u2010\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 63, 74], ["anti\u2010Ro", "GENE_OR_GENE_PRODUCT", 76, 83], ["antiglial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 85, 120], ["antiribosomal P", "GENE_OR_GENE_PRODUCT", 122, 137], ["anti\u2010dsDNA", "GENE_OR_GENE_PRODUCT", 147, 157], ["anti\u2010nucleosome antibodies", "GENE_OR_GENE_PRODUCT", 163, 189], ["patients", "ORGANISM", 225, 233], ["aCL", "PROTEIN", 58, 61], ["anti\u2010\u03b22", "PROTEIN", 63, 70], ["GPI", "PROTEIN", 71, 74], ["anti\u2010Ro", "PROTEIN", 76, 83], ["antiglial fibrillary acidic protein", "PROTEIN", 85, 120], ["antiribosomal P protein", "PROTEIN", 122, 145], ["anti\u2010dsDNA", "PROTEIN", 147, 157], ["anti\u2010nucleosome antibodies", "PROTEIN", 163, 189], ["patients", "SPECIES", 225, 233], ["our study", "TEST", 3, 12], ["aCL", "TEST", 58, 61], ["GPI", "TEST", 71, 74], ["anti\u2010Ro", "TEST", 76, 83], ["anti\u2010dsDNA", "TREATMENT", 147, 157], ["anti\u2010nucleosome antibodies", "TREATMENT", 163, 189], ["psychiatric involvement in SLE patients", "PROBLEM", 194, 233]]], ["Moreover, no association was found between AECA reactivity and aCL and anti\u2010\u03b22\u2010GPI antibodies.", [["AECA", "GENE_OR_GENE_PRODUCT", 43, 47], ["aCL", "GENE_OR_GENE_PRODUCT", 63, 66], ["anti\u2010\u03b22", "GENE_OR_GENE_PRODUCT", 71, 78], ["GPI antibodies", "GENE_OR_GENE_PRODUCT", 79, 93], ["AECA", "PROTEIN", 43, 47], ["aCL", "PROTEIN", 63, 66], ["anti\u2010\u03b22", "PROTEIN", 71, 78], ["GPI antibodies", "PROTEIN", 79, 93], ["AECA reactivity", "TEST", 43, 58], ["aCL", "TEST", 63, 66], ["GPI antibodies", "TEST", 79, 93], ["aCL", "ANATOMY", 63, 66]]], ["Remarkably, by screening a cDNA library from human umbilical artery ECs (HUAECs) with serum from an SLE patient with acute and active psychosis and elevated AECA serum level, we further identified one strongly reactive clone encoding the C\u2010terminal region (C\u2010ter) of Nedd5, an intracytoplasmic protein of the septin family [40].", [["human umbilical artery ECs", "ANATOMY", 45, 71], ["HUAECs", "ANATOMY", 73, 79], ["serum", "ANATOMY", 86, 91], ["AECA serum", "ANATOMY", 157, 167], ["SLE", "DISEASE", 100, 103], ["acute and active psychosis", "DISEASE", 117, 143], ["human", "ORGANISM", 45, 50], ["umbilical artery ECs", "CELL", 51, 71], ["HUAECs", "CELL", 73, 79], ["serum", "ORGANISM_SUBSTANCE", 86, 91], ["patient", "ORGANISM", 104, 111], ["AECA", "GENE_OR_GENE_PRODUCT", 157, 161], ["serum", "ORGANISM_SUBSTANCE", 162, 167], ["clone", "CELL", 219, 224], ["Nedd5", "GENE_OR_GENE_PRODUCT", 267, 272], ["septin", "GENE_OR_GENE_PRODUCT", 309, 315], ["cDNA library", "DNA", 27, 39], ["human umbilical artery ECs", "CELL_TYPE", 45, 71], ["HUAECs", "CELL_TYPE", 73, 79], ["AECA", "PROTEIN", 157, 161], ["C\u2010terminal region", "PROTEIN", 238, 255], ["C\u2010ter", "PROTEIN", 257, 262], ["Nedd5", "PROTEIN", 267, 272], ["intracytoplasmic protein", "PROTEIN", 277, 301], ["septin family", "PROTEIN", 309, 322], ["human", "SPECIES", 45, 50], ["patient", "SPECIES", 104, 111], ["human", "SPECIES", 45, 50], ["serum", "TEST", 86, 91], ["acute and active psychosis", "PROBLEM", 117, 143], ["elevated AECA serum level", "PROBLEM", 148, 173], ["Nedd5", "TREATMENT", 267, 272], ["umbilical artery", "ANATOMY", 51, 67], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["active", "OBSERVATION_MODIFIER", 127, 133], ["psychosis", "OBSERVATION", 134, 143], ["elevated", "OBSERVATION_MODIFIER", 148, 156], ["AECA", "OBSERVATION", 157, 161], ["reactive clone", "OBSERVATION", 210, 224], ["intracytoplasmic protein", "OBSERVATION", 277, 301]]], ["IgGs specific to Nedd5 C\u2010ter were present in 14 of 51 SLE patients (27.4%) by ELISA and the mean IgG reactivity to this protein was significantly higher in SLE patients with psychosis or mood disorders.", [["SLE", "DISEASE", 54, 57], ["SLE", "DISEASE", 156, 159], ["psychosis", "DISEASE", 174, 183], ["mood disorders", "DISEASE", 187, 201], ["IgGs", "GENE_OR_GENE_PRODUCT", 0, 4], ["Nedd5", "GENE_OR_GENE_PRODUCT", 17, 22], ["patients", "ORGANISM", 58, 66], ["IgG", "GENE_OR_GENE_PRODUCT", 97, 100], ["patients", "ORGANISM", 160, 168], ["IgGs", "PROTEIN", 0, 4], ["Nedd5 C\u2010ter", "PROTEIN", 17, 28], ["IgG", "PROTEIN", 97, 100], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 160, 168], ["C\u2010ter", "TEST", 23, 28], ["SLE patients", "TEST", 54, 66], ["ELISA", "TEST", 78, 83], ["the mean IgG reactivity", "TEST", 88, 111], ["this protein", "TEST", 115, 127], ["psychosis", "PROBLEM", 174, 183], ["mood disorders", "PROBLEM", 187, 201]]], ["On the contrary, no correlation was observed between the presence of anti\u2010Nedd5 C\u2010ter antibodies and the other clinical features.", [["anti\u2010Nedd5 C\u2010ter antibodies", "GENE_OR_GENE_PRODUCT", 69, 96], ["anti\u2010Nedd5", "PROTEIN", 69, 79], ["C\u2010ter antibodies", "PROTEIN", 80, 96], ["anti\u2010Nedd5 C\u2010ter antibodies", "TREATMENT", 69, 96]]], ["The results of these studies suggest a relationship between AECA and anti\u2010Nedd5 antibodies with neuropsychiatric involvement in SLE, supporting the hypothesis of a biological origin of these disturbances.AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesSystemic sclerosis is a multisystemic disorder of the connective tissue characterized by immune abnormalities, microvascular injury, and fibrotic changes involving skin and visceral organs, such as the lungs, heart, gastrointestinal tract, and kidneys.", [["connective tissue", "ANATOMY", 316, 333], ["microvascular", "ANATOMY", 373, 386], ["skin", "ANATOMY", 426, 430], ["visceral organs", "ANATOMY", 435, 450], ["lungs", "ANATOMY", 464, 469], ["heart", "ANATOMY", 471, 476], ["gastrointestinal tract", "ANATOMY", 478, 500], ["kidneys", "ANATOMY", 506, 513], ["SLE", "DISEASE", 128, 131], ["AECA", "DISEASE", 204, 208], ["Systemic Sclerosis", "DISEASE", 212, 230], ["Autoimmune Diseases", "DISEASE", 243, 262], ["Systemic sclerosis", "DISEASE", 262, 280], ["multisystemic disorder", "DISEASE", 286, 308], ["immune abnormalities", "DISEASE", 351, 371], ["microvascular injury", "DISEASE", 373, 393], ["AECA", "GENE_OR_GENE_PRODUCT", 60, 64], ["anti\u2010Nedd5 antibodies", "GENE_OR_GENE_PRODUCT", 69, 90], ["SLE", "CANCER", 128, 131], ["connective tissue", "TISSUE", 316, 333], ["microvascular", "TISSUE", 373, 386], ["skin", "ORGAN", 426, 430], ["visceral organs", "TISSUE", 435, 450], ["lungs", "ORGAN", 464, 469], ["heart", "ORGAN", 471, 476], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 478, 500], ["kidneys", "ORGAN", 506, 513], ["AECA", "PROTEIN", 60, 64], ["anti\u2010Nedd5 antibodies", "PROTEIN", 69, 90], ["these studies", "TEST", 15, 28], ["AECA and anti\u2010Nedd5 antibodies", "TREATMENT", 60, 90], ["neuropsychiatric involvement in SLE", "PROBLEM", 96, 131], ["these disturbances", "PROBLEM", 185, 203], ["AECA", "TEST", 204, 208], ["Systemic Sclerosis", "PROBLEM", 212, 230], ["AECA", "PROBLEM", 235, 239], ["Autoimmune Diseases", "PROBLEM", 243, 262], ["Systemic sclerosis", "PROBLEM", 262, 280], ["a multisystemic disorder of the connective tissue", "PROBLEM", 284, 333], ["immune abnormalities", "PROBLEM", 351, 371], ["microvascular injury", "PROBLEM", 373, 393], ["fibrotic changes involving skin and visceral organs, such as the lungs, heart, gastrointestinal tract, and kidneys", "PROBLEM", 399, 513], ["Systemic", "OBSERVATION_MODIFIER", 212, 220], ["Sclerosis", "OBSERVATION", 221, 230], ["AECA", "ANATOMY", 235, 239], ["Autoimmune Diseases", "OBSERVATION", 243, 262], ["Systemic", "OBSERVATION_MODIFIER", 262, 270], ["sclerosis", "OBSERVATION", 271, 280], ["multisystemic", "OBSERVATION_MODIFIER", 286, 299], ["disorder", "OBSERVATION", 300, 308], ["connective tissue", "ANATOMY", 316, 333], ["immune abnormalities", "OBSERVATION", 351, 371], ["microvascular injury", "OBSERVATION", 373, 393], ["fibrotic", "OBSERVATION", 399, 407], ["skin", "ANATOMY", 426, 430], ["visceral", "ANATOMY_MODIFIER", 435, 443], ["organs", "ANATOMY", 444, 450], ["lungs", "ANATOMY", 464, 469], ["heart", "ANATOMY", 471, 476], ["gastrointestinal tract", "ANATOMY", 478, 500], ["kidneys", "ANATOMY", 506, 513]]], ["It is well recognized that vascular injury appears frequently in the clinic course of the disease\u2014that is, Raynaud's phenomenon (RP)\u2014and that vascular dysfunction represents one of the primary events in the pathogenesis of the disease.", [["vascular", "ANATOMY", 27, 35], ["vascular", "ANATOMY", 142, 150], ["vascular injury", "DISEASE", 27, 42], ["Raynaud's phenomenon", "DISEASE", 107, 127], ["RP", "DISEASE", 129, 131], ["vascular dysfunction", "DISEASE", 142, 162], ["vascular", "MULTI-TISSUE_STRUCTURE", 27, 35], ["vascular", "MULTI-TISSUE_STRUCTURE", 142, 150], ["vascular injury", "PROBLEM", 27, 42], ["the disease\u2014that", "PROBLEM", 86, 102], ["Raynaud's phenomenon", "PROBLEM", 107, 127], ["vascular dysfunction", "PROBLEM", 142, 162], ["the disease", "PROBLEM", 223, 234], ["vascular", "ANATOMY", 27, 35], ["injury", "OBSERVATION", 36, 42], ["vascular", "ANATOMY", 142, 150], ["dysfunction", "OBSERVATION", 151, 162], ["disease", "OBSERVATION", 227, 234]]], ["Thus, it is not surprising that a significant amount of research by both clinical and basic scientists has focused on the identification of the clinical parameters and the pathogenic mechanisms of endothelial dysfunction, with AECA displaying great relevance in both fields of investigation.AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesAECA reactivity in scleroderma is quite common, having been detected with an overall prevalence varying from 19% to 85%, depending on the method used (ELISA, WB, IF), the Ig isotypes investigated, the substrate (tissue sections, source of human ECs) used, as well as the variability in the subtypes of SSc patients included (limited vs diffuse SSc) in the different studies (reviewed in Ref.", [["endothelial", "ANATOMY", 197, 208], ["tissue sections", "ANATOMY", 561, 576], ["ECs", "ANATOMY", 594, 597], ["endothelial dysfunction", "DISEASE", 197, 220], ["AECA", "DISEASE", 291, 295], ["Systemic Sclerosis", "DISEASE", 299, 317], ["Autoimmune DiseasesAECA", "DISEASE", 330, 353], ["scleroderma", "DISEASE", 368, 379], ["SSc", "DISEASE", 651, 654], ["SSc", "DISEASE", 693, 696], ["endothelial", "CELL", 197, 208], ["Ig isotypes", "GENE_OR_GENE_PRODUCT", 520, 531], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 561, 576], ["human", "ORGANISM", 588, 593], ["ECs", "CELL", 594, 597], ["patients", "ORGANISM", 655, 663], ["IF", "PROTEIN", 511, 513], ["Ig isotypes", "PROTEIN", 520, 531], ["human ECs", "CELL_TYPE", 588, 597], ["human", "SPECIES", 588, 593], ["patients", "SPECIES", 655, 663], ["human", "SPECIES", 588, 593], ["the clinical parameters", "TEST", 140, 163], ["endothelial dysfunction", "PROBLEM", 197, 220], ["AECA", "TEST", 227, 231], ["AECA", "TEST", 291, 295], ["Systemic Sclerosis", "PROBLEM", 299, 317], ["AECA", "PROBLEM", 322, 326], ["Autoimmune DiseasesAECA reactivity in scleroderma", "PROBLEM", 330, 379], ["the method", "TEST", 483, 493], ["the Ig isotypes", "TREATMENT", 516, 531], ["the different studies", "TEST", 701, 722], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["amount", "OBSERVATION_MODIFIER", 46, 52], ["endothelial dysfunction", "OBSERVATION", 197, 220], ["Systemic", "OBSERVATION_MODIFIER", 299, 307], ["Sclerosis", "OBSERVATION", 308, 317], ["AECA", "OBSERVATION", 322, 326], ["Autoimmune DiseasesAECA", "OBSERVATION", 330, 353], ["scleroderma", "OBSERVATION", 368, 379], ["SSc", "ANATOMY", 651, 654]]], ["[41]).AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesConsiderable effort has focused on the identification of associations between AECA positivity and the clinical manifestations of SSc.", [["AECA", "DISEASE", 6, 10], ["Systemic Sclerosis", "DISEASE", 14, 32], ["Autoimmune Diseases", "DISEASE", 45, 64], ["SSc", "DISEASE", 193, 196], ["AECA", "GENE_OR_GENE_PRODUCT", 142, 146], ["SSc", "PATHOLOGICAL_FORMATION", 193, 196], ["AECA", "PROTEIN", 142, 146], ["AECA in Systemic Sclerosis", "PROBLEM", 6, 32], ["AECA", "PROBLEM", 37, 41], ["Autoimmune Diseases", "PROBLEM", 45, 64], ["AECA positivity", "TEST", 142, 157], ["Systemic", "OBSERVATION_MODIFIER", 14, 22], ["Sclerosis", "OBSERVATION", 23, 32], ["AECA", "OBSERVATION", 37, 41], ["Autoimmune Diseases", "OBSERVATION", 45, 64], ["SSc", "ANATOMY", 193, 196]]], ["An early study involving 31 patients with diffuse SSc (dSSc), 36 with limited SSc (lSSc) and 13 with primary RP (PRP) reported an increased prevalence of AECA with increased severity of clinical manifestations related to SSc [42].", [["diffuse SSc", "ANATOMY", 42, 53], ["SSc", "DISEASE", 50, 53], ["dSSc", "DISEASE", 55, 59], ["SSc", "DISEASE", 78, 81], ["lSSc", "DISEASE", 83, 87], ["primary RP", "DISEASE", 101, 111], ["AECA", "DISEASE", 154, 158], ["SSc", "DISEASE", 221, 224], ["patients", "ORGANISM", 28, 36], ["dSSc", "CANCER", 55, 59], ["AECA", "CANCER", 154, 158], ["patients", "SPECIES", 28, 36], ["An early study", "TEST", 0, 14], ["diffuse SSc (dSSc", "TEST", 42, 59], ["AECA", "PROBLEM", 154, 158], ["clinical manifestations", "PROBLEM", 186, 209], ["diffuse", "OBSERVATION_MODIFIER", 42, 49], ["SSc", "ANATOMY", 50, 53], ["AECA", "OBSERVATION", 154, 158]]], ["If the analysis was limited to AECA IgG, these authors observed an AECA prevalence of 15% in patients with isolated RP, 39% in lSSc, and 77% in dSSc.", [["RP", "ANATOMY", 116, 118], ["lSSc", "ANATOMY", 127, 131], ["dSSc", "ANATOMY", 144, 148], ["RP", "DISEASE", 116, 118], ["lSSc", "DISEASE", 127, 131], ["AECA IgG", "GENE_OR_GENE_PRODUCT", 31, 39], ["patients", "ORGANISM", 93, 101], ["lSSc", "CANCER", 127, 131], ["dSSc", "CANCER", 144, 148], ["AECA IgG", "PROTEIN", 31, 39], ["patients", "SPECIES", 93, 101], ["the analysis", "TEST", 3, 15], ["AECA IgG", "TEST", 31, 39], ["an AECA prevalence", "TEST", 64, 82], ["isolated RP", "TEST", 107, 118], ["lSSc", "TEST", 127, 131]]], ["An increased prevalence of AECA in dSSc compared to lSSc was also reported by Negi et al. [43] in 76 patients with SSc with a prevalence of 40% vs 13.5%.", [["AECA", "DISEASE", 27, 31], ["SSc", "DISEASE", 115, 118], ["AECA", "CANCER", 27, 31], ["dSSc", "CANCER", 35, 39], ["lSSc", "CANCER", 52, 56], ["patients", "ORGANISM", 101, 109], ["AECA", "PROTEIN", 27, 31], ["lSSc", "DNA", 52, 56], ["patients", "SPECIES", 101, 109], ["AECA in dSSc", "TREATMENT", 27, 39], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["AECA", "OBSERVATION", 27, 31]]], ["Although these results suggested an important role for AECA in identifying different clinical subsets of SSc, they have not been confirmed in later studies, in which no difference in AECA reactivity was observed between patients with lSSc and dSSc [[44], [45]].AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesAlthough the utility of AECA in differentiating the main clinical subsets of SSc is debatable, significant associations between AECA reactivity and some of the clinical manifestations of SSc have been consistently reported [[42], [43], [44], [45]].AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesAECA were found to closely associate with capillaroscopy abnormalities as well as with severe digital ischemia and digital ulcers [[42], [43], [44]].", [["SSc", "DISEASE", 105, 108], ["AECA", "DISEASE", 261, 265], ["Systemic Sclerosis", "DISEASE", 269, 287], ["Autoimmune Diseases", "DISEASE", 300, 319], ["SSc", "DISEASE", 396, 399], ["SSc", "DISEASE", 506, 509], ["AECA", "DISEASE", 567, 571], ["Systemic Sclerosis", "DISEASE", 575, 593], ["Autoimmune DiseasesAECA", "DISEASE", 606, 629], ["ischemia", "DISEASE", 727, 735], ["ulcers", "DISEASE", 748, 754], ["AECA", "GENE_OR_GENE_PRODUCT", 55, 59], ["AECA", "GENE_OR_GENE_PRODUCT", 183, 187], ["patients", "ORGANISM", 220, 228], ["AECA", "CANCER", 343, 347], ["SSc", "CANCER", 396, 399], ["AECA", "GENE_OR_GENE_PRODUCT", 447, 451], ["SSc", "CANCER", 506, 509], ["[[42], [43], [44], [45]", "SIMPLE_CHEMICAL", 542, 565], ["AECA", "PROTEIN", 55, 59], ["AECA", "PROTEIN", 183, 187], ["AECA", "PROTEIN", 343, 347], ["patients", "SPECIES", 220, 228], ["AECA", "TREATMENT", 55, 59], ["AECA reactivity", "TEST", 183, 198], ["dSSc", "TEST", 243, 247], ["AECA in Systemic Sclerosis", "PROBLEM", 261, 287], ["AECA", "PROBLEM", 292, 296], ["Autoimmune Diseases", "PROBLEM", 300, 319], ["AECA", "TEST", 343, 347], ["AECA reactivity", "TEST", 447, 462], ["AECA in Systemic Sclerosis", "PROBLEM", 567, 593], ["AECA", "PROBLEM", 598, 602], ["Autoimmune DiseasesAECA", "PROBLEM", 606, 629], ["capillaroscopy abnormalities", "PROBLEM", 667, 695], ["severe digital ischemia", "PROBLEM", 712, 735], ["digital ulcers", "PROBLEM", 740, 754], ["Systemic", "OBSERVATION_MODIFIER", 269, 277], ["Sclerosis", "OBSERVATION", 278, 287], ["AECA", "OBSERVATION", 292, 296], ["Autoimmune Diseases", "OBSERVATION", 300, 319], ["AECA", "OBSERVATION", 343, 347], ["main", "OBSERVATION_MODIFIER", 371, 375], ["SSc", "ANATOMY", 396, 399], ["Systemic", "OBSERVATION_MODIFIER", 575, 583], ["Sclerosis", "OBSERVATION", 584, 593], ["AECA", "OBSERVATION", 598, 602], ["ischemia", "OBSERVATION", 727, 735], ["ulcers", "OBSERVATION", 748, 754]]], ["Together with vascular damage, the most striking clinical association of AECA observed in SSc relates to lung involvement.", [["vascular", "ANATOMY", 14, 22], ["SSc", "ANATOMY", 90, 93], ["lung", "ANATOMY", 105, 109], ["vascular damage", "DISEASE", 14, 29], ["AECA", "DISEASE", 73, 77], ["SSc", "DISEASE", 90, 93], ["vascular", "MULTI-TISSUE_STRUCTURE", 14, 22], ["AECA", "CANCER", 73, 77], ["SSc", "CANCER", 90, 93], ["lung", "ORGAN", 105, 109], ["AECA", "PROTEIN", 73, 77], ["vascular damage", "PROBLEM", 14, 29], ["AECA", "PROBLEM", 73, 77], ["lung involvement", "PROBLEM", 105, 121], ["vascular", "ANATOMY", 14, 22], ["damage", "OBSERVATION", 23, 29], ["AECA", "OBSERVATION", 73, 77], ["SSc", "ANATOMY", 90, 93], ["lung", "ANATOMY", 105, 109], ["involvement", "OBSERVATION", 110, 121]]], ["This is particularly important since lung involvement, manifested by either interstitial fibrosis and/or pulmonary hypertension, represents the most frequent cause of death in SSc [46].AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesAlthough evaluating lung involvement according to different clinical parameters and diagnostic procedures, at least four reports have demonstrated a strict association between AECA and one or more parameters of lung disease in SSc.AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesSalojin et al. [42] demonstrated lung involvement in 93% of AECA positive patients with SSc but only in 30% of those displaying no serum AECA reactivity.", [["lung", "ANATOMY", 37, 41], ["interstitial", "ANATOMY", 76, 88], ["pulmonary", "ANATOMY", 105, 114], ["lung", "ANATOMY", 263, 267], ["lung", "ANATOMY", 454, 458], ["lung", "ANATOMY", 565, 569], ["AECA", "ANATOMY", 592, 596], ["serum", "ANATOMY", 663, 668], ["interstitial fibrosis", "DISEASE", 76, 97], ["pulmonary hypertension", "DISEASE", 105, 127], ["death", "DISEASE", 167, 172], ["SSc", "DISEASE", 176, 179], ["AECA", "DISEASE", 185, 189], ["Systemic Sclerosis", "DISEASE", 193, 211], ["Autoimmune Diseases", "DISEASE", 224, 243], ["lung disease", "DISEASE", 454, 466], ["SSc", "DISEASE", 470, 473], ["AECA", "DISEASE", 474, 478], ["Systemic Sclerosis", "DISEASE", 482, 500], ["Autoimmune Diseases", "DISEASE", 513, 532], ["SSc", "DISEASE", 620, 623], ["lung", "ORGAN", 37, 41], ["pulmonary", "ORGAN", 105, 114], ["lung", "ORGAN", 263, 267], ["AECA", "CANCER", 419, 423], ["lung", "ORGAN", 454, 458], ["lung", "ORGAN", 565, 569], ["AECA", "CANCER", 592, 596], ["patients", "ORGANISM", 606, 614], ["serum", "ORGANISM_SUBSTANCE", 663, 668], ["AECA", "GENE_OR_GENE_PRODUCT", 669, 673], ["AECA", "PROTEIN", 419, 423], ["AECA", "PROTEIN", 669, 673], ["patients", "SPECIES", 606, 614], ["lung involvement", "PROBLEM", 37, 53], ["interstitial fibrosis", "PROBLEM", 76, 97], ["pulmonary hypertension", "PROBLEM", 105, 127], ["death", "PROBLEM", 167, 172], ["AECA in Systemic Sclerosis", "PROBLEM", 185, 211], ["AECA", "PROBLEM", 216, 220], ["Autoimmune Diseases", "PROBLEM", 224, 243], ["lung involvement", "PROBLEM", 263, 279], ["diagnostic procedures", "TEST", 327, 348], ["AECA", "TEST", 419, 423], ["lung disease", "PROBLEM", 454, 466], ["AECA", "TEST", 474, 478], ["Systemic Sclerosis", "PROBLEM", 482, 500], ["AECA", "PROBLEM", 505, 509], ["Autoimmune Diseases", "PROBLEM", 513, 532], ["lung involvement", "TEST", 565, 581], ["AECA", "TEST", 592, 596], ["SSc", "TEST", 620, 623], ["serum AECA reactivity", "PROBLEM", 663, 684], ["lung", "ANATOMY", 37, 41], ["involvement", "OBSERVATION", 42, 53], ["interstitial", "ANATOMY_MODIFIER", 76, 88], ["fibrosis", "OBSERVATION", 89, 97], ["pulmonary", "ANATOMY", 105, 114], ["hypertension", "OBSERVATION", 115, 127], ["Systemic", "OBSERVATION_MODIFIER", 193, 201], ["Sclerosis", "OBSERVATION", 202, 211], ["AECA", "OBSERVATION", 216, 220], ["Autoimmune Diseases", "OBSERVATION", 224, 243], ["lung", "ANATOMY", 263, 267], ["lung", "ANATOMY", 454, 458], ["disease", "OBSERVATION", 459, 466], ["SSc", "ANATOMY", 470, 473], ["Systemic", "OBSERVATION_MODIFIER", 482, 490], ["Sclerosis", "OBSERVATION", 491, 500], ["AECA", "ANATOMY", 505, 509], ["Autoimmune Diseases", "OBSERVATION", 513, 532], ["lung", "ANATOMY", 565, 569], ["AECA reactivity", "OBSERVATION", 669, 684]]], ["Unfortunately, no further characterization of lung disease (i.e., isolated reduction in diffusing capacity for carbon monoxide (DLco), pulmonary fibrosis, or pulmonary hypertension) and association with AECA was available in this study.", [["lung", "ANATOMY", 46, 50], ["pulmonary", "ANATOMY", 135, 144], ["pulmonary", "ANATOMY", 158, 167], ["lung disease", "DISEASE", 46, 58], ["carbon monoxide", "CHEMICAL", 111, 126], ["pulmonary fibrosis", "DISEASE", 135, 153], ["pulmonary hypertension", "DISEASE", 158, 180], ["carbon monoxide", "CHEMICAL", 111, 126], ["lung", "ORGAN", 46, 50], ["carbon monoxide", "SIMPLE_CHEMICAL", 111, 126], ["pulmonary", "ORGAN", 135, 144], ["pulmonary", "ORGAN", 158, 167], ["AECA", "CANCER", 203, 207], ["lung disease", "PROBLEM", 46, 58], ["diffusing capacity", "PROBLEM", 88, 106], ["carbon monoxide (DLco)", "PROBLEM", 111, 133], ["pulmonary fibrosis", "PROBLEM", 135, 153], ["pulmonary hypertension", "PROBLEM", 158, 180], ["AECA", "PROBLEM", 203, 207], ["this study", "TEST", 225, 235], ["lung", "ANATOMY", 46, 50], ["disease", "OBSERVATION", 51, 58], ["reduction", "OBSERVATION_MODIFIER", 75, 84], ["pulmonary", "ANATOMY", 135, 144], ["fibrosis", "OBSERVATION", 145, 153], ["pulmonary", "ANATOMY", 158, 167], ["hypertension", "OBSERVATION", 168, 180]]], ["Negi et al. [43] found a significant correlation between AECA and pulmonary arterial hypertension; Pignone et al. [44] reported a strong association with both reduced DLco and with pulmonary artery hypertension but not with pulmonary fibrosis.", [["pulmonary arterial", "ANATOMY", 66, 84], ["pulmonary artery", "ANATOMY", 181, 197], ["pulmonary", "ANATOMY", 224, 233], ["pulmonary arterial hypertension", "DISEASE", 66, 97], ["pulmonary artery hypertension", "DISEASE", 181, 210], ["pulmonary fibrosis", "DISEASE", 224, 242], ["AECA", "SIMPLE_CHEMICAL", 57, 61], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 66, 84], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 181, 197], ["pulmonary", "ORGAN", 224, 233], ["AECA", "TEST", 57, 61], ["pulmonary arterial hypertension", "PROBLEM", 66, 97], ["both reduced DLco", "PROBLEM", 154, 171], ["pulmonary artery hypertension", "PROBLEM", 181, 210], ["pulmonary fibrosis", "PROBLEM", 224, 242], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["AECA", "OBSERVATION", 57, 61], ["pulmonary arterial", "ANATOMY", 66, 84], ["hypertension", "OBSERVATION", 85, 97], ["reduced DLco", "OBSERVATION", 159, 171], ["pulmonary artery", "ANATOMY", 181, 197], ["hypertension", "OBSERVATION", 198, 210], ["not with", "UNCERTAINTY", 215, 223], ["pulmonary", "ANATOMY", 224, 233], ["fibrosis", "OBSERVATION", 234, 242]]], ["This observation is of particular interest considering that isolated DLco reduction has been indicated as a predictor of subsequent development of pulmonary hypertension [47].", [["pulmonary", "ANATOMY", 147, 156], ["DLco reduction", "DISEASE", 69, 83], ["pulmonary hypertension", "DISEASE", 147, 169], ["DLco", "GENE_OR_GENE_PRODUCT", 69, 73], ["pulmonary", "ORGAN", 147, 156], ["isolated DLco reduction", "TREATMENT", 60, 83], ["pulmonary hypertension", "PROBLEM", 147, 169], ["pulmonary", "ANATOMY", 147, 156], ["hypertension", "OBSERVATION", 157, 169]]], ["Finally, Ihn et al. [45] observed a significant association between AECA and reduced percent vital capacity (%VC), decreased DLco as well as pulmonary fibrosis, with the strongest association with severe interstitial lung disease.AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesAlthough prospective studies have not yet been carried out, all the available data suggest that AECA may have a profound clinical relevance in identifying SSc patients at major risk of developing more advanced vascular damage and severe pulmonary disease manifested either as interstitial fibrosis and/or pulmonary hypertension.", [["pulmonary", "ANATOMY", 141, 150], ["interstitial lung", "ANATOMY", 204, 221], ["vascular", "ANATOMY", 498, 506], ["pulmonary", "ANATOMY", 525, 534], ["interstitial", "ANATOMY", 564, 576], ["pulmonary", "ANATOMY", 593, 602], ["pulmonary fibrosis", "DISEASE", 141, 159], ["interstitial lung disease", "DISEASE", 204, 229], ["AECA", "DISEASE", 230, 234], ["Systemic Sclerosis", "DISEASE", 238, 256], ["Autoimmune Diseases", "DISEASE", 269, 288], ["SSc", "DISEASE", 443, 446], ["vascular damage", "DISEASE", 498, 513], ["pulmonary disease", "DISEASE", 525, 542], ["interstitial fibrosis", "DISEASE", 564, 585], ["pulmonary hypertension", "DISEASE", 593, 615], ["AECA", "GENE_OR_GENE_PRODUCT", 68, 72], ["DLco", "GENE_OR_GENE_PRODUCT", 125, 129], ["pulmonary", "ORGAN", 141, 150], ["lung", "ORGAN", 217, 221], ["AECA", "SIMPLE_CHEMICAL", 384, 388], ["patients", "ORGANISM", 447, 455], ["vascular", "MULTI-TISSUE_STRUCTURE", 498, 506], ["pulmonary", "ORGAN", 525, 534], ["pulmonary", "ORGAN", 593, 602], ["AECA", "PROTEIN", 68, 72], ["DLco", "PROTEIN", 125, 129], ["patients", "SPECIES", 447, 455], ["AECA", "TEST", 68, 72], ["reduced percent vital capacity", "PROBLEM", 77, 107], ["decreased DLco", "PROBLEM", 115, 129], ["pulmonary fibrosis", "PROBLEM", 141, 159], ["severe interstitial lung disease", "PROBLEM", 197, 229], ["AECA in Systemic Sclerosis", "PROBLEM", 230, 256], ["AECA", "PROBLEM", 261, 265], ["Autoimmune Diseases", "PROBLEM", 269, 288], ["prospective studies", "TEST", 297, 316], ["AECA", "PROBLEM", 384, 388], ["advanced vascular damage", "PROBLEM", 489, 513], ["severe pulmonary disease", "PROBLEM", 518, 542], ["interstitial fibrosis", "PROBLEM", 564, 585], ["pulmonary hypertension", "PROBLEM", 593, 615], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["decreased DLco", "OBSERVATION", 115, 129], ["pulmonary", "ANATOMY", 141, 150], ["fibrosis", "OBSERVATION", 151, 159], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["interstitial", "ANATOMY_MODIFIER", 204, 216], ["lung", "ANATOMY", 217, 221], ["disease", "OBSERVATION", 222, 229], ["Systemic", "OBSERVATION_MODIFIER", 238, 246], ["Sclerosis", "OBSERVATION", 247, 256], ["AECA", "OBSERVATION", 261, 265], ["Autoimmune Diseases", "OBSERVATION", 269, 288], ["advanced", "OBSERVATION_MODIFIER", 489, 497], ["vascular", "ANATOMY", 498, 506], ["damage", "OBSERVATION", 507, 513], ["severe", "OBSERVATION_MODIFIER", 518, 524], ["pulmonary", "ANATOMY", 525, 534], ["disease", "OBSERVATION", 535, 542], ["interstitial", "ANATOMY_MODIFIER", 564, 576], ["fibrosis", "OBSERVATION", 577, 585], ["pulmonary", "ANATOMY", 593, 602], ["hypertension", "OBSERVATION", 603, 615]]], ["Longitudinal studies on a large number of patients are awaited to confirm the possible clinical utility of AECA as disease markers in SSc.AECA in Systemic Sclerosis ::: AECA in Autoimmune DiseasesPutative antigens responsible for AECA reactivity in sera of SSc patients have been identified by several groups as protein bands of various molecular weights obtained by WB analysis of sera reacting against cytoplasmic or membrane proteins extracted from HUVECs or ECs from other sources.", [["sera", "ANATOMY", 249, 253], ["sera", "ANATOMY", 382, 386], ["cytoplasmic", "ANATOMY", 404, 415], ["membrane", "ANATOMY", 419, 427], ["HUVECs", "ANATOMY", 452, 458], ["ECs", "ANATOMY", 462, 465], ["SSc", "DISEASE", 134, 137], ["AECA", "DISEASE", 138, 142], ["Systemic Sclerosis", "DISEASE", 146, 164], ["Autoimmune DiseasesPutative antigens", "DISEASE", 177, 213], ["SSc", "DISEASE", 257, 260], ["patients", "ORGANISM", 42, 50], ["AECA", "SIMPLE_CHEMICAL", 107, 111], ["AECA", "GENE_OR_GENE_PRODUCT", 230, 234], ["sera", "ORGANISM_SUBSTANCE", 249, 253], ["patients", "ORGANISM", 261, 269], ["sera", "ORGANISM_SUBSTANCE", 382, 386], ["cytoplasmic", "ORGANISM_SUBSTANCE", 404, 415], ["membrane", "CELLULAR_COMPONENT", 419, 427], ["HUVECs", "CELL", 452, 458], ["ECs", "CELL", 462, 465], ["AECA", "PROTEIN", 107, 111], ["AECA", "PROTEIN", 230, 234], ["cytoplasmic or membrane proteins", "PROTEIN", 404, 436], ["HUVECs", "CELL_LINE", 452, 458], ["ECs", "CELL_TYPE", 462, 465], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 261, 269], ["Longitudinal studies", "TEST", 0, 20], ["AECA", "PROBLEM", 107, 111], ["AECA", "TEST", 138, 142], ["Systemic Sclerosis", "PROBLEM", 146, 164], ["AECA", "PROBLEM", 169, 173], ["Autoimmune DiseasesPutative antigens", "PROBLEM", 177, 213], ["AECA reactivity", "TEST", 230, 245], ["protein bands", "TEST", 312, 325], ["various molecular weights", "TEST", 329, 354], ["WB analysis", "TEST", 367, 378], ["sera reacting", "PROBLEM", 382, 395], ["cytoplasmic or membrane proteins", "PROBLEM", 404, 436], ["HUVECs", "PROBLEM", 452, 458], ["AECA", "OBSERVATION", 107, 111], ["SSc", "ANATOMY", 134, 137], ["Systemic", "OBSERVATION_MODIFIER", 146, 154], ["Sclerosis", "OBSERVATION", 155, 164], ["AECA", "OBSERVATION", 169, 173]]], ["However, in the absence of a molecular biology approach to identify the nature of the antigens observed, the exact endothelial antigenic targets recognized by AECA in SSc remain elusive.", [["endothelial", "ANATOMY", 115, 126], ["SSc", "ANATOMY", 167, 170], ["SSc", "DISEASE", 167, 170], ["endothelial", "CELL", 115, 126], ["AECA", "GENE_OR_GENE_PRODUCT", 159, 163], ["SSc", "CANCER", 167, 170], ["antigens", "PROTEIN", 86, 94], ["AECA", "PROTEIN", 159, 163], ["the antigens", "PROBLEM", 82, 94], ["the exact endothelial antigenic targets", "PROBLEM", 105, 144], ["AECA", "TEST", 159, 163], ["endothelial", "ANATOMY", 115, 126]]], ["A first study reported the identification of several membrane endothelial cell specific antigens (more than 20 different bands at WB analysis) as the target of AECA in SSc patients [48].", [["membrane endothelial cell", "ANATOMY", 53, 78], ["AECA", "ANATOMY", 160, 164], ["SSc", "DISEASE", 168, 171], ["membrane endothelial cell", "CELL", 53, 78], ["AECA", "CANCER", 160, 164], ["patients", "ORGANISM", 172, 180], ["membrane endothelial cell specific antigens", "PROTEIN", 53, 96], ["WB", "PROTEIN", 130, 132], ["AECA", "PROTEIN", 160, 164], ["patients", "SPECIES", 172, 180], ["A first study", "TEST", 0, 13], ["several membrane endothelial cell specific antigens", "PROBLEM", 45, 96], ["WB analysis", "TEST", 130, 141], ["AECA", "TEST", 160, 164], ["membrane endothelial cell", "OBSERVATION", 53, 78]]], ["In particular, reactivity against a membrane antigen of \u223c19 kDa was observed in more than 50% of the patients with SSc and in 100% of SSc patients with CREST syndrome and was shown to display anticentromere activity in IFI analysis.", [["membrane", "ANATOMY", 36, 44], ["SSc", "ANATOMY", 115, 118], ["anticentromere", "ANATOMY", 192, 206], ["SSc", "DISEASE", 115, 118], ["SSc", "DISEASE", 134, 137], ["CREST syndrome", "DISEASE", 152, 166], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["patients", "ORGANISM", 101, 109], ["SSc", "CANCER", 115, 118], ["patients", "ORGANISM", 138, 146], ["anticentromere", "CANCER", 192, 206], ["membrane antigen", "PROTEIN", 36, 52], ["\u223c19 kDa", "PROTEIN", 56, 63], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 138, 146], ["a membrane antigen", "TEST", 34, 52], ["SSc", "TEST", 115, 118], ["CREST syndrome", "PROBLEM", 152, 166], ["IFI analysis", "TEST", 219, 231], ["CREST syndrome", "OBSERVATION", 152, 166]]], ["Ihn et al. [45] using HUVEC protein extracts observed reactivity of AECA positive sera, as previously assessed by cyto\u2010ELISA on HUVECs, toward four major antigens recognizable as WB bands of 60, 90, 110, and 140 kDa.", [["HUVEC", "ANATOMY", 22, 27], ["extracts", "ANATOMY", 36, 44], ["sera", "ANATOMY", 82, 86], ["HUVECs", "ANATOMY", 128, 134], ["HUVEC", "CELL", 22, 27], ["extracts", "ORGANISM_SUBSTANCE", 36, 44], ["AECA", "GENE_OR_GENE_PRODUCT", 68, 72], ["sera", "ORGANISM_SUBSTANCE", 82, 86], ["HUVECs", "CELL", 128, 134], ["AECA", "PROTEIN", 68, 72], ["cyto\u2010ELISA", "PROTEIN", 114, 124], ["HUVECs", "CELL_LINE", 128, 134], ["WB bands", "PROTEIN", 179, 187], ["60, 90, 110, and 140 kDa", "PROTEIN", 191, 215], ["HUVEC protein extracts", "TEST", 22, 44], ["AECA positive sera", "PROBLEM", 68, 86], ["HUVECs", "TEST", 128, 134], ["WB bands", "TEST", 179, 187]]], ["The most common response was observed against the 90\u2010kDa antigen and purified anti\u201090 kDa antibodies displayed a cytoplasmic pattern at IFI identical to that observed in AECA positive sera.", [["cytoplasmic", "ANATOMY", 113, 124], ["sera", "ANATOMY", 184, 188], ["anti\u201090 kDa", "GENE_OR_GENE_PRODUCT", 78, 89], ["cytoplasmic", "ORGANISM_SUBSTANCE", 113, 124], ["sera", "ORGANISM_SUBSTANCE", 184, 188], ["90\u2010kDa antigen", "PROTEIN", 50, 64], ["purified anti\u201090 kDa antibodies", "PROTEIN", 69, 100], ["IFI", "PROTEIN", 136, 139], ["the 90\u2010kDa antigen", "TEST", 46, 64], ["purified anti\u201090 kDa antibodies", "TEST", 69, 100], ["a cytoplasmic pattern at IFI", "PROBLEM", 111, 139], ["AECA positive sera", "TEST", 170, 188], ["cytoplasmic pattern", "OBSERVATION", 113, 132]]], ["No such reactivity was observed using the same sera toward protein extracted from dermal fibroblasts, suggesting specificity of the immune response against endothelial antigens.", [["sera", "ANATOMY", 47, 51], ["dermal fibroblasts", "ANATOMY", 82, 100], ["endothelial", "ANATOMY", 156, 167], ["sera", "ORGANISM_SUBSTANCE", 47, 51], ["dermal fibroblasts", "CELL", 82, 100], ["endothelial antigens", "GENE_OR_GENE_PRODUCT", 156, 176], ["dermal fibroblasts", "CELL_TYPE", 82, 100], ["endothelial antigens", "PROTEIN", 156, 176], ["such reactivity", "PROBLEM", 3, 18], ["dermal fibroblasts", "PROBLEM", 82, 100], ["endothelial antigens", "PROBLEM", 156, 176], ["reactivity", "OBSERVATION", 8, 18], ["dermal fibroblasts", "OBSERVATION", 82, 100]]], ["Wusirika et al. [49] reported reactivity of SSc sera with pulmonary involvement against multiple bands between 38 and 110 kDa obtained by WB of protein extracts from HUVECs and pulmonary microvascular ECs.", [["sera", "ANATOMY", 48, 52], ["pulmonary", "ANATOMY", 58, 67], ["extracts", "ANATOMY", 152, 160], ["HUVECs", "ANATOMY", 166, 172], ["pulmonary microvascular ECs", "ANATOMY", 177, 204], ["SSc", "ORGANISM_SUBSTANCE", 44, 47], ["sera", "ORGANISM_SUBSTANCE", 48, 52], ["pulmonary", "ORGAN", 58, 67], ["extracts", "ORGANISM_SUBSTANCE", 152, 160], ["HUVECs", "CELL", 166, 172], ["pulmonary microvascular ECs", "CELL", 177, 204], ["HUVECs", "CELL_TYPE", 166, 172], ["pulmonary microvascular ECs", "CELL_TYPE", 177, 204], ["SSc sera", "TEST", 44, 52], ["pulmonary involvement", "PROBLEM", 58, 79], ["multiple bands", "TEST", 88, 102], ["protein extracts", "TEST", 144, 160], ["HUVECs", "TEST", 166, 172], ["pulmonary microvascular ECs", "PROBLEM", 177, 204], ["pulmonary", "ANATOMY", 58, 67], ["HUVECs", "ANATOMY", 166, 172], ["pulmonary", "ANATOMY", 177, 186], ["microvascular ECs", "OBSERVATION", 187, 204]]], ["Although no further characterization of AECA antigenic target in SSc is provided in these reports, it is clear that, as observed in other autoimmune conditions, AECA reactivity in SSc is rather heterogeneous and only the identification of the exact antigens responsible for AECA activity of SSc sera may provide important clues in understanding the pathogenic mechanisms underlying endothelial dysfunction and aggression in this disorder.AECA in Systemic Vasculitis ::: AECA in Autoimmune DiseasesDetection of AECA in sera of patients affected by systemic vasculitis is a relatively common finding, with prevalence varying greatly among the different forms of vasculitis.AECA in Systemic Vasculitis ::: AECA in Autoimmune DiseasesEarly reports demonstrated the ability of sera from children with acute KD to lyse HUVECs when pretreated in vitro with either IFN\u03b3 or monokines [[50], [51]].", [["SSc sera", "ANATOMY", 291, 299], ["endothelial", "ANATOMY", 382, 393], ["sera", "ANATOMY", 518, 522], ["sera", "ANATOMY", 772, 776], ["HUVECs", "ANATOMY", 813, 819], ["SSc", "DISEASE", 65, 68], ["SSc", "DISEASE", 180, 183], ["SSc", "DISEASE", 291, 294], ["endothelial dysfunction", "DISEASE", 382, 405], ["aggression", "DISEASE", 410, 420], ["AECA", "DISEASE", 438, 442], ["Vasculitis", "DISEASE", 455, 465], ["Autoimmune Diseases", "DISEASE", 478, 497], ["systemic vasculitis", "DISEASE", 547, 566], ["vasculitis", "DISEASE", 660, 670], ["AECA", "DISEASE", 671, 675], ["Vasculitis", "DISEASE", 688, 698], ["Autoimmune Diseases", "DISEASE", 711, 730], ["AECA", "CANCER", 40, 44], ["AECA", "GENE_OR_GENE_PRODUCT", 161, 165], ["AECA", "GENE_OR_GENE_PRODUCT", 274, 278], ["sera", "ORGANISM_SUBSTANCE", 295, 299], ["endothelial", "CELL", 382, 393], ["AECA", "CANCER", 510, 514], ["sera", "ORGANISM_SUBSTANCE", 518, 522], ["patients", "ORGANISM", 526, 534], ["sera", "ORGANISM_SUBSTANCE", 772, 776], ["children", "ORGANISM", 782, 790], ["HUVECs", "CELL", 813, 819], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 857, 861], ["monokines", "SIMPLE_CHEMICAL", 865, 874], ["[51]]", "SIMPLE_CHEMICAL", 882, 887], ["AECA", "PROTEIN", 40, 44], ["AECA", "PROTEIN", 274, 278], ["HUVECs", "CELL_TYPE", 813, 819], ["IFN\u03b3", "PROTEIN", 857, 861], ["patients", "SPECIES", 526, 534], ["children", "SPECIES", 782, 790], ["further characterization", "TEST", 12, 36], ["AECA antigenic target", "TEST", 40, 61], ["other autoimmune conditions", "PROBLEM", 132, 159], ["AECA reactivity", "TEST", 161, 176], ["AECA activity of SSc sera", "PROBLEM", 274, 299], ["endothelial dysfunction", "PROBLEM", 382, 405], ["this disorder", "PROBLEM", 424, 437], ["AECA", "TEST", 438, 442], ["Systemic Vasculitis", "PROBLEM", 446, 465], ["AECA", "PROBLEM", 470, 474], ["Autoimmune Diseases", "PROBLEM", 478, 497], ["AECA in sera", "TEST", 510, 522], ["systemic vasculitis", "PROBLEM", 547, 566], ["vasculitis", "PROBLEM", 660, 670], ["AECA", "TEST", 671, 675], ["Systemic Vasculitis", "PROBLEM", 679, 698], ["AECA in Autoimmune Diseases", "PROBLEM", 703, 730], ["acute KD to lyse HUVECs", "TREATMENT", 796, 819], ["SSc", "ANATOMY", 180, 183], ["heterogeneous", "OBSERVATION_MODIFIER", 194, 207], ["endothelial dysfunction", "OBSERVATION", 382, 405], ["Systemic", "ANATOMY", 446, 454], ["Vasculitis", "OBSERVATION", 455, 465], ["AECA", "OBSERVATION", 470, 474], ["Autoimmune Diseases", "OBSERVATION", 478, 497], ["AECA", "OBSERVATION", 510, 514], ["systemic", "OBSERVATION_MODIFIER", 547, 555], ["vasculitis", "OBSERVATION", 556, 566], ["vasculitis", "OBSERVATION", 660, 670], ["Systemic", "ANATOMY", 679, 687], ["Vasculitis", "OBSERVATION", 688, 698], ["AECA", "OBSERVATION", 703, 707], ["Autoimmune Diseases", "OBSERVATION", 711, 730]]], ["This effect was observed only in patients with acute febrile KD but not in the convalescent phase of the disease and was dependent on the presence of circulating IgM with AECA activity.", [["acute febrile KD", "DISEASE", 47, 63], ["patients", "ORGANISM", 33, 41], ["IgM", "GENE_OR_GENE_PRODUCT", 162, 165], ["AECA", "GENE_OR_GENE_PRODUCT", 171, 175], ["IgM", "PROTEIN", 162, 165], ["AECA", "PROTEIN", 171, 175], ["patients", "SPECIES", 33, 41], ["acute febrile KD", "PROBLEM", 47, 63], ["the disease", "PROBLEM", 101, 112], ["circulating IgM", "TEST", 150, 165], ["AECA activity", "PROBLEM", 171, 184], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["febrile KD", "OBSERVATION_MODIFIER", 53, 63], ["disease", "OBSERVATION", 105, 112], ["AECA activity", "OBSERVATION", 171, 184]]], ["However, later studies provided conflicting evidence on the effective role of AECA in KD.", [["KD", "DISEASE", 86, 88], ["AECA", "GENE_OR_GENE_PRODUCT", 78, 82], ["AECA", "PROTEIN", 78, 82], ["later studies", "TEST", 9, 22]]], ["Guzman et al. [52] observed AECA in just 17% of 22 patients with KS and AECA were not able to differentiate KD from other febrile disorders of childhood resembling KD.", [["KS", "ANATOMY", 65, 67], ["KD", "DISEASE", 108, 110], ["febrile disorders", "DISEASE", 122, 139], ["KD", "DISEASE", 164, 166], ["AECA", "CANCER", 28, 32], ["patients", "ORGANISM", 51, 59], ["KS", "CANCER", 65, 67], ["AECA", "CANCER", 72, 76], ["patients", "SPECIES", 51, 59], ["AECA", "TEST", 28, 32], ["KS", "TEST", 65, 67], ["AECA", "TEST", 72, 76], ["other febrile disorders", "PROBLEM", 116, 139]]], ["Similar findings were reported by Nash et al. [53] in 58 children with acute KD, which showed no increased AECA reactivity compared to 35 children with febrile infections.", [["acute KD", "DISEASE", 71, 79], ["febrile infections", "DISEASE", 152, 170], ["children", "ORGANISM", 57, 65], ["AECA", "SIMPLE_CHEMICAL", 107, 111], ["children", "ORGANISM", 138, 146], ["AECA", "PROTEIN", 107, 111], ["children", "SPECIES", 57, 65], ["children", "SPECIES", 138, 146], ["acute KD", "TEST", 71, 79], ["increased AECA reactivity", "PROBLEM", 97, 122], ["febrile infections", "PROBLEM", 152, 170], ["no", "UNCERTAINTY", 94, 96], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["AECA reactivity", "OBSERVATION", 107, 122]]], ["Conversely, Kaneko et al. [54] detected IgM AECA in 73% of 22 KD children, half of which displayed complement dependent cytotoxicity in vitro against EC.", [["EC", "ANATOMY", 150, 152], ["IgM", "GENE_OR_GENE_PRODUCT", 40, 43], ["children", "ORGANISM", 65, 73], ["EC", "CELL", 150, 152], ["IgM AECA", "PROTEIN", 40, 48], ["EC", "CELL_TYPE", 150, 152], ["children", "SPECIES", 65, 73], ["IgM AECA", "TEST", 40, 48], ["complement dependent cytotoxicity", "PROBLEM", 99, 132], ["dependent cytotoxicity", "OBSERVATION", 110, 132]]], ["Finally, Falcini et al. [55] reported AECA reactivity in 26% of KD patients, with increased incidence in the acute compared to the convalescent phase while Fujieda et al. [56] observed IgM AECA in 42% and IgG AECA in 26% of KD children, confirming the increased presence of IgM with AECA reactivity in the acute phase of KD.", [["KD", "DISEASE", 321, 323], ["AECA", "GENE_OR_GENE_PRODUCT", 38, 42], ["patients", "ORGANISM", 67, 75], ["IgM", "GENE_OR_GENE_PRODUCT", 185, 188], ["IgG AECA", "GENE_OR_GENE_PRODUCT", 205, 213], ["children", "ORGANISM", 227, 235], ["IgM", "GENE_OR_GENE_PRODUCT", 274, 277], ["AECA", "SIMPLE_CHEMICAL", 283, 287], ["IgM AECA", "PROTEIN", 185, 193], ["IgG AECA", "PROTEIN", 205, 213], ["IgM", "PROTEIN", 274, 277], ["AECA", "PROTEIN", 283, 287], ["patients", "SPECIES", 67, 75], ["children", "SPECIES", 227, 235], ["AECA reactivity", "TEST", 38, 53], ["increased incidence", "PROBLEM", 82, 101], ["IgM AECA", "TEST", 185, 193], ["IgG AECA", "TEST", 205, 213], ["IgM", "PROBLEM", 274, 277], ["AECA reactivity", "PROBLEM", 283, 298], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["AECA reactivity", "OBSERVATION", 283, 298], ["acute phase", "OBSERVATION_MODIFIER", 306, 317]]], ["Although the effective role of AECA in KD is still matter of debate, there is sufficient evidence to support the concept that IgM AECA rise in a subset of patients in the acute febrile phase of the disease and may participate to endothelial inflammation leading to arteritis in KD.AECA in Systemic Vasculitis ::: AECA in Autoimmune DiseasesMore consistent evidence has been reported on AECA in anti\u2010neutrophil cytoplasmic antibody (ANCA)\u2010associated systemic vasculitis.", [["endothelial", "ANATOMY", 229, 240], ["AECA", "CHEMICAL", 31, 35], ["KD", "DISEASE", 39, 41], ["febrile", "DISEASE", 177, 184], ["inflammation", "DISEASE", 241, 253], ["arteritis", "DISEASE", 265, 274], ["AECA", "DISEASE", 281, 285], ["Vasculitis", "DISEASE", 298, 308], ["Autoimmune Diseases", "DISEASE", 321, 340], ["systemic vasculitis", "DISEASE", 449, 468], ["AECA", "GENE_OR_GENE_PRODUCT", 31, 35], ["IgM AECA", "GENE_OR_GENE_PRODUCT", 126, 134], ["patients", "ORGANISM", 155, 163], ["endothelial", "CELL", 229, 240], ["AECA", "SIMPLE_CHEMICAL", 386, 390], ["anti\u2010neutrophil cytoplasmic antibody", "GENE_OR_GENE_PRODUCT", 394, 430], ["ANCA", "GENE_OR_GENE_PRODUCT", 432, 436], ["AECA", "PROTEIN", 31, 35], ["IgM AECA", "PROTEIN", 126, 134], ["AECA", "PROTEIN", 386, 390], ["anti\u2010neutrophil cytoplasmic antibody", "PROTEIN", 394, 430], ["ANCA", "PROTEIN", 432, 436], ["patients", "SPECIES", 155, 163], ["IgM AECA rise", "PROBLEM", 126, 139], ["the acute febrile phase", "PROBLEM", 167, 190], ["the disease", "PROBLEM", 194, 205], ["endothelial inflammation", "PROBLEM", 229, 253], ["arteritis in KD", "PROBLEM", 265, 280], ["AECA", "TEST", 281, 285], ["Systemic Vasculitis", "PROBLEM", 289, 308], ["AECA", "PROBLEM", 313, 317], ["Autoimmune Diseases", "PROBLEM", 321, 340], ["AECA", "TEST", 386, 390], ["anti\u2010neutrophil cytoplasmic antibody", "TEST", 394, 430], ["ANCA", "TEST", 432, 436], ["\u2010associated systemic vasculitis", "PROBLEM", 437, 468], ["AECA", "OBSERVATION", 31, 35], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["febrile phase", "OBSERVATION_MODIFIER", 177, 190], ["disease", "OBSERVATION", 198, 205], ["endothelial", "ANATOMY", 229, 240], ["inflammation", "OBSERVATION", 241, 253], ["arteritis", "OBSERVATION", 265, 274], ["Systemic", "ANATOMY", 289, 297], ["Vasculitis", "OBSERVATION", 298, 308], ["AECA", "OBSERVATION", 313, 317], ["Autoimmune Diseases", "OBSERVATION", 321, 340], ["systemic", "OBSERVATION_MODIFIER", 449, 457], ["vasculitis", "OBSERVATION", 458, 468]]], ["Ferraro et al. observed AECA, mostly of IgG isotype, in 60% of sera of patients with microscopic polyangiitis (MPA) and 40% of those with Wegener's granulomatosis (WG).", [["sera", "ANATOMY", 63, 67], ["polyangiitis", "DISEASE", 97, 109], ["MPA", "CHEMICAL", 111, 114], ["Wegener's granulomatosis", "DISEASE", 138, 162], ["WG", "DISEASE", 164, 166], ["AECA", "CANCER", 24, 28], ["sera", "ORGANISM_SUBSTANCE", 63, 67], ["patients", "ORGANISM", 71, 79], ["AECA", "PROTEIN", 24, 28], ["IgG isotype", "PROTEIN", 40, 51], ["patients", "SPECIES", 71, 79], ["AECA", "TEST", 24, 28], ["IgG isotype", "PROBLEM", 40, 51], ["microscopic polyangiitis", "PROBLEM", 85, 109], ["MPA", "TEST", 111, 114], ["Wegener's granulomatosis", "PROBLEM", 138, 162], ["AECA", "OBSERVATION", 24, 28], ["IgG isotype", "OBSERVATION", 40, 51], ["polyangiitis", "OBSERVATION", 97, 109], ["Wegener", "OBSERVATION", 138, 145], ["granulomatosis", "OBSERVATION", 148, 162]]], ["Importantly, absorption of ANCA did not affect endothelial binding of AECA suggesting that AECA and ANCA represent two different populations of autoantibodies [57].", [["endothelial", "ANATOMY", 47, 58], ["ANCA", "GENE_OR_GENE_PRODUCT", 27, 31], ["endothelial", "CELL", 47, 58], ["AECA", "GENE_OR_GENE_PRODUCT", 70, 74], ["AECA", "GENE_OR_GENE_PRODUCT", 91, 95], ["ANCA", "GENE_OR_GENE_PRODUCT", 100, 104], ["ANCA", "PROTEIN", 27, 31], ["AECA", "PROTEIN", 70, 74], ["AECA", "PROTEIN", 91, 95], ["ANCA", "PROTEIN", 100, 104], ["autoantibodies", "PROTEIN", 144, 158], ["ANCA", "PROBLEM", 27, 31], ["AECA", "TEST", 70, 74], ["AECA", "TEST", 91, 95], ["ANCA", "PROBLEM", 100, 104], ["autoantibodies", "PROBLEM", 144, 158], ["ANCA", "OBSERVATION", 27, 31], ["AECA", "OBSERVATION", 91, 95], ["ANCA", "OBSERVATION", 100, 104]]], ["Frampton et al. described increased AECA levels in ANCA\u2010associated vasculitis with a significant correlation between the two antibodies.", [["ANCA", "DISEASE", 51, 55], ["vasculitis", "DISEASE", 67, 77], ["AECA", "SIMPLE_CHEMICAL", 36, 40], ["AECA", "PROTEIN", 36, 40], ["ANCA", "PROTEIN", 51, 55], ["antibodies", "PROTEIN", 125, 135], ["increased AECA levels", "PROBLEM", 26, 47], ["ANCA\u2010associated vasculitis", "PROBLEM", 51, 77], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["AECA levels", "OBSERVATION", 36, 47], ["ANCA", "OBSERVATION", 51, 55], ["vasculitis", "OBSERVATION", 67, 77]]], ["In addition, both AECA and ANCA correlated with disease activity [58].", [["ANCA", "DISEASE", 27, 31], ["AECA", "GENE_OR_GENE_PRODUCT", 18, 22], ["ANCA", "GENE_OR_GENE_PRODUCT", 27, 31], ["AECA", "PROTEIN", 18, 22], ["ANCA", "PROTEIN", 27, 31], ["both AECA", "TEST", 13, 22], ["ANCA", "TEST", 27, 31], ["disease activity", "PROBLEM", 48, 64], ["AECA", "OBSERVATION", 18, 22], ["ANCA", "OBSERVATION", 27, 31]]], ["These earlier results were later confirmed in an extensive evaluation of AECA reactivity in sera from 168 patients with ANCA\u2010positive MPA or WG.", [["sera", "ANATOMY", 92, 96], ["ANCA", "DISEASE", 120, 124], ["MPA", "CHEMICAL", 134, 137], ["MPA", "CHEMICAL", 134, 137], ["AECA", "SIMPLE_CHEMICAL", 73, 77], ["sera", "ORGANISM_SUBSTANCE", 92, 96], ["patients", "ORGANISM", 106, 114], ["MPA", "SIMPLE_CHEMICAL", 134, 137], ["AECA", "PROTEIN", 73, 77], ["ANCA", "PROTEIN", 120, 124], ["patients", "SPECIES", 106, 114], ["an extensive evaluation", "TEST", 46, 69], ["AECA reactivity", "TEST", 73, 88], ["sera", "TEST", 92, 96], ["ANCA", "TEST", 120, 124], ["AECA reactivity", "OBSERVATION", 73, 88], ["positive MPA", "OBSERVATION", 125, 137]]], ["AECA were present in about 60% of patients with ANCA\u2010associated vasculitis (59% IgG and 68% IgM).", [["ANCA", "DISEASE", 48, 52], ["vasculitis", "DISEASE", 64, 74], ["AECA", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 34, 42], ["AECA", "PROTEIN", 0, 4], ["ANCA", "PROTEIN", 48, 52], ["IgG", "PROTEIN", 80, 83], ["IgM", "PROTEIN", 92, 95], ["patients", "SPECIES", 34, 42], ["AECA", "TEST", 0, 4], ["ANCA\u2010associated vasculitis", "PROBLEM", 48, 74], ["IgG", "TEST", 80, 83], ["IgM", "TEST", 92, 95], ["ANCA", "OBSERVATION", 48, 52], ["vasculitis", "OBSERVATION", 64, 74]]], ["Interestingly, and differently from KD, AECA from these patients were not able to induce complement\u2010dependent cytotoxicity, even after pretreatment of ECs with cytokines, but a minority of sera induced an antibody\u2010dependent cytotoxicity [59], as described elsewhere in this chapter.", [["ECs", "ANATOMY", 151, 154], ["sera", "ANATOMY", 189, 193], ["AECA", "GENE_OR_GENE_PRODUCT", 40, 44], ["patients", "ORGANISM", 56, 64], ["ECs", "CELL", 151, 154], ["sera", "ORGANISM_SUBSTANCE", 189, 193], ["ECs", "CELL_TYPE", 151, 154], ["cytokines", "PROTEIN", 160, 169], ["patients", "SPECIES", 56, 64], ["AECA", "TEST", 40, 44], ["complement\u2010dependent cytotoxicity", "PROBLEM", 89, 122], ["cytokines", "PROBLEM", 160, 169], ["sera", "TEST", 189, 193], ["an antibody\u2010dependent cytotoxicity", "PROBLEM", 202, 236]]], ["Although Del Papa et al. [21] observed in the majority of AECA\u2010positive WG patients a relatively conserved precipitation pattern by WB analysis of EC surface extracts with five major bands of 25, 68, 125, 155, and 180 kDa, this finding awaits confirmation in larger studies; thus, as in other autoimmune conditions, the nature of the antigen(s) recognized by AECA in ANCA\u2010associated vasculitis is currently unknown.AECA in Systemic Vasculitis ::: AECA in Autoimmune DiseasesTwo studies prospectively evaluated AECA (and ANCA) levels in patients with ANCA\u2010associated vasculitis and assessed their relationship with disease activity [[60], [61]].", [["EC surface extracts", "ANATOMY", 147, 166], ["ANCA", "DISEASE", 367, 371], ["vasculitis", "DISEASE", 383, 393], ["AECA", "DISEASE", 415, 419], ["Vasculitis", "DISEASE", 432, 442], ["Autoimmune Diseases", "DISEASE", 455, 474], ["ANCA", "DISEASE", 550, 554], ["vasculitis", "DISEASE", 566, 576], ["AECA", "GENE_OR_GENE_PRODUCT", 58, 62], ["patients", "ORGANISM", 75, 83], ["EC surface extracts", "ORGANISM_SUBSTANCE", 147, 166], ["antigen", "GENE_OR_GENE_PRODUCT", 334, 341], ["AECA", "GENE_OR_GENE_PRODUCT", 359, 363], ["ANCA", "GENE_OR_GENE_PRODUCT", 367, 371], ["AECA", "SIMPLE_CHEMICAL", 510, 514], ["ANCA", "GENE_OR_GENE_PRODUCT", 520, 524], ["patients", "ORGANISM", 536, 544], ["EC", "CELL_TYPE", 147, 149], ["AECA", "PROTEIN", 359, 363], ["ANCA", "PROTEIN", 367, 371], ["AECA", "PROTEIN", 510, 514], ["ANCA", "PROTEIN", 520, 524], ["ANCA", "PROTEIN", 550, 554], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 536, 544], ["Del Papa et al.", "TEST", 9, 24], ["AECA", "TEST", 58, 62], ["WB analysis", "TEST", 132, 143], ["EC surface extracts", "TEST", 147, 166], ["five major bands", "TEST", 172, 188], ["other autoimmune conditions", "PROBLEM", 287, 314], ["AECA", "TEST", 359, 363], ["vasculitis", "PROBLEM", 383, 393], ["AECA", "TEST", 415, 419], ["Systemic Vasculitis", "PROBLEM", 423, 442], ["AECA in Autoimmune Diseases", "PROBLEM", 447, 474], ["Two studies", "TEST", 474, 485], ["AECA", "TEST", 510, 514], ["ANCA) levels", "TEST", 520, 532], ["ANCA\u2010associated vasculitis", "PROBLEM", 550, 576], ["disease activity", "PROBLEM", 614, 630], ["vasculitis", "OBSERVATION", 383, 393], ["Systemic", "ANATOMY", 423, 431], ["Vasculitis", "OBSERVATION", 432, 442], ["AECA", "ANATOMY", 447, 451], ["Autoimmune Diseases", "OBSERVATION", 455, 474], ["vasculitis", "OBSERVATION", 566, 576]]], ["Both reports demonstrated that AECA were present in the majority of patients during the observation period and fluctuation of AECA was correlated with disease activity, with increased titer in disease relapses and reduced levels during remission phases.", [["AECA", "GENE_OR_GENE_PRODUCT", 31, 35], ["patients", "ORGANISM", 68, 76], ["AECA", "GENE_OR_GENE_PRODUCT", 126, 130], ["AECA", "PROTEIN", 31, 35], ["AECA", "PROTEIN", 126, 130], ["patients", "SPECIES", 68, 76], ["AECA", "PROBLEM", 31, 35], ["fluctuation of AECA", "PROBLEM", 111, 130], ["disease activity", "PROBLEM", 151, 167], ["increased titer in disease relapses", "PROBLEM", 174, 209], ["reduced levels during remission phases", "PROBLEM", 214, 252], ["AECA", "OBSERVATION", 31, 35], ["AECA", "OBSERVATION", 126, 130], ["increased", "OBSERVATION_MODIFIER", 174, 183], ["titer", "OBSERVATION_MODIFIER", 184, 189]]], ["Although encouraging, these results do not provide definitive evidence on the possible role of AECA, alone or in association with ANCAs, as predictive factors of clinical relapses in ANCA\u2010associated vasculitis.AECA in Systemic Vasculitis ::: AECA in Autoimmune DiseasesLess information is available regarding the role of AECA in other forms of systemic vasculitis.", [["ANCA", "DISEASE", 183, 187], ["vasculitis", "DISEASE", 199, 209], ["AECA", "DISEASE", 210, 214], ["Vasculitis", "DISEASE", 227, 237], ["Autoimmune DiseasesLess", "DISEASE", 250, 273], ["systemic vasculitis", "DISEASE", 344, 363], ["AECA", "GENE_OR_GENE_PRODUCT", 95, 99], ["ANCAs", "GENE_OR_GENE_PRODUCT", 130, 135], ["AECA", "GENE_OR_GENE_PRODUCT", 321, 325], ["AECA", "PROTEIN", 95, 99], ["ANCAs", "PROTEIN", 130, 135], ["AECA", "PROBLEM", 95, 99], ["ANCAs", "PROBLEM", 130, 135], ["clinical relapses", "PROBLEM", 162, 179], ["ANCA\u2010associated vasculitis", "PROBLEM", 183, 209], ["AECA", "TEST", 210, 214], ["Systemic Vasculitis", "PROBLEM", 218, 237], ["AECA", "PROBLEM", 242, 246], ["AECA", "PROBLEM", 321, 325], ["systemic vasculitis", "PROBLEM", 344, 363], ["AECA", "OBSERVATION", 95, 99], ["vasculitis", "OBSERVATION", 199, 209], ["Systemic", "ANATOMY", 218, 226], ["Vasculitis", "OBSERVATION", 227, 237], ["AECA", "OBSERVATION", 242, 246], ["AECA", "OBSERVATION", 321, 325], ["systemic", "ANATOMY", 344, 352], ["vasculitis", "OBSERVATION", 353, 363]]], ["In Takayasu arteritis (TA), Eichhorn et al. [62] reported a striking incidence of AECA of 95%, but this finding was not confirmed in a later study reporting an incidence of 33% [63].", [["Takayasu arteritis", "DISEASE", 3, 21], ["AECA", "DISEASE", 82, 86], ["AECA", "CANCER", 82, 86], ["Takayasu arteritis", "PROBLEM", 3, 21], ["AECA", "TEST", 82, 86], ["a later study", "TEST", 133, 146], ["Takayasu", "OBSERVATION_MODIFIER", 3, 11], ["arteritis", "OBSERVATION", 12, 21]]], ["Limited evidence is also available for Churg\u2013Strauss syndrome (CSS), with Schmitt et al. [64] reporting AECA in 50% of 16 CSS patients but, in contrast with ANCAs, without any association with disease activity.AECA in Systemic Vasculitis ::: AECA in Autoimmune DiseasesFinally, interesting findings have been reported regarding the presence of IgA AECA in patients with HSP.", [["Churg\u2013Strauss syndrome", "DISEASE", 39, 61], ["AECA", "DISEASE", 210, 214], ["Vasculitis", "DISEASE", 227, 237], ["Autoimmune Diseases", "DISEASE", 250, 269], ["HSP", "DISEASE", 370, 373], ["AECA", "CANCER", 104, 108], ["patients", "ORGANISM", 126, 134], ["ANCAs", "CANCER", 157, 162], ["IgA", "GENE_OR_GENE_PRODUCT", 344, 347], ["patients", "ORGANISM", 356, 364], ["HSP", "GENE_OR_GENE_PRODUCT", 370, 373], ["IgA AECA", "PROTEIN", 344, 352], ["HSP", "PROTEIN", 370, 373], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 356, 364], ["Churg\u2013Strauss syndrome", "PROBLEM", 39, 61], ["AECA", "TEST", 104, 108], ["disease activity", "PROBLEM", 193, 209], ["AECA", "TEST", 210, 214], ["Systemic Vasculitis", "PROBLEM", 218, 237], ["AECA", "PROBLEM", 242, 246], ["Autoimmune Diseases", "PROBLEM", 250, 269], ["IgA AECA", "PROBLEM", 344, 352], ["HSP", "PROBLEM", 370, 373], ["Systemic", "ANATOMY", 218, 226], ["Vasculitis", "OBSERVATION", 227, 237], ["AECA", "ANATOMY", 242, 246], ["Autoimmune Diseases", "OBSERVATION", 250, 269]]], ["Fujieda et al. [65] observed IgA AECA in nearly 50% of HSP patients with nephritis but, interestingly, in no HSP patients without nephritis.", [["HSP", "DISEASE", 55, 58], ["nephritis", "DISEASE", 73, 82], ["HSP", "DISEASE", 109, 112], ["nephritis", "DISEASE", 130, 139], ["IgA", "GENE_OR_GENE_PRODUCT", 29, 32], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 113, 121], ["IgA AECA", "PROTEIN", 29, 37], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 113, 121], ["IgA AECA", "TEST", 29, 37], ["nephritis", "PROBLEM", 73, 82], ["nephritis", "PROBLEM", 130, 139], ["nephritis", "OBSERVATION", 73, 82], ["no", "UNCERTAINTY", 106, 108], ["without", "UNCERTAINTY", 122, 129], ["nephritis", "OBSERVATION", 130, 139]]], ["Similar results were obtained by Yang et al. [66] who detected AECA IgA in 45% and 35% using HUVECs and human dermal microvascular endothelial cell (HDMECs) as substrates, respectively, with HUVEC AECA IgA titers correlating significantly with disease activity.AECA in Systemic Vasculitis ::: AECA in Autoimmune DiseasesIn summary, detection of AECAs in sera of patients affected by systemic vasculitis is a relatively common finding, with prevalence varying greatly among the different forms of vasculitis.", [["HUVECs", "ANATOMY", 93, 99], ["dermal microvascular endothelial cell", "ANATOMY", 110, 147], ["HDMECs", "ANATOMY", 149, 155], ["HUVEC", "ANATOMY", 191, 196], ["sera", "ANATOMY", 354, 358], ["AECA", "DISEASE", 261, 265], ["Vasculitis", "DISEASE", 278, 288], ["Autoimmune Diseases", "DISEASE", 301, 320], ["systemic vasculitis", "DISEASE", 383, 402], ["vasculitis", "DISEASE", 496, 506], ["IgA", "GENE_OR_GENE_PRODUCT", 68, 71], ["HUVECs", "CELL", 93, 99], ["human", "ORGANISM", 104, 109], ["dermal microvascular endothelial cell", "CELL", 110, 147], ["HDMECs", "CELL", 149, 155], ["HUVEC", "CELL", 191, 196], ["IgA", "GENE_OR_GENE_PRODUCT", 202, 205], ["AECAs", "GENE_OR_GENE_PRODUCT", 345, 350], ["sera", "ORGANISM_SUBSTANCE", 354, 358], ["patients", "ORGANISM", 362, 370], ["AECA IgA", "PROTEIN", 63, 71], ["HUVECs", "CELL_TYPE", 93, 99], ["human dermal microvascular endothelial cell", "CELL_TYPE", 104, 147], ["HDMECs", "CELL_TYPE", 149, 155], ["IgA", "PROTEIN", 202, 205], ["AECAs", "PROTEIN", 345, 350], ["human", "SPECIES", 104, 109], ["patients", "SPECIES", 362, 370], ["human", "SPECIES", 104, 109], ["AECA IgA", "TEST", 63, 71], ["HUVECs", "TEST", 93, 99], ["human dermal microvascular endothelial cell", "PROBLEM", 104, 147], ["HUVEC AECA IgA titers", "TEST", 191, 212], ["disease activity", "PROBLEM", 244, 260], ["AECA", "TEST", 261, 265], ["AECA in Autoimmune Diseases", "PROBLEM", 293, 320], ["AECAs in sera", "PROBLEM", 345, 358], ["systemic vasculitis", "PROBLEM", 383, 402], ["vasculitis", "PROBLEM", 496, 506], ["dermal microvascular", "ANATOMY", 110, 130], ["endothelial cell", "OBSERVATION", 131, 147], ["Systemic", "ANATOMY", 269, 277], ["Vasculitis", "OBSERVATION", 278, 288], ["AECA", "OBSERVATION", 293, 297], ["Autoimmune Diseases", "OBSERVATION", 301, 320], ["systemic", "ANATOMY", 383, 391], ["vasculitis", "OBSERVATION", 392, 402], ["vasculitis", "OBSERVATION", 496, 506]]], ["Some of the differences observed may be related to the prevalent use of HUVEC as a substrate to detect AECA, despite the evidence that different form of systemic vasculitis target preferentially vessels of different size.", [["HUVEC", "ANATOMY", 72, 77], ["AECA", "ANATOMY", 103, 107], ["vessels", "ANATOMY", 195, 202], ["vasculitis", "DISEASE", 162, 172], ["HUVEC", "CELL", 72, 77], ["AECA", "CANCER", 103, 107], ["vessels", "MULTI-TISSUE_STRUCTURE", 195, 202], ["HUVEC", "CELL_LINE", 72, 77], ["HUVEC", "TREATMENT", 72, 77], ["AECA", "PROBLEM", 103, 107], ["systemic vasculitis", "PROBLEM", 153, 172], ["systemic", "OBSERVATION_MODIFIER", 153, 161], ["vasculitis", "OBSERVATION", 162, 172], ["different", "OBSERVATION_MODIFIER", 206, 215], ["size", "OBSERVATION_MODIFIER", 216, 220]]], ["In the future, evaluation of AECA using as substrates ECs from macro\u2010 as well as microvasculature may be important to assess more precisely AECA reactivity in the various forms of vasculitis.", [["ECs", "ANATOMY", 54, 57], ["microvasculature", "ANATOMY", 81, 97], ["vasculitis", "DISEASE", 180, 190], ["AECA", "GENE_OR_GENE_PRODUCT", 29, 33], ["ECs", "CELL", 54, 57], ["microvasculature", "TISSUE", 81, 97], ["AECA", "GENE_OR_GENE_PRODUCT", 140, 144], ["AECA", "PROTEIN", 29, 33], ["ECs", "CELL_TYPE", 54, 57], ["evaluation", "TEST", 15, 25], ["AECA", "TEST", 29, 33], ["substrates ECs from macro\u2010", "TEST", 43, 69], ["vasculitis", "PROBLEM", 180, 190], ["AECA", "OBSERVATION", 29, 33], ["vasculitis", "OBSERVATION", 180, 190]]], ["In addition, this approach may also provide information on the preferential localization of antigenic targets in different forms of vasculitis and allow the identification of new antigenic specificities of AECA, which may reveal of pathogenic importance.", [["vasculitis", "DISEASE", 132, 142], ["AECA", "GENE_OR_GENE_PRODUCT", 206, 210], ["vasculitis", "PROBLEM", 132, 142], ["AECA", "TEST", 206, 210], ["pathogenic importance", "PROBLEM", 232, 253], ["vasculitis", "OBSERVATION", 132, 142], ["new", "OBSERVATION_MODIFIER", 175, 178], ["AECA", "OBSERVATION", 206, 210]]], ["In this regard, although inconclusive, preliminary attempts to detect AECA by using ECs from different sources in various autoimmune conditions suggest that this may represent a promising experimental approach [[7], [49], [66], [67]].AECA in Other Diseases ::: AECA in Autoimmune DiseasesAECA have been described in a number of systemic autoimmune\u2010inflammatory diseases other than those already mentioned.", [["ECs", "ANATOMY", 84, 87], ["AECA", "DISEASE", 234, 238], ["Autoimmune DiseasesAECA", "DISEASE", 269, 292], ["autoimmune\u2010inflammatory diseases", "DISEASE", 337, 369], ["AECA", "GENE_OR_GENE_PRODUCT", 70, 74], ["ECs", "CELL", 84, 87], ["[49]", "SIMPLE_CHEMICAL", 216, 220], ["[66]", "SIMPLE_CHEMICAL", 222, 226], ["[67]", "SIMPLE_CHEMICAL", 228, 232], ["AECA", "PROTEIN", 70, 74], ["ECs", "CELL_TYPE", 84, 87], ["AECA", "TEST", 70, 74], ["ECs", "TEST", 84, 87], ["various autoimmune conditions", "PROBLEM", 114, 143], ["AECA", "PROBLEM", 261, 265], ["Autoimmune DiseasesAECA", "PROBLEM", 269, 292], ["systemic autoimmune\u2010inflammatory diseases", "PROBLEM", 328, 369], ["autoimmune", "OBSERVATION", 122, 132], ["may represent", "UNCERTAINTY", 162, 175], ["Diseases", "OBSERVATION", 248, 256], ["AECA", "OBSERVATION", 261, 265], ["Autoimmune DiseasesAECA", "OBSERVATION", 269, 292], ["systemic", "OBSERVATION_MODIFIER", 328, 336], ["autoimmune\u2010inflammatory", "OBSERVATION", 337, 360]]], ["For instance, increased AECA production was observed in patients with mixed connective tissue disease (MCTD) [67].", [["connective tissue", "ANATOMY", 76, 93], ["connective tissue disease", "DISEASE", 76, 101], ["MCTD", "DISEASE", 103, 107], ["AECA", "GENE_OR_GENE_PRODUCT", 24, 28], ["patients", "ORGANISM", 56, 64], ["connective tissue", "TISSUE", 76, 93], ["AECA", "PROTEIN", 24, 28], ["patients", "SPECIES", 56, 64], ["increased AECA production", "PROBLEM", 14, 39], ["mixed connective tissue disease", "PROBLEM", 70, 101], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["AECA production", "OBSERVATION", 24, 39], ["mixed", "OBSERVATION_MODIFIER", 70, 75], ["connective tissue disease", "OBSERVATION", 76, 101]]], ["AECA from MCTD patients may activate ECs by the upregulation of E\u2010selectin expression and may be implicated in the pathogenesis of MCTD.", [["ECs", "ANATOMY", 37, 40], ["MCTD", "DISEASE", 10, 14], ["MCTD", "DISEASE", 131, 135], ["AECA", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 15, 23], ["ECs", "CELL", 37, 40], ["E\u2010selectin", "GENE_OR_GENE_PRODUCT", 64, 74], ["MCTD", "CANCER", 131, 135], ["ECs", "CELL_TYPE", 37, 40], ["E\u2010selectin", "PROTEIN", 64, 74], ["patients", "SPECIES", 15, 23], ["AECA", "TEST", 0, 4], ["MCTD", "PROBLEM", 131, 135], ["MCTD", "OBSERVATION", 10, 14], ["MCTD", "OBSERVATION", 131, 135]]], ["D'Cruz et al. [68] described an interesting association between AECA levels and interstitial lung disease in all forms of idiopathic inflammatory myopathies.", [["interstitial lung", "ANATOMY", 80, 97], ["interstitial lung disease", "DISEASE", 80, 105], ["idiopathic inflammatory myopathies", "DISEASE", 122, 156], ["AECA", "GENE_OR_GENE_PRODUCT", 64, 68], ["lung", "ORGAN", 93, 97], ["AECA", "PROTEIN", 64, 68], ["AECA levels", "TEST", 64, 75], ["interstitial lung disease", "PROBLEM", 80, 105], ["idiopathic inflammatory myopathies", "PROBLEM", 122, 156], ["interstitial", "ANATOMY_MODIFIER", 80, 92], ["lung", "ANATOMY", 93, 97], ["disease", "OBSERVATION", 98, 105], ["idiopathic", "OBSERVATION_MODIFIER", 122, 132], ["inflammatory myopathies", "OBSERVATION", 133, 156]]], ["In Behcet's disease (BD), the reported prevalence of AECA varied widely [69].", [["Behcet's disease", "DISEASE", 3, 19], ["BD", "DISEASE", 21, 23], ["AECA", "DISEASE", 53, 57], ["AECA", "CANCER", 53, 57], ["Behcet's disease", "PROBLEM", 3, 19], ["AECA", "TEST", 53, 57], ["Behcet", "OBSERVATION", 3, 9]]], ["A significant association between AECA and thrombosis and vasculitis as well as disease activity in BD has been reported [[70], [71]].", [["thrombosis", "DISEASE", 43, 53], ["vasculitis", "DISEASE", 58, 68], ["AECA", "GENE_OR_GENE_PRODUCT", 34, 38], ["BD", "GENE_OR_GENE_PRODUCT", 100, 102], ["BD", "PROTEIN", 100, 102], ["AECA", "PROBLEM", 34, 38], ["thrombosis", "PROBLEM", 43, 53], ["vasculitis", "PROBLEM", 58, 68], ["disease activity in BD", "PROBLEM", 80, 102], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["AECA", "OBSERVATION", 34, 38], ["thrombosis", "OBSERVATION", 43, 53], ["vasculitis", "OBSERVATION", 58, 68]]], ["Dinc et al. [72] described a low prevalence of AECA in a large series of Turkish Behcet's patients without significant differences from healthy controls.", [["AECA", "DISEASE", 47, 51], ["Behcet", "DISEASE", 81, 87], ["AECA", "CANCER", 47, 51], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["AECA", "PROBLEM", 47, 51]]], ["A new technique was described by Lee et al. [73] demonstrating for the first time that AECA IgM from sera of patients with active BD reacted strongly with human alpha\u2010enolase, a protein of the HDMEC.AECA in Other Diseases ::: AECA in Autoimmune DiseasesAECA were frequently detected in inflammatory bowel disease, and although they were associated with both active and extensive colitis, they seem to be less disease specific than other autoantibodies [74].", [["sera", "ANATOMY", 101, 105], ["bowel", "ANATOMY", 299, 304], ["AECA", "DISEASE", 199, 203], ["Autoimmune DiseasesAECA", "DISEASE", 234, 257], ["inflammatory bowel disease", "DISEASE", 286, 312], ["colitis", "DISEASE", 379, 386], ["AECA IgM", "GENE_OR_GENE_PRODUCT", 87, 95], ["sera", "ORGANISM_SUBSTANCE", 101, 105], ["patients", "ORGANISM", 109, 117], ["BD", "GENE_OR_GENE_PRODUCT", 130, 132], ["human", "ORGANISM", 155, 160], ["alpha\u2010enolase", "GENE_OR_GENE_PRODUCT", 161, 174], ["HDMEC", "GENE_OR_GENE_PRODUCT", 193, 198], ["AECA", "GENE_OR_GENE_PRODUCT", 226, 230], ["bowel", "ORGAN", 299, 304], ["colitis", "PATHOLOGICAL_FORMATION", 379, 386], ["AECA IgM", "PROTEIN", 87, 95], ["BD", "PROTEIN", 130, 132], ["human alpha\u2010enolase", "PROTEIN", 155, 174], ["HDMEC", "PROTEIN", 193, 198], ["AECA", "PROTEIN", 226, 230], ["autoantibodies", "PROTEIN", 437, 451], ["patients", "SPECIES", 109, 117], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["A new technique", "TREATMENT", 0, 15], ["AECA IgM", "TEST", 87, 95], ["active BD", "PROBLEM", 123, 132], ["human alpha\u2010enolase", "TREATMENT", 155, 174], ["AECA", "TEST", 226, 230], ["Autoimmune DiseasesAECA", "PROBLEM", 234, 257], ["inflammatory bowel disease", "PROBLEM", 286, 312], ["both active and extensive colitis", "PROBLEM", 353, 386], ["less disease specific than other autoantibodies", "PROBLEM", 404, 451], ["new", "OBSERVATION_MODIFIER", 2, 5], ["Diseases", "OBSERVATION", 213, 221], ["Autoimmune DiseasesAECA", "OBSERVATION", 234, 257], ["inflammatory", "OBSERVATION_MODIFIER", 286, 298], ["bowel", "ANATOMY", 299, 304], ["disease", "OBSERVATION", 305, 312], ["active", "OBSERVATION_MODIFIER", 358, 364], ["extensive", "OBSERVATION_MODIFIER", 369, 378], ["colitis", "OBSERVATION", 379, 386]]], ["Nevertheless, at least in Crohn's disease, intestinal vascular injury mediated by AECA may be an important event [75].AECA in Other Diseases ::: AECA in Autoimmune DiseasesIncreasing evidence is accumulating on the possibility that AECA may play an important role in the development and progression of atherosclerotic lesions.", [["intestinal vascular", "ANATOMY", 43, 62], ["atherosclerotic lesions", "ANATOMY", 302, 325], ["Crohn's disease", "DISEASE", 26, 41], ["vascular injury", "DISEASE", 54, 69], ["AECA", "DISEASE", 118, 122], ["Autoimmune Diseases", "DISEASE", 153, 172], ["AECA", "CHEMICAL", 232, 236], ["atherosclerotic", "DISEASE", 302, 317], ["intestinal vascular", "MULTI-TISSUE_STRUCTURE", 43, 62], ["AECA", "GENE_OR_GENE_PRODUCT", 82, 86], ["AECA", "GENE_OR_GENE_PRODUCT", 232, 236], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 302, 325], ["AECA", "PROTEIN", 232, 236], ["Crohn's disease", "PROBLEM", 26, 41], ["intestinal vascular injury", "PROBLEM", 43, 69], ["AECA", "PROBLEM", 82, 86], ["AECA", "PROBLEM", 145, 149], ["Autoimmune Diseases", "PROBLEM", 153, 172], ["AECA", "PROBLEM", 232, 236], ["atherosclerotic lesions", "PROBLEM", 302, 325], ["Crohn", "OBSERVATION", 26, 31], ["intestinal", "ANATOMY_MODIFIER", 43, 53], ["vascular", "ANATOMY", 54, 62], ["injury", "OBSERVATION", 63, 69], ["Diseases", "OBSERVATION", 132, 140], ["AECA", "OBSERVATION", 145, 149], ["Autoimmune Diseases", "OBSERVATION", 153, 172], ["AECA", "OBSERVATION", 232, 236], ["progression", "OBSERVATION_MODIFIER", 287, 298], ["atherosclerotic", "OBSERVATION_MODIFIER", 302, 317], ["lesions", "OBSERVATION", 318, 325]]], ["Farsi et al. [76] described a higher rate of AECA in patients with unstable angina than in those with effort angina.", [["AECA", "DISEASE", 45, 49], ["unstable angina", "DISEASE", 67, 82], ["effort angina", "DISEASE", 102, 115], ["AECA", "CANCER", 45, 49], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["AECA", "PROBLEM", 45, 49], ["unstable angina", "PROBLEM", 67, 82], ["effort angina", "PROBLEM", 102, 115], ["AECA", "OBSERVATION", 45, 49], ["unstable", "OBSERVATION_MODIFIER", 67, 75], ["angina", "OBSERVATION", 76, 82]]], ["Only 3 out of 12 AECA positive patients were also positive for anti\u2010\u03b22\u2010GPI supporting the idea that \u03b22\u2010GPI is not the major AECA target antigen.", [["AECA", "GENE_OR_GENE_PRODUCT", 17, 21], ["patients", "ORGANISM", 31, 39], ["anti\u2010\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 63, 74], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 100, 106], ["AECA", "CANCER", 124, 128], ["anti\u2010\u03b22", "PROTEIN", 63, 70], ["GPI", "PROTEIN", 71, 74], ["\u03b22\u2010GPI", "PROTEIN", 100, 106], ["AECA target antigen", "PROTEIN", 124, 143], ["patients", "SPECIES", 31, 39], ["anti\u2010\u03b22\u2010GPI", "PROBLEM", 63, 74]]], ["Thus, AECA may contribute to the instability of angina and are associated with the high\u2010restenosis rate after percutaneous transluminal coronary angioplasty.", [["percutaneous", "ANATOMY", 110, 122], ["coronary", "ANATOMY", 136, 144], ["angina", "DISEASE", 48, 54], ["high\u2010restenosis", "DISEASE", 83, 98], ["AECA", "GENE_OR_GENE_PRODUCT", 6, 10], ["coronary", "MULTI-TISSUE_STRUCTURE", 136, 144], ["AECA", "PROTEIN", 6, 10], ["AECA", "PROBLEM", 6, 10], ["angina", "PROBLEM", 48, 54], ["the high\u2010restenosis rate", "PROBLEM", 79, 103], ["percutaneous transluminal coronary angioplasty", "TREATMENT", 110, 156], ["AECA", "OBSERVATION", 6, 10], ["may contribute to", "UNCERTAINTY", 11, 28], ["angina", "OBSERVATION", 48, 54], ["coronary", "ANATOMY", 136, 144], ["angioplasty", "OBSERVATION", 145, 156]]], ["In contrast, patients with or without coronary atherosclerosis, confirmed by angiography, showed similar AECA levels [77].", [["coronary", "ANATOMY", 38, 46], ["coronary atherosclerosis", "DISEASE", 38, 62], ["patients", "ORGANISM", 13, 21], ["coronary", "MULTI-TISSUE_STRUCTURE", 38, 46], ["AECA", "PROTEIN", 105, 109], ["patients", "SPECIES", 13, 21], ["coronary atherosclerosis", "PROBLEM", 38, 62], ["angiography", "TEST", 77, 88], ["similar AECA levels", "TEST", 97, 116], ["without", "UNCERTAINTY", 30, 37], ["coronary", "ANATOMY", 38, 46], ["atherosclerosis", "OBSERVATION", 47, 62]]], ["The target antigen of AECA in acute myocardial infarction may be the endothelial protein C receptor, as reported by Montes et al. [78].AECA in Other Diseases ::: AECA in Autoimmune DiseasesThe AECA seem to be involved in the complex pathogenesis of vascular complications in diabetes [79], although others have suggested that they are only associated with coexisting autoimmune disorders [80].", [["myocardial", "ANATOMY", 36, 46], ["endothelial", "ANATOMY", 69, 80], ["vascular", "ANATOMY", 249, 257], ["myocardial infarction", "DISEASE", 36, 57], ["AECA", "DISEASE", 135, 139], ["Autoimmune Diseases", "DISEASE", 170, 189], ["vascular complications", "DISEASE", 249, 271], ["diabetes", "DISEASE", 275, 283], ["autoimmune disorders", "DISEASE", 367, 387], ["AECA", "GENE_OR_GENE_PRODUCT", 22, 26], ["myocardial", "MULTI-TISSUE_STRUCTURE", 36, 46], ["endothelial", "CELL", 69, 80], ["protein C receptor", "GENE_OR_GENE_PRODUCT", 81, 99], ["vascular", "MULTI-TISSUE_STRUCTURE", 249, 257], ["AECA", "PROTEIN", 22, 26], ["endothelial protein C receptor", "PROTEIN", 69, 99], ["AECA", "PROBLEM", 22, 26], ["acute myocardial infarction", "PROBLEM", 30, 57], ["the endothelial protein C receptor", "TREATMENT", 65, 99], ["AECA", "PROBLEM", 162, 166], ["Autoimmune Diseases", "PROBLEM", 170, 189], ["The AECA", "PROBLEM", 189, 197], ["vascular complications", "PROBLEM", 249, 271], ["diabetes", "PROBLEM", 275, 283], ["coexisting autoimmune disorders", "PROBLEM", 356, 387], ["AECA", "OBSERVATION", 22, 26], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["myocardial", "ANATOMY", 36, 46], ["infarction", "OBSERVATION", 47, 57], ["Diseases", "OBSERVATION", 149, 157], ["AECA", "OBSERVATION", 162, 166], ["Autoimmune Diseases", "OBSERVATION", 170, 189], ["vascular", "ANATOMY", 249, 257], ["complications", "OBSERVATION", 258, 271]]], ["A putative cytotoxic role of AECA vs ECs of the inner ear in immune\u2010mediated sudden sensorineural deafness has been suggested [[81], [82]].AECA in Other Diseases ::: AECA in Autoimmune DiseasesUnderstanding the relationship between autoimmune disease and infection has been a topic of interest for several decades.", [["ECs", "ANATOMY", 37, 40], ["inner ear", "ANATOMY", 48, 57], ["sudden sensorineural deafness", "DISEASE", 77, 106], ["AECA", "DISEASE", 139, 143], ["Autoimmune Diseases", "DISEASE", 174, 193], ["autoimmune disease", "DISEASE", 232, 250], ["infection", "DISEASE", 255, 264], ["AECA", "GENE_OR_GENE_PRODUCT", 29, 33], ["ECs", "CELL", 37, 40], ["inner ear", "TISSUE", 48, 57], ["AECA", "PROTEIN", 29, 33], ["ECs", "CELL_TYPE", 37, 40], ["AECA", "TEST", 29, 33], ["immune\u2010mediated sudden sensorineural deafness", "PROBLEM", 61, 106], ["AECA", "PROBLEM", 166, 170], ["Autoimmune Diseases", "PROBLEM", 174, 193], ["autoimmune disease", "PROBLEM", 232, 250], ["infection", "PROBLEM", 255, 264], ["cytotoxic", "OBSERVATION_MODIFIER", 11, 20], ["AECA", "OBSERVATION", 29, 33], ["inner", "ANATOMY_MODIFIER", 48, 53], ["ear", "ANATOMY", 54, 57], ["sensorineural deafness", "OBSERVATION", 84, 106], ["Diseases", "OBSERVATION", 153, 161], ["AECA", "OBSERVATION", 166, 170], ["Autoimmune Diseases", "OBSERVATION", 174, 193], ["infection", "OBSERVATION", 255, 264]]], ["It is noteworthy that autoimmune diseases may be caused or triggered by infections.", [["autoimmune diseases", "DISEASE", 22, 41], ["infections", "DISEASE", 72, 82], ["autoimmune diseases", "PROBLEM", 22, 41], ["infections", "PROBLEM", 72, 82], ["autoimmune", "OBSERVATION", 22, 32], ["infections", "OBSERVATION", 72, 82]]], ["AECA are a common finding in several infections, such as HCV infection where these autoantibodies are often associated with mixed cryoglobulins [83].", [["infections", "DISEASE", 37, 47], ["HCV infection", "DISEASE", 57, 70], ["AECA", "GENE_OR_GENE_PRODUCT", 0, 4], ["HCV", "ORGANISM", 57, 60], ["autoantibodies", "PROTEIN", 83, 97], ["cryoglobulins", "PROTEIN", 130, 143], ["HCV", "SPECIES", 57, 60], ["AECA", "PROBLEM", 0, 4], ["several infections", "PROBLEM", 29, 47], ["HCV infection", "PROBLEM", 57, 70], ["these autoantibodies", "PROBLEM", 77, 97], ["mixed cryoglobulins", "PROBLEM", 124, 143], ["several", "OBSERVATION_MODIFIER", 29, 36], ["infections", "OBSERVATION", 37, 47], ["HCV", "OBSERVATION_MODIFIER", 57, 60], ["infection", "OBSERVATION", 61, 70]]], ["Moreover, AECA associated with aCL, but not anti\u2010\u03b22\u2010GPI, were found in HIV infection [84].", [["HIV infection", "DISEASE", 71, 84], ["AECA", "GENE_OR_GENE_PRODUCT", 10, 14], ["aCL", "GENE_OR_GENE_PRODUCT", 31, 34], ["anti\u2010\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 44, 55], ["HIV", "ORGANISM", 71, 74], ["AECA", "PROTEIN", 10, 14], ["aCL", "PROTEIN", 31, 34], ["anti\u2010\u03b22", "PROTEIN", 44, 51], ["GPI", "PROTEIN", 52, 55], ["HIV", "SPECIES", 71, 74], ["AECA", "PROBLEM", 10, 14], ["aCL", "PROBLEM", 31, 34], ["GPI", "TEST", 52, 55], ["HIV infection", "PROBLEM", 71, 84], ["AECA", "OBSERVATION", 10, 14]]], ["AECA and anti\u2010epithelial human cell antibodies were described in severe acute respiratory syndrome (SARS) caused by infection with the SARS\u2010associated coronavirus and in patients with leprosy [[85], [86]].AECA in Other Diseases ::: AECA in Autoimmune DiseasesNatural AECA were described in healthy subjects and Ronda et al. [87] showed that these antibodies interact with living ECs, affecting their function after a ligand\u2013receptor\u2010like mechanism of internalization.", [["cell", "ANATOMY", 31, 35], ["ECs", "ANATOMY", 379, 382], ["acute respiratory syndrome", "DISEASE", 72, 98], ["SARS", "DISEASE", 100, 104], ["infection", "DISEASE", 116, 125], ["SARS", "DISEASE", 135, 139], ["coronavirus", "DISEASE", 151, 162], ["leprosy", "DISEASE", 184, 191], ["AECA", "DISEASE", 205, 209], ["Autoimmune Diseases", "DISEASE", 240, 259], ["AECA", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 25, 30], ["coronavirus", "ORGANISM", 151, 162], ["patients", "ORGANISM", 170, 178], ["ECs", "CELL", 379, 382], ["AECA", "PROTEIN", 0, 4], ["anti\u2010epithelial human cell antibodies", "PROTEIN", 9, 46], ["antibodies", "PROTEIN", 347, 357], ["ECs", "CELL_TYPE", 379, 382], ["human", "SPECIES", 25, 30], ["coronavirus", "SPECIES", 151, 162], ["patients", "SPECIES", 170, 178], ["human", "SPECIES", 25, 30], ["SARS\u2010associated coronavirus", "SPECIES", 135, 162], ["AECA", "TEST", 0, 4], ["anti\u2010epithelial human cell antibodies", "TEST", 9, 46], ["severe acute respiratory syndrome", "PROBLEM", 65, 98], ["SARS", "PROBLEM", 100, 104], ["infection", "PROBLEM", 116, 125], ["the SARS\u2010associated coronavirus", "PROBLEM", 131, 162], ["AECA", "PROBLEM", 232, 236], ["Autoimmune Diseases", "PROBLEM", 240, 259], ["Natural AECA", "PROBLEM", 259, 271], ["these antibodies", "PROBLEM", 341, 357], ["anti\u2010epithelial human cell antibodies", "OBSERVATION", 9, 46], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["respiratory syndrome", "OBSERVATION", 78, 98], ["infection", "OBSERVATION", 116, 125], ["AECA", "OBSERVATION", 232, 236]]], ["Natural AECA showed a more restricted pattern of reactivity compared to AECA from SLE patients [88].", [["SLE", "DISEASE", 82, 85], ["AECA", "GENE_OR_GENE_PRODUCT", 8, 12], ["AECA", "CANCER", 72, 76], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["Natural AECA", "TEST", 0, 12], ["AECA", "TEST", 72, 76], ["more restricted", "OBSERVATION_MODIFIER", 22, 37]]], ["A significantly higher level of IgM\u2010AECA was found during normal pregnancy compared with that in healthy nonpregnant controls and pregnant patients with SLE [89].", [["SLE", "DISEASE", 153, 156], ["IgM", "GENE_OR_GENE_PRODUCT", 32, 35], ["AECA", "GENE_OR_GENE_PRODUCT", 36, 40], ["patients", "ORGANISM", 139, 147], ["IgM", "PROTEIN", 32, 35], ["AECA", "PROTEIN", 36, 40], ["patients", "SPECIES", 139, 147], ["A significantly higher level of IgM\u2010AECA", "PROBLEM", 0, 40], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["higher", "OBSERVATION_MODIFIER", 16, 22]]], ["On the contrary, IgG\u2010AECA levels were significantly higher in the serum of normal pregnant women and pregnant SLE patients than in the serum of healthy nonpregnant controls.", [["serum", "ANATOMY", 66, 71], ["serum", "ANATOMY", 135, 140], ["SLE", "DISEASE", 110, 113], ["IgG\u2010AECA", "GENE_OR_GENE_PRODUCT", 17, 25], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["women", "ORGANISM", 91, 96], ["patients", "ORGANISM", 114, 122], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["IgG\u2010AECA", "PROTEIN", 17, 25], ["women", "SPECIES", 91, 96], ["patients", "SPECIES", 114, 122], ["IgG\u2010AECA levels", "TEST", 17, 32], ["significantly", "OBSERVATION_MODIFIER", 38, 51], ["higher", "OBSERVATION_MODIFIER", 52, 58]]], ["Taken together, these findings support a physiological role of AECA in fetal tolerance of normal pregnant women, as well as a pathogenic role in impaired reproductive function frequently found in pregnant SLE.Cytotoxicity and Apoptotic Effects of AECA ::: Pathogenic Mechanisms of AECAThe pathogenic ability of AECAs to induce an endothelial perturbation is suggested by the demonstration of complement\u2010dependent cytotoxicity on HUVECs from sera of patients with systemic vasculitis [[50], [51], [54], [57], [90]] and SLE [91].", [["fetal", "ANATOMY", 71, 76], ["endothelial", "ANATOMY", 330, 341], ["HUVECs", "ANATOMY", 429, 435], ["sera", "ANATOMY", 441, 445], ["AECA", "CHEMICAL", 63, 67], ["impaired reproductive function", "DISEASE", 145, 175], ["SLE", "DISEASE", 205, 208], ["systemic vasculitis", "DISEASE", 463, 482], ["SLE", "DISEASE", 518, 521], ["AECA", "GENE_OR_GENE_PRODUCT", 63, 67], ["fetal", "ANATOMICAL_SYSTEM", 71, 76], ["women", "ORGANISM", 106, 111], ["AECA", "SIMPLE_CHEMICAL", 247, 251], ["AECAs", "SIMPLE_CHEMICAL", 311, 316], ["endothelial", "CELL", 330, 341], ["HUVECs", "CELL", 429, 435], ["sera", "ORGANISM_SUBSTANCE", 441, 445], ["patients", "ORGANISM", 449, 457], ["[57]", "SIMPLE_CHEMICAL", 502, 506], ["AECA", "PROTEIN", 63, 67], ["HUVECs", "CELL_LINE", 429, 435], ["women", "SPECIES", 106, 111], ["patients", "SPECIES", 449, 457], ["AECA", "PROBLEM", 63, 67], ["impaired reproductive function", "PROBLEM", 145, 175], ["pregnant SLE", "PROBLEM", 196, 208], ["Cytotoxicity", "PROBLEM", 209, 221], ["an endothelial perturbation", "PROBLEM", 327, 354], ["complement\u2010dependent cytotoxicity", "PROBLEM", 392, 425], ["HUVECs", "TEST", 429, 435], ["systemic vasculitis", "PROBLEM", 463, 482], ["SLE", "TEST", 518, 521], ["impaired", "OBSERVATION_MODIFIER", 145, 153], ["reproductive function", "OBSERVATION", 154, 175], ["Apoptotic Effects", "OBSERVATION", 226, 243], ["endothelial", "OBSERVATION", 330, 341], ["vasculitis", "OBSERVATION", 472, 482]]], ["In particular, early reports in the 1980s demonstrated that purified IgM and, to a much lesser extent, IgG from patients with acute but not convalescent KD were able to lyse HUVECs, assessed by 111In release, in the presence of fresh (but not heat inactivated) rabbit serum.", [["HUVECs", "ANATOMY", 174, 180], ["serum", "ANATOMY", 268, 273], ["IgM", "GENE_OR_GENE_PRODUCT", 69, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 103, 106], ["patients", "ORGANISM", 112, 120], ["HUVECs", "CELL", 174, 180], ["111In", "SIMPLE_CHEMICAL", 194, 199], ["rabbit", "ORGANISM", 261, 267], ["serum", "ORGANISM_SUBSTANCE", 268, 273], ["IgM", "PROTEIN", 69, 72], ["IgG", "PROTEIN", 103, 106], ["HUVECs", "CELL_TYPE", 174, 180], ["patients", "SPECIES", 112, 120], ["rabbit", "SPECIES", 261, 267], ["rabbit", "SPECIES", 261, 267], ["purified IgM", "PROBLEM", 60, 72], ["convalescent KD", "PROBLEM", 140, 155], ["rabbit serum", "TEST", 261, 273], ["IgM", "OBSERVATION", 69, 72]]], ["Conversely, the simple incubation of KD IgM or IgG failed to induce any direct cytotoxicity; in addition, the lytic effect was observed only when HUVECs were prestimulated with either IFN\u03b3 [50] or monokines [51] suggesting that exposure of neo\u2010antigen on endothelial cells was necessary for the binding of cytotoxic antibodies.", [["HUVECs", "ANATOMY", 146, 152], ["endothelial cells", "ANATOMY", 255, 272], ["neo\u2010antigen", "CHEMICAL", 240, 251], ["IgM", "GENE_OR_GENE_PRODUCT", 40, 43], ["IgG", "GENE_OR_GENE_PRODUCT", 47, 50], ["HUVECs", "CELL", 146, 152], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 184, 188], ["neo\u2010antigen", "CELL", 240, 251], ["endothelial cells", "CELL", 255, 272], ["KD IgM", "PROTEIN", 37, 43], ["IgG", "PROTEIN", 47, 50], ["HUVECs", "CELL_LINE", 146, 152], ["IFN", "PROTEIN", 184, 187], ["endothelial cells", "CELL_TYPE", 255, 272], ["cytotoxic antibodies", "PROTEIN", 306, 326], ["KD IgM", "PROBLEM", 37, 43], ["IgG", "TREATMENT", 47, 50], ["any direct cytotoxicity", "PROBLEM", 68, 91], ["the lytic effect", "PROBLEM", 106, 122], ["HUVECs", "TEST", 146, 152], ["neo\u2010antigen on endothelial cells", "PROBLEM", 240, 272], ["cytotoxic antibodies", "PROBLEM", 306, 326], ["lytic", "OBSERVATION_MODIFIER", 110, 115], ["cytotoxic antibodies", "OBSERVATION", 306, 326]]], ["The different preincubation time required for IFN\u03b3 or monokines inducing binding of AECA and conferring cytotoxicity in vitro and absorption experiments with IFN\u03b3\u2010 or monokine\u2010treated HUVECs suggested that different epitopes were recognized by AECA from KD following different HUVECs stimulation.", [["HUVECs", "ANATOMY", 184, 190], ["HUVECs", "ANATOMY", 277, 283], ["AECA", "CHEMICAL", 84, 88], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 46, 50], ["monokines", "SIMPLE_CHEMICAL", 54, 63], ["AECA", "SIMPLE_CHEMICAL", 84, 88], ["IFN\u03b3\u2010", "GENE_OR_GENE_PRODUCT", 158, 163], ["HUVECs", "CELL", 184, 190], ["AECA", "GENE_OR_GENE_PRODUCT", 244, 248], ["HUVECs", "CELL", 277, 283], ["IFN\u03b3", "PROTEIN", 46, 50], ["AECA", "PROTEIN", 84, 88], ["IFN\u03b3\u2010 or monokine\u2010treated HUVECs", "CELL_LINE", 158, 190], ["epitopes", "PROTEIN", 216, 224], ["AECA", "PROTEIN", 244, 248], ["HUVECs", "CELL_LINE", 277, 283], ["The different preincubation time", "TREATMENT", 0, 32], ["IFN\u03b3", "TREATMENT", 46, 50], ["monokines", "TREATMENT", 54, 63], ["AECA", "PROBLEM", 84, 88], ["cytotoxicity", "PROBLEM", 104, 116], ["vitro and absorption experiments", "TREATMENT", 120, 152], ["IFN\u03b3\u2010", "TREATMENT", 158, 163], ["monokine\u2010treated HUVECs", "TREATMENT", 167, 190], ["different epitopes", "PROBLEM", 206, 224], ["different HUVECs stimulation", "TREATMENT", 267, 295]]], ["Similar results were reported in SLE by Moscato et al. [91] who showed that SLE sera and purified IgGs were able to fix complement in vitro leading to deposition of the complement component C3 and disruption of the endothelial monolayer.", [["sera", "ANATOMY", 80, 84], ["endothelial monolayer", "ANATOMY", 215, 236], ["SLE", "DISEASE", 33, 36], ["SLE", "ORGANISM", 76, 79], ["sera", "ORGANISM_SUBSTANCE", 80, 84], ["IgGs", "GENE_OR_GENE_PRODUCT", 98, 102], ["complement component C3", "GENE_OR_GENE_PRODUCT", 169, 192], ["endothelial monolayer", "CELL", 215, 236], ["purified IgGs", "PROTEIN", 89, 102], ["complement component C3", "PROTEIN", 169, 192], ["endothelial monolayer", "CELL_TYPE", 215, 236], ["SLE sera", "TEST", 76, 84], ["IgGs", "TEST", 98, 102], ["disruption of the endothelial monolayer", "PROBLEM", 197, 236], ["C3", "OBSERVATION_MODIFIER", 190, 192], ["endothelial monolayer", "OBSERVATION", 215, 236]]], ["Noteworthy, differently from early reports on KD sera, this effect was observed in unstimulated HUVECs under basal conditions and suggests that cytotoxic SLE AECA may recognise different epitopes on ECs, which do not require endothelial activation by inflammatory cytokines.Cytotoxicity and Apoptotic Effects of AECA ::: Pathogenic Mechanisms of AECAWhile complement\u2010dependent cytotoxicity may be an important mechanism by which AECA induce endothelial perturbation and cell damage in SLE and systemic vasculitis, the ability of AECA to fix complement and induce complement\u2010dependent cytotoxicity have not been always confirmed in other autoimmune diseases.", [["sera", "ANATOMY", 49, 53], ["HUVECs", "ANATOMY", 96, 102], ["ECs", "ANATOMY", 199, 202], ["endothelial", "ANATOMY", 225, 236], ["endothelial", "ANATOMY", 441, 452], ["cell", "ANATOMY", 470, 474], ["SLE", "DISEASE", 485, 488], ["vasculitis", "DISEASE", 502, 512], ["autoimmune diseases", "DISEASE", 637, 656], ["sera", "ORGANISM_SUBSTANCE", 49, 53], ["HUVECs", "CELL", 96, 102], ["AECA", "GENE_OR_GENE_PRODUCT", 158, 162], ["ECs", "CELL", 199, 202], ["endothelial", "CELL", 225, 236], ["AECA", "SIMPLE_CHEMICAL", 312, 316], ["AECAWhile", "GENE_OR_GENE_PRODUCT", 346, 355], ["AECA", "SIMPLE_CHEMICAL", 429, 433], ["endothelial", "CELL", 441, 452], ["cell", "CELL", 470, 474], ["AECA", "SIMPLE_CHEMICAL", 529, 533], ["complement\u2010", "GENE_OR_GENE_PRODUCT", 563, 574], ["unstimulated HUVECs", "CELL_LINE", 83, 102], ["epitopes", "PROTEIN", 187, 195], ["ECs", "CELL_TYPE", 199, 202], ["inflammatory cytokines", "PROTEIN", 251, 273], ["AECA", "PROTEIN", 429, 433], ["AECA", "PROTEIN", 529, 533], ["KD sera", "TEST", 46, 53], ["cytotoxic SLE AECA", "PROBLEM", 144, 162], ["different epitopes on ECs", "PROBLEM", 177, 202], ["endothelial activation", "PROBLEM", 225, 247], ["inflammatory cytokines", "PROBLEM", 251, 273], ["Cytotoxicity", "PROBLEM", 274, 286], ["AECAWhile complement\u2010dependent cytotoxicity", "PROBLEM", 346, 389], ["endothelial perturbation", "PROBLEM", 441, 465], ["cell damage", "PROBLEM", 470, 481], ["SLE", "PROBLEM", 485, 488], ["systemic vasculitis", "PROBLEM", 493, 512], ["AECA", "TREATMENT", 529, 533], ["complement\u2010dependent cytotoxicity", "PROBLEM", 563, 596], ["other autoimmune diseases", "PROBLEM", 631, 656], ["inflammatory", "OBSERVATION_MODIFIER", 251, 263], ["Apoptotic Effects", "OBSERVATION", 291, 308], ["cell damage", "OBSERVATION", 470, 481], ["systemic", "OBSERVATION_MODIFIER", 493, 501], ["vasculitis", "OBSERVATION", 502, 512], ["autoimmune", "OBSERVATION", 637, 647]]], ["In particular, reports in the mid\u2010 and late 1980s failed to demonstrate the ability of sera from patients with SSc to induce complement\u2010dependent cytotoxicity in vitro.", [["sera", "ANATOMY", 87, 91], ["SSc", "DISEASE", 111, 114], ["sera", "ORGANISM_SUBSTANCE", 87, 91], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["SSc", "TREATMENT", 111, 114], ["complement\u2010dependent cytotoxicity", "PROBLEM", 125, 158]]], ["However, it has been shown that other mechanisms, namely antibody\u2010dependent cellular cytotoxicity (ADCC) and induction of ECs apoptosis, may account for the pathogenic potential of AECA from SSc and other autoimmune diseases, including SLE and vasculitis.Cytotoxicity and Apoptotic Effects of AECA ::: Pathogenic Mechanisms of AECAThe ability of AECA to induce ECs damage via an ADCC\u2010like mechanism was originally demonstrated in the 1980s by in vitro evaluation of the cytotoxic effect of SSc sera on HUVEC monolayers [[92], [93], [94], [95], [96]] (Fig. 2A).", [["cellular", "ANATOMY", 76, 84], ["ECs", "ANATOMY", 122, 125], ["AECA", "ANATOMY", 181, 185], ["ECs", "ANATOMY", 361, 364], ["sera", "ANATOMY", 494, 498], ["HUVEC monolayers", "ANATOMY", 502, 518], ["SSc", "DISEASE", 191, 194], ["autoimmune diseases", "DISEASE", 205, 224], ["SLE", "DISEASE", 236, 239], ["vasculitis", "DISEASE", 244, 254], ["AECA", "CHEMICAL", 346, 350], ["cellular", "CELL", 76, 84], ["ECs", "CELL", 122, 125], ["AECA", "CANCER", 181, 185], ["AECA", "SIMPLE_CHEMICAL", 293, 297], ["AECA", "SIMPLE_CHEMICAL", 346, 350], ["ECs", "CELL", 361, 364], ["sera", "ORGANISM_SUBSTANCE", 494, 498], ["HUVEC monolayers", "CELL", 502, 518], ["[92], [93], [94], [95], [96]]", "SIMPLE_CHEMICAL", 520, 549], ["ECs", "CELL_TYPE", 122, 125], ["AECA", "PROTEIN", 346, 350], ["ECs", "CELL_TYPE", 361, 364], ["HUVEC monolayers", "CELL_LINE", 502, 518], ["namely antibody\u2010dependent cellular cytotoxicity", "PROBLEM", 50, 97], ["ECs apoptosis", "PROBLEM", 122, 135], ["AECA", "PROBLEM", 181, 185], ["SSc", "PROBLEM", 191, 194], ["other autoimmune diseases", "PROBLEM", 199, 224], ["SLE", "PROBLEM", 236, 239], ["vasculitis", "PROBLEM", 244, 254], ["Cytotoxicity", "PROBLEM", 255, 267], ["AECA", "PROBLEM", 346, 350], ["ECs damage", "PROBLEM", 361, 371], ["an ADCC\u2010like mechanism", "PROBLEM", 376, 398], ["vitro evaluation", "TEST", 446, 462], ["SSc sera", "TEST", 490, 498], ["HUVEC monolayers", "TEST", 502, 518], ["cellular cytotoxicity", "OBSERVATION", 76, 97], ["may account for", "UNCERTAINTY", 137, 152], ["AECA", "OBSERVATION", 181, 185], ["SSc", "ANATOMY", 191, 194], ["autoimmune diseases", "OBSERVATION", 205, 224], ["vasculitis", "OBSERVATION", 244, 254], ["Apoptotic Effects", "OBSERVATION", 272, 289]]], ["The cytotoxic activity on ECs of either venous or arterial origin was assessed by morphological changes, decreased DNA [3H]thymidine incorporation, reduced fibronectin production, or increased 51Cr release and was present only in a minority of sera from SSc patients, ranging from 19% to 41%.", [["ECs", "ANATOMY", 26, 29], ["venous", "ANATOMY", 40, 46], ["arterial", "ANATOMY", 50, 58], ["sera", "ANATOMY", 244, 248], ["[3H]thymidine", "CHEMICAL", 119, 132], ["51Cr", "CHEMICAL", 193, 197], ["SSc", "DISEASE", 254, 257], ["[3H]thymidine", "CHEMICAL", 119, 132], ["51Cr", "CHEMICAL", 193, 197], ["ECs", "CELL", 26, 29], ["venous", "MULTI-TISSUE_STRUCTURE", 40, 46], ["arterial", "MULTI-TISSUE_STRUCTURE", 50, 58], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["thymidine", "SIMPLE_CHEMICAL", 123, 132], ["fibronectin", "GENE_OR_GENE_PRODUCT", 156, 167], ["51Cr", "SIMPLE_CHEMICAL", 193, 197], ["sera", "ORGANISM_SUBSTANCE", 244, 248], ["patients", "ORGANISM", 258, 266], ["ECs", "CELL_TYPE", 26, 29], ["fibronectin", "PROTEIN", 156, 167], ["patients", "SPECIES", 258, 266], ["decreased DNA", "PROBLEM", 105, 118], ["3H]thymidine incorporation", "TREATMENT", 120, 146], ["reduced fibronectin production", "PROBLEM", 148, 178], ["increased 51Cr release", "PROBLEM", 183, 205], ["cytotoxic activity", "OBSERVATION", 4, 22], ["venous", "ANATOMY", 40, 46], ["arterial origin", "ANATOMY", 50, 65], ["reduced", "OBSERVATION_MODIFIER", 148, 155], ["fibronectin production", "OBSERVATION", 156, 178]]], ["In some cases, the same sera were also able to induce a cytotoxic effect on dermal fibroblasts [92], an observation which may have relevance in understanding the mechanisms leading to skin fibroblast dysfunction and which can be partially explained by possible cross\u2010reactivity between endothelial and fibroblast antigens as suggested by the evidence that absorption of purified IgG from SSc sera on dermal fibroblasts greatly reduced reactivity toward ECs [97].", [["sera", "ANATOMY", 24, 28], ["dermal fibroblasts", "ANATOMY", 76, 94], ["skin fibroblast", "ANATOMY", 184, 199], ["endothelial", "ANATOMY", 286, 297], ["fibroblast", "ANATOMY", 302, 312], ["sera", "ANATOMY", 392, 396], ["dermal fibroblasts", "ANATOMY", 400, 418], ["ECs", "ANATOMY", 453, 456], ["fibroblast dysfunction", "DISEASE", 189, 211], ["sera", "ORGANISM_SUBSTANCE", 24, 28], ["dermal fibroblasts", "CELL", 76, 94], ["skin fibroblast", "CELL", 184, 199], ["endothelial", "CELL", 286, 297], ["fibroblast antigens", "GENE_OR_GENE_PRODUCT", 302, 321], ["IgG", "GENE_OR_GENE_PRODUCT", 379, 382], ["sera", "ORGANISM_SUBSTANCE", 392, 396], ["dermal fibroblasts", "CELL", 400, 418], ["ECs", "CELL", 453, 456], ["dermal fibroblasts", "CELL_TYPE", 76, 94], ["endothelial and fibroblast antigens", "PROTEIN", 286, 321], ["purified IgG", "PROTEIN", 370, 382], ["dermal fibroblasts", "CELL_TYPE", 400, 418], ["ECs", "CELL_TYPE", 453, 456], ["a cytotoxic effect on dermal fibroblasts", "PROBLEM", 54, 94], ["an observation", "TEST", 101, 115], ["skin fibroblast dysfunction", "PROBLEM", 184, 211], ["cross\u2010reactivity between endothelial and fibroblast antigens", "PROBLEM", 261, 321], ["purified IgG", "TREATMENT", 370, 382], ["SSc sera", "TEST", 388, 396], ["dermal fibroblasts", "PROBLEM", 400, 418], ["ECs", "TEST", 453, 456], ["skin", "ANATOMY", 184, 188], ["fibroblast dysfunction", "OBSERVATION", 189, 211], ["endothelial", "ANATOMY", 286, 297]]], ["Although some differences in the various reports exist, it is generally convincing that whole sera or purified IgG from SSc patients were not able to induce a cytotoxic effect on ECs per se or in the simple presence of complement, but that the cytotoxic mechanism was dependent on the presence of effector cells in the culture medium [[96], [97]].", [["sera", "ANATOMY", 94, 98], ["ECs", "ANATOMY", 179, 182], ["effector cells", "ANATOMY", 297, 311], ["SSc", "DISEASE", 120, 123], ["sera", "ORGANISM_SUBSTANCE", 94, 98], ["IgG", "GENE_OR_GENE_PRODUCT", 111, 114], ["patients", "ORGANISM", 124, 132], ["ECs", "CELL", 179, 182], ["cells", "CELL", 306, 311], ["purified IgG", "PROTEIN", 102, 114], ["ECs", "CELL_TYPE", 179, 182], ["effector cells", "CELL_TYPE", 297, 311], ["patients", "SPECIES", 124, 132], ["whole sera", "TEST", 88, 98], ["a cytotoxic effect", "PROBLEM", 157, 175], ["the cytotoxic mechanism", "PROBLEM", 240, 263], ["effector cells", "PROBLEM", 297, 311], ["the culture medium", "TEST", 315, 333], ["effector cells", "OBSERVATION", 297, 311]]], ["In vitro coculture experiments using ECs, SSc sera, and peripheral blood mononuclear cells (PBMCs) demonstrated that the cytotoxicity was dependent on IgG with AECA reactivity and the presence of Fc receptors on the effector cells with a mechanism highly reminiscent of ADCC [[93], [94], [96]].", [["ECs", "ANATOMY", 37, 40], ["SSc sera", "ANATOMY", 42, 50], ["peripheral blood mononuclear cells", "ANATOMY", 56, 90], ["PBMCs", "ANATOMY", 92, 97], ["effector cells", "ANATOMY", 216, 230], ["ECs", "CELL", 37, 40], ["SSc sera", "CELL", 42, 50], ["peripheral blood mononuclear cells", "CELL", 56, 90], ["PBMCs", "CELL", 92, 97], ["IgG", "GENE_OR_GENE_PRODUCT", 151, 154], ["AECA", "SIMPLE_CHEMICAL", 160, 164], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 196, 208], ["cells", "CELL", 225, 230], ["ECs", "CELL_TYPE", 37, 40], ["peripheral blood mononuclear cells", "CELL_TYPE", 56, 90], ["PBMCs", "CELL_TYPE", 92, 97], ["IgG", "PROTEIN", 151, 154], ["AECA", "PROTEIN", 160, 164], ["Fc receptors", "PROTEIN", 196, 208], ["effector cells", "CELL_TYPE", 216, 230], ["ECs", "TEST", 37, 40], ["SSc sera", "TEST", 42, 50], ["peripheral blood mononuclear cells", "TEST", 56, 90], ["PBMCs", "TEST", 92, 97], ["the cytotoxicity", "PROBLEM", 117, 133], ["IgG", "TEST", 151, 154], ["AECA reactivity", "TEST", 160, 175], ["Fc receptors", "PROBLEM", 196, 208], ["ADCC", "TEST", 270, 274], ["peripheral", "ANATOMY_MODIFIER", 56, 66], ["blood", "ANATOMY", 67, 72], ["mononuclear cells", "OBSERVATION", 73, 90]]], ["The pathogenic relevance of these observations in determining endothelial dysfunction in vivo in patients with SSc is still not known; as discussed previously, only a minority of SSc sera display cytotoxic activity in vitro.Cytotoxicity and Apoptotic Effects of AECA ::: Pathogenic Mechanisms of AECASimilarly, Del Papa et al. [98] showed that IgG AECA from patients with WG, can be cytotoxic for ECs in the presence of human normal PBMC but not in the presence of polymorphonuclear leukocytes or adherent mononuclear cells.", [["endothelial", "ANATOMY", 62, 73], ["sera", "ANATOMY", 183, 187], ["ECs", "ANATOMY", 397, 400], ["PBMC", "ANATOMY", 433, 437], ["polymorphonuclear leukocytes", "ANATOMY", 465, 493], ["mononuclear cells", "ANATOMY", 506, 523], ["endothelial dysfunction", "DISEASE", 62, 85], ["SSc", "DISEASE", 111, 114], ["SSc", "DISEASE", 179, 182], ["endothelial", "CELL", 62, 73], ["patients", "ORGANISM", 97, 105], ["sera", "ORGANISM_SUBSTANCE", 183, 187], ["AECA", "SIMPLE_CHEMICAL", 262, 266], ["IgG", "ORGANISM", 344, 347], ["AECA", "GENE_OR_GENE_PRODUCT", 348, 352], ["patients", "ORGANISM", 358, 366], ["ECs", "CELL", 397, 400], ["human", "ORGANISM", 420, 425], ["PBMC", "CELL", 433, 437], ["polymorphonuclear leukocytes", "CELL", 465, 493], ["adherent mononuclear cells", "CELL", 497, 523], ["IgG AECA", "PROTEIN", 344, 352], ["ECs", "CELL_TYPE", 397, 400], ["human normal PBMC", "CELL_TYPE", 420, 437], ["polymorphonuclear leukocytes", "CELL_TYPE", 465, 493], ["adherent mononuclear cells", "CELL_TYPE", 497, 523], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 358, 366], ["human", "SPECIES", 420, 425], ["human", "SPECIES", 420, 425], ["these observations", "TEST", 28, 46], ["endothelial dysfunction", "PROBLEM", 62, 85], ["SSc sera", "TEST", 179, 187], ["Cytotoxicity", "PROBLEM", 224, 236], ["Pathogenic Mechanisms of AECASimilarly", "PROBLEM", 271, 309], ["Del Papa et al.", "TEST", 311, 326], ["IgG AECA", "TEST", 344, 352], ["polymorphonuclear leukocytes", "PROBLEM", 465, 493], ["adherent mononuclear cells", "PROBLEM", 497, 523], ["endothelial dysfunction", "OBSERVATION", 62, 85], ["cytotoxic activity", "OBSERVATION", 196, 214], ["Apoptotic Effects", "OBSERVATION", 241, 258], ["normal PBMC", "OBSERVATION", 426, 437], ["polymorphonuclear leukocytes", "OBSERVATION", 465, 493], ["adherent mononuclear cells", "OBSERVATION", 497, 523]]], ["Nevertheless, it is well known that AECA represent an extremely heterogeneous family of autoantibodies, not only because of the variety of their target antigens, but also for the heterogeneity of their effects [99].Cytotoxicity and Apoptotic Effects of AECA ::: Pathogenic Mechanisms of AECATogether with cytotoxicity, apoptosis of ECs mediated by binding of AECA has emerged as a novel mechanism by which AECA may exert a pathogenic role in autoimmune conditions (Fig. 2B).", [["ECs", "ANATOMY", 332, 335], ["AECA", "CHEMICAL", 406, 410], ["AECA", "GENE_OR_GENE_PRODUCT", 36, 40], ["AECA", "SIMPLE_CHEMICAL", 253, 257], ["ECs", "CELL", 332, 335], ["AECA", "GENE_OR_GENE_PRODUCT", 359, 363], ["AECA", "GENE_OR_GENE_PRODUCT", 406, 410], ["AECA", "PROTEIN", 36, 40], ["autoantibodies", "PROTEIN", 88, 102], ["target antigens", "PROTEIN", 145, 160], ["ECs", "CELL_TYPE", 332, 335], ["AECA", "PROTEIN", 359, 363], ["AECA", "PROTEIN", 406, 410], ["AECA", "PROBLEM", 36, 40], ["autoantibodies", "PROBLEM", 88, 102], ["Cytotoxicity", "PROBLEM", 215, 227], ["cytotoxicity", "PROBLEM", 305, 317], ["apoptosis of ECs", "PROBLEM", 319, 335], ["AECA", "PROBLEM", 359, 363], ["a pathogenic role in autoimmune conditions", "PROBLEM", 421, 463], ["extremely", "OBSERVATION_MODIFIER", 54, 63], ["heterogeneous", "OBSERVATION", 64, 77], ["Apoptotic Effects", "OBSERVATION", 232, 249], ["AECA", "OBSERVATION", 359, 363]]], ["In particular, studies have focused on the apoptotic effect of AECA from SSc patients, since Sgonc et al. [100] provided evidence that ECs in the deeper dermis of patients with SSc undergo apoptosis at very early stages in the course of the disease process, and only in areas characterized by early or prefibrotic skin lesions.", [["ECs", "ANATOMY", 135, 138], ["dermis", "ANATOMY", 153, 159], ["SSc", "ANATOMY", 177, 180], ["skin lesions", "ANATOMY", 314, 326], ["AECA", "CHEMICAL", 63, 67], ["SSc", "DISEASE", 73, 76], ["SSc", "DISEASE", 177, 180], ["AECA", "SIMPLE_CHEMICAL", 63, 67], ["patients", "ORGANISM", 77, 85], ["ECs", "CELL", 135, 138], ["dermis", "TISSUE", 153, 159], ["patients", "ORGANISM", 163, 171], ["skin lesions", "PATHOLOGICAL_FORMATION", 314, 326], ["ECs", "CELL_TYPE", 135, 138], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 163, 171], ["AECA", "TEST", 63, 67], ["SSc undergo apoptosis", "PROBLEM", 177, 198], ["the disease process", "PROBLEM", 237, 256], ["early or prefibrotic skin lesions", "PROBLEM", 293, 326], ["deeper", "ANATOMY_MODIFIER", 146, 152], ["dermis", "ANATOMY", 153, 159], ["SSc", "ANATOMY", 177, 180], ["apoptosis", "OBSERVATION", 189, 198], ["disease", "OBSERVATION", 241, 248], ["early", "OBSERVATION_MODIFIER", 293, 298], ["skin", "ANATOMY", 314, 318], ["lesions", "OBSERVATION", 319, 326]]], ["These results were also confirmed in an avian model of SSc, University of California at Davis (UCD) lines 200/206 chicken, which spontaneously developed a scleroderma\u2010like disease characterized by perivascular lymphocytic infiltration of the dermis with fibrosis of skin and internal organs and the presence of serum autoantibodies such as antinuclear antibodies, aCL antibodies, and AECA [[100], [101], [102], [103]].", [["perivascular lymphocytic", "ANATOMY", 197, 221], ["dermis", "ANATOMY", 242, 248], ["skin", "ANATOMY", 266, 270], ["internal organs", "ANATOMY", 275, 290], ["serum", "ANATOMY", 311, 316], ["SSc", "DISEASE", 55, 58], ["scleroderma\u2010like disease", "DISEASE", 155, 179], ["fibrosis", "DISEASE", 254, 262], ["chicken", "ORGANISM", 114, 121], ["perivascular lymphocytic", "PATHOLOGICAL_FORMATION", 197, 221], ["dermis", "TISSUE", 242, 248], ["skin", "ORGAN", 266, 270], ["organs", "ORGAN", 284, 290], ["serum", "ORGANISM_SUBSTANCE", 311, 316], ["aCL antibodies", "GENE_OR_GENE_PRODUCT", 364, 378], ["AECA", "SIMPLE_CHEMICAL", 384, 388], ["[102]", "SIMPLE_CHEMICAL", 404, 409], ["serum autoantibodies", "PROTEIN", 311, 331], ["antinuclear antibodies", "PROTEIN", 340, 362], ["aCL antibodies", "PROTEIN", 364, 378], ["AECA", "PROTEIN", 384, 388], ["chicken", "SPECIES", 114, 121], ["chicken", "SPECIES", 114, 121], ["a scleroderma\u2010like disease", "PROBLEM", 153, 179], ["perivascular lymphocytic infiltration of the dermis", "PROBLEM", 197, 248], ["fibrosis of skin and internal organs", "PROBLEM", 254, 290], ["serum autoantibodies", "PROBLEM", 311, 331], ["antinuclear antibodies", "TEST", 340, 362], ["aCL antibodies", "TEST", 364, 378], ["AECA", "TEST", 384, 388], ["SSc", "ANATOMY", 55, 58], ["scleroderma\u2010like disease", "OBSERVATION", 155, 179], ["perivascular", "ANATOMY_MODIFIER", 197, 209], ["lymphocytic infiltration", "OBSERVATION", 210, 234], ["dermis", "ANATOMY", 242, 248], ["fibrosis", "OBSERVATION", 254, 262], ["skin", "ANATOMY", 266, 270], ["internal organs", "ANATOMY", 275, 290]]], ["In addition, in most cases, endothelial cell apoptosis was associated with positive staining of microvessels for Ig, supporting the hypothesis that AECA could mediate vascular damage.", [["endothelial cell", "ANATOMY", 28, 44], ["microvessels", "ANATOMY", 96, 108], ["vascular", "ANATOMY", 167, 175], ["vascular damage", "DISEASE", 167, 182], ["endothelial cell", "CELL", 28, 44], ["microvessels", "TISSUE", 96, 108], ["Ig", "GENE_OR_GENE_PRODUCT", 113, 115], ["AECA", "GENE_OR_GENE_PRODUCT", 148, 152], ["vascular", "MULTI-TISSUE_STRUCTURE", 167, 175], ["Ig", "PROTEIN", 113, 115], ["AECA", "PROTEIN", 148, 152], ["endothelial cell apoptosis", "PROBLEM", 28, 54], ["positive staining of microvessels", "PROBLEM", 75, 108], ["Ig", "TREATMENT", 113, 115], ["AECA", "PROBLEM", 148, 152], ["vascular damage", "PROBLEM", 167, 182], ["endothelial cell apoptosis", "OBSERVATION", 28, 54], ["AECA", "OBSERVATION", 148, 152], ["vascular", "ANATOMY", 167, 175], ["damage", "OBSERVATION", 176, 182]]], ["Sgonc et al. [104] later demonstrated that AECA from a subset of patients with SSc were able to induce apoptosis of HDMECs, but not HUVECs, through ADCC via CD95/Fas, as demonstrated by in vitro inhibition of NK\u2010mediated EC apoptosis with the use of blocking anti\u2010FasL antibodies.Proinflammatory Effects of AECA ::: Pathogenic Mechanisms of AECAThere is convincing evidence to support the notion that AECA are able to induce overexpression of endothelial adhesion molecules, such as E\u2010selectin, ICAM\u20101, VCAM\u20101, as well as secretion of proinflammatory cytokines by ECs leading to an upregulation of leukocyte adhesion to ECs (Fig. 2C).", [["HDMECs", "ANATOMY", 116, 122], ["HUVECs", "ANATOMY", 132, 138], ["NK", "ANATOMY", 209, 211], ["EC", "ANATOMY", 221, 223], ["ECs", "ANATOMY", 564, 567], ["leukocyte", "ANATOMY", 598, 607], ["ECs", "ANATOMY", 620, 623], ["SSc", "DISEASE", 79, 82], ["AECA", "GENE_OR_GENE_PRODUCT", 43, 47], ["patients", "ORGANISM", 65, 73], ["HDMECs", "CELL", 116, 122], ["HUVECs", "CELL", 132, 138], ["ADCC", "GENE_OR_GENE_PRODUCT", 148, 152], ["CD95", "GENE_OR_GENE_PRODUCT", 157, 161], ["Fas", "GENE_OR_GENE_PRODUCT", 162, 165], ["NK", "CELL", 209, 211], ["EC", "CELL", 221, 223], ["FasL", "GENE_OR_GENE_PRODUCT", 264, 268], ["AECA", "SIMPLE_CHEMICAL", 401, 405], ["endothelial adhesion molecules", "GENE_OR_GENE_PRODUCT", 443, 473], ["E\u2010selectin", "GENE_OR_GENE_PRODUCT", 483, 493], ["ICAM\u20101", "GENE_OR_GENE_PRODUCT", 495, 501], ["VCAM\u20101", "GENE_OR_GENE_PRODUCT", 503, 509], ["ECs", "CELL", 564, 567], ["leukocyte", "CELL", 598, 607], ["ECs", "CELL", 620, 623], ["AECA", "PROTEIN", 43, 47], ["HDMECs", "CELL_TYPE", 116, 122], ["HUVECs", "CELL_LINE", 132, 138], ["CD95", "PROTEIN", 157, 161], ["Fas", "PROTEIN", 162, 165], ["EC", "CELL_TYPE", 221, 223], ["anti\u2010FasL antibodies", "PROTEIN", 259, 279], ["AECA", "PROTEIN", 401, 405], ["endothelial adhesion molecules", "PROTEIN", 443, 473], ["E\u2010selectin", "PROTEIN", 483, 493], ["ICAM\u20101", "PROTEIN", 495, 501], ["VCAM\u20101", "PROTEIN", 503, 509], ["proinflammatory cytokines", "PROTEIN", 535, 560], ["ECs", "CELL_TYPE", 564, 567], ["ECs", "CELL_TYPE", 620, 623], ["patients", "SPECIES", 65, 73], ["AECA", "PROBLEM", 43, 47], ["SSc", "TREATMENT", 79, 82], ["apoptosis of HDMECs", "PROBLEM", 103, 122], ["NK\u2010mediated EC apoptosis", "PROBLEM", 209, 233], ["blocking anti\u2010FasL antibodies", "TREATMENT", 250, 279], ["AECA", "PROBLEM", 401, 405], ["endothelial adhesion molecules", "PROBLEM", 443, 473], ["E\u2010selectin", "TEST", 483, 493], ["proinflammatory cytokines", "PROBLEM", 535, 560], ["leukocyte adhesion", "PROBLEM", 598, 616], ["AECA", "OBSERVATION", 43, 47], ["AECA", "ANATOMY", 307, 311], ["endothelial", "ANATOMY", 443, 454], ["leukocyte adhesion", "OBSERVATION", 598, 616]]], ["This suggests an important role for AECA in contributing to vascular damage in autoimmune conditions such as SLE as well as in other form of vasculitis [[105], [106], [107], [108]].", [["vascular", "ANATOMY", 60, 68], ["vascular damage", "DISEASE", 60, 75], ["SLE", "DISEASE", 109, 112], ["vasculitis", "DISEASE", 141, 151], ["AECA", "GENE_OR_GENE_PRODUCT", 36, 40], ["vascular", "MULTI-TISSUE_STRUCTURE", 60, 68], ["AECA", "PROTEIN", 36, 40], ["AECA", "PROBLEM", 36, 40], ["vascular damage", "PROBLEM", 60, 75], ["autoimmune conditions", "PROBLEM", 79, 100], ["SLE", "PROBLEM", 109, 112], ["vasculitis", "PROBLEM", 141, 151], ["vascular", "ANATOMY", 60, 68], ["damage", "OBSERVATION", 69, 75], ["vasculitis", "OBSERVATION", 141, 151]]], ["In particular, AECA from patients with WG induced the secretion of IL\u20101\u03b2, IL\u20106, IL\u20108, and MCP\u20101 by ECs [109].", [["ECs", "ANATOMY", 99, 102], ["WG", "DISEASE", 39, 41], ["AECA", "CANCER", 15, 19], ["patients", "ORGANISM", 25, 33], ["IL\u20101\u03b2", "GENE_OR_GENE_PRODUCT", 67, 72], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 74, 78], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 80, 84], ["MCP\u20101", "GENE_OR_GENE_PRODUCT", 90, 95], ["ECs", "CELL", 99, 102], ["AECA", "PROTEIN", 15, 19], ["IL", "PROTEIN", 67, 69], ["IL\u20106", "PROTEIN", 74, 78], ["IL\u20108", "DNA", 80, 84], ["MCP\u20101", "DNA", 90, 95], ["ECs", "CELL_TYPE", 99, 102], ["patients", "SPECIES", 25, 33], ["AECA", "TEST", 15, 19], ["IL", "TEST", 67, 69], ["IL", "TEST", 74, 76], ["MCP", "TEST", 90, 93], ["ECs", "TEST", 99, 102], ["AECA", "OBSERVATION", 15, 19]]], ["Several of these effects may be related to an autocrine or paracrine action of IL\u20101 generated by ECs in response to AECA [110].", [["ECs", "ANATOMY", 97, 100], ["IL\u20101", "GENE_OR_GENE_PRODUCT", 79, 83], ["ECs", "CELL", 97, 100], ["IL\u20101", "PROTEIN", 79, 83], ["ECs", "CELL_TYPE", 97, 100], ["an autocrine", "TREATMENT", 43, 55], ["paracrine action of IL\u2010", "TREATMENT", 59, 82], ["AECA", "TEST", 116, 120], ["may be related to", "UNCERTAINTY", 25, 42]]], ["Moreover, IgM AECA may stimulate endothelin\u20101 release from HUVECs, thus increasing vascular damage [111] as suggested in preeclampsia [112].", [["HUVECs", "ANATOMY", 59, 65], ["vascular", "ANATOMY", 83, 91], ["vascular damage", "DISEASE", 83, 98], ["preeclampsia", "DISEASE", 121, 133], ["IgM AECA", "GENE_OR_GENE_PRODUCT", 10, 18], ["endothelin\u20101", "GENE_OR_GENE_PRODUCT", 33, 45], ["HUVECs", "CELL", 59, 65], ["vascular", "MULTI-TISSUE_STRUCTURE", 83, 91], ["IgM AECA", "PROTEIN", 10, 18], ["endothelin\u20101", "PROTEIN", 33, 45], ["HUVECs", "CELL_TYPE", 59, 65], ["IgM AECA", "TEST", 10, 18], ["HUVECs", "PROBLEM", 59, 65], ["increasing vascular damage", "PROBLEM", 72, 98], ["preeclampsia", "PROBLEM", 121, 133], ["vascular", "ANATOMY", 83, 91]]], ["Expression of potential antigens on ECs has been suggested because the treatment of these cells with tumor necrosis factor alpha increased IgG binding from sera of some patients with active SLE [113].", [["ECs", "ANATOMY", 36, 39], ["cells", "ANATOMY", 90, 95], ["sera", "ANATOMY", 156, 160], ["tumor", "DISEASE", 101, 106], ["necrosis", "DISEASE", 107, 115], ["SLE", "DISEASE", 190, 193], ["ECs", "CELL", 36, 39], ["cells", "CELL", 90, 95], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 101, 128], ["IgG", "GENE_OR_GENE_PRODUCT", 139, 142], ["sera", "ORGANISM_SUBSTANCE", 156, 160], ["patients", "ORGANISM", 169, 177], ["ECs", "CELL_TYPE", 36, 39], ["tumor necrosis factor alpha", "PROTEIN", 101, 128], ["IgG", "PROTEIN", 139, 142], ["patients", "SPECIES", 169, 177], ["these cells", "PROBLEM", 84, 95], ["tumor necrosis factor", "PROBLEM", 101, 122], ["alpha increased IgG binding", "PROBLEM", 123, 150], ["active SLE", "PROBLEM", 183, 193], ["tumor", "OBSERVATION", 101, 106]]], ["The heterogeneity of the AECA effects was observed by Bordron et al. [99] who clearly showed that AECA from different patients induced activation of ECs, while AECA from others induced apoptosis.", [["ECs", "ANATOMY", 149, 152], ["AECA", "CANCER", 25, 29], ["AECA", "SIMPLE_CHEMICAL", 98, 102], ["patients", "ORGANISM", 118, 126], ["ECs", "CELL", 149, 152], ["AECA", "GENE_OR_GENE_PRODUCT", 160, 164], ["AECA", "PROTEIN", 98, 102], ["ECs", "CELL_TYPE", 149, 152], ["AECA", "PROTEIN", 160, 164], ["patients", "SPECIES", 118, 126], ["the AECA effects", "PROBLEM", 21, 37], ["AECA", "PROBLEM", 98, 102], ["AECA", "TEST", 160, 164], ["apoptosis", "PROBLEM", 185, 194], ["heterogeneity", "OBSERVATION_MODIFIER", 4, 17], ["AECA effects", "OBSERVATION", 25, 37], ["AECA", "OBSERVATION", 98, 102], ["apoptosis", "OBSERVATION", 185, 194]]], ["The activation of ECs was further validated by Yazici et al. [114], who described proinflammatory effects on live ECs due to a monoclonal IgG AECA generated by hybridoma formation with human SLE B cells.", [["ECs", "ANATOMY", 18, 21], ["ECs", "ANATOMY", 114, 117], ["hybridoma", "ANATOMY", 160, 169], ["SLE B cells", "ANATOMY", 191, 202], ["ECs", "CELL", 18, 21], ["ECs", "CELL", 114, 117], ["AECA", "GENE_OR_GENE_PRODUCT", 142, 146], ["hybridoma", "CELL", 160, 169], ["human", "ORGANISM", 185, 190], ["SLE B cells", "CELL", 191, 202], ["ECs", "CELL_TYPE", 18, 21], ["live ECs", "CELL_TYPE", 109, 117], ["monoclonal IgG AECA", "PROTEIN", 127, 146], ["human SLE B cells", "CELL_TYPE", 185, 202], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 185, 190], ["proinflammatory effects", "PROBLEM", 82, 105], ["a monoclonal IgG AECA", "PROBLEM", 125, 146], ["hybridoma formation", "PROBLEM", 160, 179], ["human SLE B cells", "TREATMENT", 185, 202]]], ["In particular, this mAb bound to a 42\u2010kDa EC cell membrane protein and induced an overexpression of E\u2010selectin and ICAM\u20101 through NF\u2010\u03baB activation.", [["EC cell membrane", "ANATOMY", 42, 58], ["mAb", "GENE_OR_GENE_PRODUCT", 20, 23], ["E\u2010selectin", "GENE_OR_GENE_PRODUCT", 100, 110], ["ICAM\u20101", "GENE_OR_GENE_PRODUCT", 115, 121], ["NF\u2010\u03baB", "GENE_OR_GENE_PRODUCT", 130, 135], ["mAb", "PROTEIN", 20, 23], ["42\u2010kDa EC cell membrane protein", "PROTEIN", 35, 66], ["E\u2010selectin", "PROTEIN", 100, 110], ["ICAM", "PROTEIN", 115, 119], ["\u20101", "PROTEIN", 119, 121], ["NF\u2010\u03baB", "PROTEIN", 130, 135], ["E\u2010selectin", "TEST", 100, 110], ["ICAM", "TEST", 115, 119]]], ["Similar findings were observed with mAb AECA from a patient with TA, which bound and activated macrovascular ECs but not microvascular ECs [115] and with mAb from a patient with WG [116].", [["macrovascular ECs", "ANATOMY", 95, 112], ["microvascular ECs", "ANATOMY", 121, 138], ["mAb AECA", "SIMPLE_CHEMICAL", 36, 44], ["patient", "ORGANISM", 52, 59], ["TA", "CANCER", 65, 67], ["ECs", "CELL", 109, 112], ["microvascular ECs", "CELL", 121, 138], ["patient", "ORGANISM", 165, 172], ["mAb AECA", "PROTEIN", 36, 44], ["macrovascular ECs", "CELL_TYPE", 95, 112], ["microvascular ECs", "CELL_TYPE", 121, 138], ["mAb", "PROTEIN", 154, 157], ["patient", "SPECIES", 52, 59], ["patient", "SPECIES", 165, 172], ["mAb AECA", "TEST", 36, 44], ["activated macrovascular ECs", "PROBLEM", 85, 112], ["microvascular ECs", "TEST", 121, 138], ["mAb", "TEST", 154, 157], ["WG", "TEST", 178, 180], ["macrovascular ECs", "OBSERVATION", 95, 112]]], ["The proinflammatory phenotype of ECs due to binding of AECA may also be dependent on the origin of ECs.", [["ECs", "ANATOMY", 33, 36], ["ECs", "ANATOMY", 99, 102], ["ECs", "CELL", 33, 36], ["AECA", "GENE_OR_GENE_PRODUCT", 55, 59], ["ECs", "CELL", 99, 102], ["ECs", "CELL_TYPE", 33, 36], ["AECA", "PROTEIN", 55, 59], ["ECs", "CELL_TYPE", 99, 102], ["The proinflammatory phenotype of ECs", "PROBLEM", 0, 36], ["AECA", "PROBLEM", 55, 59], ["proinflammatory phenotype", "OBSERVATION", 4, 29], ["AECA", "OBSERVATION", 55, 59], ["may also be", "UNCERTAINTY", 60, 71], ["dependent", "OBSERVATION_MODIFIER", 72, 81]]], ["Affinity\u2010purified AECA F(ab)2 from patients with thrombotic thrombocytopenic purpura (TTP) bound to and activated only microvascular ECs but not large vessel ECs [117].", [["microvascular ECs", "ANATOMY", 119, 136], ["vessel ECs", "ANATOMY", 151, 161], ["thrombotic thrombocytopenic purpura", "DISEASE", 49, 84], ["TTP", "DISEASE", 86, 89], ["AECA F(ab)2", "GENE_OR_GENE_PRODUCT", 18, 29], ["patients", "ORGANISM", 35, 43], ["microvascular ECs", "CELL", 119, 136], ["microvascular ECs", "CELL_TYPE", 119, 136], ["large vessel ECs", "CELL_TYPE", 145, 161], ["patients", "SPECIES", 35, 43], ["Affinity\u2010purified AECA F(ab)", "TEST", 0, 28], ["thrombotic thrombocytopenic purpura", "PROBLEM", 49, 84], ["TTP) bound", "PROBLEM", 86, 96], ["microvascular ECs", "TEST", 119, 136], ["large vessel ECs", "PROBLEM", 145, 161], ["thrombotic", "OBSERVATION_MODIFIER", 49, 59], ["thrombocytopenic purpura", "OBSERVATION", 60, 84], ["microvascular ECs", "ANATOMY", 119, 136], ["not", "UNCERTAINTY", 141, 144], ["large", "OBSERVATION", 145, 150], ["vessel", "ANATOMY", 151, 157]]], ["On the contrary, in uremic patients undergoing hemodialysis AECA reactivity with HUVECs but not with microvascular or EaHy 929 EC lines was observed [118].Proinflammatory Effects of AECA ::: Pathogenic Mechanisms of AECACarvalho et al. [110] were the first to report that AECA from SSc patients are able to functionally affect in vitro interactions between ECs and leukocytes by increasing adhesion of the myelomonocytic cell line U937 to cultured HUVECs.", [["HUVECs", "ANATOMY", 81, 87], ["microvascular", "ANATOMY", 101, 114], ["EC lines", "ANATOMY", 127, 135], ["ECs", "ANATOMY", 357, 360], ["leukocytes", "ANATOMY", 365, 375], ["myelomonocytic cell line U937", "ANATOMY", 406, 435], ["HUVECs", "ANATOMY", 448, 454], ["uremic", "DISEASE", 20, 26], ["SSc", "DISEASE", 282, 285], ["patients", "ORGANISM", 27, 35], ["HUVECs", "CELL", 81, 87], ["microvascular", "CELL", 101, 114], ["EaHy 929 EC lines", "CELL", 118, 135], ["AECA", "GENE_OR_GENE_PRODUCT", 272, 276], ["patients", "ORGANISM", 286, 294], ["ECs", "CELL", 357, 360], ["leukocytes", "CELL", 365, 375], ["myelomonocytic cell line U937", "CELL", 406, 435], ["HUVECs", "CELL", 448, 454], ["HUVECs", "CELL_LINE", 81, 87], ["microvascular or EaHy 929 EC lines", "CELL_LINE", 101, 135], ["ECs", "CELL_TYPE", 357, 360], ["leukocytes", "CELL_TYPE", 365, 375], ["myelomonocytic cell line U937", "CELL_LINE", 406, 435], ["cultured HUVECs", "CELL_LINE", 439, 454], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 286, 294], ["hemodialysis AECA reactivity", "TREATMENT", 47, 75], ["HUVECs", "TREATMENT", 81, 87], ["EaHy 929 EC lines", "TREATMENT", 118, 135], ["AECA", "TEST", 182, 186], ["AECA", "TEST", 272, 276], ["leukocytes", "TEST", 365, 375], ["the myelomonocytic cell line", "TREATMENT", 402, 430], ["HUVECs", "TEST", 448, 454], ["uremic", "OBSERVATION_MODIFIER", 20, 26], ["myelomonocytic cell line", "OBSERVATION", 406, 430]]], ["This effect was reproducibly mediated by both sera as well as purified IgG from AECA positive SSc patients binding to ECs and related to de novo increased expression of selectins and adhesion molecules (i.e., E\u2010selectin, ICAM\u20101, and VCAM\u20101) by HUVECs.", [["sera", "ANATOMY", 46, 50], ["ECs", "ANATOMY", 118, 121], ["HUVECs", "ANATOMY", 244, 250], ["SSc", "DISEASE", 94, 97], ["sera", "ORGANISM_SUBSTANCE", 46, 50], ["IgG", "GENE_OR_GENE_PRODUCT", 71, 74], ["AECA", "GENE_OR_GENE_PRODUCT", 80, 84], ["patients", "ORGANISM", 98, 106], ["ECs", "CELL", 118, 121], ["selectins", "GENE_OR_GENE_PRODUCT", 169, 178], ["E\u2010selectin", "GENE_OR_GENE_PRODUCT", 209, 219], ["ICAM\u20101", "GENE_OR_GENE_PRODUCT", 221, 227], ["VCAM\u20101", "GENE_OR_GENE_PRODUCT", 233, 239], ["HUVECs", "CELL", 244, 250], ["purified IgG", "PROTEIN", 62, 74], ["ECs", "CELL_TYPE", 118, 121], ["selectins", "PROTEIN", 169, 178], ["adhesion molecules", "PROTEIN", 183, 201], ["E\u2010selectin", "PROTEIN", 209, 219], ["ICAM\u20101", "PROTEIN", 221, 227], ["VCAM\u20101", "PROTEIN", 233, 239], ["HUVECs", "CELL_TYPE", 244, 250], ["patients", "SPECIES", 98, 106], ["purified IgG", "TEST", 62, 74], ["AECA positive SSc patients binding", "PROBLEM", 80, 114], ["selectins and adhesion molecules", "TREATMENT", 169, 201], ["E\u2010selectin, ICAM\u2010", "TREATMENT", 209, 226], ["HUVECs", "ANATOMY", 244, 250]]], ["In this in vitro system, leukocyte\u2013endothelial cell interactions were not dependent on Fc engagement on U937 cells since Fab fragments also induced leukocyte adhesion with a similar efficacy compared to whole IgG.", [["leukocyte\u2013endothelial cell", "ANATOMY", 25, 51], ["U937 cells", "ANATOMY", 104, 114], ["fragments", "ANATOMY", 125, 134], ["leukocyte", "ANATOMY", 148, 157], ["leukocyte\u2013endothelial cell", "CELL", 25, 51], ["Fc", "GENE_OR_GENE_PRODUCT", 87, 89], ["U937 cells", "CELL", 104, 114], ["Fab", "GENE_OR_GENE_PRODUCT", 121, 124], ["leukocyte", "CELL", 148, 157], ["IgG", "GENE_OR_GENE_PRODUCT", 209, 212], ["Fc", "PROTEIN", 87, 89], ["U937 cells", "CELL_LINE", 104, 114], ["Fab fragments", "PROTEIN", 121, 134], ["IgG", "PROTEIN", 209, 212], ["leukocyte\u2013endothelial cell interactions", "PROBLEM", 25, 64], ["U937 cells", "TREATMENT", 104, 114], ["Fab fragments", "PROBLEM", 121, 134], ["leukocyte adhesion", "PROBLEM", 148, 166], ["whole IgG", "TEST", 203, 212], ["leukocyte\u2013endothelial cell", "OBSERVATION", 25, 51], ["leukocyte adhesion", "OBSERVATION", 148, 166]]], ["However, as suggested by the kinetics of leukocyte adhesion and adhesion molecule expression, the effect of AECA was dependent on the direct stimulation of soluble mediator(s) from HUVECs since the ability of inducing leukocyte adhesion to ECs was maintained using IgG\u2010depleted AECA\u2010conditioned HUVEC medium.", [["leukocyte", "ANATOMY", 41, 50], ["HUVECs", "ANATOMY", 181, 187], ["leukocyte", "ANATOMY", 218, 227], ["ECs", "ANATOMY", 240, 243], ["HUVEC", "ANATOMY", 295, 300], ["AECA", "CHEMICAL", 108, 112], ["AECA", "CHEMICAL", 108, 112], ["leukocyte", "CELL", 41, 50], ["AECA", "SIMPLE_CHEMICAL", 108, 112], ["HUVECs", "CELL", 181, 187], ["leukocyte", "CELL", 218, 227], ["ECs", "CELL", 240, 243], ["HUVEC", "CELL", 295, 300], ["adhesion molecule", "PROTEIN", 64, 81], ["soluble mediator", "PROTEIN", 156, 172], ["HUVECs", "CELL_TYPE", 181, 187], ["ECs", "CELL_TYPE", 240, 243], ["IgG\u2010depleted AECA\u2010conditioned HUVEC medium", "CELL_LINE", 265, 307], ["leukocyte adhesion", "PROBLEM", 41, 59], ["adhesion molecule expression", "TREATMENT", 64, 92], ["AECA", "PROBLEM", 108, 112], ["the direct stimulation of soluble mediator", "TREATMENT", 130, 172], ["HUVECs", "TREATMENT", 181, 187], ["inducing leukocyte adhesion", "PROBLEM", 209, 236], ["IgG\u2010depleted AECA\u2010conditioned HUVEC medium", "TREATMENT", 265, 307], ["leukocyte adhesion", "OBSERVATION", 41, 59], ["adhesion molecule expression", "OBSERVATION", 64, 92], ["leukocyte adhesion", "OBSERVATION", 218, 236]]], ["Inhibition experiments using a cocktail of blocking antibodies suggested that the effect AECA was, at least in part, mediated by stimulation of cytokine production, and in particular IL\u20101, from HUVECs in vitro.", [["HUVECs", "ANATOMY", 194, 200], ["AECA", "SIMPLE_CHEMICAL", 89, 93], ["IL\u20101", "GENE_OR_GENE_PRODUCT", 183, 187], ["HUVECs", "CELL", 194, 200], ["blocking antibodies", "PROTEIN", 43, 62], ["cytokine", "PROTEIN", 144, 152], ["IL\u20101", "PROTEIN", 183, 187], ["HUVECs", "CELL_LINE", 194, 200], ["Inhibition experiments", "TREATMENT", 0, 22], ["a cocktail of blocking antibodies", "TREATMENT", 29, 62], ["the effect AECA", "PROBLEM", 78, 93], ["cytokine production", "PROBLEM", 144, 163], ["cytokine production", "OBSERVATION", 144, 163], ["HUVECs", "ANATOMY", 194, 200]]], ["Although an exhaustive proof of the ability of AECA from SSc patients to directly induce cytokine production in HUVECs was missing in this study, AECA from other rheumatic conditions (i.e., WG as reported previously) have been shown to be to upregulate cytokine expression from ECs in vitro [109].AECA and Thrombotic Vascular Involvement ::: Pathogenic Mechanisms of AECAThe role of aPL and AECA in the pathogenesis of APS is now well investigated.", [["HUVECs", "ANATOMY", 112, 118], ["ECs", "ANATOMY", 278, 281], ["Vascular", "ANATOMY", 317, 325], ["SSc", "DISEASE", 57, 60], ["AECA", "DISEASE", 297, 301], ["aPL", "DISEASE", 383, 386], ["APS", "DISEASE", 419, 422], ["AECA", "SIMPLE_CHEMICAL", 47, 51], ["patients", "ORGANISM", 61, 69], ["HUVECs", "CELL", 112, 118], ["AECA", "SIMPLE_CHEMICAL", 146, 150], ["ECs", "CELL", 278, 281], ["Vascular", "MULTI-TISSUE_STRUCTURE", 317, 325], ["aPL", "GENE_OR_GENE_PRODUCT", 383, 386], ["AECA", "GENE_OR_GENE_PRODUCT", 391, 395], ["AECA", "PROTEIN", 47, 51], ["cytokine", "PROTEIN", 89, 97], ["HUVECs", "CELL_LINE", 112, 118], ["cytokine", "PROTEIN", 253, 261], ["ECs", "CELL_TYPE", 278, 281], ["aPL", "PROTEIN", 383, 386], ["AECA", "PROTEIN", 391, 395], ["patients", "SPECIES", 61, 69], ["cytokine production in HUVECs", "PROBLEM", 89, 118], ["this study", "TEST", 134, 144], ["AECA", "PROBLEM", 146, 150], ["other rheumatic conditions", "PROBLEM", 156, 182], ["AECA", "TEST", 297, 301], ["AECA", "TREATMENT", 391, 395], ["Thrombotic", "OBSERVATION", 306, 316], ["Vascular", "ANATOMY", 317, 325], ["aPL", "ANATOMY", 383, 386], ["AECA", "OBSERVATION", 391, 395]]], ["Since the first description of AECA, it was evident that antibodies directed against negatively charged phospholipids can explain part of the AECA reactivity [119].", [["AECA", "CANCER", 31, 35], ["antibodies directed against negatively charged phospholipids", "SIMPLE_CHEMICAL", 57, 117], ["AECA", "SIMPLE_CHEMICAL", 142, 146], ["AECA", "PROTEIN", 31, 35], ["antibodies", "PROTEIN", 57, 67], ["AECA", "PROTEIN", 142, 146], ["AECA", "PROBLEM", 31, 35], ["antibodies", "TREATMENT", 57, 67], ["negatively charged phospholipids", "PROBLEM", 85, 117], ["the AECA reactivity", "TEST", 138, 157], ["AECA", "OBSERVATION", 31, 35]]], ["In fact, absorption with cardiolipin liposomes partially inhibited AECA reactivity [[119], [120]].", [["cardiolipin", "CHEMICAL", 25, 36], ["cardiolipin", "CHEMICAL", 25, 36], ["cardiolipin liposomes", "SIMPLE_CHEMICAL", 25, 46], ["AECA", "SIMPLE_CHEMICAL", 67, 71], ["AECA", "PROTEIN", 67, 71], ["cardiolipin liposomes", "TREATMENT", 25, 46], ["AECA reactivity", "TEST", 67, 82]]], ["Thus, it is likely that AECA directed against aPL may be involved in thrombotic diathesis via more than one mechanism.", [["AECA", "CHEMICAL", 24, 28], ["aPL", "DISEASE", 46, 49], ["thrombotic diathesis", "DISEASE", 69, 89], ["AECA", "SIMPLE_CHEMICAL", 24, 28], ["aPL", "GENE_OR_GENE_PRODUCT", 46, 49], ["AECA", "PROTEIN", 24, 28], ["aPL", "PROTEIN", 46, 49], ["AECA", "PROBLEM", 24, 28], ["aPL", "PROBLEM", 46, 49], ["thrombotic diathesis", "PROBLEM", 69, 89], ["AECA", "OBSERVATION", 24, 28], ["thrombotic", "OBSERVATION_MODIFIER", 69, 79], ["diathesis", "OBSERVATION", 80, 89]]], ["First, these antibodies may activate ECs through apoptotic or nonapoptotic mechanisms [121] (Fig. 2B and C); second, these autoantibodies may induce significant increases in tissue factor (TF) transcription and expression by ECs [122], as well as by monocytes [[123], [124]].AECA and Thrombotic Vascular Involvement ::: Pathogenic Mechanisms of AECAIncubation of EC with IgG, from patients positive for aPL, increased the expression of VCAM\u20101, E\u2010selectin, and MCP\u20101 as previously reported for AECA [125].", [["ECs", "ANATOMY", 37, 40], ["ECs", "ANATOMY", 225, 228], ["monocytes", "ANATOMY", 250, 259], ["Vascular", "ANATOMY", 295, 303], ["EC", "ANATOMY", 363, 365], ["AECA", "DISEASE", 275, 279], ["aPL", "DISEASE", 403, 406], ["ECs", "CELL", 37, 40], ["C", "GENE_OR_GENE_PRODUCT", 105, 106], ["tissue factor", "GENE_OR_GENE_PRODUCT", 174, 187], ["TF", "GENE_OR_GENE_PRODUCT", 189, 191], ["ECs", "CELL", 225, 228], ["monocytes", "CELL", 250, 259], ["Vascular", "MULTI-TISSUE_STRUCTURE", 295, 303], ["EC", "CELL", 363, 365], ["IgG", "GENE_OR_GENE_PRODUCT", 371, 374], ["patients", "ORGANISM", 381, 389], ["aPL", "GENE_OR_GENE_PRODUCT", 403, 406], ["VCAM\u20101", "GENE_OR_GENE_PRODUCT", 436, 442], ["E\u2010selectin", "GENE_OR_GENE_PRODUCT", 444, 454], ["MCP\u20101", "GENE_OR_GENE_PRODUCT", 460, 465], ["antibodies", "PROTEIN", 13, 23], ["ECs", "CELL_TYPE", 37, 40], ["autoantibodies", "PROTEIN", 123, 137], ["tissue factor", "PROTEIN", 174, 187], ["TF", "PROTEIN", 189, 191], ["ECs", "CELL_TYPE", 225, 228], ["monocytes", "CELL_TYPE", 250, 259], ["EC", "CELL_TYPE", 363, 365], ["IgG", "PROTEIN", 371, 374], ["aPL", "PROTEIN", 403, 406], ["VCAM", "PROTEIN", 436, 440], ["\u20101", "PROTEIN", 440, 442], ["E\u2010selectin", "PROTEIN", 444, 454], ["MCP\u20101", "PROTEIN", 460, 465], ["patients", "SPECIES", 381, 389], ["these antibodies", "TEST", 7, 23], ["nonapoptotic mechanisms", "TEST", 62, 85], ["these autoantibodies", "PROBLEM", 117, 137], ["significant increases in tissue factor", "PROBLEM", 149, 187], ["monocytes", "TEST", 250, 259], ["AECA", "TEST", 275, 279], ["Thrombotic Vascular Involvement", "PROBLEM", 284, 315], ["IgG", "TEST", 371, 374], ["aPL", "PROBLEM", 403, 406], ["VCAM", "TEST", 436, 440], ["AECA", "TEST", 493, 497], ["significant", "OBSERVATION_MODIFIER", 149, 160], ["increases", "OBSERVATION_MODIFIER", 161, 170], ["Thrombotic", "OBSERVATION", 284, 294], ["Vascular", "ANATOMY", 295, 303]]], ["Studies have shown that upregulation of adhesion molecules on ECs by aPL correlates with an increased adhesion of leukocytes to ECs in mouse microcirculation and with enhanced thrombosis in vivo [126].", [["ECs", "ANATOMY", 62, 65], ["leukocytes", "ANATOMY", 114, 124], ["ECs", "ANATOMY", 128, 131], ["aPL", "DISEASE", 69, 72], ["thrombosis", "DISEASE", 176, 186], ["ECs", "CELL", 62, 65], ["aPL", "GENE_OR_GENE_PRODUCT", 69, 72], ["leukocytes", "CELL", 114, 124], ["ECs", "CELL", 128, 131], ["mouse", "ORGANISM", 135, 140], ["adhesion molecules", "PROTEIN", 40, 58], ["ECs", "CELL_TYPE", 62, 65], ["aPL", "PROTEIN", 69, 72], ["leukocytes", "CELL_TYPE", 114, 124], ["ECs", "CELL_TYPE", 128, 131], ["mouse", "SPECIES", 135, 140], ["mouse", "SPECIES", 135, 140], ["Studies", "TEST", 0, 7], ["upregulation of adhesion molecules", "PROBLEM", 24, 58], ["ECs", "TEST", 62, 65], ["an increased adhesion of leukocytes", "PROBLEM", 89, 124], ["enhanced thrombosis in vivo", "PROBLEM", 167, 194], ["upregulation", "OBSERVATION_MODIFIER", 24, 36], ["adhesion molecules", "OBSERVATION", 40, 58], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["adhesion", "OBSERVATION", 102, 110], ["leukocytes", "OBSERVATION", 114, 124], ["mouse microcirculation", "OBSERVATION", 135, 157], ["enhanced", "OBSERVATION_MODIFIER", 167, 175], ["thrombosis", "OBSERVATION", 176, 186]]], ["Pretreatment of ECs with fluvastatin further increased the expression of EC activation as well as TF expression [125], and pretreatment with aspirin decreased VCAM\u20101 at the cell surface of ECs [127].", [["ECs", "ANATOMY", 16, 19], ["EC", "ANATOMY", 73, 75], ["cell surface", "ANATOMY", 173, 185], ["ECs", "ANATOMY", 189, 192], ["fluvastatin", "CHEMICAL", 25, 36], ["aspirin", "CHEMICAL", 141, 148], ["fluvastatin", "CHEMICAL", 25, 36], ["aspirin", "CHEMICAL", 141, 148], ["ECs", "CELL", 16, 19], ["fluvastatin", "SIMPLE_CHEMICAL", 25, 36], ["EC", "CELL", 73, 75], ["TF", "GENE_OR_GENE_PRODUCT", 98, 100], ["aspirin", "SIMPLE_CHEMICAL", 141, 148], ["VCAM\u20101", "GENE_OR_GENE_PRODUCT", 159, 165], ["cell surface", "CELLULAR_COMPONENT", 173, 185], ["ECs", "CELL", 189, 192], ["ECs", "CELL_TYPE", 16, 19], ["EC", "CELL_TYPE", 73, 75], ["TF", "PROTEIN", 98, 100], ["VCAM", "PROTEIN", 159, 163], ["\u20101", "PROTEIN", 163, 165], ["ECs", "CELL_TYPE", 189, 192], ["fluvastatin", "TREATMENT", 25, 36], ["EC activation", "TREATMENT", 73, 86], ["aspirin", "TREATMENT", 141, 148], ["VCAM", "TREATMENT", 159, 163]]], ["On the contrary, a previous study showed that fluvastatin was able to inhibit the expression of TF expression on ECs induced by aPL from patients with APS as well as by affinity\u2010purified polyclonal IgG\u2010aPL and IgM human monoclonal anti\u2010\u03b22\u2010GPI antibodies [[128], [129]].", [["ECs", "ANATOMY", 113, 116], ["fluvastatin", "CHEMICAL", 46, 57], ["APS", "DISEASE", 151, 154], ["fluvastatin", "CHEMICAL", 46, 57], ["fluvastatin", "SIMPLE_CHEMICAL", 46, 57], ["TF", "GENE_OR_GENE_PRODUCT", 96, 98], ["ECs", "CELL", 113, 116], ["aPL", "GENE_OR_GENE_PRODUCT", 128, 131], ["patients", "ORGANISM", 137, 145], ["IgG\u2010aPL", "GENE_OR_GENE_PRODUCT", 198, 205], ["human", "ORGANISM", 214, 219], ["TF", "PROTEIN", 96, 98], ["ECs", "CELL_TYPE", 113, 116], ["aPL", "PROTEIN", 128, 131], ["affinity\u2010purified polyclonal IgG\u2010aPL", "PROTEIN", 169, 205], ["IgM human monoclonal anti\u2010\u03b22\u2010GPI antibodies", "PROTEIN", 210, 253], ["patients", "SPECIES", 137, 145], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["a previous study", "TEST", 17, 33], ["fluvastatin", "TREATMENT", 46, 57], ["TF expression", "PROBLEM", 96, 109], ["APS", "TREATMENT", 151, 154], ["affinity", "TEST", 169, 177], ["polyclonal IgG\u2010aPL", "TEST", 187, 205], ["IgM human monoclonal anti\u2010\u03b22", "TEST", 210, 238], ["GPI antibodies", "TEST", 239, 253]]], ["Moreover, fluvastatin in a mouse model significantly diminishes aPL\u2010mediated thrombosis and EC activation in vivo [130].AECA and Thrombotic Vascular Involvement ::: Pathogenic Mechanisms of AECAA novel pathway for EC activation induced by aPL/anti\u2010\u03b22\u2010GPI antibodies may be due to the cross\u2010linking or clustering of annexin A2 on the endothelial surface [121].AECA and Thrombotic Vascular Involvement ::: Pathogenic Mechanisms of AECADieude et al. [3] showed that AECA from SLE patients with APS bind to the surface of ECs and share reactivity against a 60\u2010kDa EC surface polypeptide that was identified as human HSP60.", [["EC", "ANATOMY", 92, 94], ["Vascular", "ANATOMY", 140, 148], ["EC", "ANATOMY", 214, 216], ["endothelial surface", "ANATOMY", 333, 352], ["Vascular", "ANATOMY", 379, 387], ["surface", "ANATOMY", 507, 514], ["ECs", "ANATOMY", 518, 521], ["fluvastatin", "CHEMICAL", 10, 21], ["aPL", "DISEASE", 64, 67], ["thrombosis", "DISEASE", 77, 87], ["AECA", "DISEASE", 120, 124], ["AECA", "DISEASE", 359, 363], ["SLE", "DISEASE", 473, 476], ["APS", "DISEASE", 491, 494], ["fluvastatin", "CHEMICAL", 10, 21], ["fluvastatin", "SIMPLE_CHEMICAL", 10, 21], ["mouse", "ORGANISM", 27, 32], ["aPL", "GENE_OR_GENE_PRODUCT", 64, 67], ["EC", "CELL", 92, 94], ["Vascular", "MULTI-TISSUE_STRUCTURE", 140, 148], ["AECAA", "GENE_OR_GENE_PRODUCT", 190, 195], ["EC", "CELL", 214, 216], ["aPL", "GENE_OR_GENE_PRODUCT", 239, 242], ["anti\u2010\u03b22\u2010GPI antibodies", "GENE_OR_GENE_PRODUCT", 243, 265], ["annexin A2", "GENE_OR_GENE_PRODUCT", 315, 325], ["endothelial surface", "CELLULAR_COMPONENT", 333, 352], ["Vascular", "MULTI-TISSUE_STRUCTURE", 379, 387], ["AECA", "GENE_OR_GENE_PRODUCT", 463, 467], ["patients", "ORGANISM", 477, 485], ["APS", "SIMPLE_CHEMICAL", 491, 494], ["surface", "CELLULAR_COMPONENT", 507, 514], ["ECs", "CELL", 518, 521], ["human", "ORGANISM", 606, 611], ["HSP60", "GENE_OR_GENE_PRODUCT", 612, 617], ["aPL", "PROTEIN", 64, 67], ["EC", "CELL_TYPE", 92, 94], ["EC", "CELL_TYPE", 214, 216], ["aPL", "PROTEIN", 239, 242], ["anti\u2010\u03b22", "PROTEIN", 243, 250], ["GPI antibodies", "PROTEIN", 251, 265], ["annexin A2", "PROTEIN", 315, 325], ["AECA", "PROTEIN", 463, 467], ["APS", "PROTEIN", 491, 494], ["ECs", "CELL_TYPE", 518, 521], ["60\u2010kDa EC surface polypeptide", "PROTEIN", 553, 582], ["human HSP60", "PROTEIN", 606, 617], ["mouse", "SPECIES", 27, 32], ["patients", "SPECIES", 477, 485], ["human", "SPECIES", 606, 611], ["mouse", "SPECIES", 27, 32], ["human", "SPECIES", 606, 611], ["fluvastatin", "TREATMENT", 10, 21], ["a mouse model", "TREATMENT", 25, 38], ["mediated thrombosis", "PROBLEM", 68, 87], ["EC activation", "TREATMENT", 92, 105], ["AECA", "TEST", 120, 124], ["Thrombotic Vascular Involvement", "PROBLEM", 129, 160], ["AECAA novel pathway", "PROBLEM", 190, 209], ["EC activation", "PROBLEM", 214, 227], ["aPL/anti\u2010\u03b22\u2010GPI antibodies", "TEST", 239, 265], ["the cross\u2010linking", "PROBLEM", 280, 297], ["annexin A2", "PROBLEM", 315, 325], ["AECA", "TEST", 359, 363], ["Thrombotic Vascular Involvement", "PROBLEM", 368, 399], ["AECA", "PROBLEM", 463, 467], ["APS bind", "TREATMENT", 491, 499], ["a 60\u2010kDa EC surface polypeptide", "TREATMENT", 551, 582], ["human HSP60", "TEST", 606, 617], ["thrombosis", "OBSERVATION", 77, 87], ["Thrombotic", "OBSERVATION", 129, 139], ["Vascular", "ANATOMY", 140, 148], ["aPL", "ANATOMY", 239, 242], ["annexin A2", "OBSERVATION", 315, 325], ["endothelial", "ANATOMY", 333, 344], ["Thrombotic", "OBSERVATION", 368, 378], ["Vascular", "ANATOMY", 379, 387], ["AECA", "OBSERVATION", 463, 467]]], ["Moreover, the incubation of ECs with purified anti\u2010HSP60 antibodies induced apoptosis as demonstrated by the exposure of the phosphatidylserine on the plasma membrane [131].", [["ECs", "ANATOMY", 28, 31], ["plasma membrane", "ANATOMY", 151, 166], ["phosphatidylserine", "CHEMICAL", 125, 143], ["phosphatidylserine", "CHEMICAL", 125, 143], ["ECs", "CELL", 28, 31], ["anti\u2010HSP60 antibodies", "GENE_OR_GENE_PRODUCT", 46, 67], ["phosphatidylserine", "SIMPLE_CHEMICAL", 125, 143], ["plasma membrane", "CELLULAR_COMPONENT", 151, 166], ["ECs", "CELL_TYPE", 28, 31], ["anti\u2010HSP60 antibodies", "PROTEIN", 46, 67], ["purified anti\u2010HSP60 antibodies", "TREATMENT", 37, 67], ["apoptosis", "PROBLEM", 76, 85]]], ["Although AECA with this reactivity were not exclusive to SLE patients an intriguing association was observed between these antibodies and LAC.", [["LAC", "ANATOMY", 138, 141], ["SLE", "DISEASE", 57, 60], ["AECA", "CANCER", 9, 13], ["patients", "ORGANISM", 61, 69], ["LAC", "CANCER", 138, 141], ["antibodies", "PROTEIN", 123, 133], ["patients", "SPECIES", 61, 69], ["AECA", "PROBLEM", 9, 13], ["these antibodies", "TEST", 117, 133], ["LAC", "TREATMENT", 138, 141], ["AECA", "OBSERVATION", 9, 13], ["LAC", "OBSERVATION", 138, 141]]], ["This may represent the first pathogenic hit for induction of AECA and for endothelial perturbations followed by a second hit represented by aPL antibodies binding to ECs.", [["endothelial", "ANATOMY", 74, 85], ["ECs", "ANATOMY", 166, 169], ["AECA", "CANCER", 61, 65], ["endothelial", "CELL", 74, 85], ["aPL antibodies", "GENE_OR_GENE_PRODUCT", 140, 154], ["ECs", "CELL", 166, 169], ["AECA", "PROTEIN", 61, 65], ["aPL antibodies", "PROTEIN", 140, 154], ["ECs", "CELL_TYPE", 166, 169], ["AECA", "TREATMENT", 61, 65], ["endothelial perturbations", "PROBLEM", 74, 99], ["a second hit", "PROBLEM", 112, 124], ["aPL antibodies binding", "PROBLEM", 140, 162], ["may represent", "UNCERTAINTY", 5, 18]]], ["In line with these results anti\u2010HSP60 purified from patients with coronary\u2010artery disease may cause apoptosis of nonstressed ECs; this can be considered a primary event in the pathogenesis of atherosclerosis [132].", [["coronary\u2010artery", "ANATOMY", 66, 81], ["ECs", "ANATOMY", 125, 128], ["coronary\u2010artery disease", "DISEASE", 66, 89], ["atherosclerosis", "DISEASE", 192, 207], ["anti\u2010HSP60", "GENE_OR_GENE_PRODUCT", 27, 37], ["patients", "ORGANISM", 52, 60], ["ECs", "CELL", 125, 128], ["anti\u2010HSP60", "PROTEIN", 27, 37], ["nonstressed ECs", "CELL_TYPE", 113, 128], ["patients", "SPECIES", 52, 60], ["coronary\u2010artery disease", "PROBLEM", 66, 89], ["apoptosis of nonstressed ECs", "PROBLEM", 100, 128], ["atherosclerosis", "PROBLEM", 192, 207], ["atherosclerosis", "OBSERVATION", 192, 207]]], ["According to this hypothesis, Chen et al. [133] showed that aPL binding to ECs occurs only after activation of these cells.", [["ECs", "ANATOMY", 75, 78], ["cells", "ANATOMY", 117, 122], ["aPL", "GENE_OR_GENE_PRODUCT", 60, 63], ["ECs", "CELL", 75, 78], ["cells", "CELL", 117, 122], ["aPL", "PROTEIN", 60, 63], ["ECs", "CELL_TYPE", 75, 78], ["aPL binding", "PROBLEM", 60, 71], ["aPL", "OBSERVATION", 60, 63]]], ["Worda et al. [134] reported evidence of in vivo binding of AECA to the microvascular endothelium associated with a significant increase in EC apoptosis.", [["microvascular endothelium", "ANATOMY", 71, 96], ["EC", "ANATOMY", 139, 141], ["AECA", "GENE_OR_GENE_PRODUCT", 59, 63], ["microvascular endothelium", "TISSUE", 71, 96], ["EC", "CELL", 139, 141], ["AECA", "PROTEIN", 59, 63], ["EC", "CELL_TYPE", 139, 141], ["a significant increase in EC apoptosis", "PROBLEM", 113, 151], ["AECA", "OBSERVATION", 59, 63], ["microvascular endothelium", "ANATOMY", 71, 96], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["EC apoptosis", "OBSERVATION", 139, 151]]], ["In line with these evidences, AECA might induce an endothelial perturbation with the release of endothelial microparticles that were described in sera from patients with APS [135].", [["endothelial", "ANATOMY", 51, 62], ["endothelial microparticles", "ANATOMY", 96, 122], ["sera", "ANATOMY", 146, 150], ["AECA", "CHEMICAL", 30, 34], ["APS", "DISEASE", 170, 173], ["AECA", "SIMPLE_CHEMICAL", 30, 34], ["endothelial", "CELL", 51, 62], ["endothelial microparticles", "CELLULAR_COMPONENT", 96, 122], ["sera", "ORGANISM_SUBSTANCE", 146, 150], ["patients", "ORGANISM", 156, 164], ["endothelial microparticles", "CELL_TYPE", 96, 122], ["patients", "SPECIES", 156, 164], ["AECA", "PROBLEM", 30, 34], ["an endothelial perturbation", "PROBLEM", 48, 75], ["the release of endothelial microparticles", "TREATMENT", 81, 122], ["endothelial perturbation", "OBSERVATION", 51, 75], ["endothelial", "ANATOMY", 96, 107]]], ["Taken together, these findings support the idea that AECA may be pathogenic and may be able to induce aPL production.", [["AECA", "CHEMICAL", 53, 57], ["aPL", "DISEASE", 102, 105], ["AECA", "GENE_OR_GENE_PRODUCT", 53, 57], ["aPL", "GENE_OR_GENE_PRODUCT", 102, 105], ["aPL", "PROTEIN", 102, 105], ["AECA", "PROBLEM", 53, 57], ["pathogenic", "PROBLEM", 65, 75], ["aPL production", "PROBLEM", 102, 116], ["AECA", "OBSERVATION", 53, 57], ["may be", "UNCERTAINTY", 58, 64]]], ["The effects of aPL on ECs may be mediated by an overexpression of TF.", [["ECs", "ANATOMY", 22, 25], ["aPL", "DISEASE", 15, 18], ["aPL", "GENE_OR_GENE_PRODUCT", 15, 18], ["ECs", "CELL", 22, 25], ["TF", "GENE_OR_GENE_PRODUCT", 66, 68], ["aPL", "PROTEIN", 15, 18], ["ECs", "CELL_TYPE", 22, 25], ["TF", "PROTEIN", 66, 68], ["aPL on ECs", "TREATMENT", 15, 25], ["an overexpression of TF", "TREATMENT", 45, 68], ["aPL", "OBSERVATION", 15, 18]]], ["In line with this hypothesis, Vega\u2010Ostertag et al. [122] showed that treatment with IgG from patients with aPL induced significant increases in TF transcription, expression, and activity in HUVECs and was mediated by the phosphorylation of p38 MAPK and activation of NF\u2010\u03baB.AECA and Thrombotic Vascular Involvement ::: Pathogenic Mechanisms of AECAAECA represent a heterogeneous family of autoantibodies directed to several antigens, including partially overlapping specificities.", [["HUVECs", "ANATOMY", 190, 196], ["Vascular", "ANATOMY", 293, 301], ["aPL", "DISEASE", 107, 110], ["IgG", "GENE_OR_GENE_PRODUCT", 84, 87], ["patients", "ORGANISM", 93, 101], ["aPL", "GENE_OR_GENE_PRODUCT", 107, 110], ["TF", "GENE_OR_GENE_PRODUCT", 144, 146], ["HUVECs", "CELL", 190, 196], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 240, 248], ["NF\u2010\u03baB.AECA", "GENE_OR_GENE_PRODUCT", 267, 277], ["Vascular", "MULTI-TISSUE_STRUCTURE", 293, 301], ["AECAAECA", "GENE_OR_GENE_PRODUCT", 343, 351], ["IgG", "PROTEIN", 84, 87], ["aPL", "PROTEIN", 107, 110], ["TF", "PROTEIN", 144, 146], ["HUVECs", "CELL_TYPE", 190, 196], ["p38 MAPK", "PROTEIN", 240, 248], ["NF\u2010\u03baB.AECA", "PROTEIN", 267, 277], ["AECAAECA", "PROTEIN", 343, 351], ["autoantibodies", "PROTEIN", 388, 402], ["antigens", "PROTEIN", 423, 431], ["patients", "SPECIES", 93, 101], ["IgG", "TREATMENT", 84, 87], ["TF transcription", "TREATMENT", 144, 160], ["Pathogenic Mechanisms of AECAAECA", "PROBLEM", 318, 351], ["autoantibodies", "PROBLEM", 388, 402], ["partially overlapping specificities", "PROBLEM", 443, 478], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["increases", "OBSERVATION_MODIFIER", 131, 140], ["TF transcription", "OBSERVATION", 144, 160], ["Thrombotic", "OBSERVATION", 282, 292], ["Vascular", "ANATOMY", 293, 301], ["heterogeneous", "OBSERVATION_MODIFIER", 364, 377]]], ["Several findings suggest \u03b22\u2010GPI as the most relevant antigen of APS also showing AECA reactivity [136]. \u03b22\u2010GPI is a plasma protein able to bind to anionic phospholipids; this apolipoprotein represents a cofactor required for the generation of the antigenic epitopes recognized by some aPL.", [["plasma", "ANATOMY", 116, 122], ["APS", "DISEASE", 64, 67], ["aPL", "DISEASE", 285, 288], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 25, 31], ["APS", "GENE_OR_GENE_PRODUCT", 64, 67], ["AECA", "SIMPLE_CHEMICAL", 81, 85], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 104, 110], ["plasma", "ORGANISM_SUBSTANCE", 116, 122], ["anionic phospholipids", "SIMPLE_CHEMICAL", 147, 168], ["apolipoprotein", "GENE_OR_GENE_PRODUCT", 175, 189], ["aPL", "GENE_OR_GENE_PRODUCT", 285, 288], ["\u03b22\u2010GPI", "PROTEIN", 25, 31], ["APS", "PROTEIN", 64, 67], ["AECA", "PROTEIN", 81, 85], ["\u03b22", "PROTEIN", 104, 106], ["GPI", "PROTEIN", 107, 110], ["plasma protein", "PROTEIN", 116, 130], ["apolipoprotein", "PROTEIN", 175, 189], ["antigenic epitopes", "PROTEIN", 247, 265], ["aPL", "PROTEIN", 285, 288], ["\u03b22\u2010GPI", "PROBLEM", 25, 31], ["APS", "TEST", 64, 67], ["AECA reactivity", "TEST", 81, 96], ["a plasma protein", "TEST", 114, 130], ["anionic phospholipids", "TREATMENT", 147, 168], ["this apolipoprotein", "PROBLEM", 170, 189], ["a cofactor", "PROBLEM", 201, 211], ["the antigenic epitopes", "TREATMENT", 243, 265], ["AECA reactivity", "OBSERVATION", 81, 96], ["aPL", "OBSERVATION", 285, 288]]], ["Pure anti\u2010\u03b22\u2010GPI antibodies have been also detected [[137], [138], [139]].", [["anti\u2010\u03b22\u2010GPI antibodies", "GENE_OR_GENE_PRODUCT", 5, 27], ["anti\u2010\u03b22", "PROTEIN", 5, 12], ["GPI antibodies", "PROTEIN", 13, 27], ["Pure anti\u2010\u03b22\u2010GPI antibodies", "TEST", 0, 27]]], ["The binding of \u03b22\u2010GPI to several cells, such as apoptotic thymocytes, trophoblast cells, macrophages, platelets, and ECs, has been previously reported [140].", [["cells", "ANATOMY", 33, 38], ["thymocytes", "ANATOMY", 58, 68], ["trophoblast cells", "ANATOMY", 70, 87], ["macrophages", "ANATOMY", 89, 100], ["platelets", "ANATOMY", 102, 111], ["ECs", "ANATOMY", 117, 120], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 15, 21], ["cells", "CELL", 33, 38], ["thymocytes", "CELL", 58, 68], ["trophoblast cells", "CELL", 70, 87], ["macrophages", "CELL", 89, 100], ["platelets", "CELL", 102, 111], ["ECs", "CELL", 117, 120], ["\u03b22", "PROTEIN", 15, 17], ["GPI", "PROTEIN", 18, 21], ["apoptotic thymocytes", "CELL_TYPE", 48, 68], ["trophoblast cells", "CELL_TYPE", 70, 87], ["macrophages", "CELL_TYPE", 89, 100], ["platelets", "CELL_TYPE", 102, 111], ["ECs", "CELL_TYPE", 117, 120], ["apoptotic thymocytes", "TEST", 48, 68], ["trophoblast cells", "PROBLEM", 70, 87], ["macrophages", "TEST", 89, 100], ["platelets", "TEST", 102, 111], ["ECs", "TEST", 117, 120], ["apoptotic thymocytes", "OBSERVATION", 48, 68], ["trophoblast cells", "OBSERVATION", 70, 87]]], ["In particular, the immunoreactivity of \u03b22\u2010GPI has been largely investigated in ECs but whether this reactivity is due to plasma adhesion or to a direct intracellular synthesis of the glycoprotein by ECs is still debated.", [["ECs", "ANATOMY", 79, 82], ["plasma", "ANATOMY", 121, 127], ["intracellular", "ANATOMY", 152, 165], ["ECs", "ANATOMY", 199, 202], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 39, 45], ["ECs", "CELL", 79, 82], ["plasma", "ORGANISM_SUBSTANCE", 121, 127], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 152, 165], ["ECs", "CELL", 199, 202], ["\u03b22", "PROTEIN", 39, 41], ["GPI", "PROTEIN", 42, 45], ["ECs", "CELL_TYPE", 79, 82], ["glycoprotein", "PROTEIN", 183, 195], ["ECs", "CELL_TYPE", 199, 202], ["the immunoreactivity", "TEST", 15, 35], ["plasma adhesion", "PROBLEM", 121, 136], ["a direct intracellular synthesis", "PROBLEM", 143, 175]]], ["The disappearance of \u03b22\u2010GPI immunoreactivity has been described following extensive washing of HUVECs or culture in serum\u2010free medium [141].", [["HUVECs", "ANATOMY", 95, 101], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 21, 27], ["HUVECs", "CELL", 95, 101], ["\u03b22", "PROTEIN", 21, 23], ["HUVECs", "CELL_LINE", 95, 101], ["The disappearance of \u03b22\u2010GPI immunoreactivity", "PROBLEM", 0, 44], ["HUVECs", "TEST", 95, 101], ["culture in serum\u2010free medium", "TEST", 105, 133]]], ["Interestingly, such a phenomenon was not found using primary human EC culture from skin or brain microcirculation suggesting the capability of these cell types to synthesize \u03b22\u2010GPI [141].", [["EC", "ANATOMY", 67, 69], ["skin", "ANATOMY", 83, 87], ["brain", "ANATOMY", 91, 96], ["cell", "ANATOMY", 149, 153], ["human", "ORGANISM", 61, 66], ["EC", "CELL", 67, 69], ["skin", "ORGAN", 83, 87], ["brain", "ORGAN", 91, 96], ["cell", "CELL", 149, 153], ["primary human EC culture", "CELL_LINE", 53, 77], ["\u03b22", "PROTEIN", 174, 176], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["a phenomenon", "PROBLEM", 20, 32], ["primary human EC culture", "TEST", 53, 77], ["GPI", "TEST", 177, 180], ["skin", "ANATOMY", 83, 87], ["brain", "ANATOMY", 91, 96]]], ["In this regard, our group clearly demonstrated \u03b22\u2010GPI mRNA expression in ECs cultured both in the absence and presence of \u03b22\u2010GPI in the culture medium [140].", [["ECs", "ANATOMY", 73, 76], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 47, 53], ["ECs", "CELL", 73, 76], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 122, 128], ["\u03b22\u2010GPI mRNA", "RNA", 47, 58], ["ECs", "CELL_TYPE", 73, 76], ["\u03b22\u2010GPI", "PROTEIN", 122, 128], ["ECs cultured", "TEST", 73, 85], ["the culture medium", "TEST", 132, 150]]], ["It is conceivable that ECs constitutively express \u03b22\u2010GPI mRNA, since culture in the absence of \u03b22\u2010GPI for several days does not influence \u03b22\u2010GPI mRNA synthesis in ECs.", [["ECs", "ANATOMY", 23, 26], ["ECs", "ANATOMY", 163, 166], ["ECs", "CELL", 23, 26], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 50, 56], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 95, 101], ["\u03b22", "GENE_OR_GENE_PRODUCT", 138, 140], ["GPI", "GENE_OR_GENE_PRODUCT", 141, 144], ["ECs", "CELL", 163, 166], ["ECs", "CELL_TYPE", 23, 26], ["\u03b22\u2010GPI mRNA", "RNA", 50, 61], ["\u03b22\u2010GPI", "PROTEIN", 95, 101], ["GPI mRNA", "RNA", 141, 149], ["ECs", "CELL_TYPE", 163, 166], ["GPI mRNA", "PROBLEM", 53, 61], ["culture", "TEST", 69, 76], ["GPI mRNA synthesis in ECs", "PROBLEM", 141, 166]]], ["This finding is also supported by the observation that in ECs \u03b22\u2010GPI is located and accumulates in late endosome [[142], [143]].", [["ECs", "ANATOMY", 58, 61], ["late endosome", "ANATOMY", 99, 112], ["ECs", "CELL", 58, 61], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 62, 68], ["late endosome", "CELLULAR_COMPONENT", 99, 112], ["ECs", "CELL_TYPE", 58, 61], ["\u03b22", "PROTEIN", 62, 64], ["GPI", "PROTEIN", 65, 68]]], ["The same results were observed for astrocytes, neurons, and human monocytes [124].", [["astrocytes", "ANATOMY", 35, 45], ["neurons", "ANATOMY", 47, 54], ["monocytes", "ANATOMY", 66, 75], ["astrocytes", "CELL", 35, 45], ["neurons", "CELL", 47, 54], ["human", "ORGANISM", 60, 65], ["monocytes", "CELL", 66, 75], ["astrocytes", "CELL_TYPE", 35, 45], ["neurons", "CELL_TYPE", 47, 54], ["human monocytes", "CELL_TYPE", 60, 75], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65]]], ["There is evidence that \u03b22\u2010GPI is also expressed in vivo on trophoblast vessels in term placentas as well as in circulating monocytes [124].", [["trophoblast vessels", "ANATOMY", 59, 78], ["placentas", "ANATOMY", 87, 96], ["monocytes", "ANATOMY", 123, 132], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 23, 29], ["trophoblast vessels", "MULTI-TISSUE_STRUCTURE", 59, 78], ["placentas", "MULTI-TISSUE_STRUCTURE", 87, 96], ["monocytes", "CELL", 123, 132], ["\u03b22\u2010GPI", "PROTEIN", 23, 29], ["circulating monocytes", "CELL_TYPE", 111, 132], ["circulating monocytes", "TEST", 111, 132], ["trophoblast", "ANATOMY_MODIFIER", 59, 70], ["vessels", "ANATOMY", 71, 78]]], ["The immunoreactivity of \u03b22\u2010GPI expressed by several cells involved in the photogenic scenario of APS may be due, in part, to a direct \u03b22\u2010GPI synthesis.", [["cells", "ANATOMY", 52, 57], ["APS", "DISEASE", 97, 100], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 24, 30], ["cells", "CELL", 52, 57], ["APS", "SIMPLE_CHEMICAL", 97, 100], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 134, 140], ["\u03b22\u2010GPI", "PROTEIN", 24, 30], ["APS", "PROTEIN", 97, 100], ["\u03b22", "PROTEIN", 134, 136], ["The immunoreactivity", "TEST", 0, 20], ["several cells", "PROBLEM", 44, 57]]], ["On the other hand, it is possible to speculate that the \u03b22\u2010GPI synthesis may be increased in vitro by stress conditions, such as serum depletion, from the culture medium.", [["serum", "ANATOMY", 129, 134], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 56, 62], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["\u03b22", "PROTEIN", 56, 58], ["the \u03b22\u2010GPI synthesis", "PROBLEM", 52, 72], ["stress conditions", "PROBLEM", 102, 119], ["serum depletion", "PROBLEM", 129, 144], ["the culture medium", "TEST", 151, 169], ["may be", "UNCERTAINTY", 73, 79], ["increased", "OBSERVATION_MODIFIER", 80, 89]]], ["In fact, it is important to point out that plasma protein, such as \u03b22\u2010GPI may also be absorbed on the cell membrane directly or through an endothelial receptor(s).", [["plasma", "ANATOMY", 43, 49], ["cell membrane", "ANATOMY", 102, 115], ["endothelial", "ANATOMY", 139, 150], ["plasma", "ORGANISM_SUBSTANCE", 43, 49], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 67, 73], ["cell membrane", "CELLULAR_COMPONENT", 102, 115], ["endothelial receptor", "GENE_OR_GENE_PRODUCT", 139, 159], ["plasma protein", "PROTEIN", 43, 57], ["\u03b22", "PROTEIN", 67, 69], ["GPI", "PROTEIN", 70, 73], ["endothelial receptor", "PROTEIN", 139, 159], ["plasma protein", "TEST", 43, 57]]], ["In line with such a hypothesis, it has been suggested that \u03b22\u2010GPI might interact with anionic EC membrane structures such as heparan sulfate (HS), annexin A2, and apolipoprotein E receptor 2 (reviewed in Ref.", [["EC membrane structures", "ANATOMY", 94, 116], ["heparan sulfate", "CHEMICAL", 125, 140], ["heparan sulfate", "CHEMICAL", 125, 140], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 59, 65], ["heparan sulfate", "SIMPLE_CHEMICAL", 125, 140], ["HS", "SIMPLE_CHEMICAL", 142, 144], ["annexin A2", "GENE_OR_GENE_PRODUCT", 147, 157], ["apolipoprotein E receptor 2", "GENE_OR_GENE_PRODUCT", 163, 190], ["\u03b22\u2010GPI", "PROTEIN", 59, 65], ["annexin A2", "PROTEIN", 147, 157], ["apolipoprotein E receptor 2", "PROTEIN", 163, 190], ["Ref", "PROTEIN", 204, 207], ["anionic EC membrane structures", "TREATMENT", 86, 116], ["heparan sulfate (HS)", "TREATMENT", 125, 145], ["annexin A2", "TREATMENT", 147, 157], ["apolipoprotein E receptor", "TREATMENT", 163, 188]]], ["Although a previous study showed a minimal influence of \u03b22\u2010GPI for AECA reactivity [120], to date it is well accepted that \u03b22\u2010GPI on ECs may be a target for AECA.", [["ECs", "ANATOMY", 133, 136], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 56, 62], ["AECA", "GENE_OR_GENE_PRODUCT", 67, 71], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 123, 129], ["ECs", "CELL", 133, 136], ["AECA", "CANCER", 157, 161], ["\u03b22\u2010GPI", "PROTEIN", 56, 62], ["AECA", "PROTEIN", 67, 71], ["\u03b22\u2010GPI", "PROTEIN", 123, 129], ["ECs", "CELL_TYPE", 133, 136], ["AECA", "PROTEIN", 157, 161], ["a previous study", "TEST", 9, 25], ["AECA reactivity", "TEST", 67, 82], ["ECs", "TEST", 133, 136], ["AECA", "PROBLEM", 157, 161], ["minimal", "OBSERVATION_MODIFIER", 35, 42]]], ["Raschi et al. [145] clearly demonstrated that both human monoclonal IgM antibodies anti\u2010\u03b22\u2010GPI as well as affinity\u2010purified polyclonal anti\u2010\u03b22\u2010GPI induce phosphorylation of the IL\u20101 receptor\u2010activated kinase (IRAK) and suggest that \u03b22\u2010GPI might interact with the TLR4 because of his homology with microbial structures.ConclusionsAECA represent a heterogeneous family of autoantibodies directed to several antigens, including partially overlapping specificities.", [["human", "ORGANISM", 51, 56], ["IgM", "GENE_OR_GENE_PRODUCT", 68, 71], ["anti\u2010\u03b22", "GENE_OR_GENE_PRODUCT", 83, 90], ["GPI", "GENE_OR_GENE_PRODUCT", 91, 94], ["anti\u2010\u03b22", "GENE_OR_GENE_PRODUCT", 135, 142], ["GPI", "GENE_OR_GENE_PRODUCT", 143, 146], ["IL\u20101 receptor\u2010activated kinase", "GENE_OR_GENE_PRODUCT", 177, 207], ["IRAK", "GENE_OR_GENE_PRODUCT", 209, 213], ["\u03b22\u2010GPI", "GENE_OR_GENE_PRODUCT", 232, 238], ["TLR4", "GENE_OR_GENE_PRODUCT", 263, 267], ["human monoclonal IgM antibodies", "PROTEIN", 51, 82], ["anti\u2010\u03b22", "PROTEIN", 83, 90], ["GPI", "PROTEIN", 91, 94], ["affinity\u2010purified polyclonal anti\u2010\u03b22", "PROTEIN", 106, 142], ["GPI", "PROTEIN", 143, 146], ["IL\u20101 receptor\u2010activated kinase", "PROTEIN", 177, 207], ["IRAK", "PROTEIN", 209, 213], ["\u03b22", "PROTEIN", 232, 234], ["GPI", "PROTEIN", 235, 238], ["TLR4", "PROTEIN", 263, 267], ["ConclusionsAECA", "PROTEIN", 318, 333], ["autoantibodies", "PROTEIN", 370, 384], ["antigens", "PROTEIN", 405, 413], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["both human monoclonal IgM antibodies", "TEST", 46, 82], ["GPI", "TEST", 91, 94], ["affinity", "TEST", 106, 114], ["polyclonal anti\u2010\u03b22", "TREATMENT", 124, 142], ["GPI", "TEST", 143, 146], ["the IL", "TEST", 173, 179], ["autoantibodies", "PROBLEM", 370, 384], ["partially overlapping specificities", "PROBLEM", 425, 460], ["heterogeneous", "OBSERVATION_MODIFIER", 346, 359]]], ["Despite the fact that most studies have shown a higher prevalence of AECA in autoimmune diseases, the clinical relevance of these autoantibodies is still a matter of debate and need to be confirmed by longitudinal studies on a large number of patients.", [["AECA", "DISEASE", 69, 73], ["autoimmune diseases", "DISEASE", 77, 96], ["AECA", "GENE_OR_GENE_PRODUCT", 69, 73], ["patients", "ORGANISM", 243, 251], ["autoantibodies", "PROTEIN", 130, 144], ["patients", "SPECIES", 243, 251], ["most studies", "TEST", 22, 34], ["AECA in autoimmune diseases", "PROBLEM", 69, 96], ["these autoantibodies", "PROBLEM", 124, 144], ["longitudinal studies", "TEST", 201, 221], ["AECA", "OBSERVATION", 69, 73], ["autoimmune diseases", "OBSERVATION", 77, 96]]], ["Nevertheless, there are many evidences about the pathogenic role of AECA in SLE, APS, SSc, and vasculitis.", [["SLE", "DISEASE", 76, 79], ["APS", "DISEASE", 81, 84], ["SSc", "DISEASE", 86, 89], ["vasculitis", "DISEASE", 95, 105], ["AECA", "GENE_OR_GENE_PRODUCT", 68, 72], ["SLE", "CANCER", 76, 79], ["AECA", "PROTEIN", 68, 72], ["AECA in SLE", "PROBLEM", 68, 79], ["APS", "PROBLEM", 81, 84], ["SSc", "PROBLEM", 86, 89], ["vasculitis", "PROBLEM", 95, 105], ["AECA", "OBSERVATION", 68, 72], ["SLE", "ANATOMY", 76, 79], ["SSc", "ANATOMY", 86, 89], ["vasculitis", "OBSERVATION", 95, 105]]], ["Moreover, in the future, evaluation of AECA using as substrates ECs from macro\u2010 and microvasculature may be important to assess more precisely AECA reactivity in the various forms of autoimmune diseases.", [["ECs", "ANATOMY", 64, 67], ["microvasculature", "ANATOMY", 84, 100], ["autoimmune diseases", "DISEASE", 183, 202], ["AECA", "GENE_OR_GENE_PRODUCT", 39, 43], ["ECs", "CELL", 64, 67], ["microvasculature", "TISSUE", 84, 100], ["AECA", "GENE_OR_GENE_PRODUCT", 143, 147], ["AECA", "PROTEIN", 39, 43], ["ECs", "CELL_TYPE", 64, 67], ["evaluation", "TEST", 25, 35], ["AECA", "TEST", 39, 43], ["substrates ECs", "TEST", 53, 67], ["AECA reactivity", "PROBLEM", 143, 158], ["autoimmune diseases", "PROBLEM", 183, 202], ["AECA", "OBSERVATION", 39, 43], ["autoimmune", "OBSERVATION", 183, 193]]], ["For these reasons, we believe that a more precise definition of the AECA role in autoimmune diseases has to be included in the research agenda.", [["AECA", "DISEASE", 68, 72], ["autoimmune diseases", "DISEASE", 81, 100], ["AECA", "CANCER", 68, 72], ["the AECA role", "PROBLEM", 64, 77], ["autoimmune diseases", "PROBLEM", 81, 100], ["AECA", "OBSERVATION", 68, 72], ["autoimmune diseases", "OBSERVATION", 81, 100]]]]}